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ABSTRACT 
 
During tuberculosis (TB) disease, host-derived stresses and chemotherapy are thought to drive 
tubercle bacilli into differential growth states. This is evidenced by the presence of 
differentially culturable tubercle bacilli (DCTB) in the sputum of treatment naïve TB patients. 
These bacteria do not form colonies on solid media but can be cultured following 
supplementation of liquid media with culture filtrate as a source of growth stimulatory 
molecules.  As DCTB are non-replicating and phenotypically drug tolerant, these organisms 
are thought to underpin the lengthy culture diagnosis and protracted treatment period required 
for TB disease. The purpose of this study was to investigate the use of culture filtrate in 
unmasking DCTB populations to: (1) quantify these populations in treatment naïve individuals, 
(2) assess the response of DCTB versus conventionally culturable bacteria to first-line 
treatment, (3) determine the relationship between DCTB cultured in the most probable number 
(MPN) assay with other TB culture methods and (4) to enhance currently employed culture 
diagnostic methods. The results from this study confirmed that treatment naïve individuals co-
infected with HIV had significantly lower quanta of DCTB in their sputum compared to their 
HIV-negative counterparts. These findings implicate the host immune response in influencing 
the prevalence of DCTB in sputum. During treatment, four patterns of decline in DCTB were 
described. One quarter of the patient population accumulated DCTB during the first seven days 
of treatment, whilst approximately the same number of individuals displayed a rapid decline in 
DCTB during this period. The remaining individuals either displayed static or atypical patterns 
of DCTB over the first 14 days of treatment. Following treatment completion, residual DCTB 
was cultured in approximately two thirds of the patients analysed, suggesting that 
bacteriological sterilization of lungs was not achieved. These observations were confirmed 
using a novel fluorogenic probe specific for the detection of live Mycobacterium tuberculosis. 
DCTB cultured in the MPN assay was shown to directly correlate with current TB culture 
methods. These findings demonstrate a potential utility for the MPN assay in early bactericidal 
activity studies to assess the sterilising effect of new TB drugs on DCTB populations. 
Furthermore, the addition of culture filtrate to the BACTEC MGIT 960 assay reduced the rates 
of TB detection in smear-negative, HIV-positive individuals. Collectively, these observations 
demonstrate that the detection of DCTB in sputum can serve as a possible biomarker for 
treatment response. Further long term studies are required to determine if DCTB can use used 
to assess the risk of relapse disease and to test the efficacy of new drugs on persistent bacterial 
populations. 
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CHAPTER 1 
TUBERCULOSIS 
When it rained down sorrow 
It rained all over me 
When it rained down sorrow 
It rained all over me 
'Cause my body rattles 
Like a train on that old S.P. 
I've got the T.B. blues 
        TB blues, Jimmie Rogers, 1932 
1.1 INTRODUCTION 
Tuberculosis (TB) is a communicable disease in humans caused by the actinobacterium, 
Mycobacterium tuberculosis. TB is characterised pathologically by necrotising granulomatous 
inflammations that occur predominantly in the lung, but any organ or body tissue can be 
affected (Jagirdar et al., 1996, Pai et al., 2016, Dheda et al., 2016, Skoura et al., 2015). TB 
remains a significant global health challenge and remains a public health threat in current times, 
as it has been throughout history. With an estimated 1.4 million deaths per annum, TB is now 
the leading cause of death due to an infectious agent and ranks as one of the top ten causes of 
death worldwide (WHO, 2017a). Several factors continue to contribute to the public health 
crisis associated with TB, including a complex clinical presentation, delayed diagnosis, low 
rates of diagnostic pickup in low-income countries, HIV/TB co-infection and protracted 
treatment (Koul et al., 2011, Corbett et al., 2003, Pablos-Mendez et al., 1996, Pablos-Mendez 
et al., 1997, Byrd Jr et al., 2003, Pai et al., 2016, Greenaway et al., 2002). Another major barrier 
to the eradication of TB is the emergence of drug resistant strains of M. tuberculosis which has 
demanded the urgent development of new drugs (Koul et al., 2011, Ghandi et al., 2006, Tiberi 
et al., 2017, Pai et al., 2016, Laughon and Nacy, 2017, Tang et al., 2013, Dheda et al., 2017). 
Furthermore, the vaccine currently used for TB, Bacillus Calmette-Guérin (BCG), has 
demonstrated efficacy in protecting mostly against severe forms of disseminated childhood TB 
but fails to provide any meaningful protection against adult pulmonary TB (Colditz et al., 1994, 
Fine, 1995, Fine, 1988, Hart and Sutherland, 1977, Andersen and Doherty, 2005, Vaudry, 2003, 
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Mangtani et al., 2013).  As a result, vaccination has limited impact interrupting the transmission 
of TB in adults (Franco-Paredes et al., 2006). Regrettably, advances in the development of a 
new TB vaccine have been hampered by a poor understanding of what constitutes protective 
immunity and how best to exploit this to create a vaccine with long lasting protection.  
To meet the goals proposed by the END-TB strategy, multiple factors are in need of attention. 
These include the development of new and effective drugs, shortening of current treatment 
regimens, reducing the turn-around-time of diagnosis and improvements in public health 
related factors, such as poverty, social inequities, lack of infrastructure and access to health 
care facilities (Pai et al., 2016, Dheda et al., 2016). In addition, TB disease cannot be viewed 
in isolation and drivers of the TB epidemic, such as HIV co-infection, need to be tackled 
concurrently if there is any hope of completely eradicating this disease. 
 
1.2 EPIDEMIOLOGY 
1.2.1 The Global TB burden 
TB is curable disease, yet recent estimates state that one quarter of the world’s population is 
latently infected with M. tuberculosis (Raviglione and Sulis, 2016, Houben and Dodd, 2016). 
Whilst the global incidence has declined at a rate of 1.5% per year for the past 13 years, this 
decline has been insufficient to achieve the first target set by the WHO-endorsed END-TB 
strategy, which requires this decline to accelerate to 5% per annum (set for 2020, the strategy 
aims to achieve a 20% reduction in the TB incidence rate compared to the figures reported in 
2015) (WHO, 2014a). In 2016 globally, there was an estimated 10.4 million incident cases of 
TB, equivalent to 142 cases per 100 000 population)(WHO, 2017a). It was estimated that 
approximately 65% of these cases were male and 90% of cases were adults (WHO, 2017a). TB 
disease is also associated with the most vulnerable populations and is disproportionately 
increased in HIV-infected individuals (Tornheim and Dooley, 2017). In 2016 it was estimated 
that 10% of all incident TB cases (74% in Africa) occurred in people living with HIV (WHO, 
2017a). Globally, approximately 6.9% of new TB cases occur in children (<15 years) (WHO, 
2017a), with exposed infants having the highest risk of contracting TB disease (Marais et al., 
2006b).  
South Africa was ranked amongst the top six countries with the highest total number of 
estimated incident cases in 2016 (Table 1.1), along with India, Indonesia, China, the 
Philippines and Pakistan, six countries which collectively accounted for 60% of the global total. 
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The reported incident cases per 100 000 population for these countries are depicted in Table 
1.1, along with the associated HIV-positive TB incidence and mortality rates (WHO, 2017a).  
 
Table 1.1 Burden of TB in 2016 for top six high burden countries.  
Country Population 
Incident 
cases  
 (2016) a 
 
Incidence b 
HIV 
prevalence 
in incident 
TB (%) 
HIV 
negative TB 
mortality b 
HIV 
positive TB 
mortality b 
India 1 324 billion 2790 211 3.10 32 0.92  
Indonesia 261 million 1020 391 4.40 42 5.10 
China 1 404 billion 895 64 1.20 3.6 0.13  
Philippines 103 million 573 554 1.10 21 0.29 
Pakistan 193 million 518 268 1.30 23 1.10 
South Africa 56 million 438 781  59.0 41 181 
a Numbers in thousands 
b Rates reported per 100 000 population 
  Sourced from WHO, Global Tuberculosis Report, 2017 
 
1.2.2 HIV/TB co-infection  
HIV infection is the most significant risk factor for TB disease (Havlir et al., 2008, Mahtab and 
Coetzee, 2017, Bruchfeld et al., 2015). Globally, an estimated 10% of TB incident cases 
occurred among individuals co-infected with HIV; In South Africa, this was reported as high 
as 59% (Table 1.1) (WHO, 2017a). Overall, 12% of all new active disease cases and 25% of 
all TB-related deaths occur in HIV-positive individuals (Pai et al., 2016). Furthermore, a 
systematic review of the literature reported that TB was the leading cause of hospitalisation 
and in-hospital mortality in both adults (18%) and children (10%) living with HIV worldwide 
(Ford et al., 2015). Africa is the epicentre for the global AIDS pandemic and consequently, the 
majority (approximately 75%) of HIV-associated active TB disease cases and deaths occur on 
this continent, mainly in sub-Saharan Africa (Pai et al., 2016).  
HIV infection has an amplifying effect on the incidence of TB as it increases the risk of 
reactivation disease in latently infected individuals as well as facilitates the rapid progression 
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to clinical disease soon after an individual has been infected or re-infected with M. tuberculosis 
(Shafer et al., 1996, Daley et al., 1992, Havlir et al., 2008, Ai et al., 2016). A molecular 
epidemiological study employing IS6110 restriction fragment length polymorphism (IS6110 
RFLP) genotyping illustrated a rapid spread and progression of TB disease in a residential 
facility for HIV-infected persons in San Francisco (Daley et al., 1992). Consistent with this, 
the risk of TB disease was shown to double within the first year following HIV-infection in a 
cohort of South African miners (Sonnenberg et al., 2005). The risk of disease progression is 
enhanced with advancing HIV disease (Lodi et al., 2013, Wood et al., 2000) and significantly 
reduced with the administration of antiretroviral therapy (ART) (Badri et al., 2002, 
Collaboration, 2005). An additional complication associated with HIV-TB coinfection is 
immune reconstitution inflammatory syndrome (IRIS). IRIS is a poorly understood 
immunological phenomenon whereby a paradoxical worsening of TB or unmasking of sub-
clinical TB disease occurs within the first few months following ART initiation (Manabe et al., 
2009, Abdool Karim et al., 2011). Management of IRIS is challenging and further underscores 
the need for new TB regimens that can be administered with ART.   
 
1.2.3 Drug resistance 
WHO reports routinely highlight multidrug-resistant TB (MDR-TB), wherein strains are 
resistant to isoniazid (INH) and rifampicin (RIF), the two most effective drugs used in the 
treatment of TB. Since May 2016, the WHO has issued guidance, that RIF mono-resistance is 
to be treated with an MDR-TB regimen (WHO, 2016). Globally in 2016, there were an 
estimated 600 000 cases of MDR-TB and rifampicin resistant TB (RR-TB) (4.1% occurring 
among new cases, and 19% amongst retreatment cases), with China, India and the Russian 
Federation reported as having the largest number of MDR/RR-TB cases (47% of the global 
total) (WHO, 2017a). Furthermore, treatment of extremely drug-resistant TB [XDR-TB; 
resistance to INH and RIF as well as to any fluoroquinolone and at least one of the three second 
line injectable drugs (i.e. amikacin, capreomycin and kanamycin)] was reported in 72 countries, 
with the majority of notified cases occurring in India (2464), Ukraine (1195), South Africa 
(967), Belarus (572) and China (525). The emergence of totally drug-resistant TB has been 
reported in several countries, including Italy, Iran, India and South Africa (Udwadia et al., 
2012, Velayati et al., 2009, Klopper et al., 2013). These composite forms of drug-resistant TB 
are a major concern and continue to hamper current TB control efforts.  
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1.2.4 Drivers of the TB epidemic 
Whilst HIV infection is a major driver of the TB epidemic, particularly in Africa, HIV-positive 
individuals only constitute 0.5-0.8% of the global population (Pai et al., 2016). Other 
contributors to the spread of TB include poverty, overcrowding, urbanization, poor housing, 
sanitation, stigma and other socio-economic/socio-cultural conditions which sustain 
transmission of both drug-susceptible and drug-resistant strains in communities. Many 
developing  countries face particular challenges with regard to national TB control programs,  
several of which relating to social and public health issues, with social inequities, poor 
infrastructure and a lack of basic education featuring prominently (Lönnroth et al., 2009, 
Harling et al., 2008). Living in rural settlements that are secluded from public health facilities 
often results in diagnostic delays, poor healthcare delivery and decreased access to anti-TB and 
HIV medication. Furthermore, treatment programs for HIV and TB are often not sufficiently 
integrated at clinic and community level, thus complicating management of individuals with 
coincident infection. Further risk factors that are associated with TB disease include smoking 
(Bates et al., 2007, Murrison et al., 2016, Lin et al., 2007), type-II diabetes mellitus (Jeon and 
Murray, 2008, Lönnroth et al., 2014), alcohol abuse (Rehm et al., 2009, Imtiaz et al., 2017), 
malnutrition (Lönnroth et al., 2009, Cegielski and McMurray, 2004, Chandrasekaran et al., 
2017) and air pollution (Sumpter and Chandramohan, 2013, Lönnroth et al., 2009, Lin et al., 
2007, Lai et al., 2016) all of which highlight the need for public health interventions 
(Narasimhan et al., 2013, WHO, 2017a, Mathema et al., 2017). TB elimination therefore 
requires a combination of both therapeutic/diagnostic strategies along with prevention 
strategies aimed at reducing transmission and the progression to active disease taking into 
account the large reservoir of latent TB cases globally. 
 
1.3 AETIOLOGY  
The aetiology of TB was first described by Robert Koch on the 24th of March in 1882 at the 
Berlin Physiological Society, a day which is now commemorated as world TB day. Koch 
developed a staining procedure based on Methylene blue counterstained with versuvin allowing 
for the discovery of the contagion: 
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“…it seems likely that the tubercle bacillus is surrounded with a special 
wall of unusual properties, and that the penetration of a dye through this 
wall can occur when a alkali, aniline, or similar substance is present.” 
                                                                                                    (Koch, 1882) 
 
1.3.1 Taxonomy and morphology 
1.3.1.1 Taxonomy 
1.3.1.1.1 The Mycobacterium tuberculosis complex 
Bacteria of the family Mycobacteriaceae (of the order Actinomycetales) contain the genus of 
Mycobacteria, of which more than 150 different species have been identified, Figure 1.1. The 
vast majority of these bacteria are non-pathogenic and are classified as non-tuberculous/ 
environmental mycobacteria (NTM) (see section 1.3.1.1.2). There are however, several non-
environmental mycobacterial species that are pathogenic. These include members of the M. 
tuberculosis complex (MTBC) as well as Mycobacterium leprae and Mycobacterium ulcerans.  
The MTBC consists of eight genetically related Mycobacterium species and subspecies 
including M. tuberculosis, Mycobacterium bovis, M. bovis BCG, M. bovis subsp caprae, 
Mycobacterium africanum, Mycobacterium microti, Mycobacterium pinnipedii, and 
Mycobacterium canettii. The majority of TB cases are caused by M. tuberculosis and M. 
africanum, while a small number of cases can be caused by zoonotic members of the MTBC 
(see Table 1.2). While members of the MTBC vary greatly in their phenotypic characteristics, 
mammalian host ranges, geographic distribution and pathogenicity, they represent an extreme 
example of genetic homogeneity, with 99.9% similarity at the nucleotide level and identical 
16S rRNA sequences (Aranaz et al., 1999, Cousins et al., 1998, Brosch et al., 2002, 
Böddinghaus et al., 1990, Sreevatsan et al., 1997). There is also evidence to show that members 
of the MTBC evolved from a common ancestor, Mycobacterium prototuberculosis (Brosch et 
al., 2002, Gutierrez et al., 2005, Sreevatsan et al., 1997).  
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Figure 1.1 Taxonomic tree for Mycobacterium tuberculosis complex, non-tuberculosis mycobacteria and 
related species. MTBC, Mycobacterium tuberculosis complex; NTM, non-tuberculosis mycobacteria. Adapted 
from (Iseman, 2000).  
 
Table 1.2 Primary host, mode of transmission and geographic distribution of members of 
the Mycobacterium tuberculosis complex 
Organism Primary reservoir/ Host Transmission? Geographic distribution 
Mycobacterium 
tuberculosis 
Human Inhalation of droplet nuclei * Worldwide 
Mycobacterium bovis Human and range animals 
(e.g. cattle) 
Ingestion of contaminated 
milk from infected cows †; 
Airborne transmission ‡ 
Worldwide 
M. bovis BCG Human – 
commercial vaccine 
Via immunization Worldwide 
Mycobacterium 
africanum 
Human ⸹ Inhalation of droplet nuclei East and west tropical 
Africa. Been reported in 
USA 
Mycobacterium caprae Wide range of host animals 
(e.g. goat); human infection 
is rare 
Inhalation of droplet nuclei Europe 
Mycobacterium microti Vole, rodents Inhalation of droplet nuclei Europe, Great Britain, 
Netherlands 
Mycobacterium mungi Banded mongoose ND Africa 
Mycobacterium canettii ND 
human infection is rare 
ND Africa 
Mycobacterium orygis Larger mammals (e.g. oryxes, 
antelope, gazelle and 
waterbuck) 
ND Africa 
Mycobacterium 
pinnipedii 
Seal, sea-lion ND; Transmission from sea-
lion to human has been 
reported 
Europe 
* Infection can occasionally occur via the skin or gastrointestinal tract.  
† The incidence has significantly decreased since the universal pasteurization of milk and milk products.  
‡ Can occur human-to-human, animal-to-human and human-to-animal.  
⸹ Infection in animals are not excluded.  
   Reproduced from (Tille, 2013) 
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1.3.1.1.2 Non-tuberculosis mycobacteria 
 A number of mycobacterial saprophytes are opportunistic and cause disease when the 
immunity of the host is compromised. For example, Mycobacterium avium-intracelluare of the 
Mycobacterium avium-intracelluare complex is associated with pulmonary disease and to a 
lesser extent, focal disease involving intestines or lymph nodes in HIV-positive patients.  
Disseminated disease with bacteraemia may also develop in AIDS patients with very low CD4 
T-cell counts (<100/mm3) (Gillespie and Hawkey, 2006). Examples of non-tuberculosis 
mycobacteria that are associated with clinical infection are given in Table 1.3. 
 
Table 1.3 Examples of clinically relevant non-tuberculosis mycobacteria* 
Disease association Species 
Pulmonary M. avium-intracelluare 
 M. kansasii 
 M. xenopi 
 M. absessus 
 M. fortuitum 
Lymph node M. avium-intracelluare 
 M. scrofulaceae 
 M. malmoense 
Cutaneous M. ulcerans 
 M. absessus 
 M. fortuitum 
 M. avium-intracelluare 
Disseminated M. avium-intracelluare 
 M. kansasii 
 M. fortuitum 
 M. chelonae 
* Reproduced from and reviewed in (Gillespie and Hawkey, 2006) 
 
1.3.1.2 Morphology 
Mycobacteria resist conventional stains, such as Gram staining, due to the high lipid content 
of their cell walls (approximately 60%), often appearing as ‘neutral’ or as unstained ghost 
forms. These bacteria have a unique tinctorial property whereby acid fast stains such as Ziehl-
Neelsen (ZN) or auramine are used for microscopic identification. Microscopically, TB bacilli 
11 
 
typically appear as straight or slightly curved rods (Palomino et al., 2007). When cultivated in 
vitro, the shape and length of these bacilli can vary depending on the age of the culture and 
growth conditions (Shleeva et al., 2011). The different morphologies range from coccobacilli 
to long rods and the reported lengths and widths of these organisms range from one to 10 μm 
(typically 3 to 5 μm) and 0.2 to 0.6 μm, respectively (Velayati et al., 2011, Velayati and Farnia, 
2012).  In liquid culture, MTBC often exhibits serpentine cording allowing for the rapid and 
presumptive identification of TB infection using microscopy (Gonzlez et al., 1998).  
 
1.4 TUBERCULOSIS PATHOGENESIS  
The pathogenesis of TB is a complex process beginning with transmission, which can either 
result in the establishment of a contained infection, no infection or active disease. These and 
related aspects are discussed below.  
 
1.4.1 Transmission  
TB is transmitted through the production of aerosolized particles harbouring M. tuberculosis 
by infected individuals through high-velocity exhalation actions such as coughing or sneezing 
(Wells, 1934). These aerosols dehydrate to form droplet nucleic (1 to 5 μm) that remain 
suspended in the air and can subsequently be inhaled into the alveoli of a new prospective host.  
 
“…most droplets atomized into air evaporate almost instantly, leaving 
disease germs drifting like cigarette smoke in the droplet nuclei.” 
       (Riley and O'Grady, 1961) 
 
In March 2016, a workshop was held at the National Institute of Health to identify potential 
research gaps and find possible solutions to halt TB transmission with the ultimate goal of 
reducing new infections to zero. The three major themes that were addressed included: (1) 
infectiousness and susceptibility (i.e. which individuals are infectious and who is prone to 
becoming infected?), (2) drivers of the TB epidemic and (3) interventions to halt transmission 
(Shah et al., 2017b, Churchyard et al., 2017, Turner et al., 2017, Mathema et al., 2017, Dowdy 
et al., 2017, Auld et al., 2017). Transmission of M. tuberculosis involves both host and 
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bacterial-related factors. For example, factors associated with infectiousness include the 
immune status of the index case as well as lung cavitation, extent of disease and bacillary load 
(Dheda et al., 2010, Turner et al., 2017, Churchyard et al., 2017). In terms of susceptibility and 
exposure, closeness of contact, exposure duration, room ventilation, barrier host defences as 
well as the new host’s immune status (including macrophage function and mucosal immunity) 
are important in the establishment of a new infection (Turner et al., 2017). Furthermore, certain 
strains, including drug-resistant strains, have also been associated with increased virulence and 
transmission. Indeed, primary resistance (transmission of resistant TB strains) has been 
reported globally (Ghandi et al., 2006, Wells et al., 2007, Moro et al., 1998, Ritacco et al., 
1997, Shah et al., 2017a). An in-depth understanding of factors that drive transmission are also 
required, as well as tools to monitor ongoing transmission within a community (Mathema et 
al., 2017). Until the advent of molecular methods for the typing and characterization of M. 
tuberculosis strains, primary TB disease, usually in children, was generally thought to occur as 
a consequence of infection with a single M. tuberculosis strain which becomes dormant, 
resulting in latent TB infection (LTBI). Active TB disease in adults was considered to be 
predominantly the result of endogenous reactivation of the dormant strain that caused the 
original infection or failure to contain the initial infecting episode in the form of LTBI (Stead, 
1967). With the advent of molecular-based genotyping, various studies have subsequently 
demonstrated that many incident TB cases occur as a result of recent transmission (associated 
with a short latency/incipient period) as opposed to reactivation of a historic infection, thus 
challenging past ‘misconceptions’ regarding the transmission of TB (Alland et al., 1994, Small 
et al., 1994). Studies indicating high rates of re-infection versus relapse disease, recent 
transmission and mixed infections have also challenged previous paradigms regarding TB 
transmission (McIvor et al., 2017).  
TB transmission is a process that is complex. An improved understanding of this and ongoing 
research is required to improve knowledge and understanding in this regard. In addition, the 
implementation of multiple strategies that include both established and new interventions (at 
biomedical and social levels) are required to halt transmission.  
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1.4.2 Outcomes of infection 
Following primary infection, multiple scenarios can take place. The first involves the clearance 
and complete eradication of organisms by the host immune system. However, in most cases 
primary infection may lead to the establishment of LTBI, whereby the disease is contained and 
in this case, the physiological state of the bacilli remains enigmatic. In few cases (roughly 5-
10%), the inhaled bacilli may begin to multiply resulting in the rapid progression to active 
disease, Figure 1.2 (Koul et al., 2011).   
 
 
Figure 1.2 Stages of M. tuberculosis infection.  Infection with M. tuberculosis can occur via the inhalation of 
viable organisms (bacterial strain x, red), where close enough contact to the diseased host seems necessary. 
Following a transmission event, in the majority of cases, latent tuberculosis infection (LTBI) is established (blue 
box), but a small number of individuals will rapidly progress to active TB disease (red box). Globally, there is a 
large reservoir of latent TB cases. These individuals, if immune-competent, carry a 10% life time risk of 
developing active disease (†). Disease reactivation is commonly associated with immune suppression and this 
event can occur years after the initial infection. Immune-compromised individuals have an increased risk of 
developing active disease at a rate of seven to 10% per annum. In drug-susceptible TB disease (denoted by *), 
approximately 70 to 95% of patients will recover following treatment completion (Chaulk and Kazandjian, 1998), 
whereas 5% will relapse (bacterial strain x, red) (Koul et al., 2011). The treatment success rates in drug-resistant 
TB disease are much poorer (ranging from 40 to 70% in multi-drug resistant cases, to 20 to 60% in patients with 
extremely drug-resistant TB) (Dheda et al., 2014). Furthermore, patients with previous TB infection are at 
increased risk of being re-infected with a different strain (bacterial strain y, green). Patients who are untreated 
(denoted by **) have high mortality rates. Adapted from Koul et al. 2011. Drawn by Amanda McIvor.  
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1.4.3 Immune pathogenesis 
Following inhalation, the infecting bacilli are engulfed by resident alveolar macrophages 
(Schlesinger et al., 1990, Tailleux et al., 2005, Hirsch et al., 1994, Kang et al., 2005), epithelial 
cells, dendritic cells (Tailleux et al., 2003, Geijtenbeek et al., 2003) and neutrophils that are 
directed at killing bacteria. However, M. tuberculosis is able to resist eradication and uses 
macrophages as a niche for survival and replication. Through the process of phagocytosis, 
tubercle bacteria gain access into the macrophage through the recognition of cell wall 
glycolipids and the formation of toll-like receptor heterodimers (Aderem and Ulevitch, 2000, 
Flynn and Ernst, 2000). Following entry, M. tuberculosis is able to prevent phagosome 
maturation by preventing fusion of the phagosome and lysosome (Russell, 1998, Russell, 
2011). The infected macrophages migrate and transport M. tuberculosis via the lymphatic 
system to the hilar lymph nodes where a primary lesion known as the ‘Ghon focus’ is formed 
(Frieden et al., 2003), and T-cells are primed, followed by clonal expansion (Dheda et al., 
2010).  
Bacteria are able to move hematogenously to various sites in the body and through the draining 
lymph system. The presence of M. tuberculosis in the pulmonary interstitium leads to a local 
inflammatory response attracting dendritic cells, monocytes, macrophages and T-cells to the 
infected area where the primary lesion matures into a granuloma – the hallmark of TB. Early 
stages of granuloma development are dependent on the production of tumour necrosis alpha 
(TNF-α) by infected macrophages and T-cells (Guirado and Schlesinger, 2013, Algood et al., 
2005, Russell et al., 2009). TNF-α along with other inflammatory cytokines [e.g. IL-1β, IL-2, 
IL-6, IL-12, IL-15, IL-17, IL-18, IFN-γ (pro-inflammatory Th1 profile)], anti-inflammatory 
cytokines [IL-4, IL-10, TGF-β (Th2 profile)]  and chemokines (e.g. IL-8) attract natural killer 
T cells, neutrophils, CD4 and CD8 to the area of infection (Ramakrishnan, 2012, Pagan and 
Ramakrishnan, 2017, Russell, 2007). Sustained signalling of TNF-α is required to maintain 
these chemokine levels resulting in cellular recruitment and retention (Russell et al., 2009, 
Algood et al., 2005, Kindler et al., 1989, Roach et al., 2002, Saunders and Britton, 2007). 
Interestingly, a granulatomous response has been shown to occur in TNF-deficient mice; 
However, this response is delayed in onset and the structures remain poorly organized and 
become necrotic (Gil et al., 2006). Maintenance of the granuloma and outcome of infection is 
determined by the interplay between pro-inflammatory and anti-inflammatory cytokines. 
While TNF-α is one of the predominant cytokines in granuloma formation, an excess may lead 
to severe inflammation resulting in necrosis, liquefaction and overt tissue destruction. An 
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example of this is IRIS in HIV/TB co-infected patients with low CD4 T-cell counts on highly 
active anti-retroviral therapy (HAART). The resulting expansion of CD4 cells in the presence 
of a high antigen load or bacterial burden results in an aggressive granulomatous response 
manifesting in new, worsening or recurrent signs and symptoms (Lipman and Breen, 2006, 
Namale et al., 2015).  
The granuloma is often described as a ‘double edged sword’, preventing dissemination of 
disease but also functioning as a site for bacterial replication (Gideon et al., 2015, Ehlers and 
Schaible, 2012, Ramakrishnan, 2012). Originally viewed as protective physical barrier 
preventing dissemination of the invading pathogen (Saunders and Cooper, 2000), studies 
conducted in infected zebra fish embryos (M. marinum) have suggested that the granuloma 
may function as a protective niche for the pathogen allowing for replication and facilitation of 
transmission (Ramakrishnan, 2012, Davies et al., 2014).  
PET-CT scans have illustrated the dynamic nature of granulomas in patients with active TB 
not responding to therapy (Coleman et al., 2014). In human infection, three types of granulomas 
have been described, namely solid, necrotic and caseous granulomas (Gengenbacher and 
Kaufmann, 2012).  
 
1.4.4 Progression from latent infection to active disease 
In most cases of LTBI, the infection is contained by the host’s immune system involving a 
balance of macrophages, dendritic cells and T-cells, resulting in asymptomatic infection. 
However, in a subset of these individuals (approximately 5-10%) reactivation to active disease 
will occur (Selwyn et al., 1989, Selwyn et al., 1992).  Reactivation disease can take place after 
a few months or decades following the initial infection and sub-clinical persistence. Risk 
factors that are associated with reactivation disease include HIV-infection, poverty, 
malnutrition, alcoholism, diabetes, tobacco smoking, silicosis, chronic renal failure needling 
dialysis, immune suppressive therapy as well as individuals older than the age of 65 (Ai et al., 
2016, Lönnroth et al., 2009). 
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Figure 1.3 The spectrum of tuberculosis disease – from M. tuberculosis infection to active pulmonary 
disease. Historically, tuberculosis (TB) disease was viewed in a binary fashion comprising either latent TB 
infection (LTBI) or active disease. More recently, TB disease is considered as a spectrum, extending from 
sterilizing immunity to active infection and clinical disease (Barry et al., 2009).  Furthermore, the extent of 
infection/disease can advance or reverse depending on changes in host immunity and disease comorbidities. In 
one scenario, complete eradication of M. tuberculosis may occur following exposure by the host’s innate or 
acquired immune response. When M. tuberculosis is not eliminated by the immune system, bacilli can exist in a 
non-replicating state (associated with LTBI). LTBI can be detected by a positive tuberculin skin test (TST) and 
interferon gamma release assay (IGRA) and the absence of clinical symptoms. The clinical spectrum of TB disease 
is also inclusive of subclinical TB (mild or no clinical symptoms but positive culture results), pre-diagnostic TB 
(symptoms are present, but not severe enough to seek clinical attention) and clinical disease (clinical seeking of 
care, positive diagnosis) (Mathema et al., 2017). Treatment of TB disease (subclinical to active disease) requires 
a multidrug treatment (Tx) regimen. Adapted from Pai et al. 2016. Drawn by Amanda McIvor.  
 
1.5 CLINICAL PRESENTATION OF TB DISEASE 
The various outcomes of infection include LTBI, primary disease, secondary disease (also 
referred to as post-primary/progressive or reactivation disease) and extra-pulmonary TB 
disease. These stages of TB disease have different clinical presentations and further detailed 
below: 
 
1.5.1 Latent infection 
Persons with LTBI are infected with M. tuberculosis as evident by means of a positive 
immunological test result, i.e. tuberculin skin test (TST) or IFN-γ release assays (IGRA), but 
have no clinical symptoms of disease. In LTBI, bacilli can persist in the host for many years or 
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a life time without causing active disease. Indeed, evidence for extremely long latency periods 
in untreated humans was illustrated in a molecular-based study conducted in Denmark. While 
typing historical freeze dried M. tuberculosis strains, the investigators came across a 13-band 
DNA pattern collected in 1961 that matched the fingerprint of a specimen obtained in 1994. 
The isolates were from a father (1961) and son (1994) (Lillebaek et al., 2002).  
LTBI in clinical medicine was previously viewed as a homogenous entity; however, current 
data suggests that LTBI can exist as a spectrum of infectious states ranging from sterilizing 
immunity where M. tuberculosis is eradicated by the host immune response, or incipient TB 
(characterized by a biomarker signature of progression), or subclinical disease, where the 
probability of reactivation is high (Barry et al., 2009, Esmail et al., 2016, Shnappinger and Ehrt, 
2016, Fiore-Gartland et al., 2017). Indeed, [8F]-fluoro-2-deoxy-D-glucose (FDG) positron 
emission tomography (PET) in combination with computed tomography (PET/CT) imaging 
identified heterogeneous lesions in patients with LTBI including infiltrates, fibrotic scars and 
active nodules which were indicative of active disease (Esmail et al., 2016). A subset of 
individuals with PET/CT scans indicative of subclinical disease developed TB symptoms 
during a 6 month follow-up period illustrating an increased risk of reactivation disease. These 
findings further complicate diagnosis and treatment and stress the need for the identification of 
biomarkers that discriminate patients at risk for reactivation disease who can be prioritised for 
preventative therapy. The use of a highly specific transcriptomic biomarker (Zak et al., 2016) 
is being considered for a risk-targeted, test-and-treat strategy with the aim of identifying 
individuals who have a high risk of progressing to active TB disease (Fiore-Gartland et al., 
2017). The performance of this biomarker is currently being assessed in a South African study 
designated ‘CORTIS’ (Correlate of Risk Targeted Intervention Study) involving a large cohort 
of both high-risk and low-risk individuals (Fiore-Gartland et al., 2017).   
 
1.5.2 Pulmonary TB Disease  
Traditionally, pulmonary TB has been characterised as either primary or secondary based on 
the time between the initial infection and the development of clinical disease. Primary disease 
has been defined to occur within ‘five years of the initial infection’ (Vynnycky and Fine, 1997, 
Holm, 1969) and in molecular epidemiology terms is said to occur as a result of recent 
transmission events. Primary and secondary TB disease have different clinical and radiographic 
presentations which are discussed below.  
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1.5.2.1 Primary TB disease 
Primary disease occurs in a host that is previously unexposed and therefore unsensitised, and 
is characterised by the formation of the Ghon complex (ATS, 2000, Small and Fujiwara, 2001, 
Ober, 1983). This pathognomic macroscopical lesion consists of a granuloma, normally in the 
middle or lower zones of the lung (referred to as the Ghon focus) in conjunction with hilar 
and/or paratracheal lymphadenopathy (Heemskerk et al., 2016). Primary disease is often 
asymptomatic and the only evidence of disease is a positive immunological diagnostic test 
(Palomino et al., 2007). In some cases, symptoms may include low-grade fever, malaise and 
erythema nodosum. Generally primary TB disease has a favourable outcome, with healing 
resulting in fibrosis and/or calcification in the majority of individuals cases resulting in a Ranke 
complex which is visible on a chest X-ray (Heemskerk et al., 2016). In adult patients, primary 
TB disease is paucibacillary, non-contagious, difficult to diagnose and varies in severity 
(Palomino et al., 2007). 
 
1.5.2.2 Post-primary TB disease 
Post primary TB is defined as TB disease that arises in a previously sensitized host, i.e. 
infection can progress despite an adequate specific immune response (Palomino et al., 2007, 
ATS, 2000, Small and Fujiwara, 2001). Post-primary TB disease often occurs many years after 
the initial infection as a result of ‘endogenous’ reactivation of the primary focus. However, 
post-primary disease can also occur by the inhalation of new bacilli, referred to as ‘exogenous’ 
re-infection. Often, reactivation disease (defined as the re-emergence of a historic infection that 
was contained by the immune system) and re-infection (defined as exogenous reinfection with 
a distinct M. tuberculosis strain to that from the original infection) are clinically 
indistinguishable and molecular fingerprinting methods such as IS6110, spacer oligonucleotide 
genotyping or whole genome sequencing are required for differentiation (Heemskerk et al., 
2016).  
Post-primary TB most commonly manifests as pulmonary disease, although lymphatic 
dissemination can occur and almost any organ of the body can be involved (see section, 1.5.3). 
In pulmonary disease, radiographic manifestations typically include upper lobe lesions, 
cavitation and fibrosis (Lee et al., 1993, Lee et al., 2000, Jeong and Lee, 2008). However, 
molecular epidemiology studies employing IS6110 RFLP genotyping to differentiate primary 
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disease (by recent infection) from reactivation disease have shown that the radiographic 
features are often similar between the two (Jones et al., 1997, Geng et al., 2005).   
The signs and symptoms during the initial disease phase are often not severe, non-specific and 
gradual in onset. With disease progression, the most frequently reported symptom is a 
persistent and productive cough with purulent or mucous expectoration, as well as the typical 
triad of fever, weight loss/wasting and night sweats reported in 95, 75, 55 and 45% of patients, 
respectively (Davies et al., 2014). For further information, the reader is referred to an excellent 
review regarding the pathogenesis of post-primary TB (Hunter et al., 2014).  
 
1.5.3 Extra-pulmonary TB disease 
Prior to the HIV epidemic, the majority of reported TB cases were pulmonary (about 85%)  
with the remaining 15% being extra-pulmonary or involving both pulmonary and extra-
pulmonary sites (Farer et al., 1979). In 2006, analysis of 13,779 TB cases in the United States 
reported that 21% of these cases displayed extra-pulmonary (EP) TB, 6.9% were concurrent 
EP-pulmonary TB and approximately 1.8% were disseminated (milliary TB) (CDC, 2007). 
Various studies have shown that whilst there has been a decrease in the total number of TB 
cases, there has been a proportionate increase in the number of EPTB cases (Peto et al., 2009, 
Farer et al., 1979, Rieder et al., 1990, García-Rodríguez et al., 2011). Factors that contribute to 
the risk of acquiring EPTB include HIV status, gender, ethnicity, age and BCG vaccination 
status (Yang et al., 2004, Rodrigues et al., 1993, Peto et al., 2009, Cailhol et al., 2005, Antony 
et al., 1995, Yang and Kong, 2015).  In HIV-infected patients, the risk of developing EPTB is 
5-fold that in HIV-negative patients (Yang et al., 2004, Yang and Kong, 2015) which is most 
likely associated with a deficiency in CD4 T-cells (Jones et al., 1993). In terms of the ethnicity, 
African-Americans and individuals born in South Asian countries (living in the United States) 
have higher incidence rates of EPTB compared to Caucasians (Farer et al., 1979, Yang et al., 
2004, Asghar et al., 2008, Fiske et al., 2010). The observed increase in risk may be due to host-
related genetic factors, social factors or vitamin D deficiency (Sita-Lumsden et al., 2007, Yang 
and Kong, 2015). Female gender and young age (less than 25 years) have also been described 
as risk factors for EPTB (Yang et al., 2004, Rieder et al., 1990). It is not clear why women are 
more likely to have EPTB compared to men; however, hormones, smoking status and TB 
exposure have been put forward as possible reasons for the increase in risk (Hudelson, 1996, 
Holmes et al., 1998, Yang and Kong, 2015).  In addition, virulence of different M. tuberculosis 
20 
 
strains, mode of transmission and the innate immunity of the host have also been considered 
(Farer et al., 1979, Yang and Kong, 2015). The most common forms of EPTB are pleural TB, 
lymph node TB and disseminated TB (Palomino et al., 2007, Pai et al., 2016). Diagnosis of 
EPTB is challenging as it can present with varied clinical manifestations that mimic other 
diseases and sampling of sites can prove challenging (Yoon et al., 2004). For these reasons, the 
WHO now recommends the GeneXpert MTB/RIF assay to diagnose TB lymphadenitis and 
meningitis (Steingart et al., 2014, Pai et al., 2016, Boehme et al., 2010).  
 
1.6 DIAGNOSIS  
1.6.1 Latent infection 
Diagnosis of LTBI can be made after active TB disease has been ruled out as current 
immunological tests have limited capacity to distinguish between active disease and latent 
infection. For adults, the exclusion of active TB disease is based on the absence of clinical 
symptoms, including a normal chest radiograph, as well as a negative bacteriological result [i.e. 
sputum smear microscopy, culture or nucleic acid amplification tests (NAAT)]. For children, 
the absence of clinical symptoms is usually sufficient to exclude active disease. The 
commercially available tests to diagnose LTBI include the TST or ‘Mantoux test’ as well as 
whole blood IGRA tests. 
 
1.6.1.1. Tuberculin skin testing 
The TST is a method of assessing cell-mediated immunity to purified protein derivative (PPD) 
tuberculin, and has been widely used as a screening tool for LTBI since the 1930s (Daniel, 
2006). The test is performed by administering an intradermal injection of 5 tuberculin units 
(TU) of PPD S or 2 TU of PPD RT23 (WHO, 2014b). The reaction is measured 48 to 72 hours 
following administration by measuring the diameter of the induration on the forearm in mm 
(WHO, 2014b, Nayak and Acharjya, 2012, Menzies et al., 2008). The sensitivity of this test is 
compromised in patients with poor immunity (i.e. HIV-infection, malnutrition, corticosteroid 
therapy or children following measles infection) or in cases of overwhelming TB disease (for 
e.g. miliary TB disease in young children) (Nayak and Acharjya, 2012) 
(www.cdc.gov/tb/publications/factsheets/testing/skintesting.pdf). False positive reactions can 
also occur due to cross reactivity with the BCG vaccine, although this is unlikely after the first 
two years following vaccination at birth, or exposure to NTM in the environment (Nayak and 
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Acharjya, 2012, Farhat et al., 2006). The interpretation a positive result varies according to the 
population or individual tested, i.e.  The cut-off for a negative skin test is lowered from 10 mm 
to 5 mm in patients who are immune compromised (Pai et al., 2014, Dheda et al., 2016). The 
TST is the most widely used test for the screening of LTBI due to its low cost and ease of use 
and is the preferred method in certain groups such as young children and routine screening of 
laboratory personnel and health care workers (Enarson, 2004, Pai and Banaei, 2013). A skin 
test, utilising more specific M. tuberculosis antigens (RD1) is currently under development to 
replace PPD (Pai and Sotgiu, 2016).      
 
1.6.1.2 Interferon gamma release assays 
The two currently used whole blood IGRA tests that are available on the market are the 
QuantiFERON®-TB Gold In-Tube tests (Cellestis/Qiagen, Carnegie, Australia) and the T-
SPOT.TB assay (Oxford Immunotec, Abingdon, United Kingdom) (Pai et al., 2014). These in 
vitro diagnostic tests measure the amount of IFN-γ produced by T-cells in whole blood on 
exposure to RD-1 encoded M. tuberculosis antigens (namely a 6kDa early secretory antigenic 
target and culture filtrate protein 10) (Sørensen et al., 1995, Pai et al., 2014, Mahairas et al., 
1996). The concentration of IFN-γ present is determined using an ELISA test. The advantages 
of IGRA tests is that they are more specific than TST as the antigens included in the assay are 
highly specific to M. tuberculosis and are not encoded in the BCG genome and most NTMs 
(Pai et al., 2016, Andersen et al., 2000). Therefore, infection with NTMs is unlikely to yield a 
false positive result. In addition, previous vaccination with BCG will not affect the results. The 
drawbacks of these assays are that they are expensive and require more expertise to perform 
than the TST, making it difficult to implement this technology for routine use in developing 
nations with a high burden of TB (WHO, 2015b). 
Whilst research has shown that the TST and IGRA are acceptable methods for the diagnosis of 
LTBI, both tests have a low predictive value and cannot differentiate between active disease 
and LTBI (Pai et al., 2014, Sester et al., 2011, Pai et al., 2016, Pai and Sotgiu, 2016). The 
development of high predictive tests that are able to identify individuals who are at risk of 
reactivation disease and would benefit from preventative therapy would serve as an invaluable 
tool and strategic method of treatment to reduce the numbers of individuals with active disease 
and thus reduce transmission of M. tuberculosis within the community.  
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1.6.2 Active disease 
Screening for active TB disease can be performed using imaging technologies such as chest X-
rays and PET/CT scans; however, diagnosis of the disease primarily relies on microbiological 
methods including smear microscopy, culture-based methods and molecular methods, each of 
which is detailed below.  
 
1.6.2.1 Smear microscopy  
Sputum smear microscopy is currently widely used in low- to middle-income countries to 
diagnose active TB disease. It has several advantages including low cost, it is relatively simple 
to perform, it has a fast turn-around-time and it can be performed in very basic laboratory set-
ups (Ryu, 2015). Furthermore, it has a high specificity in areas where TB is prevalent. For a 
smear to be positive, microscopy requires at least 5000 to 10 000 acid fast bacilli (AFB) per 
mL of sputum (Getahun et al., 2007), thus enabling it to identify the most infectious individuals 
(Luelmo, 2004, Perkins, 2000). Whilst some studies have reported a sensitivity of more than 
80% in diagnosing pulmonary TB disease (Grzybowski et al., 1974, Behr et al., 1999), others 
have reported low and variable results (range 20 to 60%) (Aber et al., 1980, Urbanczik, 1985). 
Whilst smears are convincingly positive in individuals with cavitary pulmonary disease, they 
are often negative in individuals with extensive, non-cavitary disease (Canetti, 1955, Gomes et 
al., 2003, Palaci et al., 2007). In HIV-positive individuals, smear microscopy has a reduced 
sensitivity detecting only 22 to 43% of active cases (Getahun et al., 2007, Tattersfield, 2005). 
In addition, the diagnosis of paediatric TB remains a challenge due to difficulty in collecting 
respiratory specimens and the presentation of TB disease in children (Marais et al., 2006b, Zar 
et al., 2005, Marais et al., 2006a, Chiang et al., 2015). Smear-negative TB is associated with 
unfavourable treatment outcomes, highlighting the need for more sensitive and rapid tests to 
detect smear-negative cases (Hargreaves et al., 2001, Harries et al., 1999). For these reasons, 
the WHO now conditionally recommends the GeneXpert MTB/RIF as the initial line of 
diagnosis in adults and children who are suspected of having active TB disease (WHO, 2013b) 
The two most commonly used microscopy techniques to diagnose active TB disease are 
conventional microscopy [carbol-fuschin methods, i.e. ZN or Kinyoun acid-fast stains] and 
fluorescent microscopy (auramine-O or auramine-rhodamine). Conventional staining can be 
viewed using artificial light or reflected sunlight (Foulds and O'brien, 1998), whereas 
fluorescent microscopy utilises an acid-fast fluorochrome dye and bacilli are viewed under an 
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intense light, i.e. a halogen lamp or high-pressure mercury vapour lamp (Steingart et al., 2006). 
A systematic review analysing 45 studies comparing conventional microscopy with fluorescent 
microscopy concluded that fluorescent microscopy was more sensitive than conventional 
microscopy (Steingart et al., 2006). It was suggested that the successful widespread 
implementation of fluorescence microscopy in TB endemic regions may improve TB case-
finding via the increased sensitivity of the method as well as the decreased time spent on 
microscopic examination, whereby fluorescent microscopy uses a 25X objective lens 
compared to conventional microscopy that requires a 100X objective lens (Steingart et al., 
2006). The limitations of fluorescent microscopy are that it is more expensive and it requires 
additional maintenance and operational requirements. These factors hamper its application as 
a point-of-care diagnostic in poorer regions. Efforts to improve the sensitivity of microscopy 
have been assessed and these include prior decontamination of the specimen with NaOH or 
bleach (Cattamanchi et al., 2010, Srikanth et al., 2009) as well as concentration through 
centrifugation  and the use of magnetic beads (Albert et al., 2011).  
 
1.6.2.2 Culture-based methods 
Sputum culture remains the gold standard method for the diagnosis of active TB disease and is 
required for downstream line drug-susceptibility testing (DST), mycobacterial speciation and 
strain typing (Chegou et al., 2011).  In resource poor settings, where this technology cannot be 
afforded for every specimen, the WHO recommends that culture is performed on patients with 
suspected pulmonary TB who are repeatedly smear-negative. In addition, it is also 
recommended for drug-susceptibility surveillance as well as to confirm cases of treatment 
failure and relapse disease (WHO, 2017b).  Culture is more sensitive than microscopy and 
requires between ten and 100 viable organisms per mL of sputum (Colebunders and Bastian, 
2000, van Zyl-Smit et al., 2011). The improved sensitivity of culture in HIV-positive 
individuals was demonstrated in a review of a consecutive sample of 109 patients from 
Khayalitsha, South Africa, where 49% of patients had negative direct microscopy smears but 
positive M. tuberculosis cultures (Coetzee et al., 2004). The main limitation with respect to 
culture is that M. tuberculosis is a slow growing pathogen, requiring up to eight weeks to yield 
a positive result (Ryu, 2015, Reinisch and Kaufmann, 1961). This delay is further exacerbated 
in regions where HIV is prevalent since the incubation time is linked to the bacillary load which 
is generally reduced in HIV-positive individuals (Johnson et al., 1998, Brindle et al., 1993). 
Conventional culture involves the growth of organisms on solid media made from egg 
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[Löwenstein–Jensen (LJ)] or specialised agar (e.g. Middlebrook 7H10/11). More recently, 
automated liquid culture systems such as the MB/BacT (Biomerieux), BACTEC 9000 (Becton 
Dickinson Diagnostic Systems, Sparks, MD) and BACTEC MGIT 960 assay (Becton 
Dickinson Diagnostic Systems, Sparks, MD), have become more widely available (Pfyffer et 
al., 1997b, Pfyffer et al., 1997a, Chew et al., 1998). These systems detect growth by measuring 
changes in gas pressure, the production of carbon dioxide or the consumption of oxygen 
fluorometrically or colourimetrically.  Liquid culture systems have a faster turn-around-time 
and are more sensitive than solid culture; however, a drawback of these methods are that they 
are more prone to contamination (Hanna et al., 1999, Cruciani et al., 2004).  
 
1.6.2.2.1 Culture-based drug-susceptibility testing 
Traditionally, the procedure to determine phenotypic drug resistance was carried out using the 
proportion method with solid agar. An M. tuberculosis isolate was considered to be resistant if 
more than 1% of colonies grew on media containing a critical concentration of a particular drug 
(Canetti et al., 1969). This method is being replaced by a standardised protocol adapted for the 
BACTEC MGIT 960 (Dheda et al., 2016).  
 
 
1.6.2.3 Molecular diagnostics 
In the past, identification of M. tuberculosis from culture was made on the basis of colony 
morphology, growth characteristics and select biochemical reactions in the laboratory (Mabilat 
et al., 1994). Recently developed molecular methods have allowed for the definitive 
identification of M. tuberculosis DNA, metabolites and cell wall products from culture 
samples. These methods include nucleic acid hybridization probes, line probe hybridization 
assays, DNA sequencing and matrix-assisted laser desorption/ionisation time of flight mass 
spectrometry (Anochie et al., 2012, Ceyssens et al., 2017). Concerns regarding the severity of 
TB disease, nosocomial transmission and patient management have led to the further 
development of molecular assays that can be performed directly on patient specimens so as to 
eliminate the culture step and subsequently reduce the turn-around-time (Moore et al., 2005). 
In addition, these assays allow for the identification of common genetic mutations that lead to 
phenotypic resistance with certain first-line antibiotics. These methods include the commercial, 
WHO approved Hain MTBDRplus line probe assay (Hain Lifescience, Nehren, Germany)  and 
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nucleic acid amplification tests (NAATS), namely the GeneXpert MTB/RIF test (Cepheid 
Sunnyvale, CA) as well as the amplified M. tuberculosis direct test (MTD; Hologic Gen-
Probe), which have both received FDA approval and clearance.  
The GeneXpert MTB/RIF assay (Cepheid, Sunnyvale, CA), developed in 2004, is a PCR-based 
test that integrates DNA extraction, genomic amplification as well as the semi-quantitative 
detection of MTBC and resistance to RIF (WHO, 2014d). Resistance to RIF is determined 
using a hemi-nested PCR to amplify the resistance determining region of the rpoB gene (Helb 
et al., 2010). The test is performed in a single, commercially available cartridge that is simple 
to perform and greatly reduces the risk of contamination due to its closed amplification system. 
Initially, designed as a point of care tool, the GeneXpert MTB/RIF assay has a fast turn-around-
time, providing results within two hours. In addition, the test is simple to perform and requires 
minimal training, therefore making it an ideal diagnostic for peripheral health care facilities.  
Since 2010, the WHO has recommended the use of this test for individuals with suspected 
pulmonary disease in developing nations with a high prevalence of TB (WHO, 2014d). The 
assay has a limit of detection of 131 organisms per mL (Helb et al., 2010, Theron et al., 2011) 
and a sensitivity of 89% and 67% in smear-positive and –negative individuals with pulmonary 
TB disease, respectively (Steingart et al., 2014). Since the GeneXpert MTB/RIF assay is able 
to detect M. tuberculosis in approximately 70% of smear-negative pulmonary TB cases, it is 
an attractive diagnostic tool in the HIV-positive population (Boehme et al., 2011), particularly 
as this demographic are still capable of transmitting TB (Behr et al., 1999). However, in two 
studies the sensitivities were reported to be as low as 43 and 28% in smear-negative TB patients 
(Lawn et al., 2011, Sohn et al., 2014). The assay is also beneficial in identifying certain forms 
of EPTB disease, i.e. TB meningitis in HIV-infected individuals (Patel et al., 2013). Between 
2010 and 2016, the assay has been implemented in 130 countries with more that 23 million test 
cartridges purchased (Albert et al., 2016). This test has had a drastic impact on TB diagnosis, 
with a 3- to 8-fold increase in MDR-TB detection and testing worldwide (Albert et al., 2016). 
In 2017, the next-generation GeneXpert MTB/RIF Ultra assay (Ultra) was developed with 
improved TB detection capabilities and more definitive identification of RIF susceptibility and 
resistance (Chakravorty et al., 2017). The Ultra assay showed a 6.5% increase in sensitivity in 
clinical sputum samples (81 versus 87.5%) and a 13% increase in sputum smear-negative 
samples (78.9 versus 66.1%) when compared to the GeneXpert. Changes to the cartridge 
design, thermal cycling parametres, mutation detection chemistry and semi-quantitative 
categories are available (Chakravorty et al., 2017). The Ultra is currently being rolled-out in 
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South Africa in a phased approach, moving from Gauteng into additional provinces (WHO, 
2017c). 
While the GeneXpert is a major advancement in TB diagnostics, this assay still has several 
limitations. Firstly, it can only detect resistance to RIF. While RIF resistance serves as a marker 
for MDR-TB, the GeneXpert is unable to detect INH/RIF mono-resistance and increasing rates 
of RIF mono-resistance (RMR) have been reported (Mukinda et al., 2012, Dramowski et al., 
2012, Sanders et al., 2006). The rise in RMR-TB requires that INH resistance needs to be 
confirmed phenotypically, if genotypic RMR-TB is detected (Mukinda et al., 2012). Lastly, 
the Xpert does not provide any information with regards to resistance to any other TB drugs, 
therefore it cannot replace conventional DST (at least in its current format) which requires a 
positive M. tuberculosis culture. For these reasons, culture remains the gold standard for TB 
diagnosis as it not only confirms the presence of viable M. tuberculosis organisms, but provides 
valuable material for down-the-line DST and speciation (Ryu, 2015). Additionally, the 
GeneXpert assay can only be used as an initial diagnostic tool and not for treatment monitoring 
as the system cannot differentiate between live and dead organisms (WHO, 2014d).  
 
1.6.2.4 Other diagnostic assays  
The urine lipoarabinomannan (LAM) assay is used to detect the mycobacterial antigen, LAM, 
in urine which serves as a biomarker for active TB disease. A systematic review and meta-
analysis of seven studies reported a sensitivity and specificity range of 13 – 93 and 87 – 99%, 
respectively in microbiologically confirmed TB cases (Minion et al., 2011). The sensitivity was 
inversely correlated with CD4 count illustrating that the test is appropriate for individuals with 
advanced immunosuppression; however, the sensitivity was still suboptimal for clinical use 
(Minion et al., 2011). Whilst the LAM assay is an attractive tool for TB diagnosis in HIV-
positive and paediatric patients due to its low-cost, ease of use and point-of-care features, it is 
currently not recommended as a screening tool for active TB disease. It can however be used 
to assist in the diagnosis in individuals a CD4 count of less than 100 cells per μL or HIV-
positive patients that are extremely ill (WHO, 2015c, Lawn et al., 2009). Future promising 
diagnostic assays that require validation include the identification of volatile organic 
compounds in breath, sweat and urine (Zetola et al., 2017, Chambers et al., 2012, Banday et 
al., 2011) as well as blood-based host transcriptional profiles (Berry et al., 2010, Anderson et 
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al., 2014). For further information on other point-of-care diagnostics the reader is referred to 
an excellent review on the subject (Dheda et al., 2013). 
 
1.7 TREATMENT 
1.7.1 Drug-susceptible TB 
Treatment of drug-susceptible TB consists of a six-month, four-drug combination regimen that 
was developed more than four decades ago (Zumla et al., 2013, Kerantzas and Jacobs, 2017). 
The first two months of treatment, termed the initial phase or early bactericidal phase, 
comprises administration of four-drugs including INH, RIF, pyrazinamide (PZA) and 
ethambutol (EMB). The remaining four months of treatment, termed the continuation or 
sterilization phase, includes RIF and INH (Nahid et al., 2016). The treatment of TB with 
combination drugs is multifaceted and has three identifiable goals which include the following: 
 
1. Target the actively replicating bacilli that exist within the lung and elsewhere. This will 
ultimately reduce the bacterial load, decrease the severity of disease and reduce the 
duration of infectiousness by achieving smear- and culture-negativity. 
2. Prevent the emergence of drug-resistant strains. Treatment of TB with a single 
antibiotic may result in the selection of resistant strains leading to treatment failure and 
transmission of resistant strains within the community. Hetero-resistance, defined as 
the occurrence of both drug-susceptible and drug-resistance isolates within the same 
clinical sample has been described, and complicates treatment management (Kaplan et 
al., 2003, Post et al., 2004, Shamputa et al., 2004). 
3. Achieve complete sterilization of the infection. This is achieved through the 
‘continuation phase’ of therapy that aims to eliminate bacteria that are less 
metabolically active or ‘sporadically multiplying’ as these organisms carry the risk of 
potential relapse disease (Mitchison, 1985, Mitchison, 1979).  
 
Figure 1.4 illustrates a hypothetical model for TB chemotherapy. Overall, the treatment success 
rates using this regimen are high amongst all new TB cases (86%) (WHO, 2015a). In South 
Africa, these rates vary across the country, with high success rates reported in Uthungulu, 
Kwazulu Natal (90%), Western Cape (83%) and Johannesburg (80%) and poor success rates 
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in Limpopo (58% at provincial level and 47% in Vhembe) (Budgell et al., 2016, Day et al., 
2011).   
 
 
Figure 1.4 Hypothetical model of the bactericidal activity and sterilizing effect of first-line tuberculosis 
chemotherapy. The model depicts three populations of M. tuberculosis found in active disease. The green circle 
represents the bulk of the bacterial population. These actively replicating bacilli are present in the liquefied caseum 
of pulmonary cavities. The large numbers of organisms in this population may contribute to the acquisition of 
drug-resistant mutations in sub-optimal treatment conditions. The blue circle consists of bacteria that replicate 
more slowly due to stress factors including local acidic conditions, reduced oxygen concentration as well as the 
presence of reactive oxygen and nitrogen intermediates, amongst others. The clearance of organisms in population 
A and B during the ‘intensive’ phase of first-line treatment result in conversion to sputum smear- and culture-
negative. Adapted from Iseman et al. (2000). Drawn by Amanda McIvor. 
 
Whilst this regimen is referred to as ‘short course’, the treatment duration is long, making non-
adherence amongst patients a likely possibility. A systematic review based on 14 studies 
concluded that default was most likely to occur after the two month intensive phase and later 
during the 6-month regimen, highlighting the urgent need to shorten the current regimen (Kruk 
et al., 2008). In the 1900’s, directly observed therapy (DOTS) was implemented worldwide 
into TB control programs to encourage patient adherence and prevent resistance to RIF (WHO, 
2002, WHO, 2003). DOTS is an internationally recommended approach to TB control and is 
endorsed by both the WHO and International Union Against Tuberculosis and Lung Disease 
(WHO, 2002, WHO, 2003). DOTs has five key components which include the following: (i) 
political commitment, (ii) case detection by smear microscopy, (iii) systems to ensure a regular 
and uninterrupted supply of antibiotics, (iv) standard recording and reporting systems and (v) 
standard short course chemotherapy that is administered where patient treatment is observed 
and supervised. Various studies have yielded conflicting results of the effectiveness of DOTS 
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(Zwarenstein et al., 1998, Wright et al., 2004, Walley et al., 2001, Volmink and Garner, 1997, 
Pope and Chaisson, 2003, Newell et al., 2006). Results from a systemic Cochrane review 
concluded that DOT had no important effect on TB treatment or cure when compared to self-
administration of TB treatment (Volmink and Garner, 2007).   
 
1.7.2 Drug-resistant TB 
Treatment of MDR-TB is based on a standardised (DOTS-plus) approach and the 
recommended guidelines are outlined in Table 1.4. The regimen consists of treatment with at 
least four drugs for eight months (intensive phase) and a total treatment duration of 21 to 24 
months (WHO, 2011). The recommended treatment duration for patients with newly diagnosed 
TB (i.e. patients not previously treated for TB disease) is 20 months and can be adjusted 
depending on patient response. Treatment of MDR-TB is toxic, (Loveday et al., 2015) poorly 
tolerated, prolonged, more expensive and has a poor treatment success rate compared to drug-
susceptible TB (around 50%) (Pai et al., 2016, Liu et al., 2011, Pietersen et al., 2014, Dheda et 
al., 2014). The growing number of MDR-TB cases has led to the decentralization of treatment 
facilities to peripheral clinics which has resulted in better outcomes (Loveday et al., 2015). In 
contrast to the standardised treatment regimen employed for MDR-TB, treatment of XDR-TB 
is based on an individual approach whereby the DST results and the patients’ medical history 
is taken into account, Table 1.4. In recent years, the emergence of incurable and/or totally drug-
resistant TB (i.e. XDR treatment failures or resistance spanning beyond XDR-TB) has been 
reported in many counties including South Africa (Dheda et al., 2014). Due to the scarcity of 
long-stay treatment facilities, XDR treatment failure patients who are discharged from hospital 
can transmit untreatable strains in the community (Pietersen et al., 2014). Indeed, XDR-TB 
strains have been demonstrated to be highly transmissible (Shah et al., 2017a, Ghandi et al., 
2006, Wells et al., 2007, Moro et al., 1998, Ritacco et al., 1997, Pearson et al., 1992). These 
findings have raised many ethical, legal and logistical predicaments and debates regarding 
patient long-term accommodation as well as individual rights regarding unrestricted travel and 
work (Dheda and Migliori, 2012). Interrupting the transmission of drug-resistant and 
untreatable TB strains within the community should be a top priority of national TB control 
programmes. Furthermore, efforts to reduce this treatment regimen, limit drug-toxicity and 
promote treatment adherence are urgently required. 
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Table 1.4 Recommended treatment regimens for MDR and XDR-TB 
Treatment of MDR-TB Treatment of XDR-TB 
Use at least four drugs to which the strain is 
susceptible or likely to be susceptible (drugs that were 
included in a previous regimen for ≥ 3 months are not 
recommended; excludes PZA and EMB) (WHO, 2011) 
Regimens should be based on individual DST 
profiles and similar principles as those outlined for 
MDR-TB, i.e. the use of at least four drugs is likely 
to be successful 
Use a backbone of later-generation FQ (e.g. 
moxifloxacin or levofloxacin) and injectable drug 
(AMK, KAN or CAP)  
(WHO, 2011) 
Adverse events are associated with CAP (renal 
failure, hypokalemia, hypomagnesia and hearing 
loss) 
 (Müller et al., 2013) 
Add any first-line drug or group four drug to which 
isolate is susceptible to a ‘non-failing’ regimen 
Differential susceptibility to FQs can occur and 
genotypic susceptibility testing can be used to 
optimise the treatment regimen (clofazamine, 
linezolid and high dose-INH) (Müller et al., 2011, 
Jacobson et al., 2010). 
Injectable drugs are to be used for 6 to 8 months, and 
21 to 24 months total treatment is recommended 
(WHO, 2011)  
Group 4 and group 5 drugs can be used, but their 
effectiveness is uncertain. 
(Dheda et al., 2014) 
Oxazalidonones (linezolid) can be used for an effective 
regimen in the treatment of MDR-TB (is the isolate is 
resistant to fluoroquinolones) and XDR-TB. 
Monitoring for toxicity (neuropathy and bone marrow 
depression) is essential (Sotgiu et al., 2012, Lange et 
al., 2014, Chang et al., 2013) 
 
Bedaquiline and Delaminid can be added in cases of 
high toxicity or if high-grade resistance precludes the 
use of a four-or-more drug regimen that is likely to be 
successful. Monitoring is required since both of these 
drugs prolong QT interval* (WHO, 2014c, WHO, 
2013c) 
 
Psychosocial and financial support are required for 
adherence 
 
Patients should be monitored for adverse reactions 
which are common with the use of second-line drugs 
(Müller et al., 2013) 
 
A single drug should not be added to a failing regimen  
Abbreviations: MDR-TB = multidrug-resistant TB; XDR-TB = extremely drug resistant TB; DST = drug 
susceptibility testing; INH = isoniazid; PZA = pyrazinamide; EMB = ethambutol; AMK = amikacin; CAP = 
capreomycin; KAN = kanamycin; * QT interval: In cardiology, a QT interval is defined as a measure of the time 
between the start of the Q wave and the end of the T wave in the hearts electrical cycle. Adapted from (Dheda et 
al., 2016)  
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1.7.3 New drugs  
After many years of stagnation, promising new TB drugs are under clinical development and 
are summarised in Table 1.5. Two of these drugs, namely Bedaquiline and Delamanid, have 
been registered for the treatment of drug-resistant TB. Other drug candidates currently in 
clinical trials initially used to treat other infectious diseases have shown efficacy against M. 
tuberculosis. Examples of these repurposed drugs include the later generation fluoroquinlones 
(i.e. moxifloxacin, levofloxacin and gatifloxacin), the oxazolidinones, linezolid and sutezolid 
as well as clofazamine (initially used in the treatment of leprosy). Advances in new TB drugs, 
treatments and algorithms are reviewed extensively elsewhere (Zumla et al., 2013). 
 
Table 1.5 New chemical entities for the treatment of tuberculosis 
Antibiotic Approval Mechanism of action 
Genes associated with 
resistance 
Bedaquiline/ TMC 207 
(class: diarylquinolone) 
Yes  
USA (FDA), European 
Union (EMA), Russian 
Federation 
(Pharmstandard), South 
Korea (MFDS) and 
South Africa (MCC) 
Inhibition of M. 
tuberculosis ATP 
synthase 
atpE gene mutation 
encoding subunit C of 
ATP synthase; 
Mutations in Rv0678 
coding for repressor of 
M. tuberculosis efflux 
pump 
Pretomanid/ PA-824 
(class: nitroimidazole) 
None 
Inhibition of mycolic 
acid biosynthesis and 
generation of 
mycobactericidal 
nitrogen oxide 
derivatives (dormant M. 
tuberculosis) 
Mutation in fbiA, fbiB 
or fbiC lead to impaired 
coenzyme F420 
synthesis; Mutation in 
Rv3547 coding for 
deazaflavin-dependent 
nitroreductase (inhibit 
activation of pro-drug) 
Delamanid/ OPC 67683 
(class: nitroimidazole) 
European Union (EMA) 
Inhibits mycolic acid 
biosynthesis 
Mutation in 
mycobacterial Rv3547 
prevents activation of 
drug 
SQ-109 (class: diamines) None 
Inhibits mycobacterial 
cell wall synthesis, 
specifically targeting the 
transmembrane 
transporter, encoded by 
the mmpl3 gene  
Possibly mutation in 
mmpl3 gene? 
Abbreviations: FDA = Food and Drug Administration; EMA = European Medicines Agency; MFDS = Ministry 
of Food and Drug Safety; MCC = Medicines Control Council. Table adapted from Dheda et al. 2016. 
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1.7.4 Prophylaxis 
Preventative treatment aims to eliminate LTBI before reactivation disease occurs and forms a 
significant component of the WHO’s post-2015 strategy to eliminate TB disease (WHO, 
2013a). In high burden settings such as South Africa, preventative therapy is generally 
restricted to high risk populations, including HIV-positive individuals and children under the 
age of five who have household contacts with active disease. In low burden countries, 
immigrants with LTBI are targeted for preventative therapy. Generally, low burden countries 
such as the USA, prefer preventative therapy than mass vaccination with BCG of new born 
infants which is practised in South Africa. The identification of biomarkers that are able to 
identify ‘high risk’ individuals with LTBI that are likely to develop active TB disease is an 
important area of research. The identification of these individuals would target them for 
preventative therapy ultimately reducing the pool of latently infected individuals and protecting 
the greater population. It is however important to rule out active TB disease before 
administering preventative treatment as this may result in the acquisition of drug resistance.  
 
1.8 PREVENTION AND CONTROL IN SOUTH AFRICA 
The national tuberculosis treatment program (NTP) was established in 1994 with the goal of 
integrating TB services into primary healthcare systems (Karim et al., 2009, Churchyard et al., 
2014). The NTP was confronted with multiple challenges including the emergence of the HIV 
epidemic and the increasing burden of MDR and XDR-TB strains. To combat this dual 
epidemic of TB and HIV, the National Strategic Plan for HIV, sexually transmitted infections 
(STIs) was developed in South Africa (2012 – 2016) to halve the incidence and mortality due 
to TB disease by 2016 and to eliminate all new TB infections, death and stigma by 2032 
(Churchyard et al., 2014). The three main strategies to achieve these goals include Find, Treat 
and Prevent (Churchyard et al., 2014). These are detailed further below.  
 
1.8.1 Find 
The identification of patients who are infectious is a key priority in the control of TB disease. 
To identify these patients, South Africa has an extensive network of microscopy centres and 
diagnostic laboratories, some of which are equipped with the facilities to perform culture and 
DST (Churchyard et al., 2014). In 2011, the GeneXpert was introduced with the intention of 
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ultimately replacing smear microscopy. In addition to identification of infectious individuals, 
an additional strategy specified by the CDC also includes the identification and treatment of 
persons who are non-infectious. Examples of patients who are non-infections include those 
with EPTB disease, primary pulmonary disease (in children), bacteriologically unconfirmed 
cases of pulmonary disease (i.e. subclinical disease) and LTBI (CDC, 1988). An additional 
component of ‘Find’ includes case finding and contact tracing (Palomino et al., 2007). In low 
TB prevalent countries, such as the USA, a great deal of emphasis is placed on contact tracing; 
however, in high burden countries such as RSA, contact tracing remains a significant challenge. 
 
1.8.2 Treat 
In South Africa, the introduction of community-based tracing teams has led to a significant 
improvement in the treatment success rates in both smear-positive and –negative/EPTB cases 
(79 and 76%, respectively) (Churchyard et al., 2014). The treatment success rates among 
retreatment cases is poorer at 66.3%.  Loss to follow-up remains a major challenge where up 
to 25% of patients do not start treatment and continue to transmit M. tuberculosis in the 
community (Claassens et al., 2013). In addition to treating TB, it is important that HIV-infected 
patients are placed on anti-retroviral medication and these patients are not lost to follow-up 
(Dalal et al., 2008). 
 
1.8.3 Prevent  
The prevention of TB constitutes a neglected area of TB control in South Africa. Examples for 
the prevention of TB disease include the following: (i) screening of high risk individuals to 
improve case detection, (ii) treatment of LTBI with isoniazid preventative therapy, (iii) 
infection control, (iv) early ART initiation for HIV-positive individuals and (v) TB vaccination 
programmes.  
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1.9 KNOWLEDGE GAPS RELATED TO THIS PhD: 
The long duration of therapy required to cure TB disease remains one of the core challenges to 
eradicating this disease. It is believed that this protracted treatment stems from the ability of 
M. tuberculosis to achieve a non-replicating state in the host, thereby establishing sub-
populations of bacteria that are difficult to eradicate. As the majority of TB drugs are only 
effective against actively replicating organisms, these organisms can become phenotypically 
resistant to many of these drugs. In this thesis, the non-replicating of state of M. tuberculosis 
in patients with drug-susceptible, active pulmonary disease was investigated. Chapter two 
includes a literature review of these non-replicating states in M. tuberculosis as well as other 
bacterial organisms. Furthermore, other pathogenic organisms that are able to persist in the 
host are discussed. A further issue addressed in this thesis is the long duration of culture. To 
address this, methods to reduce the time to culture diagnosis, particularly in HIV-positive 
individuals, were investigated.  
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CHAPTER 2 
MICROBIAL DORMANCY 
“Counsel: I beg your pardon m’lud. 
Judge: Well, I mean, your witness is dead. 
Counsel: Yes m’lud. Er, well, er, virtually, m’lud. 
Judge: He’s not completely dead? 
Counsel: No, he’s not completely dead m’lud. No. But he’s not at all well.” 
      Monty Pythons Flying Circus, Episode 3, Court Scene 
 
2.1 THE GREAT PLATE COUNT ANOMALY 
In 1985, a concept known as the “great plate count anomaly” was described by scientists, Staley 
and Kanopka (Staley and Konopka, 1985). This phenomenon illustrated the discrepancies 
observed between the numbers of cells that can be viewed under a microscope, which are orders 
of magnitude greater than the number of viable organisms that can be cultured in the laboratory 
under certain conditions. These observations illustrate that bacterial organisms isolated in pure 
culture form are not representative of the true biodiversity that occurs in the natural environment. 
In fact, the organisms that are culturable represent less than 1% of all microbial species and have 
previously been described as the ‘weeds’ of the microbial world (Hugenholtz, 2002), Figure 2.1. 
These observations, in association with morphological, microbiological and molecular evidence, 
suggest that a large proportion of these organisms are in a metabolically inactive or dormant state 
when trying to recover them in the lab.  
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Figure 2.1 The great plate count anomaly. Plate cell counts obtained by cultivation (right) are orders of magnitude 
lower than cell counts observed under the microscope (left). Figure adapted from: 
https://commons.wikimedia.org/wiki/File:Great-plate-count-anomaly.svg. Figure drawn by Amanda McIvor.  
 
2.2 TERMINOLOGY AND DEFINITIONS 
In nature, harsh and unpredictable environments often result in conditions that are not favourable 
for growth and reproduction. When subjected to these conditions, many taxa, including 
microorganisms, have evolved mechanisms to ensure their survival by entering into a reversible 
state of low metabolic activity or dormancy to reduce energy expenditure and increase preservation 
of the genotype (Guppy and Withers, 1999). These metabolically inactive states are most likely 
responsible for the large microbial bio-diversity whereby repeated transitions to and from the ‘seed 
bank’ preserve the taxonomic richness of many ecosystems (Jones and Lennon, 2010, Lennon and 
Jones, 2011, Stevenson, 1977). Definitions of terms relating to these states of low metabolic 
activity in the laboratory and in disease and pathogenesis are commonly encountered in the 
literature are outlined in detail below: 
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2.2.1 Dormancy 
Dormancy can be broadly defined as a ‘reversible state of low metabolic activity in which cells 
can persist for extended periods without division’ (Kell and Young, 2000).  Dormancy is a 
phenotype of the bacilli and common term that is used across many disciplines, extending from 
botany (i.e. seeds and buds) (Soppe and Bentsink, 2016) to cancer research (Wheelock et al., 1981, 
Sosa et al., 2014), where tumours can enter into a state of dormancy and non-proliferation. In the 
microbial world, the spore is the most often cited form of dormancy. In some bacterial species, for 
example Bacillus spp. and Clostridium spp., asymmetric cell division can occur in response to 
growth-restrictive conditions whereby a hardy and inactive daughter cell, termed a spore, is 
produced (Stragier and Losick, 1996). Sporulation is a complex process that occurs in response to 
nutritional deficiency, inhibition of GTP synthesis or stationary growth where a defined and 
enriched medium is exhausted. Sporulation is tightly regulated and involves transcriptional and 
subsequent morphological changes that result in the formation of a biologically resilient and robust 
spore (Dworkin and Shah, 2010). A defining characteristic of the spore morphotype is a thick 
protective coat made of unique glycoproteins, equipping the organism with a ‘damage-proof’ 
phenotype, rendering the spore resistant to heat, radiation, desiccation, antibiotics and other forms 
of external pressure (Setlow, 2011).  Spores can remain dormant for many years and possess the 
ability to re-enter a vegetative state when conditions that favour growth prevail. Much interest in 
germination of spores stems from food spoilage and foodborne disease, and their role in infectious 
disease (for e.g. Bacillus anthracis and pulmonary anthrax). Few reports have suggested that M. 
tuberculosis and close relatives are able to form spore-like structures (Ghosh et al., 2009, Csillag, 
1961, Singh et al., 2010), although these results have not been reproducible (Traag et al., 2010). 
Consequently, the use of this term in the TB field is fraught with problems as there is neither strong 
evidence for or against the formation of specialist spore-like morphotypes in mycobacteria. 
 
2.2.2 Microbial seed bank 
Dormancy results in the generation of a seedbank, which has been defined as ‘a reservoir of 
dormant individuals that can potentially be resuscitated in the future under different environmental 
conditions’ (Lennon and Jones, 2011). From an ecological perspective, seedbanks are essential as 
they maintain biodiversity (i.e. allow for competing organisms to coexist), preserve community 
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stability, influence fundamental evolutionary processes and safeguard organisms from extinction 
following perturbation events (Lennon and Jones, 2011, Locey et al., 2017, Aanderud et al., 2015, 
Wang et al., 2015, Shoemaker and Lennon, 2018). While macroscale factors such as nutrient and 
resource limitation were understood to govern the transitions to and from dormancy (Lennon and 
Jones, 2011), microscale factors including the spatial structure of the environment and trophic 
complexity have also been implicated in seedbank dynamics (Locey et al., 2017).  
 
2.2.3 The viable but non-culturable state and cellular quiescence 
The ‘viable but non-culturable state’ (VBNC) or cellular quiescence are both terms used in the 
literature to describe cells that fail to grow under standard culture and laboratory conditions and is 
similar to dormancy however, some cases of VBNC have been associated with measurable 
metabolic activity, maintenance of membrane potential and no drastic morphological 
differentiation (Mukamolova et al., 2003, Rao et al., 2008, Gengenbacher et al., 2010, Rittershaus 
et al., 2013). This state is reversible and cells are able to resuscitate and resume normal metabolic 
activity when subject to a subset of conditions such as nutrient rich medium or culture filtrate (CF) 
from growing cells (Dworkin and Shah, 2010). There is however some controversy where the 
terms dormancy and VBNC are used interchangeably to describe the same physiological state. The 
VBNC state was first described in  Vibrio cholera and Escherichia coli (Xu et al., 1982) and has 
subsequently been described in numerous bacterial human pathogens including Campylobacter 
spp. (Cappelier et al., 1999), Listeria monocytogenes (Besnard et al., 2000), Helicobacter pylori 
(Adams et al., 2003), Mycobacterium tuberculosis (Shleeva et al., 2002, Mukamolova et al., 2010), 
Enterococcus faecalis (Figdor et al., 2003), Salmonella spp. (Morishige et al., 2013, Cho and Kim, 
1999, Waldner et al., 2012), Legionella pneumophila (Faulkner and Garduño, 2002), Micrococcus 
luteus (Mukamolova 1998) and Vibrio vulnificus (Whitesides and Oliver, 1997, Oliver and 
Bockian, 1995) to name a few.  
 
2.2.4 Tolerance and persistence 
Bacterial tolerance refers to the ability of cells to survive killing by antibiotics without expressing 
or using genetic resistance mechanisms (Lewis, 2007). In this case, bacteria may exist in a state 
where the drug target is not vulnerable but other areas of metabolism are active. Persister cells 
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were originally described in 1944 by Bigger, who made the observation that in a growing 
population of Staphylococcus spp., a subpopulation of cells that were not genetically penicillin-
resistant, displayed increased tolerance in the presence of this antibiotic, while others died (Bigger, 
1944). When transferred to fresh medium, the population expanding from these penicillin-tolerant 
organisms were now susceptible (Bigger, 1944).  It was proposed that the penicillin-tolerant 
populations of Staphylococcus were dormant and non-dividing however, as the observation 
became more frequently reported, the term persister became widely used. Other terms commonly 
used to describe these populations include ‘phenotypically resistant’ as well as ‘phenotypically 
tolerant’. In 1957, persistence was described in M. tuberculosis to two different antibiotics: INH 
and para-aminosalicylate (Hobby and Lenert, 1957). As the mechanism of action of these two 
compounds, along with penicillin, are unique (i.e. INH inhibits mycolic acid synthesis, para-
aminosalicylate inhibits folate synthesis and penicillin targets peptidoglycan synthesis), 
persistence was shown to be independent from the antibiotic used and its associated pathway (Gold 
and Nathan, 2017).  As persister cells constitute only a small percentage of the total population, 
there have been suggestions that persistence is a form of kin selection (Lewis, 2007, Lennon and 
Jones, 2011, Balaban et al., 2004, Avery, 2006, Gardner et al., 2007). Therefore, in the presence 
of a lethal agent, such as antibiotics, whereby most of the population is killed, these persister cells 
can propagate to restore the population containing the genome that they shared with their kin. For 
more detailed information, excellent reviews of the biology of persister cells and insights into their 
role in infectious diseases are available (Lewis, 2007, Gold and Nathan, 2017).  
 
2.3 STAGES OF MICROBIAL DORMANCY 
2.3.1 Initiation 
There are two ways in which cellular dormancy can be triggered, namely responsive and 
spontaneous initiation (Lennon and Jones, 2011). In terms of responsive initiation, the transition 
to the dormant state occurs in response to environmental cues, such as changes in abiotic factors 
(i.e. temperature, pH, osmotic pressure and light) and/ or nutrient limitation/starvation. 
Microorganisms can detect changes in the environment (abiotic factors) via membrane-bound 
histidine kinase sensors (Lennon and Jones, 2011). These changes elicit an intracellular cascade 
of events that ultimately lead to alterations in gene expression and subsequent modifications in 
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protein synthesis (Mascher, 2006). Furthermore, nutrient limitation, involving intracellular 
depletion of amino acids, fatty acids and carbon sources, can trigger a stringent response (Aertsen 
and Michiels, 2004). Spore formation is an example of responsive dormancy initiation and 
involves a tightly regulated process that requires a great deal of energy investment. Sporulation 
has been described in members of the Bacillus and Clostridium genus as well as certain Fungi 
(Paredes-Sabja et al., 2011, Piggot and Hilbert, 2004, Olguín-Araneda et al., 2015, Sloan et al., 
1960, Errington, 1993, Paredes-Sabja and Sarker, 2009). Briefly, the transition of B. subtilis from 
the vegetative state to form an endospore is controlled by the master transcriptional regulator, 
Spo0A. The transcriptional activity of SpoA in turn is activated by a ‘phosphorelay’ system 
consisting of five histidine kinases (KinA-E) (Tan and Ramamurthi, 2014). Ultimately, activation 
of Spo0A leads asymmetrical division of the cytoplasm resulting a mother cell and smaller 
forespore, both of which ultimately have different fates (Tan and Ramamurthi, 2014).  
In some organisms, the switch from the vegetative state to the dormant state occurs spontaneously. 
It has been proposed that spontaneous switching is favoured under stable environmental 
conditional, whereas responsive switching is the preferred mechanism in fluctuating 
environmental conditions (Kussell and Leibler, 2005). Spontaneous switching has three distinct 
advantages over responsive switching: (i) organisms avoid the cost of active sensory machinery 
required for sensing the environment, (ii) these cells represent an “insurance policy” that allows 
for population survival in stochastic perturbation events and (iii) reduced growth rates of these 
sub-populations can indirectly benefit other bacteria by reducing the competition for limited 
nutrients or resources (Gardner et al., 2007, Avery, 2006, Dubnau and Losick, 2006). Persister 
cells are a good example of spontaneous responsiveness (Lennon and Jones, 2011). 
 
2.3.2 The resting cell 
A wide variety of dormant phenotypes exist in the microbial world, some of which have evolved 
drastic morphological changes such as spores (e.g. Bacillus and Clostridium spp.), conidia (e.g. 
Aspergillus fumigatus), cysts or akinetes (thick wall resting structures) (e.g. Cylindrospermum 
spp.). Additional phenotypes include a reduction in cell size to form ‘dwarf’ cells (Stevenson, 
1977, Oliver, 2000, Porter et al., 1995), and coccoid forms (Shleeva et al., 2002, Boucher et al., 
1994, Pascoe et al., 2014). While quiescent cells exhibit a wide array of morphological phenotypes, 
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these cells share some common features. One such feature is the accumulation of carbon stores 
(Rittershaus et al., 2013). For example, many bacterial species, including M. tuberculosis, store 
fatty acids such as triacylglycerides (TAGS) or wax esters (WE) in the VBNC or persistent state 
(Garton et al., 2008, Daniel et al., 2004, Kalscheuer et al., 2007). Carbon storage has also been 
reported in the yeast cell, Saccharomyces cerevisiae that accumulates carbon in the form of 
glycogen, trehalose and TAGS during low growth rates (Gray et al., 2004) and pathogenic Vibrio 
cholera that utilises glycogen stores to prolong survival under nutrient-poor conditions (Bourassa 
and Camilli, 2009). It is hypothesized that these carbon stores are important source of energy 
reserves for survival during dormancy and for regrowth when environmental conditions improve. 
Evidence for these carbon stores as a fuel source for re-growth following cellular quiescence has 
been demonstrated in the budding yeast, S. cerevisiae. Upon exit from quiescence, the trehalose 
stores that accumulated in stationary phase cultures are utilised as an energy source to initiate 
growth. Furthermore, Δtps1 mutants (i.e. cells that could not synthesize trehalose) displayed 
reduced growth rates and survival (Shi et al., 2010). 
A noteworthy feature of quiescent cells is modification of the cell wall. Virtually all bacteria are 
surrounded by peptidoglycan (PG), an elastic-like meshwork that conserves the cellular integrity 
of the organism under changing environmental conditions. PG is a complex polymer that consists 
of long glycan strands of the repeating disaccharide N-acetyl glucosamine- N-acetyl muramic acid 
(NAG-NAM), which are cross-linked via penta-peptide stem chains. Numerous studies have 
shown alterations in the structural composition of PG in replicating versus non-replicating bacteria. 
For example, E. coli grown to stationary phase exhibits both an increase in absolute PG content 
(Mengin-Lecreulx and van Heijenoort, 1985) as well as an increase in pentaglycine bridges (cross-
linking the glycan chains) (Dougherty and Pucci, 1994). Furthermore, in E. coli, changes in the 
type of cross-links in the PG stem peptides have been reported in declining growth rates where 
under logarithmic growth conditions, 4 → 3 inter-peptide linkages are produced but in late 
exponential phase, 3 → 3 inter-peptide linkages occur (Goffin and Ghuysen, 2002). Changes in 
the level and gradient of PG cross-linking during stationary phase has also been reported in S. 
aureus where fewer pentaglycine cross bridges are present, the cell-wall is significantly thicker 
than in log-phase cultures (Zhou and Cegelski, 2012).  Changes in the cell-wall and the degree of 
PG cross-linking are also important in spore formation (Atrih et al., 1996). Cell wall modification 
in M. tuberculosis is discussed in detail in section 2.5.2.4.  
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Additional features of quiescent cells include reduced energy expenditure and primary 
metabolism. While bacterial endospores are metabolically inert (Setlow, 1995), quiescent cells 
require energy to support non-growth functions as well as to maintain their membrane potential 
for ATP synthesis (Lennon and Jones, 2011, Morita, 1982, Van Bodegom, 2007, Rao et al., 2008). 
Indeed, in non-replicating M. tuberculosis cells, ATP levels are maintained constantly at levels 
approximately 5-fold lower than those measured in actively dividing cells (Rao et al., 2008). Other 
features of quiescent organisms include macromolecular synthesis and mechanisms for stability 
and preservation of genome integrity (Rittershaus et al., 2013). 
 
2.3.3 Exit from dormancy 
Similar to adopting the dormant state, exit from dormancy can occur stochastically or in response 
to environmental cues. An increase in the availability of environmental resources allow endospores 
to undergo a process of germination. These so-called ‘germinants’, tend to be low-molecular-
weight compounds (i.e. single amino acids, sugars or purine nucleotides) that bind to receptors in 
the inner membrane of spores (Setlow, 2003). This interaction leads to enzymatic activity and 
hydrolysis of the PG layer of the spore cortex, followed by vegetative outgrowth of the cell 
(Setlow, 2003, Rittershaus et al., 2013). Stochastic emergence has been reported in non-spore 
forming organisms including E. coli (Balaban et al., 2004), M. smegmastis (Buerger et al., 2012b), 
and to a lesser degree in the spore forming B. subtilis (Paidhungat and Setlow, 2000). In addition 
to sensing environmental cues, bacteria can also exit dormancy in response to signals released by 
growing bacteria (Votyakova et al., 1994, Kaprelyants and Kell, 1996, Dworkin and Shah, 2010) 
For example, B. subtilis germination occurs in response to muropeptides release from growing B. 
subtilis cells (Shah et al., 2008).  
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2.4 CELLULAR QUIESCENCE AND INTRACELLULAR HUMAN PATHOGENS 
Treponema pallidum (Syphilis), Borrelia borgdoferia (Lyme disease), Coxiella burnetii (Q fever), 
Chlamydia spp. (range of chronic infections) and M. tuberculosis are examples of intracellular 
human pathogens that are able to persist within the human host for many years without causing 
disease. It is thought that the dormant intracellular state adopted by these organisms is responsible 
for the asymptomatic, latent stage of disease and also facilitates pathogenesis. For example, B. 
borgdoferia, the causative agent of Lyme disease, can exist in the form of spirochete round bodies 
when environmental conditions that are not conducive for growth (Sapi et al., 2011, Brorson et al., 
2009). It is thought that these round bodies facilitate the persistence of this pathogen in the host. 
Chlamydia spp. are obligate human pathogens with a unique developmental lifecycle. These 
species can exist as inert, metabolically inactive elementary bodies (EB), facilitating their uptake 
by the host cell following infection. The EB remains in a host-derived vacuole (termed the 
inclusion) after which they are able differentiate into larger and metabolically active reticulate 
bodies (Hogan et al., 2004). Various line of evidence (for example, disease recurrence and in-vitro 
studies investigating persistence) suggest that these species are able to persist in altered states in 
the host during chronic infection, and it is supposed that the EB form is responsible for long-term 
infection. Indeed, EBs are induced following exposure to antibiotics and cytokines, as well as in 
response to nutrient depletion (Hogan et al., 2004, Harper et al., 2000).   
Latency is a clinical term used to describe asymptomatic M. tuberculosis infection and was defined 
by Amberson as ‘the presence of any tuberculous lesion which fails to produce symptoms in its 
presence’ (Amberson Jr, 1938). LTBI is established by the arrest of mycobacterial growth prior to 
the onset of disease or the spontaneous resolution of primary TB disease (Gomez and McKinney, 
2004). In most individuals, a cell-mediated immune response is able to arrest disease progression 
at the site of infection, i.e. the Ghon complex (Ghon, 1923). LTBI is the typical outcome for the 
majority of individuals exposed to M. tuberculosis and chronic infection is likely to persist in the 
absence of antibiotic intervention. Following years or decades of subclinical persistence, 
reactivation disease can occur in approximately 10% of cases resulting in active disease and 
possible transmission (Selwyn et al., 1989, Selwyn et al., 1992). As mentioned previously, it 
remains unclear whether LTBI is characterised by a population of non-replicating, dormant-like 
bacilli.  
 
 
58 
 
2.5 MYCOBACTERIUM TUBERCULOSIS: LATENCY, ACTIVE DISEASE, THE VBNC 
STATE AND RESUSCITATION  
M. tuberculosis has immune-evading capabilities that enables this organism to survive and persist 
in the host environment for extended periods of time in the form of LTBI before converting to 
active, contagious disease (Peddireddy et al., 2017, Gengenbacher and Kaufmann, 2012). In the 
mammalian host, M. tuberculosis infection occurs via the inhalation of airborne droplet nuclei that 
end up in the lodged in the alveoli where infection is initiated (Kaufmann, 2001). Following 
infection, these bacteria are subsequently phagocytosed by alveolar macrophages which serve as 
the host’s primary defence mechanism against invading pathogens (Russell et al., 2009). Inside 
the phagosome, M. tuberculosis is subjected to severe environmental conditions that include 
increased acidification, exposure to reactive oxygen and nitrogen species (ROS and RNS)  as well 
as hydrolytic enzymes and antimicrobial peptides (Flannagan et al., 2009, Nathan and Shiloh, 
2000, Huynh and Grinstein, 2007). Therefore, in order to ensure survival, the tubercle bacillus is 
equipped with a high metabolic plasticity that enables it to switch to an altered state of non-
replicating persistence until conditions are favourable to revert to normal replication, resulting in 
reactivation disease.  It is now generally well accepted that M. tuberculosis organisms co-exist at 
different stages of replication during both LTBI and during active disease (Barry et al., 2009). 
Evidence to support this heterogeneous state can be explained by the use of INH as a successful 
chemo prophylactic treatment of LTBI in various developed countries. The mechanism of action 
of INH involves the inhibition of cell wall synthesis and thus only targets replicating organisms. 
These observations imply that M. tuberculosis converts to an INH-susceptible state at some point 
during latent infection (Fox, 1999). Presently, the factors that control the progression from LTBI 
to active disease or the factors that maintain the equilibrium between these two states remains 
poorly understood. Various hypotheses have been suggested and are discussed in further detail 
below. 
 
2.5.1 The ‘scout’ hypothesis 
An attractive model termed the microbial ‘scout’ hypothesis describes the equilibrium between 
dormant and replicating organisms and their association with the transition from LTBI to active 
TB disease (Epstein, 2009b, Epstein, 2009a, Gengenbacher and Kaufmann, 2012). In LTBI, where 
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the vast majority of bacteria are hypothesized to exist in a dormant state, few organisms resuscitate 
stochastically and independent from environmental cues. These ‘scouts’ or newly active cells sense 
the environment for available resources and conditions conducive for growth. In adverse 
environments (i.e. chemotherapeutic treatment, host immunity or lack of available resources) the 
scout will die, thus preserving the vast majority of the population that will remain in a dormant 
state. In an on-going process, it appears that at random a small fraction of the dormant population 
will successively resuscitate in turn to become scouts. If a scout forms under conditions that are 
permissible for survival and growth, this organism will elicit biochemical signals, possibly 
resuscitation-promoting factors (Rpfs), that will alert the non-replicating population to re-emerge 
and multiply, thus achieving the ultimate goal of proliferation of the species (Epstein, 2009b, Chao 
and Rubin, 2010, Buerger et al., 2012b, Buerger et al., 2012a). The resuscitation and replication 
of these organisms will ultimately tip the scales of the balance, causing the transition from a 
‘controlled’ LTBI to pathology and reactivation disease. In active disease, the majority of the 
population will actively divide; however, a small percentage of the population will remain 
dormant, which may explain the presence of a persister population that is tolerant, requiring longer 
periods for eradication (Lewis, 2010, Lewis, 2007). Following treatment completion, the 
remaining non-replicating population will be undetected by conventional culture methods 
suggesting clinical cure and that sterilization and eradication of M. tuberculosis has been achieved. 
The stochastic awakening of M. tuberculosis cells that survived treatment and were not eliminated 
by the immune system are possibly responsible for recurrent TB disease due to relapse. In light of 
the above, recurrent disease due to reinfection could also result in active TB disease and possibly 
a mixed strain infection, if residual bacteria remain viable after the first episode of TB. For 
example, the inhalation of a new M. tuberculosis strain into a host with LTBI may send signals to 
awake the remaining ‘dormant’ population, from a previous infection, leading to reactivation 
disease (McIvor et al., 2017). One line of evidence to support this is that disease attributable to 
reinfection after successful treatment completion is four times higher than that attributable to new 
disease (Verver et al., 2005). However, many factors contribute to this increased susceptibility to 
a second (or subsequent) episode of TB infection such as lung damage as well as the hosts’ genetic 
predisposition. Further work is needed to associate this phenomenon with pre-existing, non-
replicating bacteria. Experimental observations in support of the scout hypothesis were illustrated 
by the revival of environmental cells and spores [including Bradyrhizobium and Mycobacterium 
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spp. (non-spore forming) and Bacillus and Streptomyces (spore forming)] as well as in model 
microbial species (Escheria coli and Mycobacterium smegmatis) (Buerger et al., 2012b).  
 
 
Figure 2.2 Schematic representation of the scout hypothesis. Latent tuberculosis infection (LTBI) is characterized 
by predominantly non-replicating bacilli (red). Few active scouts (blue) spontaneously resuscitate to sense whether 
environmental conditions are conducive for growth. Under favourable conditions, i.e. in caseous/necrotic granulomas, 
scouts release biochemical signalling molecules such as resuscitation-promoting factors (Rpfs), and possibly other 
molecules, that signal non-replicating bacilli to become active and in-turn, also release similar stimulator molecules. 
In active TB disease, the majority of the population are actively dividing (green); however, a small proportion of the 
population remain in a non-replicative and phenotypically tolerant state. These organisms are likely responsible for 
the long treatment period required to cure active TB disease. In active TB disease, bacilli are transmitted via high 
velocity exhalation manoeuvres such as coughing. The bio-aerosol cloud expectorated from a diseased individual 
possibly contains a mixture of actively dividing and non-replicating bacilli, of which the latter can be detected using 
specialised culture methods. Adapted from Gengenbacher and Kaufmann et al. 2013. Drawn by Amanda McIvor.  
 
2.5.2 Phenotypic characteristics of non-replicating Mycobacterium tuberculosis 
Non-replicating/persisting tubercle bacilli exhibit unique phenotypic characteristics that include 
tolerance to antibiotics, loss of acid fastness, inability to form colonies on solid media and the 
accumulation of TAG lipid droplets that may possibly be utilized as an energy source during 
dormancy and reactivation disease. These characteristics are discussed below. 
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2.5.2.1 Accumulation of lipid bodies 
Auramine-Nile Red labelling has demonstrated the presence of lipid inclusion bodies in M. 
tuberculosis populations derived directly from patient sputum samples. The frequency of these 
lipid-body positive (LBP) cells ranged from 3 to 86% (2 to 8 lipid bodies per cell) in 82 patients 
from the Gambia and the UK (Garton et al., 2008). These results indicate that LBP tubercle bacteria 
are a commonly observed in smear positive patients. Consistent with this, the same study revealed 
that M. tuberculosis grown under hypoxic conditions enters into a drug tolerant, non-replicating 
state and accumulate lipid inclusion bodies (Garton et al., 2008). In a separate study, an in-vitro, 
multiple stress assay employing low oxygen (5%), high CO2 (10%), low nutrient (10% Dubos 
medium) and acid pH (5.0) resulted in the accumulation of storage lipids (both TAG and WE) in 
M. tuberculosis cells (Deb et al., 2009). Measurement of gene transcript levels of M. tuberculosis 
subjected to these stress conditions indicated the up-regulation of several TAG and WE genes, 
including tgs1 (Deb et al., 2009). The tgs1 deletion mutant failed to accumulate TAG, which was 
restored following complementation with tgs1 under the same multiple stress conditions (Deb et 
al., 2009). The accumulation of these lipids suggests that they serve as an important carbon source 
during periods of non-replication and reactivation. Evidence for the use of TAGs for regrowth was 
shown in M bovis BCG, where entry and exit from hypoxia-induced dormancy was accompanied 
by the appearance and disappearance of intracellular lipid particles, respectively (Low et al., 2009). 
Furthermore, the deletion of both (but neither one alone) isocitrate lyase (ICL) genes (icl1 and 
icl2) in M. tuberculosis resulted in complete impairment of intracellular replication in 
macrophages and rapid elimination from the mouse lung (Munos-Elias and McKinney, 2005). 
Since ICL is a key metabolic enzyme in fatty acid utilization, these findings provide further 
evidence that mycobacteria use fatty acids (as opposed to only carbohydrates) as a carbon source 
during infection. ICL inhibitors may therefore serve as a novel therapeutic in the treatment of TB. 
In work involving clinical strains, the upregulation of DosR, the so-called “dormancy” regulon, 
along with the concomitant accumulation of TAGs in W-Beijing strains has been suggested as an 
adaptive strategy for these strains in the stressful environments encountered during infection (Reed 
et al., 2007). Indeed Beijing strains, that are globally distributed, have been associated with 
outbreaks, drug resistance and hyper-virulence (Cowley et al., 2008, Hanekom et al., 2007, Bifani 
et al., 2002). The link of Beijing 2 strains with relapse (Lan et al., 2003, Burman et al., 2009) may 
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therefore be associated with the ability of these strains to adapt non-replicating states, providing 
this organisms with an adaptive advantage against immune assault and/or drug treatment.  
 
2.5.2.2 Drug tolerance 
As previously discussed, the occurrence of sub-populations of non-replicating bacilli during active 
TB disease are thought to be responsible for the prolonged treatment period required. Indeed, non-
replicating mycobacteria generated by environmental stressors (i.e. low oxygen, nutrient starvation 
or nitric oxide exposure) in-vitro, show tolerance to antibiotics (Gengenbacher et al., 2010, Rao et 
al., 2008, Xie et al., 2005, Hussain et al., 2009, Gold and Nathan, 2017). The phenomenon of 
phenotypic drug tolerance and its association with non-replicating tubercle bacilli were compared  
using ten anti-tuberculous compounds (Sarathy et al., 2013). With the exception of two compounds 
(i.e. mefloquine and thioridazine), a drastic decrease in drug susceptibility was observed in nutrient 
starved, non-replicating M. tuberculosis H37Rv cells when compared to replicating cells. In line 
with this, the accumulation of intracellular drug levels (measured by liquid chromatography 
coupled with mass spectrophotometry) was lower in non-replicating organisms for the majority of 
drugs tested (Sarathy et al., 2013). In a recent publication, M. tuberculosis bacilli residing in the 
cavity caseum from rabbits were shown to exhibit extreme tolerance to many first- and second-
line drugs (Sarathy et al., 2018).  
 
2.5.2.3 Loss of acid fastness 
ZN microscopy is a widely utilised diagnostic for TB disease; however, many patients that are ZN 
negative still have clinical signs of disease or are positive for disease via other diagnostic methods 
(i.e. positive culture or NAAT). The loss of acid fastness in non-replicating organisms was 
demonstrated in-vivo in both C57BL/6 mice and samples from TB patients (Seiler et al., 2003). In 
experiments involving mice, ZN staining from lung sections after infection were analysed using 
two different detection techniques: (1) conventional, cell-wall dependent ZN staining and (2) cell-
wall independent immunohistochemistry using a polyclonal rabbit anti–M. bovis Bacille-
Calmette-Guérin serum (pAbBCG) (Wiley et al., 1990). Four weeks following infection, typical 
pink rod-shaped bacilli were observed using the conventional cell-wall dependent staining method; 
however, ten weeks after infection ZN-positive stains were gradually lost and barely no bacilli 
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were visible 39 to 40 weeks post-infection (Seiler et al., 2003). Broad staining of infected tissue 
was detectable using pAbBCG. In the same study, the results were confirmed using auramine, 
another staining method that is cell-wall dependent. Tissue sections from patients with acute or 
reactivated TB (five patients) were positive using both cell-wall dependent and pAbBCG staining. 
In contrast, samples from patients with persistent latent TB were positive by pAbBCG staining, 
but were ZN negative (Seiler et al., 2003). While the mechanism for loss of acid fastness is not 
fully understood, important metabolic processes such as the accumulation of TAG and changes to 
the cell wall are thought to be important (Vilcheze and Kremer, 2017).  
 
2.5.2.4 Cell-wall remodelling and non-replicating persistence 
As with many other bacterial organisms, changes in the PG cross-linking in the M. tuberculosis 
cell wall occurs during different growth states (Rittershaus et al., 2013, Lavollay et al., 2008). 
Analysis of PG content from M. tuberculosis H37Rv stationary phase cultures was performed 
using reverse phase high performance liquid chromatography and mass spectrophotometry to 
evaluate the contribution of D,D- and L,D-transpeptidases in the formation of 4→3 and 3→3 PG 
cross-links, respectively (Lavollay et al., 2008). The results revealed that approximately 80% these 
cross-links were 3→3, generated by L,D-transpeptidation. It was proposed that these cross-links 
are likely to play a pivotal  role in the adaptation of M. tuberculosis to stationary phase (Lavollay 
et al., 2008). As 3→3 cross-links are insensitive to β-lactam antibiotics, a decrease in 4→3 cross-
links may explain the reduction in susceptibility in non-replicating cells. To further investigate the 
role of PG and its susceptibility to anti-TB drugs, the L,D-transpeptidase protein, MT2594 in M. 
tuberculosis, was inactivated (Gupta et al., 2010). The loss of this protein led to altered colony 
morphology, reduced virulence and an increase in susceptibility to the β-lactam antibiotic, 
Amoxicillin (Gupta et al., 2010).  These findings indicate that a combination of a L,D-
transpeptidase and  β-lactamase inhibitor may be  an attractive treatment option to target non-
replicating bacilli in TB disease (Gupta et al., 2010). Indeed, meropenem-clavulanate has been 
shown to be effective against drug-resistant M. tuberculosis (Hugonnet et al., 2009, Forsman et 
al., 2015).  
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Figure 2.3 Mycobacterial cell-wall structure and remodelling. The mycobacterial cell wall is composed of three 
macromolecules, namely mycolic acids, arabinogalactan and peptidoglycan. The high density of lipids in the cell wall 
resist accurate gram staining; however, acid-fast stains such as the Ziehl-Neelson stain can be used. The peptidoglycan 
layer consists of repeating units of the disaccharide N-acetyl glucosamine– N-acetyl muramic acid (NAG–NAM) that 
are linked via peptide bridges. In stationary phase cultures 3→3 cross-links predominante (Lavollay et al., 2008). 
 
In recent cell wall remodelling investigations, in-vitro M. tuberculosis subjected to hypoxic 
conditions (1% O2 and 5% CO2) led to the catabolic remodelling of cell-surface trehalose 
mycolates (Eoh et al., 2017). The break-down of cell surface-derived trehalose resulted in the 
accumulation of pentose phosphate pathway intermediates that are thought to be involved in PG 
biosynthesis (Eoh et al., 2017). These findings broadly implicate metabolically regulated pathways 
 
 
65 
 
for the transition of M. tuberculosis into altered growth states and these adaptations allow for an 
anticipatory response (Eoh et al., 2017). In a study published the previous year, a double 
deprivation model (i.e. O2 and nutrient depletion) resulted in the generation on non-replicating TB 
bacilli after 728 days of latency. High resolution atomic force microscopy on filtered culture media 
(where cells adhered to silicon surfaces coated with antibodies), showed the presence of non-AFB 
that exhibited not only a change in morphology (round or oval shape) and reduction in size (150 – 
300 μm in length), but also cell-wall deficiency (Velayati et al., 2016). Spoligotyping and WGS 
confirmed these cells as M. tuberculosis. The spoligotype pattern was identified as H37Rv; 
however, spacers 2, 14, 20, 21 and 33-36 were absent. While cell-wall deficient M. tuberculosis 
was previously hypothesized to exist (Khomenko, 1987, Stanford, 1987), this study provided the 
first-line of evidence for the existence of these persister cells (Velayati et al., 2016).  Studies 
conducted using these cell-wall deficient cells may provide valuable insight regarding the biology, 
pathology and treatment of LTBI.  
 
2.5.3 M. tuberculosis models of non-replicating persistence 
Despite extensive investigation, the non-replicting state of the tubercle bacillus both in vivo and in 
vitro remains poorly understood. Several in vitro and in vivo models to generate and investigate 
these non-replicating persisters/ non-culturable organisms are outlined below: 
 
2.5.3.1 In vitro dormancy models 
A number of in vitro dormancy models for M. tuberculosis have been developed and are 
summarised in Table 2.1.  
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Table 2.1 Historic and currently used in vitro models to generate/study differentially 
detectable Mycobacterium tuberculosis 
Dormancy Model Principle Reference 
Corper and Cohn Experiment Adaption to stationary phase in 
conventional culture 
(Corper and Cohn, 1933) 
Nutrient starvation Carbon starvation (Loebel et al., 1933) 
The Wayne Model Gradual oxygen depletion in sealed 
culture tubes with agitation 
(Wayne and Hayes, 1996) 
Nutrient starvation Cultivation in nutrient low medium (Betts et al., 2002) 
Chemostat culture system Growth under defined conditions 
and adaptation to static culture 
through carbon starvation 
(James et al., 2002) 
Nitric oxide-based model Exposure to low-dose nitric oxide (Voskuil et al., 2003) 
In vitro granuloma model Mycobacterium bovis BCG strain 
carrying a luciferase (lux) gene and 
lung myofibroblasts mixed with 
fresh peripheral blood mononuclear 
cells to form a granuloma 
(Puissegur et al., 2004) 
100-day static culture Prolonged cultures in stationary 
phase without agitation and 
generation of rifampicin tolerance 
(Hu et al., 2006) 
Hypoxic resazurin reduction 
assay 
Culture aliquots in vacutainer tubes 
followed by adding of redox 
indicator and visual inspection 
(Taneja and Tyagi, 2007) 
Low-oxygen recovery assay 
(LORA) 
Recombinant H37Rv expressing a 
dormancy luciferase gene 
from Vibrio harveyii 
(Cho et al., 2007) 
Whole-cell nitrate reductase 
assay 
Development of Wayne model in 
microplate format and monitoring 
nitrate reductase activity 
(Khan and Sarkar, 2008) 
Multiple-stress dormancy model Combines stresses of: low oxygen 
(5%), high carbon dioxide (10%), 
low nutrient (10% Dubos medium) 
and acidic pH (5.0) 
(Deb et al., 2009) 
Gradual acidification Gradual acidification following the 
onset of stationary phase (pH 8.5 to 
4.7)  
(Shleeva et al., 2011) 
Potassium limitation Potassium limitation in nutrient-
sufficient, aerobic conditions 
(Salina et al., 2014) 
Exposure to first-line antibiotics Treatment of Mycobacterium 
tuberculosis cultures with first-line 
anti-TB drugs (RIF, EMB, INH and 
MEM) 
(Loraine et al., 2016) 
Nutrient starvation and exposure 
to RIF 
Nutrient starvation (incubation in 
PBS) followed by exposure to high-
dose RIF 
(Saito et al., 2017) 
RIF = rifampicin, EMB = ethambutol, INH = isoniazid, MEM = meropenem. Adapted from (Alnimr, 2015). 
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2.5.3.2 In vivo dormancy models 
Two murine models of dormancy (or latency as the term is used in the literature) have been 
described and are detailed below. While these models cannot truly mimic LTBI in human disease, 
they provide valuable insight into the pathogenesis of LTBI (Flynn et al., 1998, Adams et al., 1995, 
MacMicking et al., 1997, Orme, 1988, Scanga et al., 1999).  
 
2.5.3.2.1 The low-dose, chronic murine model 
In the low-dose or ‘untreated’ mouse model of latent TB, mice are infected with a low-dose (5 to 
10 CFU) of M. tuberculosis either via the aerosol route or infected intravenously. After 
approximately three months the,  pulmonary bacillary burden plateaus between 3 to 4 log  and the 
infection is contained solely by the host immune response – similar to LTBI in human disease  
(Sever and Youmans, 1957). After 15 to 18 months, the model results in a high bacillary burden 
and the mice succumb to TB disease. Whilst this model does not mimic true LTBI, it has been 
used as a model of persistent infection (Stead et al., 1968, Wayne and Sohaskey, 2001).  
 
2.5.3.2.1 The Cornell model 
The Cornell model (also known as the treated mouse model) is a historical murine model of LTBI 
(McCune and Tompsett, 1956, McCune et al., 1956). A schematic representation of this model is 
shown in Figure 2.2. In the original model, mice were infected intravenously with 1 x 106 to 3 x 
106 viable M. tuberculosis H37Rv bacilli and treated subsequently for twelve weeks with two anti-
TB chemotherapeutics, namely INH and PZA, to reduce the bacterial burden to undetectable 
levels. Following treatment cessation, reactivation disease was shown to occur either 
spontaneously (McCune and Tompsett, 1956) or was induced following immunosuppression with 
the administration of cortisone (McCune et al., 1966). Variations of the Cornell model have since 
been developed (Scanga et al., 1999). Reactivation disease was shown to occur in a modified 
Cornell model when the production of reactive nitrogen intermediates (RNI) was blocked by 
aminoguanidine, a nitric oxide synthase inhibitor, highlighting the role of RNI in preventing 
reactivation disease (Flynn et al., 1998).  The Cornell model has been employed as a tool for testing 
treatment regimens (Brooks et al., 1999, Dhillon et al., 1998, Dhillon et al., 1996, Paramsivan et 
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al., 1998), vaccines (Dhillon and Mitchison, 1994, Lowrie et al., 1999) as well as the immunology 
and bacteriology of the proposed latent state (van Pinxteren et al., 2000, Rees and Hart, 1961, De 
Wit et al., 1995, Hu et al., 2000). 
 
 
Figure 2.4 Schematic diagram of the Cornell model of dormant tuberculosis (TB). (A) Outbred mice are infected 
with ~ 105 colony forming units of M. tuberculosis H37Rv. (B) No evidence of disease is present following 12 weeks 
of treatment with both isoniazid (INH) and pyrazinamide (PZA). (C) Four weeks after cessation of treatment with 
INH and PZA, the mice appear to be well and TB infection cannot be measured by cultivation methods. This is termed 
the ‘sterile’ state of latent TB. In some models, mice are given cortisone as an immunosuppressant. (D) Mice are 
followed up for an additional eight weeks (12 weeks total following treatment cessation) and approximately 35% 
develop culture-positive, active TB disease. LOD = limit of detection, CFU = colony forming units. Figure adapted 
from (Parrish et al., 1998), Drawn by Amanda McIvor. 
 
2.5.4 Resuscitation-promoting factors 
It is now generally accepted that aged cultures of some bacterial species, including M. tuberculosis, 
contain a population of organisms that cannot form colonies on solid media, but can be resuscitated 
by the addition of CF from early stationary phase cultures (Sun and Zhang, 1999, Shleeva et al., 
2002). Rpfs are a family of muralytic enzymes that have been implicated in the reactivation of 
non-replicating bacteria. Two decades ago, the role of Rpf and its involvement in the resuscitation 
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of non-culturable bacteria was described by Mukamolova et al. (1998), where the addition of this 
protein in pico-molar concentrations increased the viable cell count of ‘non-culturable’ 
Micrococcus luteus cells 100-fold (Mukamolova et al., 1998). Furthermore, it was demonstrated 
that extensive washing of Mi. luteus cells led them to be dependent on exogenously added Rpf for 
growth (Mukamolova et al., 1998). These findings illustrated that Rpf exhibits properties 
consistent with that of a cytokine or bacterial growth factor (Callard and Gearing, 1994, 
Mukamolova et al., 2002b). 
The addition of purified M. luteus Rpf was also shown to stimulate the growth of slow growing 
mycobacteria, including M. tuberculosis (strains H37Ra and H37Rv), M. avium, M. bovis (BCG) 
and M. kansasii.  (Mukamolova et al., 1998). Moreover, aged M. tuberculosis Academia strain 
(avirulent) cultures yielding small coccoid, non-culturable cells, were obtained by filtering 
clumped cultures grown in the absence of Tween 80. These cells could only be resuscitated 
following the addition of CF or recombinant Rpf (Shleeva et al., 2002). Following phagocytosis 
by macrophages, M. tuberculosis cells reportedly lose their ability to form colonies on solid media 
suggesting the adoption of the dormant state. Biketov et al. (2000) investigated this effect of Rpf 
on non-replicating M.tuberculosis Academia cells from murine peritoneal macrophages following 
infection in vivo (Biketov et al., 2000). The viable counts of cell suspensions derived from these 
macrophages were assessed by the most probable number (MPN) serial dilution assay and 
compared to the number of CFUs obtained from lysates. Bacterial viability measured by the MPN 
assay was often much higher than that obtained by CFUs (Biketov et al., 2000). In addition, cells 
isolated from macrophages had different surface properties compared to cells grown in vitro. This 
was evidenced by the inability of these cells to absorb the bacteriophage DS6A, a reduced tendency 
to form clumps in liquid media and loss of Rpf-mediated resuscitation following freezing/thawing 
(Biketov et al., 2000). It was concluded that M. tuberculosis cells isolated from macrophages were 
either damaged or in a non-replicating state, and these cells could be recovered by the addition of 
Rpf to liquid culture media. Whilst the biological function of these proteins is not understood, 
these findings suggest a putative role for these Rpf-like proteins in modulating bacterial growth 
during disease.  
 
 
 
 
70 
 
2.5.4.1 Characterization of Rpfs  
Genes encoding Rpf-like proteins similar to that found in Mi. luteus are present among the G+C 
gram positive bacteria (i.e. Streptomyces, Corynebacterium and Mycobacteria), (Kell and Young, 
2000). M. tuberculosis has five Rpf homologues designated RpfA to RpfE 
(http://genolist.pasteur.fr/Tuberculist), of which all 5 Rpf-like proteins are reportedly found in 
actively dividing cells in vitro and in mice (Mukamolova et al., 2002b, Tufariello et al., 2004). 
Furthermore, the expression of some of these genes have been detected in granulomas from lung 
tissue sections in patients with TB disease (Fenhalls et al., 2002). The presence of multiple 
homologues of these rpf-like genes led to the hypothesis that these proteins may have overlapping 
biological functions or may be partially or wholly redundant. Subsequent gene knock-out 
experiments were performed to determine the functional role of these Rpf-like proteins in M. 
tuberculosis. Growth and survival in mutant M. tuberculosis strains wherein one of the five rpf 
homologues was deleted, was not compromised, thereby confirming that none of the rpf-like genes 
are individually essential for growth in vitro (Downing et al., 2004, Tufariello et al., 2004) or in 
the mouse model of infection (Tufariello et al., 2004). The first line of evidence to show that these 
proteins serve some discrete biological function in M. tuberculosis came from subsequent gene 
knock-out experiments whereby mutants lacking three of the five rpf genes displayed differential 
growth defects in vitro and were unable to resuscitate spontaneously in vitro (Downing et al., 
2005). Consistent with this, an rpfB defective mutant of the M. tuberculosis Erdman displayed 
delayed growth kinetics in mouse model of dormancy (Downing et al., 2005). Following these 
observations, a series of double mutants were constructed since functional redundancy among the 
Rpf family members may have obscured single knock-out phenotypes (Russell-Goldman et al., 
2008). One double mutant, ΔrpfAB, displayed altered colony morphology and elicited an altered 
macrophage cytokine response. In vivo, this mutant also displayed a reactivation deficit in 
C57BL/6 mice that were treated with the nitric oxide synthase inhibitor (aminoguanidine). This 
reactivation deficit was more severe than that of the single ΔrpfB mutant in aminoguanidine-
treated mice. Additional observations showed that this mutant exhibited a deficiency in 
persistence, a defect not observed in ΔrpfA and ΔrpfB single mutants. Together, these data provide 
evidence that RpfA and RpfB may modulate the host innate immune response to M. tuberculosis 
(Russell-Goldman et al., 2008). To further investigate the collective roles of Rpf, quadruple and 
quintuple mutants of M. tuberculosis H37Rv were constructed. In this case, all five rpf-like genes 
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were shown to be collectively dispensable for M. tuberculosis growth in vitro, again indicating 
functional redundancy (Kana et al., 2008). This is in contrast to Mi. luteus, where the single rpf 
gene was found to be essential for growth and survival (Mukamolova et al., 2002a). A quadruple 
mutant (containing only rpfD) and a quintuple mutant (lacking all five rpf genes) both displayed 
delayed colony formation and increased sensitivity to detergent (sodium dodecyl sulphate) in 
comparison to mutants containing rpfB or rpfE. Furthermore, quadruple mutants retaining the rpfD 
and rpfE genes, were attenuated for growth in mice.  These experiments suggest ‘a functional 
hierarchy within the rpf gene family, with rpfB and rpfE ranking above rpfD’ (Kana et al., 2008).   
 
2.5.4.2 Structure of the Rpf domain 
Nuclear magnetic resonance imaging of the M. tuberculosis RpfB domain provided valuable 
information on the structure of Rpfs and yielded insight into the biological function of this protein 
family (Cohen Gonsaud et al., 2005). The structure of RpfB was described as a ‘compact hybrid’ 
bearing a structural resemblance to that of a soluble lytic trans glycosylase and a c-type lysozyme 
– both of which are involved in the cleavage of PG (Cohen Gonsaud et al., 2005). The active and 
conserved catalytic glutamate was also shown to be crucial for catalytic activity (Cohen Gonsaud 
et al., 2005). Consistent with these findings, studies analysing the crystal structure of a truncated 
form of RpfB suggest that it is a cell-wall associated protein owing to the presence of a ‘comma-
like shape formed by a lysozyme-like globular protein catalytic domain’ as well as an elongated 
G5 domain (Ruggiero et al., 2009). The existence and role of a G5 domain in cell-wall associated 
proteins, cell-to-cell adhesion and biofilm formation, further suggest that that Rpf is a cell-wall 
associated protein (Rezwan et al., 2007).  The muralytic activity of the Rpf from Mi. luteus cells 
has been confirmed through the degradation of fluorescamine-labelled Mi. luteus cell walls 
(Mukamolova et al., 2006). In addition, when the active glutamate residue was altered, Rpf activity 
was substantially attenuated (Mukamolova et al., 2006). Structural characterisation of RpfB in 
solution carried out using circular dichroism spectroscopy and light scattering experiments have 
provided further insight into the functional properties of the non-catalytic domains (Ruggiero et 
al., 2017). One of the findings was that the G5-linked-Ubiquitin domain has a possible role for the 
adhesion of this enzyme to polymeric PG (Ruggiero et al., 2017, Ruggiero et al., 2016). 
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2.5.4.3 Mechanism of action of Rpfs 
Whilst the exact mechanism whereby Rpfs stimulate growth in M. tuberculosis (and other G + C 
rich gram positive bacteria) remains elusive, it is suspected that resuscitation stems from the ability 
of these enzymes to hydrolyze PG in the cell wall. Two mechanisms of growth stimulation 
whereby Rpfs remodel PG have been proposed. The first hypothesis of PG remodelling is based 
on the structure of Rpf outlined in section 2.5.4.2 whereby Rpfs directly interact with the cell wall 
by cleaving the β-1,4 glycosidic bond between NAM and NAG in PG. This cleavage may allow 
for the insertion of new PG units, ultimately leading to bacterial growth and cell division.  
The second hypothesis is that Rpfs have an indirect interaction with the mycobacterial cell wall 
and are required for the release of signalling molecules that reactivate non-replicating bacteria 
through the activity of serine-threonine protein kinases (STPKs) (Shah et al., 2008, Dworkin and 
Shah, 2010). STPKs are transmembrane proteins consisting of an external sensor domain and 
cytoplasmic protein kinase domain. Following the detection of a cognate signal, the protein kinase 
phosphorylates target proteins leading to a signal cascade and subsequent cellular response (Kana 
and Mizrahi, 2010).  The STPK, PrkC, in B. subtillus results in spore germination by sensing PG 
fragments through an external penicillin-binding protein and serine/threonine protein kinase 
(PASTA) domain (Shah et al., 2008). PknB, the homologue of PrkC in mycobacteria, has a high 
degree of structural similarity to other eukarytic STPKs, suggesting that this protein is also able to 
bind PG in a manner similar to PknB (Fernandez et al., 2006).  It has been suggested that the 
combined action of Rpfs and other enzymes such as L,D-carboxypeptidases may generate  the 
formation of a disaccharide tripeptide that  can  bind to PknB and trigger resuscitation in  non-
replicating bacteria in a  manner similar to spore germination in B. subtillus, Figure 2.4 (Kana and 
Mizrahi, 2010). Yeast two-hybrid screening to identify potential binding proteins for Rpf reported 
an interaction between RpfB and RpfE with the mycobacterial endopeptidase, designated Rpf-
interacting protein A (RipA) (Hett et al., 2007). The observation that both RipA and RpfB co-
localize to the septa of dividing cells provides further evidence for a role for both these enzymes 
in bacterial growth and division (Hett et al., 2008).  Figure 2.5 demonstrates a proposed model for 
the mechanism of action of Rpfs and RipA in the remodelling of PG in the mycobacterial cell wall 
as well as their possible involvement in host and bacterial signalling.   
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Figure 2.5 Proposed role of resuscitation-promoting factors in remodeling of peptidoglycan and production of muropeptide signaling molecules. 
Peptidoglycan (PG) is composed of both peptide and glycan strands. The glycan strands typically consist of repeating units of N-acetylmuramic acid (NAM) and 
N-acetylglucosamine (NAG), which are cross-linked by peptide groups bound to the lactyl group on the NAMs from different glycan strands (Mahapatra et al., 
2005). The stem peptide consists of D-iGLn, m-DAP, D-alanine and L-alanine residues (Kana and Mizrahi, 2010). Rpfs are through to cleave the β-1,4 glycosidic 
bond between NAM and NAG whereas endopeptidases, including RipA and carboxypeptidases, cleaves the bond between the peptide stems.  The combined action 
of resuscitation-promoting factors (Rpfs) and other enzymes may generate muropeptides that have both bacterial and/or host signaling properties.  Modified from 
Kana et al. 2010 and Hett et al. 2008. Drawn by Amanda McIvor. 
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In terms of host signalling, there is evidence to associate a role of bacterial PG fragments in 
pathogenesis (Bartoleschi et al., 2002, Boneca et al., 2007, Humann and Lenz, 2009). Figure 
2.5 shows that the combined action of RipA and RpfB is speculated to generate a disaccharide 
tripeptide (with terminyl m-DAP residue) that may be detected by the mammalian protein, 
Nod2 (nucleotide-binding oligomerization domain) (Girardin et al., 2003, Kana and Mizrahi, 
2010).  Also, the combined action of RpfB and other peptidases could generate a disaccharide 
dipeptide that  is detected by Nod1 (Girardin et al., 2003).  It is speculated that pathogenic 
mycobacteria may utilize these muropeptides to modulate the host’s innate immune response 
to their advantage (Jo, 2008, Nikitushkin et al., 2015, Wang et al., 2017).  
 
2.5.4.4 Bacterial non-replicating states in TB disease   
The clinical work investigating the phenomenon of Rpf dependency and non-replicating states 
in TB disease is extensively reviewed in the introductory sections of chapters 3, 4 and 6.  
 
2.6 KNOWLEDGE GAPS RELATED TO THIS PHD 
A great body of work has demonstrated the existence of bacterial organisms that cannot be 
cultured in the laboratory using routine culture methods. It is presumed that these cells are in a 
state of non-replicating persistence and are responsible for the phenotypic tolerance to 
antibiotics. In TB disease, it is speculated that non-replicating M. tuberculosis may underpin 
the phenomenon of clinical latency, the six month treatment period required to achieve clinical 
cure, as well as relapse disease following supposed ‘sterilisation’ and clinical cure. The ability 
to detect these non-culturable organisms will not only provide valuable insight into the 
heterogeneity (and the roles bacterial organism play) within a community, but will also have 
clinical implications in terms of diagnosing disease, monitoring treatment response and the risk 
of developing reactivation disease. Furthermore, early bactericidal activity (EBA) assays will 
also benefit from testing the sterilising efficacy of potential drug candidates on these 
differentially culturable populations. Previous work at the Centre of Excellence for Biomedical 
and TB Research (CBTBR) has demonstrated a spectrum of differencially culturable tubercle 
bacilli (DCTB) in tuberculous sputum from patients with drug-susceptible TB at baseline (i.e. 
before the commencement of anti-TB treatment) (Chengalroyen et al., 2016) (study reviewed 
in chapter 3). DCTB are defined as non-platable M. tuberculosis populations that emerge 
differentially depending on culture conditions. A key question that remains to be investigated 
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is how these organisms adapt or respond to anti-TB therapy. In this thesis, the following 
questions pertaining to these DCTB populations are studied and addressed:  
- What are the proportions of non-culturable versus conventionally culturable M. 
tuberculosis bacteria in patients with active, drug-susceptible TB disease before 
treatment initiation? 
- How do the proportions of these organisms vary between individuals with and without 
HIV coinfection? 
- How do these DCTB respond to treatment? 
- Can DCTB serve as biomarkers that are able to assess or predict how patients will 
respond to anti-TB treatment? 
- How does the MPN assay, in its 48-well micro-titre format, relate to other culture 
methods such as CFU and MGIT? Could the MPN assay possibly be used in the future 
in EBA studies to monitor the effect of new TB drugs on both actively replicating and 
non-replicating populations?  
- Can the addition of CF (as a source of Rpfs) to the BACTEC MGIT 960 assay reduce 
time to TB diagnosis? 
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CHAPTER 3 
DETECTION AND QUANTIFICATION OF DIFFERENTIALLY CULTURABLE 
BACTERIA IN TUBERCULOSIS PATIENTS: A PRETREATMENT ANALYSIS  
3.1 INTRODUCTION 
The clinical presentation of TB disease is complex, often manifesting as a spectrum of disease 
(ranging from sterilizing immunity to active disease) within a single patient (Barry et al., 2009, 
Esmail et al., 2016, Schnappinger and Ehrt, 2016, Lenaerts et al., 2015). Furthermore, a growing 
body of evidence points to a high complexity in the population structure of M. tuberculosis within 
the host environment (Turapov et al., 2016, Mukamolova et al., 2010, Chengalroyen et al., 2016, 
Manina et al., 2015, Post et al., 2004). The success of this pathogen has often been attributed to 
differences in bacterial growth states which are thought to underpin latent infection, the long 
treatment period required as well as relapse disease. Furthermore, these altered growth states, 
which include non-replicating persistence/metabolic quiescence, are likely responsible for drug-
tolerance since most anti-TB chemotherapeutics target actively replicating organisms. 
Additionally, these drug-tolerant organisms may serve as the basis for the development of 
genetically stable and drug-resistant strains (Loraine et al., 2016). It has been proposed that the 
dynamic interplay between these differential growth states and their association with host 
immunity will ultimately determine the outcome of disease. In light of this, the complexity of M. 
tuberculosis population dynamics in TB disease has become an area of intense study with the 
detection of non-replicating organisms (characterized by impaired culturability) being a leading 
focus in this area. The detection and quantification of these organisms will be of utmost importance 
in clinical trials monitoring the EBA of new drugs to determine the sterilizing efficacy of new 
treatments as well as in the diagnosis of TB (particularly in patients with paucibacillary disease), 
patient care and management and ultimately for the complete eradication of this disease. 
Accumulating microbiological studies have provided further insight into this phenotypic plasticity. 
A decade ago, M. tuberculosis cells derived from pre-treatment sputum samples were 
demonstrated to harbour varying amounts of lipid inclusion bodies by combined Nile red and 
auramine staining (Garton et al., 2008). Additional in vitro experiments revealed that M. 
tuberculosis cells in non-replicating persistence, as described by Wayne and Hayes (Wayne and 
Hayes, 1996), accumulated lipid inclusion bodies at a frequency similar to those cells seen in 
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sputum (Garton et al., 2008). The authors proposed that the presence of lipid bodies from sputum 
samples could potentially serve as a biomarker for non-replicating bacteria. Furthermore, it has 
been hypothesized that the accumulation of TAG lipid droplets may possibly be utilized as an 
energy source during non-replicating persistence and reactivation disease (Daniel et al., 2004, 
Gomez and McKinney, 2004, Zhang, 2004, Daniel et al., 2016, Daniel et al., 2011). Consistent 
with this, the upregulation of the TAG synthase gene, tgs1, (as well as several other genes in the 
DosR regulon) in clinical W-Beijing strains coincided with the accumulation of TAG, providing 
evidence of the involvement of these genes in TAG synthesis and the adoption of a non-replicative 
state (Garton et al., 2008, Reed et al., 2007).  
Rpfs were one of the first mycobacterial proteins to be implicated in the modulation of 
mycobacterial growth and have subsequently been linked to recrudescent disease in mice (Kana 
and Mizrahi, 2010). These secreted enzymes, in conjunction with other mycobacterial proteins 
such as RipA, are thought to enhance bacterial growth by the hydrolysis of the PG layer in the cell 
wall allowing for degradation of the septa in diving cells leading to cell separation (Hett et al., 
2007, Hett et al., 2008, Nikitushkin et al., 2015). The presence of an Rpf-dependent population in 
human infection was first described by Mukamolova and colleagues in 2010 (Mukamolova et al., 
2010). The authors reported that pre-treatment smear-positive sputum samples were dominated by 
a population of M. tuberculosis cells that could only be cultured by supplementation with 
recombinant RpfE or fresh M. tuberculosis CF (as a source of Rpfs) in a limiting dilution assay. 
This Rpf-dependent population was determined by comparing the number of bacterial cells 
isolated in the limiting dilution MPN assay to those detected by conventional standard agar CFU 
assays. The data illustrated that at least 80% of the bacterial population was undetected by 
conventional CFU assays, conducted on sputum samples obtained from 20 out of 25 patients 
(Mukamolova et al., 2010).  
These observations were confirmed in a recent study conducted on sputum samples from 110 pre-
treatment TB patients illustrating that 86% harboured a population of organisms that could only 
be recovered following the addition of CF (Chengalroyen et al., 2016). In this study, the authors 
define these non-platable bacteria as ‘differentially culturable tubercle bacilli’ (DCTB) as they 
emerge differentially depending on culture conditions. This study illustrated a greater complexity 
in M. tuberculosis populations than previously understood, whereby various phenotypically 
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distinct bacterial sub-populations were described in a single sputum sample, including a population 
of DCTB that emerged independently of Rpfs. The distinct populations of bacteria reported by 
Chengalroyen et al. (2016) and are depicted in Table 3.1. In addition to mixed populations of 
DCTB, which accounted for the majority (53.6%) of M. tuberculosis cells isolated from this patient 
cohort, 21 (19.1 %) patients harboured DCTB that could only be cultured in the presence of CF 
derived from the wild-type H37Rv strain (sub-population 2). In contrast, 13 (11.8 %) patients 
harboured a population of DCTB that could only be cultured by supplementation with CF derived 
from a mutant strain devoid of any Rpfs, suggesting that Rpfs may function as an inhibitor of 
growth in certain populations, (sub-population 3). Two patients (1.8%) harboured a population of 
cells that could only be cultured in the MPN assay which was not supplemented with CF (sub-
population 4). Lastly, CFUs were obtained from 15 patients (13.6%) where no DCTB were present. 
Of note was the emergence of DCTB that could be cultured not only in the presence of CF 
containing Rpfs, but also by the supplementation with CF derived from an M. tuberculosis strain 
where all five rpf genes had been deleted. These observations suggested a role for molecules other 
than Rpfs in resuscitation of DCTB. Indeed, previous studies employing in vitro systems to 
generate DCTB have implicated other molecules such as cyclic AMP (cAMP), fatty acids, 
cholesterol, muropeptides and mycobactins as factors important for the resuscitation of 
metabolically quiescent strains (Shleeva et al., 2013, Zhang et al., 2001, Nikitushkin et al., 2013, 
Soto-Ramirez et al., 2017). However, a recent study reported the generation of DCTB after 
starvation in PBS and treatment with RIF and in this case, these organisms (termed differentially 
detectable tubercle bacteria) were able to resuscitate in liquid media without CF supplementation 
(Saito et al., 2017). 
These findings contribute further insight into the complexity of TB disease and altered growth 
states that exist in pre-treatment sputum samples and highlight possible diagnostic challenges for 
TB as a single diagnostic assay may not be sufficient to detect all subpopulations in sputum 
(Dartois et al., 2016). Whilst in vitro experiments have demonstrated tolerance of Rpf-dependent 
organisms to first-line antibiotics, including, INH and streptomycin (STREP) (Turapov et al., 
2016, Mukamolova et al., 2010), (further reviewed in chapter 4), the relative proportions and rates 
of decline of these populations during first-line treatment in patients was addressed in this PhD. 
These findings are presented in chapter 4. However, before reporting these, the prevalence of 
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DCTB in the patient cohort used for this study, prior to the initiation of treatment, will be described 
in this chapter.  
 
Table 3.1 Distinct subpopulations of M. tuberculosis isolated from treatment-naïve patients 
 
Definition of abbreviations: CF = culture filtrate; MPN = most probable number assay, Rpf – = resuscitation-
promoting factor negative; CFU = colony forming unit. The number of coloured circles represents the proportion of 
patients with differentially culturable tubercle bacilli or CFU as indicated: three, > 50%; two, 2 – 50%; one <2%. 
Adapted from Dartois et al. 2016 
 
Variation in the relative proportions of CF/Rpf dependent organisms, or lack thereof, identified 
amongst TB patients suggest that host factors play a role in the generation of this phenotype. In 
this case, the stress imposed by the cell-mediated host immune response may drive bacteria into 
distinct differentially culturable states. To further support this hypothesis, Chengalroyen et al. 
(2016) reported that individuals with a comparatively better immune competency (i.e. HIV-
negative individuals or HIV-positive individuals with CD4 T-cell counts greater than 200 
cells/mm3) harboured increased numbers of CF-dependent DCTB in their sputum (Chengalroyen 
et al., 2016). In further support of this hypothesis, it was previously shown that two weeks after 
infection with  M. bovis BCG Glaxo, BALB/c mice harboured Rpf-dependent bacteria in their 
lungs, implicating the host environment in generating this population  (Turapov et al., 2014). In 
contrast, 24 hours post infection, the numbers of CFUs and bacteria isolated from CF 
supplemented MPN assays were not significantly different illustrating the absence of an Rpf-
dependent population after axenic subculture of organisms derived from mice. As the 
establishment of Rpf-dependency overlapped with the onset of the adaptive immune response in 
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mice (Vallerskog et al., 2010), it was proposed that a direct link existed between the two (Turapov 
et al., 2014). Furthermore, additional experiments suggest that Rpf-dependency occurs in the lung 
and not from the transition from the lung to sputum (Turapov et al., 2014).  Evidence to implicate 
the host macrophage environment in generating Rpf-dependent bacteria has also been reported 
(Biketov et al., 2000). Currently the role of the host immune system in generating DCTB remains 
speculative and further investigation is required.   
The presence of DCTB in sputum poses a significant challenge with regards to the diagnosis, 
treatment and management of TB disease.  As these populations are the most likely responsible 
for the prolonged treatment of TB, the acquisition of acquired drug resistance, and relapse disease, 
an understanding of their biology is of utmost importance. Circumstantial evidence for the 
potential role of DCTB in relapse disease was demonstrated by Hu et al (2015) whereby deletion 
of the hspx gene (resulting in the eradication of Rpf-dependent bacilli) resulted in a two-fold 
increase in the elimination of M. tuberculosis bacilli and a significant decrease in the rates of 
relapse disease in the Cornell mouse model when treated with standard anti-TB drugs (Hu et al., 
2015). These findings indicate that genes that are overexpressed during non-replicative 
phases/dormancy, such as hspx, may serve as important targets for anti-persister drugs that could 
be used as antibiotic adjuvants to enhance the effectiveness of conventional antibiotics and 
possibly shorten treatment duration.  
As most forms of TB disease manifest in the lungs, diagnosis and management relies 
predominantly on sputum which can problematic for multiple reasons. Firstly, a poor quality 
sample consisting predominantly of upper airway secretions may not contain many bacilli leading 
to a false negative diagnosis (Datta et al., 2017). Secondly, some patients, particularly those that 
are HIV-infected or young children, are unable to produce a diagnostically useful sputum (Moore 
et al., 2017, Datta et al., 2017). In addition, the HIV epidemic has resulted in an increase in the 
numbers of patients with smear-negative disease due to disseminated or EP disease making 
diagnosis based on sputum a challenging and in many cases a process that delays engagement into 
care (Hargreaves et al., 2001). The presence of DCTB in patient sputum adds a further level of 
complexity regarding the diagnosis and management of TB disease due to the fact that these 
organisms cannot be cultured using standard methods. Hence, further understanding of DCTB, 
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mycobacterial growth and the mechanism of resuscitation may shed further insight on how TB 
diagnosis can be improved in the future. 
In this chapter, the relative proportions of DCTB subpopulations as defined by Chengalroyen et 
al. (2016) were investigated in an independent patient cohort of drug-sensitive individuals at 
baseline. These individuals were then placed on standard TB chemotherapy to assess the response 
of DCTB to drug treatment. Results from this longitudinal component are analysed and conveyed 
separately in chapter 4. The aim and objectives for this chapter are detailed below.  
 
3.2 HYPOTHESIS 
Populations (and sub-populations as defined by Chengalroyen et al. 2016) of DCTB are present in 
a distinct cohort of treatment naïve TB patients. It is hypothesised that HIV-negative individuals 
will harbour a greater proportion of DCTB compared to their HIV-positive counterparts, due to 
greater functionality in the host immune system. 
 
3.3 AIM OF STUDY 
The aim of this study was to quantify the relative proportions of DCTB populations (by MPN) 
versus platable bacteria (by CFU) in sputum samples collected from patients infected with active 
pulmonary, drug-susceptible TB at baseline. 
 
3.3.1 Specific objectives of the study 
1. Quantify the CF-dependent, Rpf-independent, CF-independent and conventionally 
culturable bacterial populations by MPN and CFU assays, respectively. 
2. Determine whether there is a variation in the distribution of DCTB between HIV-infected 
and -uninfected individuals. 
3. If a difference is obtained in (2), ascertain whether the variation in this bacterial distribution 
is linked to host immunity. For this, patients will be stratified into two groups with CD4 T-
cell counts less than and greater than 200 cells/mm3.  
4. Describe circulating M. tuberculosis strains within the study community.  
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3.4 MATERIALS AND METHODS 
3.4.1 Patients/Sources of sputum samples 
Ethics clearance for this PhD was obtained from the Human Research Ethics Committee (medical) 
of the University of the Witwatersrand, Johannesburg [Clearance certificate number: M161058 
(Appendix 3A)]. One hundred and seventy four newly diagnosed patients presenting with drug-
susceptible pulmonary disease were recruited into the study through the clinical platforms of the 
Perinatal HIV Research Unit (PHRU). Since the aim of the study was to assess the response of 
DCTB to drug treatment, baseline samples from treatment naïve patients were required. Previous 
TB patients were excluded to eliminate any previous influence of treatment on these populations. 
The initial 132 patients were recruited from primary health care clinics in and around the Soweto 
area, greater Johannesburg, South Africa, after which recruitment relocated to Klerksdorp, North-
West Province, South Africa, where an additional 42 patients were recruited. Patients were 
approached to participate in the study on the basis of a positive GeneXpert MTB/RIF result that 
was obtained from the public sector [National Health Laboratory Service (NHLS)] before the 
commencement of treatment. Patients presenting with a RIF resistant GeneXpert result were 
excluded from the study. Once informed consent was obtained, both baseline overnight and spot 
sputum samples were collected. Previous studies on DCTB (or Rpf-dependent bacteria in sputum) 
used a single sample. To assess the robustness of measure of DCTB, we sought to take two 
independent samples from each patient at enrolment. When informed consent was administered, 
the participant was given a sputum collection vial to take home. Early the next morning and during 
the night, the participant expectorated sputum into this collection vial, which was brought to the 
clinic the next day – this was termed the overnight sample. Immediately upon arrival, the 
participant was asked to expectorate another sputum sample, this was referred to as the spot 
sample. Hence, two samples were collected from each participant at enrolment, Figure 3.1. 
Biometric parameters (including weight and height) and socio-demographic data were taken at 
enrolment. In addition, blood, medical history, previous TB treatment as well as detailed 
antiretroviral treatment (if applicable) were recorded before the onset of TB treatment. Patients 
were subsequently placed on a standardized first-line TB regimen consisting of RIF, INH, PZA 
and EMB for two months followed by an additional four months of treatment with RIF and INH. 
HIV positive individuals co-infected with TB were started on ART treatment as soon as possible 
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after starting TB treatment. However, whilst adherence to TB treatment was closely monitored, 
ARV treatment was not monitored by DOT and was administered in the public health care system. 
Hence, limited data on ART usage was available. Further details for the longitudinal component 
for this study are set out in chapter 4, Section 4.4.  
 
Figure 3.1 Patient recruitment and study methods map. Patients were recruited into the study at the Perinatal HIV 
Research Unit (PHRU) based on a positive GeneXpert result. Sputum samples collected at the clinic were transported 
that afternoon or the following morning to the Clinical Laboratory Services (CLS) for decontamination and processing. 
Following decontamination, the pellet was split. Approximately 1.5 mL of pellet was sent to the Centre of Excellence 
for Biomedical TB Research (CBTBR) for MPN and CFU assays (processed by PhD student and postdoctoral fellow), 
and 1.5 mL was kept for routine diagnostic tests. Results from these tests were communicated back to the referring 
doctor at PHRU.  
 
3.4.2 Sputum processing and routine diagnostics  
Following specimen collection, sputum samples were immediately transferred to the Clinical 
Laboratory Services (CLS) in Braamfontein. CLS is an accredited supplier of diagnostic services 
and was engaged in this project to provide MGIT, sputum smear and GeneXpert data for all 
samples. Sputum samples were decontaminated within 24 hours of sample collection and the pellet 
was split. Half of the sample was kept for routine processing and diagnostic testing while the 
remainder was used for MPN and CFU assays, Figure 3.1. 
 
3.4.2.1 Sputum decontamination 
Sputum samples were processed in the BSL3 laboratories of CLS and samples were 
decontaminated inside a class II A/B3 BSC using a N-acetyl-L-cysteine - Sodium Hydroxide 
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(NALC-NaOH) digestion-decontamination method. Briefly, an equal volume of 2% NaOH in 
NALC-NaOH-sodium citrate solution was added to the sputum in a 50 mL screw-cap plastic 
centrifuge tube (final concentration of NaOH is 1%). The 50 mL conical tube was then mixed on 
a vortexer for 15 to 30 seconds and then inverted to expose the entire surface area of the tube to 
the NALC-NaOH solution. The 50 mL tube was then left to stand for 15 to 20 minutes with 
occasional shaking to promote digestion. More NALC was added to the sample if it was still 
mucoid. Phosphate-buffered saline (PBS, p.H. 6.8) was then added to the 45 mL mark on the 
centrifuge tube. The solution was then spun down in a refrigerated centrifuge for 15 minutes at 
3000 x g. The supernatant was decanted into a container containing tuberculocidal disinfectant, 
leaving only the pellet behind. Two to four mLs of PBS was then added to the pellet which was 
re-suspended by vortexing for five to ten seconds. 1.5 mL of the pellet was used for MPN and 
CFU assays and the remaining pellet was used for the routine laboratory tests. For methods on 
routine diagnostic tests run at CLS for sputum samples please refer to Appendix 3B. Currently, 
the effect of the decontamination procedure on the selection of certain bacterial sub-populations is 
not known and this is noted as a limitation. Further research is required in this regard. 
 
3.4.3 Detection and quantification of differentially culturable tubercle bacilli and 
conventionally culturable bacilli 
Assays to detect and quantify DCTB and conventionally culturable bacilli were carried out using 
MPN and CFU assays, respectively. These assays were performed by Amanda McIvor and are 
detailed below. As samples were processed in real time, the technical demands of having fresh CF 
available every day, and real time scoring of MPN assays necessitated assistance from a 
postdoctoral fellow for the MPN assays.  
 
3.4.3.1 Most probable number assays 
3.4.3.1.1 Preparation of culture filtrate 
A fresh batch of 200 mL of CF from both the H37Rv and Rpf-deficient strain (strain BG1-ΔrpfA 
ΔrpfB ΔrpfC ΔrpfD ΔrpfE - referred to here on as BG1) was prepared on a daily basis for MPN 
processing. For this, two 50 mL cultures (in 550 mL culture flasks) were prepared from small 
dense log phase pre-cultures for each strain (in 50 mL culture flasks). Further details below. 
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Bacterial strains: For the pre-cultures, 1 mL of stock culture from frozen 1 mL aliquots of H37Rv 
and the BG1 strain (OD600nm approximately = 0.6) was added to 50 mL flasks containing 8 mL of 
7H9 media [supplemented with 0.05% Tween 80, 0.2% glycerol and 10% OADC enrichment (0,5 
g oleic acid, 50 g albumin, 20 g dextrose, 0.04 g catalase in 1 L water)]. Prior to use, 7H9 media 
was incubated for 48 hours at 37 °C to ensure sterility. Each batch of media was labelled and dated 
and the results of sterility checks were recorded in a database. An example of the sterility checks 
for media batches used in this study are reported in Appendix 3C. The culture flasks were then 
transported in a secondary containment to the incubator and left to incubate at 37 °C for three days 
(OD600nm 0.6 to 0.9).  
Two 50 mL cultures for both the H37Rv and BG1 strain were prepared in 550 mL culture flasks 
from the pre-cultures for each day of the week. Two, four or eight mLs of pre-culture was added 
to 48, 46 or 42 mLs of 7H9 broth respectively depending on the final density of each culture that 
was required for sputum processing. The flasks were labelled ‘Rv’ or ‘BG1’ and with the 
appropriate day of the week on which the OD600nm would be between 0.6 and 0.9. To streamline 
the process and for ease of use, a timetable was created for the daily preparation of bacterial pre-
cultures, cultures and CF, Figure 3.2. For example, for CF required on Wednesday, pre-cultures 
were made the previous Friday. Eight mLs of pre-culture was subsequently sub-cultured into 42 
mL of 7H9 both on the following Monday and left in the incubator at 37 C until Wednesday 
morning at which the OD600nm was measured. An OD600nm between 0.6 and 0.9 was considered late 
exponential phase and used to obtain CF for MPN assays. Figure 3.3 illustrates the preparation of 
the two M. tuberculosis strains required for CF preparation.  
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Figure 3.2 Calendar to illustrate streamlining and daily preparation of M. tuberculosis H37Rv and BG1 pre-
cultures and cultures to obtain standardised culture filtrate for most probable number assays. Preparation of 
pre-cultures and cultures was standardised and optimised to obtain log-phase cultures for processing. The timetable 
above was constructed for ease of use. The different colours indicate separate 50 mL cultures prepared for a specific 
week day. For example, culture filtrate (CF) required for processing on Monday and Tuesdays required pre-cultures 
to be prepared the previous Tuesday by the addition of 1 mL of Mycobacterium tuberculosis H37Rv and BG1 (ΔrpfA 
ΔrpfB ΔrpfC ΔrpfD ΔrpfE) to 8 mL of standard media. After three days of growth, two large cultures were made on 
the previous Friday. CF for Monday and Tuesday was obtained from blue and purple cultures, respectively. * Pre-
cultures were prepared every Tuesday and Friday, and ‡ large volume cultures from pre-cultures every Friday and 
Monday. 
 
Figure 3.3 Preparation of M. tuberculosis bacterial strains, H37Rv and BG1. Pre-cultures from the two M. 
tuberculosis strains, H37Rv and BG1 (ΔrpfA ΔrpfB ΔrpfC ΔrpfD ΔrpfE) were prepared by the addition of 1 mL of 
freezer stock to 8 mL of standard media in 50 mL culture flasks. Following incubation, a calculated volume (denoted 
by *; also see Figure 3.2) was added to 42, 46 or 48 * mL of standard media in a 550 mL flask. The circles on the 
right give a simple illustration of the molecular components of cultures H37Rv and BG1. Abbreviations: OADC = 
oleic acid, albumin, dextrose, catalase; Rpfs = resuscitation-promoting factors.  
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Filtration: Both the H37Rv and BG1 cultures were removed from the incubator and placed in a 
container before transporting to the biosafety cabinet (BSC). One mL of each culture was removed 
using a Gilson pipette and placed in a cuvette for OD600nm measurements. One mL of fresh media 
was added to another cuvette to serve as a blank control. The OD600nm of both the H37Rv and BG1 
cultures was read inside the BSC using a portable hand held spectrophotometer. After reading and 
recording the OD600nm, the cuvettes were discarded in a container containing 4% agluseptin.  
Thereafter, 45 mL of the remaining cultures was poured into appropriately labelled 50 mL falcon 
tubes and the lids closed tightly. The 50 mL falcon tubes were placed in centrifuge buckets inside 
the biosafety cabinet ensuring that the 50 mL falcon tubes were evenly distributed and the 
centrifuge was balanced. The cultures were centrifuged at 3900 x g for five minutes to harvest the 
bacterial cells. Following this, the centrifuge buckets were opened carefully inside the safety BSC 
and the 50 mL tubes were removed with care to prevent dislodging of the pellet. The centrifuge 
cabinets were wiped with 70% ethanol before returning to the centrifuge. The plunger was 
removed from the 50 mL syringe and a 0.22 µm filter (Millipore, USA) was screwed onto the tip. 
The supernatant was then gently decanted into the syringe leaving the pellet behind and the plunger 
was reinserted into the syringe. Pressure was applied to filter and remove any remaining cells in 
the CF into a 250 mL culture flask. Following filtration, the 50 mL syringes were decontaminated 
by rinsing the syringe several times in a liquid waste bucket containing 4% agluseptin. Forty six 
mL of 7H9 media and 4 mL of the antimicrobial mixture, PANTA (polymyxin B, amphotericin B, 
nalidixic acid, trimethoprim and azlocillin) was added to each culture bottle containing the filtered 
supernatant. The CF derived from the H37Rv and the BG1 strains were termed CF+ and Rpf – CF, 
respectively. 
For the media control, 4 mL of PANTA was added to a culture flask containing 96 ml of 7H9 
media.  Agluseptin (final concentration, 4%) was added to the 50 mL tubes containing the pellet 
cells before discarding and all equipment was wiped down with 4% agluseptin followed by 70% 
ethanol. Figure 3.4 illustrates the preparation of CF+ and Rpf – CF from bacterial strains H37Rv 
and BG1, respectively.  
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Figure 3.4 Preparation of culture filtrate and media control. Culture filtrate (CF) was prepared from bacterial 
strains, H37RV (red) and BG1 (ΔrpfA ΔrpfB ΔrpfC ΔrpfD ΔrpfE) (blue). To obtain CF, mycobacterial cultures were 
centrifuged at 3900 x g for 5 minutes. The resulting supernatant was filtered through a 0.22 μm syringe to remove any 
bacterial cells. The resulting CF was diluted two fold by the addition of 46 mL of 7H9 media and 4 mL polymyxin B, 
amphotericin B, nalidixic acid, trimethoprim and azlocillin (PANTA) reconstituted in oleic acid, albumin, dextrose, 
catalase (OADC). For the media control, 4 mL of PANTA was added to 96 mL of 7H9 media. 
 
3.4.3.1.2 Quality controls  
Following the daily preparation of CF+ and Rpf – CF, numerous quality controls were performed 
to ensure their sterility and that no cross contamination occurred during processing and the making 
of M. tuberculosis stocks. To ensure the sterility of the filtrate, a 1 mL aliquot of the CF+, Rpf – CF 
and media supplemented with PANTA was inoculated and spread out onto 7H11 plates and left to 
dry in the cabinet overnight. The following day, these plates were placed in the incubator at 37 ºC 
for six to eight weeks. The plates were checked on a weekly basis for the absence of contaminants 
and M. tuberculosis cells. An additional 1 mL aliquot from each filtrate was kept at 37 °C in 1 mL 
Eppendorf tube and monitored weekly to confirm the absence of bacterial growth. Liquid aliquots 
were kept for a minimum of eight weeks before being discarded. All results were recorded in an 
MS Excel spreadsheet for quality control (see Appendix 3D).  
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To ensure that the strain type was correct and no cross contamination of the CFs occurred during 
processing, a 1 mL aliquot of the CF+ and Rpf – filtrates were stored for PCR confirmation. It was 
assumed in this case that the CF derived from H37Rv and BG cultures contained DNA from the 
corresponding bacterial strain. Thus, PCR analysis, with primers targeting the rpf genes of the CF, 
would provide a means of confirming the genotype of the organism where from the CF was 
derived.  
PCR assay and preparation: The stored CF+ and Rpf – CF was removed from the -20 C freezer 
and left to thaw at ambient temperature (20 to 25 ºC). The primers were received in a powder form 
and were reconstituted using nuclease free water using instructions provided by the manufacturer. 
For the dNTPs, 10 µL of each nucleotide was added to 760 µL of nuclease free water. Primers are 
listed in Table 3.2. 
The master mix was prepared by adding the following reagents to a 2 mL Eppendorf tube: 8.0 µL 
of nuclease free water (Hyclone), 8 µL of GC rich,  8 µL dNTPs, 5 µL 10X PCR buffer, 5 µL of 
primers -F1, -R1 and –M and 0.3 µL of Taq polymerase (total volume per sample 44.3 µL). 
Following preparation, 40 µL of mastermix was added to pre-labelled PCR tubes using a 
multichannel pipette. Ten µL of CF was then added to each corresponding PCR tube. The mixture 
was placed in a PCR machine (Eppendorf Mastercycler). The thermal cycler was programmed as 
follows: five minutes at 95 ºC as initial denaturation, followed by 35 cycles of 30 seconds at 95 ºC 
for denaturation, 30 seconds at 60 ºC for annealing and 30 seconds at 72 ºC for extension. Final 
elongation was set at 72 ºC for 10 minutes.  The amplicons were stored at 4 °C until a gel was run 
to visualise the PCR products.  
Agarose gel to detect PCR products: A 1 % agarose gel was made by weighing 1 g of agarose 
powder and mixed into 100 mL of fresh 1X TAE (Tris, Acetic acid, EDTA) buffer in a 500 mL 
Erlenmeyer flask. The agarose was placed in a microwave for about two minutes until it came to 
a boil. The agarose was then placed on a magnetic plate stirrer and left to cool until it reached 
approximately 55 °C. When the agar was sufficiently cooled, 10 µL of ethidium bromide was 
added to the agarose gel and it was placed back onto the stir plate for an additional minute. Two 
thin 15 slot combs (for 28 samples and two spaces for the DNA ladder) were placed on the gel 
casting container accordingly to form wells. Approximately 30 mL of cooled agarose gel was then 
poured into the gel casting container (15 x 7 cm UVTP tray) and left to set for 30 to 60 minutes. 
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After the gel had set it was transferred to a gel box (Sub Cell GT System, Biorad) and covered 
with 1X TAE buffer. As a DNA marker, 3 µL of DNA ladder (marker VI) was added to the first 
well of each row and 3 µL of loading dye was added to 5 µL of PCR product. The products were 
then added to the appropriate well on the gel. The power supply was set to 80V and the samples 
were left to run for approximately one hour. 
Analysis: CF derived from the H37Rv and the BG1 mutant strain were assessed using two separate 
PCR reactions to ensure that the CFs were derived from the specified strains and that no cross 
contamination took place during filtration and CF preparation. For this, forward (F1), reverse (R1) 
and mutant (M) type specific primers were used to genotype both the rpfC and rpfE alleles. All 
three primers were added to the reaction mix to provide the opportunity to amplify the wild type 
or mutant bands. The CF from the H37Rv strain would yield band sizes of 371 bp and 357 bp for 
the rpfC and the rpfE wild type alleles, respectively. The CF from the BG1 strain on the other hand 
would yield PCR fragments of 556 bp and 575 bp for the rpfC and rpfE mutant alleles, respectively. 
As the mutant lacks the reverse primer 1 but has the region for the reverse primer 2 (designated 
M), the PCR product is larger, Figure 3.5. An example of a quality control analysis on a batch of 
CF is shown in Figure 3.6. This PCR analysis was done on all CF+ and Rpf – CF preparations from 
this study. If any inconsistencies were noted in CF preparations, the corresponding sputum samples 
were removed from the analysis. The results of the PCR checks on CF preparations is given in 
Appendix 3D. 
 
Table 3.2 Primers used for the amplification of wild-type and mutant Rpf strains 
Primer name Primer sequence (5’ – 3’) Application Amplicon properties 
RpfC-F1 CTCTATCAACGGGCCCTGAC Forward, reverse and mutant type 
primers used for  PCR 
genotyping of rpfC and ∆rpfC 
alleles 
371 bp amplicon from wild type 
rpfC allele using RpfC-F1/ RpfC-
R1 pair and 556 bp amplicon from 
mutant ∆rpfC allele using RpfC-
F1/ RpfC-M pair 
RpfC-R1 CACAGCAAACCCGAACTCAC 
RpfC – M GAACTGCAGTCCGCCGTATT 
RpfE-F1 TTATCGTACGGTCCCCTTGG Forward, reverse and mutant type 
primers used for  PCR 
genotyping of rpfE and ∆rpfE 
alleles 
357 bp amplicon from wild type 
rpfE allele using RpfE-F1/ RpfE-
R1 pair and 575 bp amplicon from 
∆rpfE allele using RpfE-F1/ 
RpfE-M pair 
RpfE-R1 TCAGGATCGGCCAGGTCT 
RpfE-M CGTCGGCATTGGCGATAC 
Abbreviations: Rpf = resuscitation-promoting factor; -F1 = forward primer; -R1 = reverse primer; -M = mutant  
Adapted from Kana et al. 2008. 
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Figure 3.5 PCR-based genotyping of wild-type and BG1-ΔABCDE strains. The figure above illustrates the 
amplification of rpfC (A) and rpfE (B) alleles in the wild-type and mutant strains using the primers depicted in Table 
3.2.   The southern blot figures on the right show the expected fragment sizes: rpfC, 371 bp, ΔrpfC, 556 bp rpfE, 357 
bp and Δ rpfE, 575 bp.  
 
 
Figure 3.6 Example of PCR quality control. PCR was carried out using rpfC primers on culture filtrate derived from 
M. tuberculosis H37Rv and the BG1 quintuple mutant strain (ΔrpfA ΔrpfB ΔrpfC ΔrpfD ΔrpfE) for sample batches 
processed in February 2015. Abbreviations: CF = culture filtrate; Rpf resuscitation-promoting factor. The blot 
confirms that CF was derived from the H37Rv and BG1 M. tuberculosis strain types, respectively as well as the 
absence of CF cross contamination.  
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3.4.3.1.3 MPN plate set-up and execution 
The MPN assay is based on the Poisson distribution and was designed to estimate the number of 
bacteria per mL based on serial dilution and presence-absence of growth in the resulting dilutions 
(McCrady, 1915). MPN assays were performed as previously described (Chengalroyen et al., 
2016). These assays were carried out in triplicate for each sample to detect and quantify the amount 
of CF-dependent, Rpf-independent and CF-independent bacteria present in patient sputum 
samples. Figure 3.7 defines the various DCTB populations isolated in CF-supplemented and un-
supplemented MPN assays. For the CF-dependent population, 450 µL of CF+ was added to the 
first three rows of a 48-well microtiter plates using a p1200 multichannel pipette. For the Rpf-
independent population, 450 µL of Rpf – CF was added to the last three rows of the first 48-well 
microtiter plate. As a control, 450 µL of fresh 7H9 media with no CF supplementation was added 
to the first three wells of an additional 48-well microtiter plate. 
Following decontamination, 50 µL of sputum sample was added to all the wells in the first column 
on both MPN plates. Ten-fold serial dilutions were subsequently performed for each MPN assay 
by transferring 50 µL from the first column to each subsequent well until reaching the end of the 
plate. For this, both P1200 and P300 multichannel pipettes were used. Using the left hand, the 
decontaminated sputum sample and CF were mixed using the P1200 pipette (set to 400 µL) by 
gently pipetting up and down five to ten times. Thereafter, 50 µL of liquid was transferred using 
the P300 pipette in the right hand to the adjacent well for each row. Fifty µL from the last column 
was discarded into a large petri dish (150 X 15 mm) containing disinfectant and the tips were 
rinsed by slowly pipetting up and down before discarding in a 4L sharps container.  
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Figure 3.7 Set up of culture filtrate- supplemented and un-supplemented most probable number assays. (A and 
B) Most probable number (MPN) assays were set up with culture filtrate (CF+) and resuscitation-promoting factor 
deficient (Rpf –) CF supplementation of growth media. CF was isolated from wild type Mycobacterium tuberculosis 
H37Rv and Rpf – CF from a quintuple rpf gene-knockout mutant, allowing for the detection of CF-dependent and Rpf-
independent differentially culturable tubercle bacteria (DCTB), respectively. (C) To control for the CF effect, MPN 
assays with no CF supplementation were also performed allowing for the detection of CF-independent DCTB. A 
description of the population detected in each assay is also provided.  
 
3.4.3.1.4 Incubation and plate scoring 
Once all MPN plates were diluted for the processing day, plates were sealed using yellow 
biohazard tape and placed in the incubator at 37 °C in a sealed zip-lock bag. The plates were scored 
on a weekly basis using an MPN scoring sheet. The MPN of bacteria for each assay was calculated 
using specialized software (available from: 
 http://www.wiwiss.fu.berlin.de/fachbereich/vwl/iso/ehemalige/wilrich/index.html). 
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3.4.3.1.5 Extraction and storage of MPN wells  
Following six weeks incubation, the plates were kept aside for storage of positive culture in the 
MPN wells. DNA extraction for genotyping of M. tuberculosis strains was prepared 
simultaneously. The yellow biohazard tape to seal the plates was carefully removed to ensure no 
spillage of contents into the biosafety cabinet. Twenty µL of sample from the first and last well 
with visible growth was removed from each MPN experiment type (i.e. CF+, Rpf – and No CF 
plates), and placed in a 1.5 mL Eppendorf tube containing 80 µL of TE buffer. The remainder of 
sample in the well was placed into a separate 1.5 mL Eppendorf tube for storage.  
 
3.4.3.2 Colony forming unit assays 
3.4.3.2.1 Set-up and execution 
Ten-fold serial dilutions were performed by adding 100 µL of decontaminated pellet to 1.5 mL 
Eppendorf tubes containing 900 µL of 7H9 broth. Two serial dilutions were performed for each 
sample (101 to 102) and an additional dilution was performed for baseline and particularly mucoid 
samples (103). Six 7H11 plates were left on the bench top for approximately one to two hours to 
dry and these were pre-labelled with stickers containing the sample number as well as the dilution 
factor. Each dilution was performed in duplicate. Before plating, samples were vortexed for 
approximately ten seconds to ensure adequate dispersion of organisms in the suspension. 
Following this, 100 µL from the serial dilution tubes as well as the neat sample was then transferred 
to Middlebrook 7H11 plates and a disposable loop was used to streak out the solution on the 7H11 
plate in order to obtain single colonies. For this, the plate was rotated for a minimum of four times 
after streaking was performed over the entire surface area of the 7H11 plate. 
 
3.4.3.2.2 Incubation and plate reading 
Following inoculation and streaking for single colonies, the six 7H11 plates were sealed in a gas 
permeable bag to prevent dehydration. The plates were placed in the incubator at 37 °C for a 
maximum incubation period of six weeks. The plates were examined every two weeks for growth. 
When single colonies were visible and at a size that was easy to count, the CFUs were recorded 
on a CFU scoring sheet.     
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3.4.4 Spoligotyping 
Spoligotyping was performed on positive stored MPN wells to identify M. tuberculosis strains 
present in the populations studied.  
 
3.4.4.1 Amplication of spacer DNA by PCR 
Spacer oligonucleotide genotyping or ‘spoligotyping’ was performed using the primers DRa 
[(5’biotin) GGTTTTGGGTCTGACGAC] and DRb (CCGAGAGGGGACGGAAAC) to amplify 
the entire DR region. 
 
3.4.4.1.1 Preparation of the mastermix 
The primers for spoligotyping were ordered from Mapmygenome (Hyderabad, India) for 
spoligotyping. These were received in a powder format (100 μM stock) and were reconstituted by 
the addition of 1 mL of nuclease free water. Two hundred µL aliquots were prepared for future 
spoligotyping assays. Once reconstituted, the biotin primer (DRa) was stored at 4 ºC and the DRb 
primer was stored at -20 ºC. The amplification was performed in a 25 µL reaction volume 
consisting of: 6.5 µL nuclease free water (Hyclone), 12.5 µL ReadyMix™ Taq PCR reaction mix 
(Sigma-Aldrich), and 2 µL of DRa primer, 2 µL of DRb primer and 2 µL of template DNA. 
Following preparation, the PCR tubes were spun down to remove any bubbles that may have been 
present in the tube. The mixture solution was amplified by PCR machine (Eppendorf 
Mastercycler). The thermal cycle was programmed for three minutes at 95 ºC as initial 
denaturation, followed by 30 cycles of one minute at 94 ºC for denaturation, one minute at 55 ºC 
as annealing, 30 seconds at 72 ºC for extension, and final elongation at 72 ºC for 10 minutes.  Once 
the run was completed, the PCR products were removed from the thermocycler and placed in the 
fridge at 4 °C until spoligotyping was ready to be performed.  
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3.4.4.2 Hybridization and detection 
Hybridization of biotin-labelled PCR products to immobilised spacer-oligos (membrane-bound) 
were visualised on film as black squares following incubation in streptavidin-peroxidase and ECL 
detection reagent. The presence or absence of black squares yielded a fingerprint or known 
sequence to determine the M. tuberculosis strain genotype. The process is detailed out below.  
 
3.3.4.2.1 Heat Denaturation of PCR products  
Twenty µL of PCR product was added to the appropriate pre-labelled PCR tube containing 150 
µL of 2X SSPE/ 0.1% Sodium Dodecyl Sulphate (2XSSPE/0.1% SDS) in the BSC. The diluted 
PCR products were subsequently transferred into a designated PCR rack designed to specifically 
fit into the PCR machine. The products were heat-denatured for 10 minutes at 99 ºC after which 
they were immediately transferred to ice. To prevent the tubes from popping open after transfer 
from the PCR machine to the ice, the lids were held firmly down using a paper towel.  
 
3.4.4.2.2 Membrane preparation, hybridisation and detection 
A commercially available spoligotyping membrane (Mapmygenome, India) was washed twice in 
2X SSPE/0.1% SDS and placed in the oven at 60 ºC for five minutes. Following the wash step, the 
membrane was placed on a membrane cushion in a mini-blotter (Mapmygenome, India) with the 
slots running perpendicular to the line pattern on the membrane. In order to obtain the correct 
orientation, the membrane was placed on the mini-blotter with a ‘cut-out’ shape placed on the 
bottom left of the grooved surface, with the numbered wells on the top of mini-blotter running in 
the opposite direction. The membrane was subsequently covered with a membrane cushion, after 
which any excess fluid was removed by wiping with the cushion with a paper towel. The back of 
the mini-blotter was placed on top on the cushion, after which it was flipped over and sealed tightly 
with plastic screws. Any residual fluid was removed from the slots by aspiration. Following this, 
the slots were filled with diluted PCR product (approximately 150 to 160 µL). This was done in a 
slow and controlled motion to try and avoid the creation of air bubbles. The first and last wells 
were left ‘blank’ and filled with 2X SSPE/0.1% SDS and a H37Rv and BCG strain were included 
as controls. A no DNA control was also included for each run. The mini-blotter was transferred to 
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the hybridization oven and placed on horizontal surface at 60 °C for one hour. Following 
hybridization, the samples were removed from the mini-blotter by aspiration, after which the 
blotter was opened and the membrane was washed twice in 2X SSPE/0.5% for five minutes at 60 
°C. For chemiluminescent detection, the membranes were labelled by incubation in roller bottles 
at 42 °C in 40 mL 2X SPPE/0.5% SDS containing 10 µL Streptavidin-peroxidase conjugate 
(500U/mL) for one hour.  The membrane was covered with Saran-wrap and exposed to three sheets 
of light sensitive film for 20 minutes. The X-ray films were developed manually in the dark room. 
The M. tuberculosis genotypes were determined by entering the presence or absence of spacer 
sequences with a 1 or 0 using the following website: http://tbinsight.cs.rpi.edu/run_spotclust.html, 
last accessed 10 July 2017 (Vitol et al., 2006).  
 
3.4.5 Data analysis 
Bacillary load measures (i.e. CF+, Rpf –, MPN no CF and CFU assays) were compared between 
groups using the Wilcoxon matched-pairs signed-ranks test and data are reported as medians with 
interquartile ranges. To determine the various patient populations (i.e. mixed DCTB, no DCTB, 
CF-dependent, Rpf–independent and CF-indepdent), the resuscitation index (RI) was calculated 
[RI = log (MPN/CFU)] to determine the quantum of resuscitatable bacteria. Spearman’s rank sum 
correlation was employed to further assess the relationship between CF-dependent and Rpf-
independent populations. Patient demographics and TB diagnostic data were stratified by HIV-
infection status. Absolute numbers and percentages were calculated for patient demographics (i.e. 
gender and BMI) and TB diagnostics (i.e. ZN smear status, qualitative Gene XPERT results and 
M. tuberculosis strain type) and the chi-squared test for proportions was used to compare the two 
groups. Demographics and TB diagnostics consisting of continuous variables (i.e. age, MGIT TTP, 
Gene XPERT Ct values) were compared using the students unpaired t-test. MPN and CFU data 
were compared between groups using the Mann-Whitney U test. To  assess the role of host 
immunity on the generation of DCTB, the Mann-Whitney U test was used to compare patients by 
their HIV-infection status, as well as immune competency (HIV-positive patients grouped into 
CD4 T-cell count > or < 200 cells/mm3). All statistical tests were two-sided and statistical 
significance was carried out using a 95% confidence interval. 
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3.5 RESULTS 
3.5.1 Patients included in baseline analysis 
A total of 174 patients were recruited into the study through the clinical platforms of the PHRU 
from TB diagnostic clinics in the Soweto (132 patients) and Klerksdorp (43 patients) regions. The 
participant disposition flowchart for these participants is given in Figure 3.8. From each cohort, 
the arrows depict patients that were removed from the study for various clinical and laboratory 
reasons.  Screen failures denoted by (a) include patients that were initially screened for the study 
and then found to not meet the study requirements. Additional patients were terminated from the 
study and reasons for their removal are documented in Table 3.3 (b). Technical aspects denoted by 
(c) include MPN assays performed for patient samples that were incubated in Biolite 48-well plates 
(a brand of microtiter plate that inhibited growth in the MPN assay). This aspect is further 
discussed in section 3.5.2. An additional two patients were excluded as no sputum samples were 
received for baseline MPN and CFUs (d). Data from a total of 80 patients were available for 
baseline analysis. 
Table 3.3 shows the 22 patients were that terminated from the study, denoted as (b) in Figure 3.8, 
and excluded from baseline analysis. In many cases, patients were excluded due to a previous TB 
infection (40.9%) or consent withdrawal (27.3%). The additional patients were excluded for 
reasons such as relocation (9%), death (1 patient), default (9%) or they were lost to follow-up 
(9%). In addition, data from the latter patients could not be used in baseline or early treatment 
analysis as they were also affected by technical issues (*), denoted as (c) in Figure 3.8, that affected 
the MPN results at baseline. 
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Figure 3.8 Participant disposition flow chart. A total of 174 patients were recruited into this study. These patients 
had a strong clinical suspicion for tuberculosis (TB) disease either through a positive smear or positive GeneXpert 
result. Of these, 132 and 43 were from clinics in Soweto and Klerksdorp, respectively. Twenty six (18 and 8 patients 
from each site) were classed as screen failures (a). Individuals classified as screen failures were initially enrolled into 
the study, but were later found to not meet the study criteria. An additional 22 (21 and one from each site) patients 
were terminated from the study (b). Reasons for study termination are provided in Table 3.3. An additional 45 patients 
were excluded from analysis due to technical issues (c) (see section 3.5.2). Two patients were excluded from analysis 
as no baseline sputum samples were collected (d). Baseline analysis was performed on a total of 80 patient samples.  
 
Table 3.3 Reasons for patient termination from study 
Reason for termination from study 
(n = 22) 
Number of patients (%) Patient ID 
Relocation 2 (9.1) 59001, 59124* 
Consent withdrawal 6 (27.3) 59061*, 59077*, 59116*, 59130, 
59132, 57156 
History of TB infection 9 (40.9) 59009, 59013, 59020, 59033, 
59040, 59043, 59059*, 59079*, 
59121* 
Death 1 (4.5) 59117* 
Treatment Default 2 (9.1) 59097*, 59111* 
Lost to follow-up/Missed visits 2 (9.1) 59107*, 59101* 
* Baseline patient data also affected by technical issues. These technical issues involved the use of growth inhibiting   
48-well microtiter plates sealed with autoclave tape.  
110 
 
3.5.2 Technical issues leading to inhibition of growth on MPN assays 
Data from 45 patients were excluded from baseline analysis due to a technical problem that 
occurred in the MPN assay. The brand of plates that were routinely used (Nunc from Thermo 
Scientific) were replaced with similar plates (Biolite plates from Thermo Scientific) due to cost 
saving. An assurance was provided by the supplier that bacterial growth will not be affected. 
However, MPN data for the samples were performed on Biolite 48-well plates yielded poor growth 
compared to other baseline samples processed on Nunc 48-well plates. As there was a general 
sense of baseline MPN data from a large number of patients already assessed at the CBTBR, it 
was hypothesized that the change of plates led to anomalies in the growth of bacteria. To test this, 
real-time analysis of patient data during the project revealed an inhibition of growth at baseline 
and during early treatment which became apparent when compared to the CFU data obtained. 
Initially, it was assumed that the first few patients affected belonged to subpopulation 5 described 
by Chengalroyen et al. (2016), whereby no DCTB were present and only CFUs could be obtained 
from these patients. However, these results occurred repeatedly with baseline patients. Figure 3.9, 
A, B, and C illustrates the inhibition of growth in three patients. In these patients, robust CFU 
counts were obtained at baseline and during the first few time points however, MPN data were 
consistently low.  
 
 
Figure 3.9 Examples of bacterial growth inhibition in the most probable number assay performed on Biolite 
48-well plates in three patients. (A) Log bacterial counts for most probable number (MPN) assays set up with culture 
filtrate (CF+) (red bars), resuscitation-promoting factor deficient (Rpf  –) CF (blue bars) and standard 7H9 media (green 
bars) are compared with log bacterial counts from standard colony forming unit (CFU) assays (purple bars) for patients 
(A) 59064, (B) 59066 and (C) 59072 up to 7 days post treatment initiation. The black arrows indicate unusually low 
MPN counts relative to the corresponding CFUs in several patient samples leading to the conclusion that the MPN 
assay was faulty and further investigation and troubleshooting was required.  
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Initially it was not clear as to why growth was inhibited in the MPN assay. Troubleshooting was 
performed to investigate possible reasons for the discrepancy between the MPN and CFU assay. 
This included the preparation of new media as well as Tween 80 as detergent can inhibit bacterial 
growth (Wayne, 1994). Following no improvement, the 48-well MPN plates were tested using 
axenic M. tuberculosis cultures to ensure that this phenomenon was due to growth inhibition in the 
plates per se and not due to DCTB subpopulations in sputum. In addition, two different types of 
tape (used to seal the MPN plates) were tested to assess if this could also be a potential confounder. 
For this, four experiments were performed: (1) MPN assays on NUNC plates sealed with biohazard 
tape, (2) MPN assays on NUNC plates sealed with autoclave tape, (3) MPN assays on Biolite 
plates sealed with autoclave tape and (4) MPN assays on Biolite plates sealed with biohazard tape. 
The results from this experiment indicated that optimal growth of M. tuberculosis was achieved 
using the NUNC/biohazard tape combination (1), Figure 3.10. 
Figure 3.10 Discrepancies in bacterial growth detected using two different commercially available 48-well 
microtiter plates, NUNC and Biolite, sealed with biohazard tape or autoclave tape. (A) Photographs of MPN 
plates with M. tuberculosis H37Rv growth after incubation at 37 ºC for one week. (NB) Nunc 48-well culture plates 
sealed with yellow biohazard tape, (NA) Nunc 48-well culture plate sealed with autoclave tape, (BB) Biolite 48-well 
plate sealed with yellow biohazard tape and (BA) Biolite 48-well plate sealed with autoclave tape. (B) Graph 
illustrating differences in bacterial growth across the four experiments. Abbreviations: NB = Nunc/Biohazard, NA = 
Nunc/Autoclave, BB = Biolite/Biohazard and BA = Biolite/Autoclave.  
 
MPN plates were observed after one and six week’s incubation at 37 ºC. The NUNC and Biolite 
48-well plates sealed with biohazard tape had growth in the 7th and 5th dilution wells following one 
week incubation, equivalent to 7.7 and 5.7 log bacteria per mL, respectively. The NUNC and 
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Biolite plates sealed with autoclave tape had growth in the first, and some additional central wells, 
equivalent to 2.3 and 1.7 log bacteria per mL, respectively. The MPN plates in Figure 3.10 were 
recorded after one week of growth, however, after six weeks incubation no further bacterial growth 
was present in wells that were previously scored as blank on NUNC and Biolite plates sealed with 
autoclave tape. These data suggested that sealing the MPN plates with autoclave tape, for as yet 
unknown reasons, inhibited the growth of bacteria. A potential reason for this observation may 
include the presence of growth inhibiting chemicals embedded in this particular autoclave tape. 
Alternatively, a more porous tape may have led to an increase in gas exchange or media 
evaporation, resulting in changes in the microenvironment and subsequent bacterial growth. 
Following these observations, all MPN experiments were performed only on NUNC plates sealed 
with biohazard tape for optimal recovery of bacteria. All data from Biolite plates were removed 
from further analysis. These data are reflected as patient samples that were removed from the 
analysis due to technical reasons in Figure 3.8.  
 
3.5.3 Baseline analysis 
3.5.3.1 The culture filtrate effect 
In the overall patient population, positive cultures were obtained in 59/80 patients (73.8%) by CFU 
compared to 78/80 patients in the CF+ MPN assay (97.5%). To further determine the effect of CF-
supplementation on the recovery of M. tuberculosis from patient sputa, the log bacterial loads 
obtained in the CF+, Rpf –, no CF MPNs and CFU assays were compared.  
Figure 3.11 represents a scatter plot illustrating the log bacterial loads obtained from sputum 
samples collected from the 80 patients included for analysis at baseline. In most cases, data from 
the O/N sputum samples was used. Preliminary analysis revealed a higher quantum of bacteria in 
these samples. In certain instances where data from the O/N MPN or CFU sample was 
contaminated or poor, data from the spot sample was used. Statistical significance between the 
various assays was conducted using the Wilcoxon matched-pairs signed-ranks test with a 
confidence interval set at 95%. The addition of CF (with and without Rpfs) was found to 
significantly increase the recovery of a population of M. tuberculosis cells that could not be 
detected by CF un-supplemented MPN assays and conventional CFU assays (a P value of <0.0001 
was obtained for all comparisons between both CF supplemented MPN assays when compared to 
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the MPN no CF and CFU assays). These findings are in agreement with a number of previous 
publications that have demonstrated that sputum samples are dominated by a population of cells 
that cannot be cultured using conventional microbiological methods. In addition, a higher number 
of bacteria could be recovered in the CF-supplemented MPN assay when compared to the Rpf – 
MPN assays (median log 5.95 versus log 5.72, P = 0.0320). No significant difference was observed 
between the MPN no CF and CFU assays (P = 0.8005).  
 
Figure 3.11 The effect of culture filtrate on the recovery of differentially culturable tubercle bacilli in treatment 
naïve patients. Scatter plots illustrate the bacterial load distributions obtained in 80 patients at baseline. Error bars 
represent medians and interquartile ranges. To determine statistical significance, the Wilcoxon matched-pairs signed-
ranks test was used with a 95% confidence interval. CF+ MPN (red), Rpf – MPN (blue), MPN no CF (green) and CFU 
(purple). CF = culture filtrate; MPN = most probable number assay. Significant differences are depicted in bold.  
 
To further determine whether the resuscitative effect was restricted to Rpfs (and not due to 
stimulation via other molecules present in CF), resuscitation indices were calculated for both the 
CF+ and Rpf – MPN assays. Spearman’s rank sum correlation analysis revealed a positive 
correlation of 0.84 in baseline sputum samples between these two assays, Figure 3.12, confirming 
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that a high MPN count in the CF+ assay was associated with a high count in the Rpf – CF assay. 
These results suggest that, in most cases, factors other than Rpfs are also involved in the 
resuscitation of DCTB. Indeed, cAMP and various fatty acids, such as oleic acid which are also 
present in CF, have been implicated in the resuscitation of dormant bacteria (Shleeva et al., 2013). 
On average, the CF+ MPN assay had a RI of 0.2 log greater than that observed in the Rpf – MPN 
assay indicating a marginal benefit of Rpfs in resuscitation.  
 
Figure 3.12 Correlation of resuscitation index (RI) between culture filtrate-supplemented most probable 
number assays with and without resuscitation-promoting factors (Rpfs). The resuscitative effect between most 
probable number (MPN) assays performed with culture filtrate (CF) derived from wild-type Mycobacterium 
tuberculosis H37Rv (CF+) and from a quintuple rpf gene-knockout mutant (Rpf –) was correlated to determine the 
resuscitative effect. A significant correlation was obtained between log RI Rpf- and log RI CF+ (r = 0.8383, P > 0.0001, 
Spearman rank-sum correlation). Red circles show the presence of differentially culturable organisms from two 
patients that were entirely dependent on Rpfs for growth.  
 
3.5.3.2 Patient sub-populations at baseline 
Of the 80 patient sputum samples analysed at baseline, 71 (88.8%) harboured populations of both 
CF-dependent and Rpf-independent DCTB, Figure 3.13. Within this mixed-population, 17 (24%) 
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patients displayed higher levels of Rpf-independent bacteria when compared to CF-dependent 
bacteria illustrating suppression of growth by Rpfs in this case. In contrast, 25 (35%) patients 
displayed higher levels of CF-dependent bacteria, whilst the same number of CF-dependent and 
Rpf-independent bacteria were obtained in 29 (41%) patients (see Figure 3.14).  Of the remaining 
nine patient samples, three (3.8%) yielded CF-dependent DCTB with no detected Rpf-dependent 
DCTB, one patient harboured Rpf-independent DCTB, an additional patient had a negative MPN 
and no CFUs at baseline and five patients had CFUs with no DCTB (i.e. the number of organisms 
detected in the CF-supplemented MPN assays was lower than the CFU obtained). The patient with 
negative MPNs and no CFUs (57133) at baseline was included in the study as M. tuberculosis was 
cultured at subsequent time points (see chapter 4 for the longitudinal analysis). In addition, the 
baseline spot sample for this patient was positive for MTBC in the MGIT (positive culture after 
30 days, AFB present on ZN strain, and positive for MTBC on HAIN MTBDRplus) and 
GeneXpert (Ct value: 30.6) assays. 
No patients in this cohort had CF-independent DCTB (i.e. more organisms in MPN no CF assay 
than in CF-supplemented MPN assays and CFU). Figure 3.14 illustrates the subpopulations of M. 
tuberculosis isolated from the 80 patients analysed in this PhD. Furthermore, it highlights the 
variability within the mixed DCTB patient subpopulation. 
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Figure 3.13 Distribution of differentially culturable tubercle bacilli in treatment-naïve tuberculosis patients. 
The 80 patients included for analysis are listed on the y-axis with their relative proportions of differentially culturable 
tubercle bacilli (DCTB) [i.e. the quantum of bacteria that require resuscitation relative to the colony forming units on 
solid media, reported as the resuscitation index or RI where RI = Log10 (MPN/CFU)]. Culture filtrate (CF)-dependent 
bacteria, calculated as log (CF+ MPN/CFU) are reflected in red on the right side of the y-axis, whilst Rpf-independent 
bacteria, calculated as log (Rpf – MPN/CFU), are illustrated in blue on the left side of the y-axis. In cases where the 
CFU was zero, a value of 1 was used to reflect the absence of culturable bacteria, which indicates that the entire 
population in the MPN assay constituted DCTB. Patients with both red and blue bars harboured both CF-dependent 
and Rpf-independent DCTB populations. The absence of either red/blue or both bars indicate no detectable DCTB for 
the relevant population(s). The box depicts log CFU counts in samples with no detectable DCTB populations (purple 
bars). Abbreviations: MPN = most probable number; Rpf = resuscitation-promoting factor; CFU = colony forming 
unit.  
 
 
Figure 3.14 Distinct subpopulations of M. tuberculosis isolated from 80 treatment-naïve patients analysed in 
this thesis. (A) The number of coloured circles represents the proportion of patients with differentially culturable 
tubercle bacilli or CFU as indicated: three, > 50%; two, 2 – 50%; one <2%. (B) Within subpopulation 1 which consists 
of both CF-dependent and Rpf-independent bacteria, some patients exhibited a higher quantum of either CF-dependent 
or Rpf-independent DCTB, whilst others harboured equal numbers of bacteria that could be cultured by either CF+ or 
Rpf – CF. Definition of abbreviations: CF = culture filtrate; MPN = most probable number assay, Rpf – = 
resuscitation-promoting factor negative; CFU = colony forming unit. 
 
3.5.3.3 DCTB and host immunity 
Chengalroyen et al. (2016) previously hypothesized and demonstrated that patients with 
compromised immunity have a lower quantum of DCTB when compared to individuals who are 
not HIV-infected. This observation was further investigated in a distinct cohort in this PhD. For 
this, patients were further stratified according their HIV status and HIV-positive patients were 
further divided according to their CD4 T-cell count. In addition, differences in patient 
demographics, routinely used TB diagnostics and strain type are reported, Table 3.4.   
Of the 80 patients analysed at baseline, 68.8% were HIV-positive (n = 55), 68.8% were male and 
the median age was 36 years (IQR: 27 – 44 years). Many of these patients were underweight 
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(42.5%) and the median BMI was 19.1 (IQR: 17.9 – 21.5).  The median age of the HIV-positive 
patient group was eleven years older than the HIV-negative TB group (P = 0.0558, students 
unpaired t-test). The majority of the population, both male and female, were HIV positive (61.8% 
and 84%, respectively). No significant differences were observed in BMI between the two groups. 
Lung pathology data was available for 34/48 patients analysed in the Soweto cohort only (see 
Appendix 3E). No chest X-ray data were available for any of the Klerksdorp patients. Analysis 
was carried out on the available data and no significant differences were observed between HIV-
positive and –negative individuals in terms of pleural disease and infiltrates in both the left and 
right lungs. However, HIV-positive patients were more likely to present with lung adenopathy (P 
= 0.0283). Interpretation of this data is limited due to an incomplete data set and small sample size.  
In terms of TB diagnostics, as expected, HIV-negative patients had higher rates of smear positivity 
(92%) than HIV-positive patients (67.3%) (P = 0.0179, chi-square test). Furthermore, HIV-
negative patients had high bacterial loads, with the majority of patients (60%) having a P+++ smear 
grade. A large proportion of HIV-positive patients were smear negative (32.7%) and consistent 
with this, these patients had a higher GeneXpert cycle threshold (median 22.1 versus 18.2 in HIV-
negative patients, P = 0.0644, unpaired t-test) and statistically had a significant lower qualitative 
score (P = 0.0256, chi-square test).  The median MGIT TTP was also significantly elevated in 
HIV-positive patients at 9.0 days (IQR: 5.0 – 17.0) versus 6.0 days in HIV-negative patients (IQR: 
3.5 – 7.5) (P = 0.0246, unpaired t-test).  
Differences in bacterial burden, stratified by HIV-infection status is shown in Figure 3.15 (and 
Table 3.4). Sputum samples collected from the HIV-negative cohort at baseline had significantly 
higher numbers of both CF+ and Rpf – MPN counts when compared to their HIV-positive 
counterparts (log 8.3 versus 5.2 and log 7.9 versus 4.3, respectively; unadjusted P values: 0.0375 
and 0.0276). Furthermore, HIV-negative individuals also had significantly higher levels of 
plateable bacteria as detected by CFU assays (log 4.8 versus log 2.8, P = 0.0037). These results 
suggest that patients with compromised immunity contain a lower quantum of both DCTB and 
culturable bacteria in their sputum possibly as a result of disseminated disease. Alternatively, since 
immunity is compromised, there may be less environmental pressures on these organisms to revert 
to these differentially cultured states. No differences were observed in the estimated numbers of 
bacteria cultured in the MPN no CF assay (log 3.0 versus 2.7, P = 0.2495).
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Table 3.4 Demographics, immunology, microbiology and diagnostic data for tuberculosis patients categorized by HIV-infection status and 
C4 T-cell counts 
Variable 
Overall 
(n = 80) 
HIV Negative 
(n = 25) 
HIV Positive 
(n = 55) 
P Value * † 
CD4 <200 
(n = 33 ) 
CD4 >200 
(n = 22 ) 
P Value * † 
Demographics        
Male, n (%) 55 (68.8) 21 (84.0) 34 (61.8) 0.0473 21 (63.6) 13 (59.1) 0.7739 
Female, n (%) 25 (31.3) 4 (16.0) 21 (38.1)  12 (36.4) 9 (40.9)  
Age, yr, median (IQR) 36.0 (27.0- 44.0) 27.0 (22.5 -48.0) 38.0 (31.0 – 43.0) 0.0558 39.0 (31.5 – 43.0) 35.5 (29.8 – 45.3) 0.5987 
BMI        
Underweight, n (%) 34.0 (42.5) 10.0 (40.0) 24.0 (43.6) 0.7604 14.0 (42.4) 10.0 (45.5) 0.8243 
Normal, n (%) 37.0 (46.3) 12.0 (48.0) 25.0 (45.5) 0.8324 15.0 (45.5) 10.0 (45.5) 0.3265 
Overweight, n (%) 8.0 (10.0) 2.0 (8.0) 6.0 (10.9) 0.6877 4.0 (12.1) 2.0 (9.1) 0.4788 
Unknown, n (%) 1 (1.2) 1.0 (4.0) - 0.1355 - -  
Median (IQR), kg/m2 19.1 (17.9 – 21.5) 19.1 (17.7 – 21.1) 18.9 (17.8 – 21.7) 0.4666 18.9 (17.8 – 22.2) 19.5 (17.9 – 21.6) 0.9732 
Patient Immunology 
cells/mm3, median (IQR) 
NA NA 
167.0 (93.0 – 
310.0) 
NA 
101.0 (54.0 – 
144.5) 
340.0 (245.8 – 
428.0) 
<0.0001 
Conventional TB 
diagnosis, n (%) 
       
Auramine smear        
Smear grade positive †† 60.0 (75.0) 23.0 (92.0) 37.0 (67.3) 0.0179 23.0 (69.7) 14.0 (63.6) 0.6389 
Smear grade negative 20.0 (25.0) 2.0 (8.0) 18.0 (32.7)  10.0 (30.3) 8.0 (36.4)  
Scanty 8.0 (10.0) 2.0 (8.0) 6.0 (10.9) 0.6877 4.0 (12.1) 2.0 (9.1) 0.7240 
+ 12.0 (15.0) 2.0 (8.0) 10.0 (18.2) 0.2371 7.0 (21.2) 3.0 (13.6) 0.4755 
++ 11.0 (13.8) 4.0 (16.0) 7.0 (12.7) 0.6936 5.0 (15.2) 2.0 (9.1) 0.5088 
+++ 29.0 (37.5) 15.0 (60.0) 14.0 (27.3) 0.0017 7.0 (21.2) 7.0 (31.8) 0.3764 
GeneXpert result        
High, n (%) 24.0 (30.0) 11.0 (44.0) 13.0 (23.6) 0.0654 6.0 (18.2) 7.0 (31.8) 0.2436 
Medium, n (%) 22.0 (27.5) 10.0 (40.0) 12.0 (21.8) 0.0914 8.0 (24.2) 4.0 (18.2) 0.5939 
Low, n (%) 19.0 (23.8) 2.0 (8.0) 17.0 (30.9) 0.0256 14.0 (42.4) 3.0 (13.6) 0.0236 
Very low, n (%) 10.0 (12.5) 2.0 (8.0) 8.0 (14.5) 0.4119 4.0 (12.1) 4.0 (18.2) 0.6246 
MTB not detected, n (%) 5.0 (6.3) 0 (0.0) 5.0 (9.1) 0.1368 1.0 (3.0) 4.0 (18.2) 0.3384 
Median (IQR),  
Xpert cycle threshold‡ 
20.3 (15.4 – 25.4) 18.2 (15.0 – 20.8) 22.1 (15.5 – 26.2) 0.0644 
22.6 (17.1 – 26.0) 
20.8 (14.0 – 27.6) 0.5407 
MGIT time t positivity, 
days, median (IQR) 
7.0 (4.3 – 14.8) 6.0 (3.5 – 7.5) 9.0 (5.0 – 17.0) 0.0246 8.0 (5.5 – 15.0) 9.5 (4.0 – 21.0) 0.5113 
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MPN 
CF+ MPN, log median 
(IQR) 
6.0 (2.7 – 8.7) 8.3 (3.9 – 8.7) 5.2 (2.7 – 8.7) 0.0357 5.2 (2.7 – 7.9) 5.0 (1.7 – 8.7) 0.8733 
Rpf – MPN, log median 
(IQR) 
5.7 (2.7 – 8.7) 7.9 (3.6 – 8.7) 4.3 (2.3 – 8.7) 0.0276 4.5 (2.3 – 7.3) 3.6 (1.7 – 8.7) 0.8130 
MPN no CF, log median 
(IQR) 
2.7 (1.7 – 4.7) 3.0 (1.7 – 5.9) 2.7 (1.7 – 3.7) 0.2495 2.7 (1.7 – 4.1) 1.7 (0.6 – 3.6) 0.1608 
CFU        
CFU, log median (IQR) 3.8 (0.0 – 5.1) 4.8 (3.0 – 5.6) 2.8 (0.0 – 4.5) 0.0037 3.1 (0.0 – 4.7) 2.3 (0.0 – 4.3) 0.7060 
Definition of abbreviations: BMI = body mass index; CF = culture filtrate; IQR = interquartile range; MGIT = mycobacterial growth indicator 
tube; MPN = most probable number; CFU = colony forming unit; NA = not applicable; Rpf – = resuscitation-promoting factor independent; TB = 
tuberculosis; n = number 
*P value compares HIV-positive versus HIV-negative and HIV-positive patients with CD4 count above and below 200 cells/mm3; Significant at P 
less than 0.05 (95% confidant interval) shown in bold.  
† All the proportion comparisons by HIV status or CD4 T-cell count were conducted using the chi-square test. 
†† Includes scanty, +, ++ and +++ 
‡ GeneXpert: M. tuberculosis was not detected in five patients (HIV-positive cohort). These patients were omitted from column statistics, i.e. HIV-
negative n = 25; HIV-positive n = 50. Overall column statistics obtained from 75 patients.  
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These results are in agreement with that shown by Chengalroyen et al. (2016) and provides further 
evidence that compromised host immunity is associated with a reduction in DCTB as well as 
platable bacteria. In contrast to work previously reported, a significant difference was also seen in 
Rpf – MPN bacterial sub-populations between HIV-infected and –uninfected individuals 
(Chengalroyen et al., 2016). In recent work, host factors that may modulate DCTB in EP sites was 
investigated in 18 patients (Rosser et al., 2017). A significant correlation was found between host 
peripheral lymphocyte count and DCTB (P = 0.04), but no other host parameters (including HIV-
infection status) were significantly associated with DCTB (Rosser et al., 2017). 
 
Figure 3.15 Measure of bacterial load straitified by HIV-infection status. Scatterplot depicting bacterial load 
distributions in HIV-infected/ uninfected individuals. Error bars represent medians and interquartile ranges. To 
determine statistical significance, the Mann-Whitney U test was used with a 95% confidence interval.  CF+ MPN (red), 
Rpf – MPN (blue), MPN no CF (green) and CFU (purple). Depicted in bold are significant differences between the 
two groups with a 95% confidence interval. CF = culture filtrate; MPN = most probable number assay; Rpf = 
resuscitation-promoting factors; CFU = colony forming units; HIV = human immunodeficiency virus. 
L
o
g
 b
a
c
te
r
ia
l 
c
o
u
n
t 
(M
P
N
/C
F
U
)
C
F
+
 M
P
N
R
p
f 
-  
M
P
N
M
P
N
 n
o
 C
F
C
F
U
C
F
+
 M
P
N
R
p
f 
-  
M
P
N
M
P
N
 n
o
 C
F
C
F
U
0
2
4
6
8
1 0
P  =  0 .0 3 5 7
P  =  0 .0 2 7 6
P  =  0 .2 4 9 5
P  =  0 .0 0 3 7
H IV  -
n  =  2 5
H IV  +
n  =  5 5
122 
 
As HIV-positivity was associated with reduced bacterial load as determined by the CF+ and Rpf – 
supplemented MPN assays as well as the CFU assays, the involvement of the immune system was 
further explored by dividing patients into two sub-groups according to their CD4 T-cell counts, 
i.e. less than and greater than 200 cells/mm3. This classification was used as acquired 
immunodeficiency syndrome (AIDS) is defined as all HIV positive individuals with a CD4 count 
of less than 200 cells per μL. The hypothesis was that patients with high CD4 T-cell counts will 
harbour more DCTB, similar to that observed in HIV-negative individuals. In contrast to a 
previous study, we found no significant differences between the two groups in the MPN and CFU 
supplemented assays (Figure 3.16 and Table 3.4). 
It is unclear why this difference did not manifest in our cohort. In the present study, generally a 
higher quantum of DCTB (and wider spread of organisms between patients) was isolated in the 
CF+ MPN assay compared to the previous study. For instance, in patients with a CD4 T-cell counts 
less than 200 cells/mm3 the median bacterial load in the present study was log 5.2 (IQR: 2.6 – 7.9) 
compared to the previous study where the median bacterial load was log 1.9 (IQR: 1.3 – 3.3). The 
same pattern was seen in patients with CD4 T-cell counts greater than 200 cells/mm3 [log 5.0 
(IQR: 1.7 – 8.7), current study versus log 3.6 (IQR: 2.3 – 6.2), previous study]. It is likely that the 
differences in bacterial load accounted for the different conclusions drawn with respect to CD4 T-
cell count and host immunity. The higher bacterial loads isolated in the present study may have 
occurred due to slight changes in protocol (i.e. splitting the sputum between CLS and the CBTBR 
for different assays versus splitting the pellet following decontamination for different assays). 
Other factors that may have contributed could include higher rates of smear positivity in this 
patient cohort, time prior to care seeking as well as the quality/quantity of sputum received. In the 
current study, sputum samples greater than 3 mL in volume were requested.  
To further explore the association between host immunity and the presence of bacterial sub-
populations, an alternative analysis was carried out and CD4 T-cell count was correlated with 
MPN (CF+, Rpf – and no CF) and CFU values obtained at enrolment. Using Spearman’s rank sum 
correlation statistics, no significant correlation was found between baseline MPN/CFU and CD4 
T-cell counts, Table 3.5.  
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Figure 3.16 Measure of bacterial load straitified by CD4 T-cell counts. Scatterplot depicting bacterial load 
distributions in HIV-positive patients with advanced immune suppression (low CD4 T-cell counts, i.e.  <200 
cells/mm3) versus patients with protective immunity (high CD4 T-cell counts, i.e. >200 cells/mm3). Error bars 
represents medians and interquartile ranges. To determine statistical significance, the Mann-Whitney U test was used 
with a 95% confidence interval.  CF+ MPN (red), Rpf – MPN (blue), MPN no CF (green) and CFU (purple). CF = 
culture filtrate; MPN = most probable number assay; Rpf = resuscitation-promoting factors.  
 
Table 3.5 CD4 T-cell count is not correlated with MPN or CFU values at baseline 
Spearman’s correlation CF+ MPN RPF – MPN MPN no CF CFU 
     
Correlation value (rs) -0.089 -0.100 -0.294 -0.115 
P-value 0.520 0.466 0.029 0.406 
     
Definition of abbreviations: CF = culture filtrate; Rpf = resuscitation-promoting factor; CFU = colony forming unit 
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3.5.3.4 Strain diversity  
Spoligotyping was performed on positive MPN wells from the 80 patients at baseline to (1) gain 
a better understanding of the diversity within the study population, and (2) to determine whether 
certain strain types were more likely to respond to CF-supplementation.  The M. tuberculosis 
strain distribution from Soweto and Klerksdorp regions are given in Figure 3.17.  
 
Figure 3.17 Mycobacterium tuberculosis strain distribution by geographic location. (A) M. tuberculosis strain 
distribution in the Soweto cohort. Strains from three patients could not be determined and are not reflected in the 
figure. Values for strain types identified in more than four patients are given. Values in parentheses illustrate overall 
percentages. Strains from patients that were not identified are included in the calculation of the overall percentage.  
T1 = blue, W-Beijing = red, LAM = purple, X-family = orange, CAS = pink (n =3) Haarlem = dark blue (n = 2), S-
Family = green (n = 2), EAI = yellow (n = 1), T4 = black (n=1) and F36 = white (n = 1). (B) M. tuberculosis strain 
distribution in the Klerksdorp cohort. Strains from two patients could not be determined and are not reflected on the 
map. M. tuberculosis strains from an additional four patients were identified as H37Rv, are not reflected in the figure. 
This was most likely due to contaminating DNA from the culture filtrate. Values for strain types identified in more 
than four patients are given. Values in parentheses illustrate overall percentages. Strains from patients that were not 
identified or were identified as H37Rv are included in the calculation of the overall percentage. S-Family = green, W-
Beijing = red, T1 = blue (n = 2), LAM = purple (n = 2) and X-Family = orange (n =1). Abbreviations: LAM = Latin 
American Mediterranean, CAS = Central Asian Strain, EAI = East-African Indian, F36 = Family 36. The size of the 
circles represent the relative proportions of each strain.  
 
Table 3.6 M. tuberculosis strains isolated in Soweto and Klerksdorp regions 
Strain typing, n (%) Overall 
(n = 80) 
Soweto region 
(n = 48) 
Klerksdorp region 
(n = 32) 
  P-value 
T1 15.0 (18.8) 13.0 (27.1) 2.0 (6.3) 0.0172 
Beijing 16.0 (20.0) 9.0 (18.8) 7.0 (21.9) 0.7321 
S-Family 16.0 (20.0) 2.0 (4.2) 14.0 (43.8) <0.0001 
Other* 28.0 (35.0) 21.0 (43.8) 7.0 (21.9) 0.0522 
ND 5.0 (6.3) 3.0 (6.3) 2.0 (6.25) 1.0000 
ND = not determined. * Includes the four strains that were identified as H37Rv in the Klerksdorp cohort 
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From the 80 positive MPN plates, spoligotyping results were obtained from 71 cultures. Of the 
nine patients where no results were obtained, five were not determined (i.e. blank on X-ray) and 
four were H37Rv, most likely from the CF derived from M. tuberculosis H37Rv. The predominant 
strains identified in the Soweto cohort belonged to the T1 (27.1%) and W-Beijing families 
(18.8%), followed by Latin American Mediterranean (14.6%, LAM, from sub-lineage IV), and X 
family (12.5%). Other strains identified included the Central Asian Strain (CAS, identified in three 
patients) Haarlem (identified in 2 patients), S-Family (2 patients), as well as the EA15 and F36 
family (both strains identified in 1 patient). T4 was also identified in one patient.  In the Klerksdorp 
cohort, the predominant strains identified were S-family (43.8%) and W-Beijing (21.9%). Other 
strain families identified included LAM (2 patients), T1 (2 patients), and X (one patient). When 
the two regions were compared with each other, the T1 family and S-family were significantly 
associated with the Soweto and Klerksdorp regions, respectively (P = 0.0172 and P < 0.0001). 
Whilst the sample sizes are small, the clustering of the strains, particularly the S-Family strain in 
Klerksdorp, may indicate recent transmission events (Mathema et al., 2006). No significant 
differences were observed between the other identified strains and region, although a greater 
diversity of strains were present in Soweto (other, P = 0.0522).  Six possible mixed strain infections 
(8.5%) were identified in this patient cohort, where either low intensity banding patterns of a 
secondary strain were observed in the background, or a different strain isolated in a different MPN 
well from the same sample. Previous studies have reported mixed infection rates of up to 20% in 
pulmonary specimens alone (McIvor et al., 2017, Cohen et al., 2012). To determine whether strain 
type was associated with HIV status, strains were classified into T1, Beijing, S-family and other 
(Table 3.7). There was no significant difference in the distribution of these strains between HIV-
infection status or in HIV-positive patients with CD4 counts less/ greater than 200 cells/mm3. 
Patients with a CD4 T-cell count of less than 200 cells/mm3 were more likely to be infected with 
‘other’ M. tuberculosis strains. These strains included, H37Rv (13.6%), LAM (13.6%), CAS 
(9.1%), EA15, X1 and T4 (each strain identified in a single patient, 4.5%). When the H37Rv strains 
were removed from the analysis, these differences were no longer significant, P = 0.1093.  
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Table 3.7 M. tuberculosis strain type is not associated with HIV-infection status or CD4 T-
cell count. 
Strain type 
Overall 
(n = 80) 
HIV 
Negative 
(n = 25) 
HIV 
Positive 
(n = 55) 
P Value  
CD4 <200 
(n = 33 ) 
CD4 >200 
(n = 22 ) 
P Value  
T1 15.0 (18.8) 4.0 (16.0) 11.0 (20.0) 0.6709 8.0 (24.2) 3.0 (13.6) 0.3354 
Beijing 16.0 (20.0) 6.0 (24.0) 10.0 (18.2) 0.5465 8.0 (24.2) 2.0 (9.1) 0.1535 
S-Family 16.0 (20.0) 3.0 (12.0) 13.0 (23.6) 0.2278 7.0 (21.2) 6.0 (27.3) 0.6043 
Other* 28.0 (35.0) 10.0 (40.0) 18.0 (32.7) 0.5273 7.0 (21.2) 11.0 (50.0) 0.0258 
ND 5.0 (6.2) 2.0 (8.0) 3.0 (5.5) 0.6629 3.0 (9.1) 0.0 (0.0) 0.1458 
First number is absolute number of patients with a particular strain type. Percentages are given in parentheses.  
* Includes the four strains that were identified as H37Rv. Three of these strains were in the HIV-positive and CD4   
>200 cells/mm3 categories.  
 
As the DCTB sub-populations were highly skewed with the majority of patients belonging to the 
mixed-DCTB population, assessing whether strain type was associated with any particular DCTB 
sub-population was difficult. In the CF-dependent population (three patients), the strains identified 
were W-Beijing, T1 and X1. In the single patient with an Rpf-independent bacterial population, a 
spoligotype of H37Rv was obtained and a clinical strain was not identified. Five of the patients 
analysed had no DCTB and Haarlem, Beijing and T1 (three patients) families were identified. 
Further research on a large patient cohort is required to establish the link between CF-dependency 
and strain type. Furthermore, research investigating the use of CF in unmasking mixed strain 
infections is required.  
 
3.6. DISCUSSION 
The detection and quantification of DCTB in patients with active TB disease has several important 
applications including assessing transmission dynamics, enhanced TB diagnosis, as well as 
monitoring of patient response to treatment and assessing risk of relapse disease. Furthermore, 
future studies to detect and quantify DCTB in latently infected patients or patients with 
assymptomatic sub-clinical disease may prove useful in identifying patients at risk for reactivation 
or progression to symptomatic disease, respectively. In this chapter, the relative proportions of 
conventionally culturable and differentially culturable bacterial populations in patients from 
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Soweto and Klerksdorp, South Africa, were described. Furthermore, the role of the immune system 
in generating DCTB was investigated by recruiting both HIV-positive and -negative individuals.  
As previously reported, the results from this study support the findings that sputum obtained from 
treatment-naïve patients are dominated by DCTB (Mukamolova et al., 2010, Chengalroyen et al., 
2016). Initially, it was proposed that Rpfs were key players in the resuscitation of non-culturable 
M. tuberculosis cells (Mukamolova et al., 2010). However, this finding was recently revised 
(Chengalroyen et al., 2016) where it was found that the addition of CF does not dictate the direct 
involvement of Rpfs in the resuscitation of DCTB populations. Other factors present in CF may 
be involved. 
To further investigate this, the bacterial load in the CF-supplemented (CF+ and Rpf –) and -
unsupplemented MPN assays were determined. A significant increase in bacterial load was 
observed in both CF-supplemented MPN assays when compared to CF-unsupplemented MPN and 
CFU assays (Figure 3.11), confirming that in sputum, the addition of CF does indeed enhance 
bacterial recovery. While substantive growth recovery was observed with Rpf – CF,  a significant 
difference was also observed between the bacterial load obtained in the CF+ and Rpf –  MPN assays, 
with CF supplementation yielded an MPN of 0.2 log higher than Rpf – CF supplementation  (P = 
0.0320). These observations suggest an added benefit of Rpfs (albeit marginal) in detecting DCTB 
populations but given the marginal nature of this effect, it is difficult to dissect further. 
Nevertheless,  these results in conjunction with that observed by Chengalroyen et al. (2016) 
suggest a complex phenotypic diversity in sputum resident organisms. To further investigate this 
phenomenon, the proportion of resuscitated bacteria, relative to CFUs (a value referred to as the 
resuscitation index) was determined for both CF-dependent and Rpf-independent DCTB 
populations. The results illustrated that the majority of patients (88.8%) analysed in this study 
harboured mixed populations of DCTB, i.e. DCTB were unmasked following MPN 
supplementation with CF+ and Rpf – CF, providing further evidence for the role of other molecules 
in M. tuberculosis growth stimulation. A caveat here, is that whilst the Rpf – CF does not contain 
an exogenous source of Rpfs, clinical M. tuberculosis strains are capable of producing their own 
Rpfs. Therefore the role of Rpfs in resuscitation cannot fully be excluded in experiments with the 
Rpf – CF. To further understand the role of Rpf in bacterial resuscitation, the addition of Rpf-
inhibitors to the Rpf– MPN assay will more precisely define the presence of solely Rpf-dependent 
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as well a Rpf-independent bacterial populations. Nitrolphenylthiocyanates (NPTs) have been 
identified as low molecular weight compounds that inhibit the enzymatic and biological activity 
of Rpf proteins (Demina et al., 2009, Kaprelyants et al., 2012). The effect of NPT against 
exogenous Rpfs has been previously demonstrated where the growth stimulatory effect of 
recombinant RpfSm (a truncated version of Mi. luteus Rpf) on non-replicating M. tuberculosis 
cells was abolished following the addition of NPT (compound 5; 10 μg/ml) (Kaprelyants et al., 
2012). This decrease in activity was measured by decreasing MPN counts relative to the number 
of CFUs.  
Alternatively, the addition of recombinant Rpf to the MPN assay will impicate only Rpfs in 
bacterial resuscitation as CF has many molecules that be directly or indirectly involved in 
enhancing growth of M. tuberculosis. Whilst some analysis has been done on CF 
proteins/molecules, an exhaustive analysis of the molecular composition of M. tuberculosis CF is 
lacking (Sonnenberg and Belisle, 1997, Weldingh et al., 1998, Andersen et al., 1991). Further 
research employing state-of-the-art technologies such as mass spectometry would be useful in 
identifying biologically relevant compounds in CF that may be relevant in pathogenicity, 
phenotypic plasticity, growth inhibition and resuscitation. The identification of growth 
inhibitory/stimulatory molecules in CF could also be further explored in the the development of 
new drugs. 
In contrast to that reported by Chengalroyen et al. (2016), the analysis revealed that a small number 
of patients harbored only CF-dependent or Rpf-independent DCTB (3.75% and 1.25% of the total 
patient population, respectively). Five patients (6.25%) also had no DCTB, but CFUs were isolated 
on solid media suggesting that growth in CF-supplemented liquid media is inhibitory to certain 
bacterial populations. Whilst the absolute proportions of various DCTB populations may have 
differed to those reported by Chengalroyen et al. (2016), it was encouraging to see that 
representative patterns from four out of the five previously reported populations were found in this 
study.  The complexity of bacterial sub-populations detected in this chapter highlight the 
challenges and possible gaps in current TB diagnostic algorithms and that a single diagnostic may 
miss certain bacterial populations (Dartois et al., 2016).  
The current study commenced in 2014 and was carried out according to an approved protocol that 
was designed at the CBTBR in accordance with previous published work. After the study was 
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largely complete, a new method of conducting the MPN to reduce increasing the risk of artifact 
was described (Saito et al., 2017). Previous studies have shown the addition of growth stimulatory 
factors to the MPN assay increase the bacterial yield 100-fold (Mukamolova et al., 2010), but this 
has been disputed in more recent work (Saito et al., 2017). In this study, the MPN was optimised 
using replicating axenic cultures so that the MPN result was equivalent to the CFU (i.e. DD/DCTB 
= 0). To achieve this, additional steps were employed. These steps included low speed 
centrifugation to break down large clumps. In addition, CFUs were calculated from the same 
dilution series used for the MPN assay (as opposed to a separate dilution series), the filter pipette 
tips were changed for each step in the dilution series and pentuplicate dilution series were 
performed in 96-well plates. The results from this study suggest that the reported MPN values in 
the current study could possibly be an overestimation. However, the inclusion of a MPN no CF 
control confirms the presence of DCTB in patient sputa. In addition, the CFUs obtained tended to 
be higher than the MPN no CF control suggesting that an artifactual increase may not have 
occurred. That said, we cannot exclude any artefacts but have endeavoured to apply robust methodology. 
Preliminary statistics investigating the confidence intervals and coefficience of variation in the 
triplicate assay illustrate precision in the MPN assay at baseline up until 14 days on treatment (see 
Appendix 3F). Pentuplicate assays were not carried out because of resource constraints and limited 
sputum. Future work to compare and quantify the DCTB in patient sputum samples using both 
MPN methods is required. As a separate comparator, other quantitative methods such as 
microscopy using a Petroff-Hauser chamber or flow cytometry should be included. 
In chronic granulomatous TB disease, M. tuberculosis encounter numerous environmental stresses 
that are thought to drive these organisms into a non-replicating state. To test the hypothesis that 
host immunity serves as a driver for the establishment of DCTB, patients were stratified by their 
HIV-infection status and the distribution of DCTB amonst these two groups was compared. It was 
found that HIV-negative individuals harbour more DCTB than their HIV-positive counterparts, 
suggesting that host immunity is a determining factor in the generation of DCTB. However, when 
the HIV-positive group was further stratified according to immune competency (i.e. CD4 T-cell 
count greater or less than 200 cells/mm3), no significant difference was observed between the 
distribution of DCTB. Furthermore, Spearman’s rank sum correlation statistics revealed no 
significant correlation between baseline bacterial loads in the MPN and CFU with CD4 T-cell 
counts. These results are in contrast to those reported by Chengalroyen et al. (2016), where HIV-
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positive individuals with a greater immune competency, i.e. CD4 T-cell count > 200 cells/mm3, 
displayed higher CF+ MPN values. Possible reasons for this discrepancy could be related to 
differences in disease pathology, or how the disease was acquired, i.e. recent transmission events 
versus reactivation disease. While analysis was attempted on the lung pathology data that was 
available, interpretation was limited due to an incomplete data set.  Recent studies investigating 
the association between host immunity and DCTB from EP sites showed that host peripheral 
lymphocyte counts were correlated with DCTB (termed MPN_culture supernatant/CS bacillary 
counts) (Rosser et al., 2017). Other host factors analysed including HIV-infection status, diabetes 
millitus, vitamin D status, C-reactive protein levels, neutrophil or monocyte counts were not 
significantly correlated with MPN_CS counts (Rosser et al., 2017). However, due to the small 
sample size (19 samples fro 18 patients) multivariate analysis was underpowered in these studies 
and future work should investigate the impact of host-related factors on the generation of DCTB.  
HIV-positive patients are more likely to develop disseminated disease (Palmieri et al., 2002, Gupta 
et al., 2015), resulting in lower bacillary load in sputum samples (Getahun et al., 2007, Hargreaves 
et al., 2001). Indeed, 15% of reactivation disease occurs in EP sites (Farer et al., 1979), and adipose 
tissue has been suggested as a site for M. tuberculosis persistence (Neyrolles et al., 2006, Beigier-
Bompadre et al., 2017). Investigation into the quantification of DCTB in patients with EPTB 
disease has recently been investigated (Rosser et al., 2017). The authors concluded that CS-
dependent DCTB are common in EPTB (present in 52% of patients), but to a lesser degree than 
that observed in sputum samples (Mukamolova et al., 2010, Chengalroyen et al., 2016).  
The M. tuberculosis strains isolated in this study did not cluster with HIV serostatus, however the 
T1 and S-Family genotype were highly prevalent in patients recruited from Soweto and Klerksdorp 
regions, respectively. The samples size in this study was too small to make any meanginful 
comparison of strain prevalence by DCTB population. These limitations notwithstanding, 
clustering has been associated with recent transmission (Genewein et al., 1993, Mathema et al., 
2006, Small et al., 1994), therefore large molecular epidemiological studies in these regions may 
be able to identify potential outbreaks.   
A previous study investigating M. tuberculosis transmission in a community with a high 
prevalence of HIV showed that HIV-negative individuals were almost twice as likely to be a cluster 
index case compared to HIV positive individuals. These findings suggest that HIV-negative 
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individuals may be disproportionately responsible for TB transmission within a community 
(Middelkoop et al., 2015). Previous reports have shown that following M. tuberculosis infection, 
HIV-positive individuals advance more rapidly to active TB disease than HIV-negative individuals 
(Daley et al., 1992, Selwyn et al., 1989, Dooley et al., 1992). The rapid progression to active 
disease along with the clinical presentation of HIV-TB co-infection (i.e.paucibacillary disease), 
may explain the lower rates of transmission by HIV-positive individuals (Middelkoop et al., 2015).  
Given the above findings and that HIV-negative status is associated with an increased number of 
DCTB, it could be speculated that DCTB may play a role in the transmission of TB disease by 
HIV-negative individuals. The bio-aerosol cloud generated by these individuals through coughing 
may also contain a high number of these organisms. Therefore, this data may define a novel role 
for DCTB in the transmission of DCTB by HIV-uninfected to HIV-infected individuals within the 
community, Figure 3.18. Further investigation to prove this hypothesis is required. Also, one 
cannot discount the fact that the sheer numbers of HIV-infected TB cases in the endemic settings 
such as South Africa may be sufficient for these individuals to sustain transmision as a collective. 
The role of DCTB in transmission could possibly be achieved through the use of a cough aerosol 
sampling system, although it would be challenging if not impossible to determine which organisms 
are responsible for establishing the infection. For this, in vitro models to generate DCTB, methods 
to label these organisms for subsequent identification and animal based experiments may be 
required to shed light on these phenomena.  It would also be interesting to establish whether DCTB 
and culturable organisms are linked to reactivation disease and recent transmission, respectively. 
Large molecular genotyping studies are required to shed further light on these and related topics.  
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Figure 3.18 Are HIV-negative patients more infectious due to a higher quantum of differentially culturable 
tubercle bacilli in their sputum? A number of questions regarding differentially culturable tubercle bacilli (DCTB) 
and their supposed role in transmission dynamics requires further investigation. For instance, does the bio-aersosol 
cloud generated by immune-competent individuals consists of a higher quantum  of culturable organisms (green dots) 
and DCTB (red and blue dots) than that generated by immune-compromised individuals? What is the role of DCTB 
(versus conventionally culturable bacilli) in transmission and progression of TB disease? Are DCTB more robust than 
conventionally culturable bacilli?, and if so, does this provide the organism with an adaptive advantage to survive host 
defense mechanisms? Are DCTB more likely to result in the establishment of infection and subsequent disease? Or 
are they more susceptible to damage than conventionally culturable bacteria? 
 
 
3.7 FUTURE RESEARCH/ CHAPTER CONCLUSION 
To conclude, the data illustrated herein confirm previous reports of the prevalence of DCTB in the 
sputum of treatment-naïve individuals in South Africa. Sputum from patients in the cohort reported 
herein also display a complexity in bacterial subpopulations with mixtures of CF-dependent and 
Rpf-independent DCTB. HIV-infected individuals appear to habour lower numbers of MPN 
responsive organisms when compared to their HIV-uninfected counterparts. Molecular typing of 
strains did not yield an intrinsic capacity for any given strain to adopt a differentially culturable 
state. Future research to further investigate these findings will include the following: 
1. Fractionation of the CF using membranes that discriminate by molecular weight followed 
by MPN assays on axenic cultures and patient sputa using these different fractions to 
determine the size/nature of molecules involved in resuscitaion.  
2. Previously MPNs were conducted with heat treated filtrate to eliminate enzymatic activity; 
however, in most cases, whilst growth stimulation was reduced, it was not completely 
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abolished (Chengalroyen et al., 2016). These results suggest that the enzymes involved in 
resuscitation are either heat stable or growth stimulation is also mediated by non-enzymatic 
effects. To further investigate the mechanistic basis, the CF can be treated with lipases, 
proteases (start with broad spectrum and then narrow down to individual) and glycosydases 
etc. MPN assays will determine whether certain molecules in CF stimulate or inhibit 
growth. Additionally, the CF can be subjected to p.H. and temperature adjustments. 
3. Assessment of the association of DCTB with drug-resistant pumonary disease as well as 
EPTB disease. In light of this, two new large-scale studies have recently been launched at 
the CBTBR and patients are currenly being recruited. 
4. Are DCTB more likely to occur in patients with history of TB disease (long standing latent 
infection) as opposed to recent transmission events? Large scale epidemiological studies 
employing molecular-based DNA fingerprinting techniques or whole genome sequencing 
would be required in these cases.  
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APPENDIX 3B: DIAGNOSTIC TESTS PERFORMED AT CLS 
MGIT culture (done by CLS laboratory personnel) 
Inoculation  
MGIT culture was performed on all samples using the BACTEC MGIT 960 detection system. For 
this, 800 µL of PANTA (reconstituted in 15 mL of growth supplement) was added to each labelled 
MGIT tube prior to inoculation. Thereafter, 0.5 mL of decontaminated sediment was then added 
aseptically to each tube using a 3 mL sterile disposable Pasteur pipette. The tubes were then capped 
and inverted several times before insertion into the detection system.  
Removal of positive and negative cultures 
Positive and negative MGIT cultures were removed from the detection system after the instrument 
signalled the presence of a positive or negative culture via light indicators on the drawers of the 
instrument. Samples were incubated for a maximum of 42 days after which, a negative result was 
recorded if no growth was obtained. Positive cultures were inoculated onto blood agar plates to 
check for contamination and a ZN stain was performed to confirm the presence of AFB. All 
positive MGIT cultures were also confirmed as MTBC by the HAIN MTBDRplus assay. All 
results were recorded using the CLS computational reporting system and provided with unique 
patient identifiers in an MS Excel Format.  
Smear microscopy (done by CLS laboratory personnel) 
A 20 µL drop of decontaminated pellet was transferred to a microscope slide (smear was 
approximately 1.0 cm by 2.0 cm in size), fixed for an hour at 65°C and stained with auramine 
fluorescent staining according to the laboratory SOP. For this, the slide was flooded with auramine-
O and left to stain for 15 minutes. The slide was then rinsed with water and decolorized with 0.5% 
acid-alcohol for two minutes. After rinsing with water, the slide was counterstained with potassium 
permanganate for two minutes and rinsed with water. After air drying, the slides were examined 
using 20X and 40X objective for screening. A 100X oil immersion objective was used if needed 
to confirm the characteristic morphology of fluorescing bacilli. The number of fluorescing bacilli 
was counted for 100 fields and the mean number of acid fast bacilli (AFB) per field was 
136 
 
determined. The table below is taken from the TB alliance Protocol NC-002 Microbiology Manual 
(Page 29) and was used to report the smear grading for each sputum sample tested.  
Determination of smear grade based on the number of AFB observed per field of view 
Number of AFB (400X magnification) Result 
No AFB in at least 40 fields No AFB 
1 – 19/ 40 fields Scanty 
20 – 199/ 40 fields 1+ 
5 – 50/ field 2+ 
>50/ field 3+ 
 
GeneXpert (done by CLS laboratory personnel) 
The GeneXpert (Cepheid, Sunnyvale, CA) was performed on all patient sputum samples received 
at the CLS. This system is able to integrate DNA extraction, genomic amplification and a semi-
quantitative diagnostic detection of M. tuberculosis as well as RIF resistance due to mutations in 
the rpoB gene. One and a half mL of GeneXpert MTB/RIF sample reagent was added to a 50 mL 
conical tube containing 0.5 mL of decontaminated sediment using a sterile transfer pipette. The 
sample reagent and specimen was then mixed by vigorously shaking the tube 10 to 20 times after 
which it was left to incubate at room temperature for 15 minutes with shaking at every five minute 
interval. The liquefied sample was added to the cartridge using a sterile transfer pipette and the 
test was started within 30 minutes of adding the sample to the cartridge. The results were 
interpreted by means of the GeneXpert DX system by measurement of fluorescent signals and 
mathematical algorithms. The results were quantitatively displayed as high, medium, low or very 
low bacterial load depending on the cycle threshold (Ct) value obtained (Table 3.3).  In addition, 
a quantitative Ct value was also recorded. The Ct value is defined as the number of cycles that are 
required for the fluorescent signal to exceed the threshold, i.e. exceed the level of background 
noise. The Ct value is indirectly proportional to the amount of nucleic acid present in the sample, 
therefore a low Ct value is indicative of a higher bacterial load. The table below illustrates the 
range of Ct values for each qualitative category. 
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Qualitative Xpert reporting system based on Ct value range 
MTB Result Ct Range 
High <16 
Medium 16 – 22 
Low  22 – 28 
Very Low >28 
Adapted from GeneXpert package insert.  
HAIN MTBDRplus assay (done by CLS laboratory personnel) 
The Hain MTBDRplus line probe assay (Hain Lifescience, Nehren, Germany) assay was 
performed on all MGIT samples that flagged positive to confirm the presence of MTBC and 
susceptibility towards both RIF and INH through mutations in the rpoB gene as well as the inhA 
promotor and katG genes, respectively. The assay was carried out according to manufacturer’s 
instructions. Briefly, crude DNA was extracted from 1 mL MGIT aliquots. The samples were heat 
killed at 95 ºC for 20 minutes, followed by ultra-sonification for 15 minutes. Subsequently, the 
samples were centrifuged at 13 000 x g for 5 minutes after which the supernatant was removed for 
PCR. In a separate clean room, the master mix was prepared by adding 35 μL primer nucleotide 
mix (PNM), 5 μL 10X PCR buffer, 2 μL MgCl2, 0.2 μL Hot Star Taq DNA polymerase and 3 μL 
sterile, deionised water (total volume: 50 μL per specimen). Forty five μL of master mix was 
aliquoted into to 0.2 mL PCR tubes and 5 μL of sterile deionised water was added to the first PCR 
tube to serve as the amplification control. The PCR tubes were labelled and taken into a separate 
room for amplification. In the amplification room, 5μL of DNA was added to each corresponding 
PCR tube. The thermal cycle was programmed as follows: 
i) 5 minutes at 95 ºC      1 cycle 
ii) 30 seconds at 95 ºC, 2 minutes at 58 ºC   10 cycles 
iii) 25 sec at 95 °C, 40 sec at 53 °C, 40 sec at 70 °C  30 cycles 
iv) Hold at 4 70 °C  
Once the run was completed, the PCR products were removed from the thermocycler and 
hybridised onto probe strips using a GT-blot and commercially available kit (Hain Lifescience, 
Nehren, Germany).  
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APPENDIX 3C: EXAMPLE OF MEDIA STERILITY CHECKS  
Table 3C is an example of the database and records kept for the media quality control for batches made 
between June 2014 to August 2014. 
 
 
 
 
 
 
 
 
Media Media batch number date checked for sterility Sample numbers processed Media Media batch number Date checked for sterility Sample numbers processed
7H11 JP 060614 2014/06/06 BM0002-BM0003 7H9 GB 280514 2014/05/29 BM0002-BM0003
7H11 JP 060614 2014/06/06 BM0004-BM0005 7H9 GB 280514 2014/05/29 BM0004-BM0005
7H11 JP 060614 2014/06/06 BM0006 7H9 JP 110614 2014/06/11 BM0006
7H11 AM 090614 2014/06/09 BM0007 7H9 JP 110614 2014/06/11 BM0007
7H11 AM 090614 2014/06/09 BM0008 7H9 JP 110614 2014/06/11 BM0008
7H11 AM 090614 2014/06/09 BM0009-BM0013 7H9 JP 110614 2014/06/11 BM0009-BM0013
7H11 AM 090614 2014/06/09 BM0014-BM0018 7H9 JP 110614 2014/06/11 BM0014-BM0018
7H11 AM 090614 2014/06/09 BM0019-BM0022 7H9 JP 110614 2014/06/11 BM0019-BM0022
7H11 AM 090615 2014/06/09 BM0023-BM0024 7H9 JP 110615 2014/06/11 BM0023-BM0024
7H11 JP 240614 2014/06/24 BM0025-BM0028 7H9 JP 240614 2014/06/25 BM0025-BM0028
7H11 AM 090615 2014/06/09 BM0029-BM0032 7H9 JP 240614 2014/06/25 BM0029-BM0032
7H11 JP 240614 2014/06/24 BM0033-BM0036 7H9 JP 240614 2014/06/25 BM0033-BM0036
7H11 JP 240614 2014/06/24 BM0037 - BM0040 7H9 JP 240614 2014/06/25 BM0036 - BM0040
7H11 JP 030714 2014/07/03 BM0041-BM0042 7H9 JP 240614 2014/06/25 BM0041-BM0042
7H11 JP 030714 2014/07/03 BM0043-BM0050 7H9 JP 240614 2014/06/25 BM0043-BM0050
7H11 JP 030714 2014/07/03 BM0051-BM0052 7H9 JP 240614 2014/06/25 BM0051-BM0052
7H11 JP 030714 2014/07/03 BM0053-BM0054 7H9 AM 080714 2014/07/08 BM0053-BM0054
7H11 JP 080714 2014/07/08 BM0055-BM0061 7H9 AM 080714 2014/07/08 BM0055-BM0061
7H11 JP 080714 2014/07/08 BM0062-BM0069 7H9 AM 080714 2014/07/08 BM0062-BM0069
7H11 AM 100714 2014/07/10 BM0070-BM0073 7H9 AM 080714 2014/07/08 BM0070-BM0073
7H11 AM 100714 2014/07/10 BM0074-BM0077 7H9 AM 080714 2014/07/08 BM0074-BM0077
7H11 AM 100714 2014/07/10 BM0078-BM0086 7H9 AM 080714 2014/07/08 BM0078-BM0086
7H11 AP 150714 2014/07/15 BM0087-BM0092 7H9 AM 080714 2014/07/08 BM0087-BM0092
7H11 AP 150714 2014/07/15 BM0093-BM0096 7H9 AM 080714 2014/07/08 BM0093-BM0096
7H11 AP 150714 2014/07/15 BM0097-BM0104 7H9 AP 160714 2014/07/16 BM0097-BM0104
7H11 AP160714 2014/07/16 BM0105-BM0112 7H9 AP 16072014 2014/07/16 BM0105-BM0108
7H11 JP220714 2014/07/22 BM0113-BM0133 7H9 AM 11072014 2014/07/11 BM0109-BM0120
7H11 AM240714 2014/07/24 BM0134-BM0175 7H9 GB22072014 2014/07/22 BM0121-BM0126
7H11 AP010814 2014/08/01 BM0176-BM0181 7H9 AP 22072014 2014/07/22 BM0127-BM0133
7H11 AP040814 2014/08/04 BM0182-BM204 7H9 AM110714 2014/07/11 BM0134-BM0145
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APPENDIX 3D: EXAMPLE OF CULTURE FILTRATE STERILITY CHECKS AND PCR 
 
Table 3D is an example of the records kept for the CF quality control from June 2014 to July 2014. 
Contaminated BG CFs (determined by positive M. tuberculosis growth on solid and in liquid media) were 
obtained in samples 59125 (BM 1492; day 56), 57169 (BM2003; day 180), 57135 (BM1493 and BM1491; 
enrolment overnight and spot samples) – data not in Table 3D. In these samples, growth was observed in 
all the BG1 wells on the MPN plates. These samples were excluded from analysis (Rpf-independent data 
from BG1 only).   
 
 
 
 
 
Date Processed Sample No. Solid Media Liquid Media QC Pass/Fail PCR RV/BG QC Pass/Fail
2014/06/05 BM0001 NG NG Pass Yes Pass
2014/06/09 BM0002 - BM0003 NG NG Pass Yes Pass
2014/06/11 BM0004-BM0005 NG NG Pass Yes Pass
2014/06/12 BM0006 NG NG Pass Yes Pass
2014/06/18 BM0007 NG NG Pass Yes Pass
2014/06/19 BM0008 NG NG Pass Yes Pass
2014/06/23 BM0009-BM0013 NG NG Pass Yes Pass
2014/06/24 BM0014-BM0018 NG NG Pass Yes Pass
2014/06/25 BM0019-BM0022 NG NG Pass Yes Pass
2014/06/26 BM0023-BM0024 NG NG Pass Yes Pass
2014/06/27 BM0025-BM0028 NG NG Pass Yes Pass
2014/06/30 BM0029-BM0032 NG NG Pass Yes Pass
2014/07/01 BM0033-BM0036 NG NG Pass Yes Pass
2014/07/02 BM0037 - BM0040 NG NG Pass Yes Pass
2014/07/03 BM0041-BM0042 NG NG Pass Yes Pass
2014/07/04 BM0043-BM0050 NG NG Pass Yes Pass
2014/07/07 BM0051-BM0052 NG NG Pass Yes Pass
2014/07/08 BM0053-BM0054 NG NG Pass Yes Pass
2014/07/09 BM0055-BM0061 NG NG Pass Yes Pass
2014/07/10 BM0062-BM0069 NG NG Pass Yes Pass
2014/07/11 BM0070-BM0073 NG NG Pass Yes Pass
2014/07/14 BM0074-BM0077 NG NG Pass Yes Pass
2014/07/15 BM0078-BM0086 NG NG Pass Yes Pass
2014/07/16 BM0087-BM0092 NG NG Pass Yes Pass
2014/07/17 BM0093-BM0096 NG NG Pass Yes Pass
2014/07/18 BM0097-BM0104 NG NG Pass Yes Pass
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APPENDIX 3E. LUNG PATHOLOGY  
Variable 
Overall  
(n = 34) 
HIV-Negative 
(n=12) 
HIV-Positive 
(n=22) 
P-value 
Left lung cavities 
No (%) 
Yes (%) 
 
15 (44.1) 
19 (55.9) 
 
3 (25.0) 
9 (75.0) 
 
12 (54.5) 
10 (45.5) 
0.0973 
Right lung cavities 
No (%) 
Yes (%) 
 
18 (52.9) 
16 (47.1) 
 
4 (33.3) 
8 (66.6) 
 
14 (63.6) 
8 (36.4) 
0.0907 
Left lung infiltrates 
No (%) 
Yes (%) 
 
11 (32.4) 
23 (67.6) 
 
3 (25.0) 
9 (75.0) 
 
8 (36.4) 
14 (63.6) 
0.4985 
Right lung infiltrates 
No (%) 
Yes (%) 
 
10 (29.4) 
24 (70.6) 
 
5 (41.7) 
7 (58.3) 
 
5 (22.7) 
17 (77.3) 
0.2468 
Left lung adenopathy 
No (%) 
Yes (%) 
 
27 (79.4) 
7 (20.6) 
 
12 (100.0) 
0 (0.0) 
 
15 (68.2) 
7 (31.8) 
0.0283 
Right lung adenopathy 
No (%) 
Yes (%) 
 
27 (79.4) 
7 (20.6) 
 
12 (100.0) 
0 (0.0) 
 
15 (68.2) 
7 (31.8) 
 
0.0283 
Left lung pleural 
disease 
No (%) 
Yes (%) 
 
 
33 (97.1) 
1 (2.9) 
  
 
11 (91.7) 
1 (8.3) 
 
 
22 (100.0) 
0 (0.0) 
0.1693 
Right lung pleural 
disease 
No (%) 
Yes (%) 
 
 
31 (91.2) 
3 (8.8) 
 
 
11 (91.7) 
1 (8.3) 
 
 
20 (90.9) 
2 (9.1) 
 
0.9407 
Cavitation * 
1 
2 
3 
 
17 (53.1) 
4 (12.5) 
11 (34.4) 
 
4 (33.3) 
2 (16.7) 
6 (50.0) 
 
13 (65.0) 
2 (10.0) 
5 (25.0) 
0.2181 
Extent of disease † 
A 
B 
C 
 
10 (30.3) 
9 (27.3) 
14 (42.4) 
 
2 (16.7) 
5 (41.7) 
5 (41.7) 
 
8 (38.1) 
4 (19.0) 
9 (42.9) 
0.2736 
Data were available for 34 Soweto patients included for baseline analysis 
* Data available for 32/34 patients (data from 2 HIV-positive patients were not available). 
† Extent of disease data available for 33/34 patients (data from one HIV-positive patient was not available). 
All comparisons were conducted using the chi-square test. Significance at P less than 0.05 (95% confidant interval) is 
shown in bold.  
For cavitation, 1: absent, 2: single or multiple cavities with diameter of <4cm in aggregate and 3: single or multiple 
cavities with diameter ≥4cm in aggregate. For extent of disease, A: Limited – lesion(s) involving a total lung area less 
than one-quarter the area of the entire thoracic cavity as seen on PA or AP view. B: Moderate – lesion(s) greater that 
(A), but, even if bilateral involve a total lung area of less than one-half the area of the entire thoracic cavity as seen 
on PA or AP view. C: Extensive – lesion(s) involving a total lung area, equal to or more than half the area of the entire 
thoracic cavity as seen on PA or AP view.  
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APPENDIX 3F: INTRA-ASSAY VARIATION 
 
 
Figure 3F: Most probable number intra-assay variation in sputum samples from HIV-negative (A) and –
positive (B) individuals. (1) The confidence intervals based on triple MPN dilution series from five HIV negative 
(left) and five HIV positive (right) individuals are depicted at different time points in the study. (2) The coefficient of 
variation was calculated to illustrate the extent of assay variability in relation to the mean. At earlier time points (i.e. 
days 0, 3, 7 and 14), the coefficient of variation was generally below 5% in the CF+ and Rpf- MPN assays indicating 
little variability between the replicates. A greater coefficient of variation was observed in the MPN no CF assays. At 
later time points (i.e. days 35 and 56), higher coefficients of variations are observed. These findings show that more 
variability is obtained in the MPN assay at later time points, possibly as a result of lower bacterial loads or an increase 
in artefact.  
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CHAPTER 4 
DETECTION AND QUANTIFICATION OF DIFFERENTIALLY CULTURABLE 
BACTERIA IN TUBERCULOSIS PATIENTS: A LONGITUDINAL ANALYSIS  
“It is not the strongest of the species that survive, 
nor the most intelligent, but the ones 
most responsive to change.” 
Charles Darwin 
4.1 INTRODUCTION 
Numerous studies have demonstrated the presence of DCTB in pre-treatment patient sputum 
samples at baseline (Mukamolova et al., 2010, Chengalroyen et al., 2016). Furthermore, the 
detection of both CF-dependent and Rpf-independent populations in TB disease suggests a 
high complexity of bacterial populations within a single patient which is speculated to prevent 
the rapid clearance of these organisms during treatment. However, how these populations 
respond to treatment in human disease in vivo has not previously been investigated and is the 
focal point of study in this chapter of this thesis.  
It has long been hypothesized that dormant bacilli (associated with LTBI) are more tolerant to 
TB drugs when compared to actively dividing organisms due to the physiological changes that 
these organisms incur (Gold and Nathan, 2017). Non-replicating M. tuberculosis generated by 
means of various in vitro models have been shown to exhibit an increased tolerance to RIF and 
INH compared to actively dividing organisms (Wayne and Hayes, 1996, Chao and Rubin, 
2010, Deb et al., 2009, Sala et al., 2010, Salina et al., 2014, Wayne and Sramek, 1994, Saito et 
al., 2017, Gold and Nathan, 2017). Whilst these findings are significant, it has been 
demonstrated that Rpf-dependent bacteria can be generated in response to host-related factors 
pertaining to the in vivo environment (Turapov et al., 2014a, Manina et al., 2015). Considering 
this, and the demonstration of DCTB in sputum of treatment naïve individuals, it is therefore 
important to assess how these organisms respond to treatment. Few studies have investigated 
response to treatment and tolerance to chemotherapeutics of DCTB organisms isolated from 
patient sputum samples (Turapov et al., 2016, Mukamolova et al., 2010). These studies provide 
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anecdotal evidence to suggest that DCTB display tolerance to TB drugs. However, these studies 
have been conducted on a small number of patient samples (Mukamolova et al., 2010, Turapov 
et al., 2016) and further expansion of this approach to larger cohorts will provide much needed 
answers to key questions regarding bacterial persistence. Studies investigating these 
phenomena are discussed. For clarity, we use terminology for differentially culturable 
organisms as that cited in the respective studies. As an example, MPN assays stimulated with 
CF from wild type H37Rv yield a bacterial count that has been annotated as CF-dependent 
DCTB in our work. Other groups have termed these organisms Rpf-dependent bacteria. In this 
case, we use the nomenclature that is used in the article reporting the data. We have adopted 
this approach as other authors may contend our reannotation of their results and we have, as 
yet, not published an opinion piece on this to allow for an open debate on the nomenclature. 
 
4.1.1 Studies investigating the effect of TB treatment on DCTB 
One of the first studies investigating the impact of chemotherapy on DCTB was carried out by 
Mukamolova et al. (2010). Sputum samples from three individual patients were treated directly 
with RIF for one week after which MPN and CFU assays were carried out (Mukamolova et al., 
2010). Following exposure to this antibiotic, no bacteria were detected in the CFU and CF un-
supplemented MPN assays; however, the Rpf-dependent population, as detected by the CF 
supplemented MPN assay, remained essentially unchanged, thus demonstrating tolerance of 
this population to RIF. To further monitor the response to treatment of this population, four 
sputum samples were collected from patients between seven and 11 days following the start of 
treatment. It was determined that bacterial counts detected using CFU assays declined more 
rapidly than those detected in the MPN-supplemented assays. These results demonstrated that 
Rpf-dependent cells are eliminated at a much slower rate than actively dividing bacteria 
(approximated at 20 times slower) (Mukamolova et al., 2010). An alternative explanation could 
be that Rpf-dependent bacteria are generated, from the population of replicating bacteria, in 
response to chemotherapy, possibly as a mechanism to ensure survival. Consistent with this, 
Turapov et al. (2014b) showed that exposure of M. bovis BCG to antimicrobials that target cell 
wall biosynthesis under non-permissive growth conditions yielded enhanced survival of 
DCTB. The transcriptional regulator RaaS (i.e. regulator of antimicrobial-assisted survival) 
was associated with this phenomenon, where its induction resulted in reduced expression of 
ATP-dependent efflux pumps leading to the long term survival of DCTB. Furthermore, an in-
frame deletion mutant (ΔRaaS) was unable to survive in vitro under non-permissive growth 
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conditions or during macrophage and mouse infection (Turapov et al., 2014b).  These findings 
have clinically relevant implications with regards to TB treatment and targeting non-replicating 
bacilli in vivo. For example, efflux pump inhibitors have been recognised as a group of 
antimicrobials to prevent the emergence of drug resistance in replicating bacteria (Gupta et al., 
2013). Caution should be taken when introducing these drugs into current algorithms as they 
could possibly promote the long term survival of non-replicating bacteria, leading to increased 
rates of treatment failure and recurrent TB disease due to relapse. In a separate study, 
mycobacterial cultures (M. smegmatis mc2 155 and M. tuberculosis H37Rv) treated with first-
line antibiotics led to the generation of organisms that could only be recovered with CF 
supplemented media (Loraine et al., 2016). The authors propose that this may serve as a useful 
in vitro model to generate DCTB to test the efficacy of new antimicrobials on Rpf-dependent 
bacteria (Loraine et al., 2016).   
As previously mentioned, the effect of first-line anti-chemotherapeutic agents on M. 
tuberculosis isolated from patient sputa has been investigated (Turapov et al., 2016). For this, 
drug treatment was performed by incubation of decontaminated sputa in 10 mL of 
supplemented 7H9 media containing PANTA and the relevant antimicrobial for a week (the 
final concentration of each antimicrobial were reported as follows: STREP, 10 and 20 μg/mL; 
RIF, 1 and 5 μg/mL; EMB, 10 and 20 μg/mL; INH, 1 and 10 μg/mL and PZA, 40 and 100 
g/mL). The numerically dominant Rpf-dependent populations from the sputum samples were 
reported to be more tolerant to both INH and STREP, whilst PZA had no substantial effect on 
this population and only a marginal effect was observed following incubation in EMB after 
seven days (Turapov et al., 2016). Interpretation of the results presented in this study may have 
been influenced by a number of limitations. Firstly, the conclusions made were from 
observations based on four sputum samples from four patients, this is a relatively small sample 
size and variation between patients can influence what bacterial populations emerged after drug 
treatment. The sputum samples were previously frozen at -80 ºC and selected on the basis of 
their high-volume. The freezing of samples may generate sub-populations of DCTB. The 
authors did attempt to address this limitation in their study by assessing the growth of culturable 
and Rpf-dependent populations in stored decontaminated homogenised sputum samples 
[sputum samples were stored in i) PBS, ii) 200mM trehalose in water and iii) 10% (vol/vol) 
glycerol in water]. The authors noted that in most cases there was an increase in the viable 
counts in both culturable and differentially culturable populations (Turapov et al., 2016). 
Additionally, the results may have been restricted by the range of drug concentrations chosen, 
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as well as the length of incubation in the presence of a particular drug. Nevertheless, these 
findings create the possibility for the assessment of future drug candidates using M. 
tuberculosis cells directly isolated from patient sputa. As TB is treated with a multi-drug 
combination regimen and not a single antibiotic, it would be interesting for future studies to 
assess how the different M. tuberculosis populations respond to treatment with multiple 
antibiotics. 
In an interesting new development, a method to generate differentially culturable organisms 
involving nutrient starvation, following exposure to RIF has been described (Saito et al., 2017). 
The organisms emerging from this model were termed differentially detectable TB (DDTB). 
The investigators were unable to generate DDTB from a clinical isolate with an rpoB mutation, 
showing that RIF must engage with its canonical target to generate a differentially culturable 
phenotype. DDTB produced by this method were shown to be phenotypically tolerant to INH 
and a four drug combination (RIF, INH, EMB and PZA) (Saito et al., 2017). In this case, the 
DDTB did not require CF for growth recovery in MPN assays. 
The results from the studies described above, suggest that measuring the bactericidal effects of 
currently used TB drugs may be problematic due to the reliance on CFU decline as a measure 
of drug efficacy. For example, EBA studies are used to monitor the efficacy of different 
chemotherapeutic regimens, for clinical advancement, by measuring the decline in CFU in 
sputum samples during early treatment (Sirgel et al., 2000, Jindani et al., 1980, Sirgel et al., 
1993, Sirgel et al., 1997). The preservation (and possible accumulation) of DCTB would not 
be revealed using these current methods and this may skew the readout of drug efficacy. 
Therefore future EBA studies would benefit by monitoring the effect of antimicrobials on these 
various differentially culturable M. tuberculosis populations. New methods to quantify and 
assess DCTB during treatment are important as they could aid in developing bacterial 
biomarkers for treatment response. For example, monitoring DCTB during and after treatment 
could serve as a potential marker to identify patients that are likely to fail treatment or relapse. 
This could lead to greater responsiveness in treatment algorithms, i.e. if a particular regimen is 
not working, it could be changed according to DCTB profiles. Furthermore, the presence of 
DCTB at the end of treatment may result in that particular patient receiving preventative 
treatment, thus preventing relapse disease. 
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4.1.2 Proposed spectrum of differential culturability during treatment of TB disease 
Prevailing evidence suggests that DCTB can emerge in response to drug treatment, stress 
conditions and can also be influenced by host immunity. Considering this, the spectrum of 
differentially culturable organisms, and the consequent diagnosis of TB, may change during 
treatment.  Figure 4.1 is a hypothetical model illustrating the proposed spectrum of bacterial 
culturability before and throughout the six-month TB treatment regimen. The figure also 
proposes the microbiological outcome using conventional routine diagnostic tests for diagnosis 
of disease as well as treatment monitoring. Before treatment, bacteria exist in multiple growth 
states within the lung cavities (Mukamolova et al., 2010). It is hypothesized that these 
organisms arise from the expansion of small founding populations that are seeded to the lung 
following the initial transmission event. Whilst there is no direct evidence to corroborate this, 
it is speculated that these organisms may transition into a state of increased phenotypic 
heterogeneity in response to immune assault or antibiotic therapy. These DCTB populations 
require the addition of specific growth factors to be cultured in the laboratory. During early 
treatment, actively diving bacteria are killed first. These bacteria can be isolated using standard 
laboratory methods, such as CFU assays, accounting for the measurable decline observed in 
EBA studies during early treatment. Routine diagnostic culture-based tests will remain positive 
until all actively dividing bacilli are eradicated. There is also evidence to suggest that liquid-
based culture systems may be able to detect a population of M. tuberculosis that will not be 
detected on solid media (Bowness et al., 2014, Chengalroyen et al., 2016). Smear and 
molecular-based tests may remain positive for longer depending on the sensitivity of the assay 
since DNA from dead bacteria may still be present in the sputum.  Routine culture-based tests 
will most likely become negative towards the end of early treatment. During late treatment (i.e. 
continuation phase of treatment), less organisms can be isolated using CF-supplemented 
methods as bacteria are killed during treatment, albeit at a slower rate than their actively 
dividing counterparts. At treatment completion, the presence of a few survivors, where 
sterilisation was not achieved, may create the risk of relapse disease. The reliance of DCTB on 
CF or Rpfs may possibly also change during this period, Figure 4.1 
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Figure 4.1 Hypothetical spectrum of differential culturability in pre-treatment and sputum samples 
collected throughout first-line TB treatment. In treatment-naïve patients, sputum samples consist of a mixture 
of actively diving tubercle bacilli (green) and differentially culturable tubercle bacilli (DCTB) that require 
resuscitation-promoting factors (Rpfs) (red) and/or other molecules present in culture filtrate (CF) (blue) for 
growth. Depending of the bacterial load in sputum, TB disease can be diagnosed using conventional diagnostic 
methods including smear microscopy, MGIT culture and PCR-based assays, including the GeneXpert. During 
treatment, actively diving organisms are either killed by these antibiotics or the pressures encountered by these 
bacilli drive them into variable states of limited culturabilty. These DCTB can be recovered in the laboratory using 
CF. Following prolonged treatment, the majority of these organisms will die, however, few organisms may 
remain, undetected by conventional diagnostic methods. It is speculated that these differentially culturable 
organisms may be responsible for relapse disease. RIF = rifampicin, INH = isoniazid, PZA = pyrazinamide and 
EMB = ethambutol.  
 
4.2 HYPOTHESIS 
DCTB are more tolerant to first-line TB antibiotics than conventionally culturable bacteria. 
During treatment, it is hypothesized that DCTB will decline at a slower rate or accumulate 
during the administration of anti-TB chemotherapy. 
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4.3 AIM OF THE STUDY 
To determine the relative proportions of DCTB in sputum samples collected from patients 
infected with active pulmonary, drug-susceptible TB at specified time points during first-line 
TB treatment.  
 
4.3.1 Specific objectives of the study 
1. To compare rates/patterns of decline in DCTB (measured by MPN assays) versus 
conventionally culturable bacteria (measured by growth on agar plates) during 
treatment. 
2. To assess if DCTB can serve as potential biomarkers to monitor response to treatment 
and/or relapse disease.  
3. To determine whether certain patterns of decline are associated with certain patient 
demographics and HIV-infection status. 
4. To determine if TB diagnostic data at baseline can be used as a biomarker to predict 
patterns of decline in DCTB. 
5. To compare patterns of decline obtained using MPN and CFU assays with currently 
employed routine diagnostic tests.  
6. To assess whether organisms detected at the end of treatment using the MPN assay are 
viable by other microbiological methods 
 
4.4 METHODS 
4.4.1 Patients/Sources of sputum samples 
Sputum samples for the longitudinal analysis were recruited as set out in chapter 3, section 
3.4.1 The 174 patients recruited for this study were followed up during the course of their 
treatment and were asked to return to provide both overnight and spot sputum samples at the 
following time points (acceptable deviations are enclosed in parentheses): 3 (2 – 4), 7 (5 – 10), 
14 (12 – 19), 35 (30 – 40), 56 (50 – 65), 90 (80 – 100), 150 (140 – 160) and 180 days (170 – 
190), Figure 4.2. For definitions of overnight and spot sputa, please refer to chapter 3 (see 
section 3.4.1, page 92). Following completion of treatment, the patients were followed up for 
an additional year to monitor for relapse disease (monitoring of relapse is not part of this thesis). 
Time points in this study were skewed towards early treatment and were selected based on data 
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from EBA studies where a rapid decline in bacterial load is observed in early treatment. Figure 
4.2 (A) illustrates the time points at which patients were asked to return to the clinic to provide 
sputum samples.  
 
 
Figure 4.2 Study design, directly observed therapy and sputum collection. (A) Patients were recruited at 
baseline and placed on standard TB chemotherapy for six months. Spot and overnight sputum samples were 
collected at time points indicated. Patients were followed up for an additional year to monitor for relapse disease 
(analysis of relapse fell outside the scope of this thesis). (B) Whilst on TB treatment, study participants were 
required to come to the clinic the day prior to the study visit for a directly observed therapy (DOT) visit. A DOT 
visit was also conducted on the clinic visit day. DOT was conducted to ensure that any DCTB that emerged were 
not due to issues regarding adherence to treatment. In addition to DOT, one day prior to the scheduled time point 
visit, the patient was asked to come to the clinical and collect a sputum vial. The patient took that vial home, 
expectorated sputum into it overnight and early during the morning. When returning to the clinic the next day, the 
patient returned this vial, which was used as the overnight sputum. For the spot sample, sputum collection was 
carried out two hours after the second DOT visit. Additional sputum and blood samples were also collected for 
pharmokinetic analysis of drug concentrations (not part of this thesis), and frozen at -80 °C for future analysis. 
 
The 80 patients analysed at baseline were included for longitudinal analysis; however, 
additional patients were lost/excluded at various time points throughout the study. Table 4.1 
shows the number of patients analysed at each time point and reasons for exclusion from 
analysis for each particular time point.  
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Table 4.1 Number of patients analysed at each time point stratified by both HIV-infection 
status and site location. 
Number of patients included for analysis 
  
Soweto Cohort Klerksdorp Cohort   
Time 
Point 
HIV + HIV - HIV + HIV - Total 
Missed 
time point 
Terminated 
from study 
0 32 16 23 9 80 NA NA 
3 30 16 23 9 78 0 2 
7 29 16 22 9 76 2 0 
14 28 16 22 8 74 1 3 
(5) 
35 26 16 22 7 71 2 2 
(7) 
56       26 15 21 8 70 0 3 
(10) 
180 23  15 17 7 62 0 8 
(18) 
 
Patients removed from the study before or after day 56 were classified as early and late drop 
outs, respectively. Table 4.2 describes the various reasons for patient termination/ exclusion 
from analysis.  In Table 4.1, the first value under the ‘terminated from study’ column represents 
the number of patients that were terminated from the study for that particular time point, i.e. 
the last sputum sample was received at the previous time point. The second figure in parenthesis 
represents the accumulated number of patients that were terminated at each time point. For 
decline analysis (section 4.5.3), patients who had completed at least 14 days of treatment were 
included (n = 75). A total of 62 patients were available for end of treatment analysis (sputum 
samples received 180 days following treatment initiation). The higher rate of HIV-positive 
versus HIV-negative drop-outs (27.3% versus 12%, respectively) at earlier time points can 
mainly be attributed to the severity of disease (i.e. patients were either hospitalised, could not 
produce sputum or died). At the end of treatment (i.e. day 180), the majority of HIV-positive 
patients had relocated or were lost to follow-up, which may be due to a number of factors. 
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Table 4.2 Reasons for patient termination 
 Reason for 
termination 
Number of patients 
terminated (%) 
Last sputum sample 
received 
Early drop-out 
Hospitalisation 3 (30.0) 0, 7, 35 
Death 1 (10.0) 14 
Relocation 2 (20.0) 14, 35 
Could not produce 
sputum 
3 (30.0) 0, 7, 7 
Treatment default 1 (10.0) 35 
Late drop-out 
No end-point sample 
received/ Lost to 
follow-up 
6 (75.0) 56 
Relocation 2 (25.0) 56 
 
The main reasons for ‘early’ study termination were hospitalisation (30%), unable to produce 
sputum (30%) and relocation (20%). One patient defaulted on their treatment and regrettably, 
one patient succumbed. The main reason for late termination was that patients were lost during 
follow-up or did not or were unable to attend their last clinic appointment at treatment 
completion. Two patients relocated to another area. 
 
4.4.2 Processing of sputum samples for longitudinal analysis. 
Sputum decontamination and routine TB diagnostic tests including AFB smear microscopy, 
GeneXpert, MGIT culture and HAIN MTBDRplus assays were performed on all received 
follow-up sputum samples as previously described in chapter 3 (please see Appendix 3B, page 
134). In addition, MPN and CFU assays were performed on all follow-up sputum samples as 
previously described in chapter 3 (please see section 3.4.3, page 94). Spoligotyping was 
performed on selected follow-up samples to confirm the strain type identified at baseline. 
Spoligotyping was performed as described in chapter 3 (please refer to section 3.4.4, page 105). 
 
4.4.3 Reflex assays 
Towards the end of treatment, turbidity – albeit low – in the MPN assay was noted, which was 
scored as positive. To determine whether ‘poor or limited growth’ in the MPN assay was M. 
tuberculosis and not a contaminating organism or cellular debris, reflex assays were performed 
by inoculating material from the positive MPN well into small volume liquid cultures (450 μL), 
MGIT culture and onto solid 7H11 media. In addition, the HAIN MTBDRplus was performed 
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on positive wells to confirm the presence of M. tuberculosis complex. Approximately 400 µL 
from the three replicate MPN wells were pooled together giving 1200 µL of culture. The details 
of each assay are outlined below and illustrated in Figure 4.3.  
 
4.4.3.1 Reflex into 450 μL culture 
Due to the increased volume of the MGIT (approx. 8 mL) in comparison to the MPN well (450 
µL), 50 µL of ‘positive’ culture was inoculated into 400 µL of freshly prepared standard 7H9 
media in 48-well microtiter plates. This was performed in triplicate. Growth was monitored by 
visual inspection after 6 weeks incubation at 37 °C.  
 
4.4.3.2 Reflex onto solid media 
For reflex onto solid media, 100 µL from selected low ‘positive’ MPN wells were sub-cultured 
onto 7H11 plates. Plates were inspected for M. tuberculosis growth after 6 weeks incubation at 
37 °C.  
 
4.4.3.3 Confirmation of low positive wells using the HAIN MTBDRplus assay 
After the pooled samples were reflexed into small volume cultures and onto solid media, the 
remaining sample (± 900 μL) was sent for further analysis to CLS (please refer to chapter 3 for 
a description of the CLS laboratory). The HAIN MTBDRplus assay was carried out to confirm 
the presence of M. tuberculosis complex. Approximately 500 μL of positive culture was 
required to carry out this assay. The assay was carried out according to the manufacturer’s 
instructions.  
 
4.4.3.4 Reflex into MGIT culture 
The remaining ‘positive’ culture (± 400 μL) was reflexed into MGIT cultures. After addition 
of MPN residual culture, 800 µL of PANTA reconstituted in OADC was inoculated into each 
MGIT tube. MGITs were incubated in the BACTEC MGIT 960 instrument for up to 42 days 
to confirm culture negativity. Relevant confirmatory tests including AFB microscopy, blood 
agar and TBc ID tests were performed on positive MGIT cultures. 
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Figure 4.3 Reflex assays. Positive most probable number (MPN) assays exhibiting low or limited growth were 
reflexed into small volume cultures in 48-well microtiter plates, onto solid 7H11 media and into the mycobacterial 
growth indicator tube (MGIT). Furthermore, 500 μL of positive culture was sent for HAIN MTBDRplus to 
confirm the presence of M. tuberculosis complex. Hain and MGIT assays were carried out at CLS. 
 
4.4.4 DMN-TRE staining of end-of-treatment samples 
To confirm the presence of M. tuberculosis at the end of treatment, select positive MPN 
cultures were stained using a fluorogenic derivative of trehalose conjugated to the 
solvatochromatic dye 4-N,N-dimethylamino-1,8-napthalidimide, the reagent referred to here 
on as DMN-Tre (Kamariza et al., 2018). DMN-Tre gets incorporated into the mycobacterial 
cell wall and only fluoresces when in the mycomembrane. As a result, labelling requires 
mycomembrane biosynthesis and allows for not only the identification of M. tuberculosis, but 
also indicates that the organism is viable. This is in contrast to currently employed M. 
tuberculosis staining methods, including ZN and auramine stains, that cannot distinguish live 
from dead mycobacteria.  
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4.4.4.1 DMN-Tre labelling of positive M. tuberculosis culture 
Select positive cultures from the reflex assay (see section 4.4.3) were labelled with DMN-Tre. 
These wells were selected on the basis on their turbidity, where wells displaying high, medium 
and low growth were chosen, Figure 4.4. For this, 40 μL of 10 mM DMN-Tre was added to 
400 μL of culture (final concentration: 1 mM). The stained samples were incubated at 37 ºC 
overnight. The following day the samples were fixed in a final concentration of 2.5% 
glutaraldehyde. For this, the samples were centrifuged at 3000 X g for 10 minutes after which 
the supernatant was removed and substituted with 200 µL of 2.5% gluteraldehyde. The samples 
were left to incubate in the BSL3 for 90 minutes with occasional inversion of the tubes to 
ensure that all the surfaces were decontaminated. Following incubation, the samples were 
harvested at 3000 X g for three minutes, after which the supernatant was removed and the pellet 
was re-suspended in 100 µL PBS. The samples were subsequently removed from the laboratory 
for microscopy. 
 
 
Figure 4.4 Reflex plate with high, medium and low growth for DMN-Tre labelling. Small 450 μL cultures 
reflexed from poor or limited growth MPN wells showed variation in growth ranging from high to low turbidity. 
Two wells were chosen from each turbidity (i.e. high, medium and low) and stained with DMN-Tre. 
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4.4.4.2 Preparation of slides 
A 2% agarose gel was prepared by the addition of 1 g agarose powder to 50 mL of deionised 
water in a 200 mL Erlenmyer flask. The solution was placed in a microwave for about one 
minute until it came to a boil. The agarose was left to cool until it reached approximately 55 
ºC. Approximately one mL of agar was placed on a microscope slide, after which a second 
microscope slide was placed on top of the initial slide to evenly distribute the agar. Following 
solidification of the agarose gel at ambient temperature, the top slide was carefully removed 
from the bottom slide. A 1 cm x 1 cm block of agar was cut out using a scalpel after which 20 
µL of sample was added to the agarose and enclosed with a cover slip.  
 
4.4.4.3 Fluorescent microscopy 
Microscopy was performed using a Nikon A1R confocal microscope equipped with a Plan 
Fluor 60X oil immersion objective. Images were processed using the NIS-Elements AR 
software (Nikon, Inc). Multiple images were taken for each sample in both the DIC and 
FITC/GFP channels.  
 
4.4.5 Data analysis 
To determine the relationship between CF-dependent and Rpf-independent bacterial 
populations at the various time points throughout treatment, Spearman’s rank sum correlation 
analysis was employed. Patients were stratified by their HIV-infection status and the Mann-
Whitney U test was used to determine differences in bacterial load between these two groups 
at each time point analysed. To determine the rates of decline in the different bacterial 
populations (i.e. CF-dependent, Rpf-independent, CF-independent and conventionally 
culturable bacteria), locally weighted scatterplot smoothing (LOWESS) models were 
employed. Following the overall decline analysis, patients were sub-divided into four different 
decline profiles based on their graphs of bacterial decline. To determine whether patient 
demographic data or baseline TB diagnostic data were associated with a specific pattern of 
decline, absolute numbers and percentages were calculated. An additional group where no 
CFUs were obtained from patients at all treatment time points was included. The chi-squared 
test for proportions and analysis of variance (ANOVA) was used to make comparisons between 
all five groups. For comparisons between two groups, the chi-squared test for proportions, 
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unpaired student’s t-tests and Mann-Whitney U tests were used. All statistical tests were two-
sided and statistical significance was carried out using a 95% confidence interval. 
 
4.5 RESULTS 
4.5.1 The culture filtrate effect 
In chapter three, analysis of pre-treatment sputum samples revealed that there was a direct 
correlation between the number of bacteria derived in the CF+ supplemented MPN assay and 
Rpf – supplemented MPN assay at baseline. This suggested that whilst the presence of Rpfs in 
CF provided a marginal benefit in bacterial recovery, the majority of the growth stimulatory 
effect was Rpf-independent. We hypothesized that this relationship between CF-dependent and 
Rpf-independent DCTB may change during treatment, with a greater dependency on Rpfs 
emerging as treatment progresses. To assess this, Spearman’s rank sum correlation was 
employed to determine the relationship between the CF+ supplemented and Rpf – supplemented 
MPN assays at day 3, 7, 14, 35, 56 and 180. A positive correlation was observed at all time 
points illustrating that factors, other than Rpfs, present in CF can also resuscitate DCTB in 
sputum from patients throughout treatment. No significant dependency on Rpfs emerged 
during treatment. 
161 
 
 
Figure 4.5 Correlation of resuscitation index between culture filtrate-supplemented most probable number 
assays with and without resuscitation-promoting factors. The resuscitative effect between most probable 
number (MPN) assays performed with culture filtrate (CF+) derived from wild-type M. tuberculosis H37Rv and 
resuscitation-promoting factor (Rpf) – CF from a quintuple rpf gene-knockout mutant was correlated at each time 
point throughout treatment, i.e. day 3 (A), day 7 (B), day 14 (C), day 35 (D), day 56 (E) and day 180 (F). The 
resuscitation index (RI) was calculated using the following equation: RI = log (MPN/CFU). Culture filtrate (CF)-
dependent bacteria, calculated as log (CF+ MPN/CFU) are reflected on the x-axis, whilst Rpf-independent 
bacteria, calculated as log (Rpf – MPN/CFU), are represented on the y-axis. In cases where the CFU was zero, the 
denominator was set to 1 to reflect the absence of culturable bacteria. In instances where there was no growth in 
any of the three MPN conditions or the CFU, patient data for that particular time point were all set to 0. If the 
CFU was greater than the MPN and a negative RI was obtained, the RI was set to 0 to indicate no resuscitation. 
In cases where contamination was present on solid media and a CFU could not be obtained, patient data for that 
particular time point was removed from analysis. Spearman’s rank-sum correlation analysis was two sided and 
used with a 95% confidence interval.  
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4.5.2 HIV-negative patients harbour more DCTB than their HIV counterparts during early 
treatment 
To determine whether DCTB are more prevalent in HIV-uninfected individuals, HIV-infected 
versus -uninfected groups were compared at each time point using the Mann-Whitney U test. 
Significant differences were observed in the CF-supplemented MPN assays conducted three, 
seven and 14 days following treatment initiation, with HIV-negative individuals harbouring 
more CF-dependent DCTB than their HIV-infected counterparts. Significant differences in the 
number of CFUs isolated from these two groups were also observed up to 35 days following 
treatment initiation. These results are in agreement with that observed in treatment-naïve 
patients. At later time points (i.e. sputum samples collected at days 35, 56 and 180 days post 
treatment initiation), no differences were observed in the quantum of DCTB in sputum 
regardless of HIV status, Figure 4.6. However, in all cases, MPN values were substantively 
higher than CFUS. 
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Figure 4.6 Measures of bacterial load stratified by HIV-infection status at selected time-points throughout 
first-line TB treatment. Scatterplots depicting bacterial load distributions in HIV-infected and -uninfected 
individuals at: (A) three (n = 78), (B) seven (n = 76), (C) 14 (n = 74), (D) 35 (n = 71), (E) 56 (n = 70) and (F) 180 
(n = 62) days post-treatment initiation. Error bars represent medians and interquartile ranges. To determine 
statistical significance, the Mann-Whitney U test was used with a 95% confidence interval. CF+ MPN (red), Rpf 
– MPN (blue), MPN no CF (green) and CFU (purple).    
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4.5.3 Rates of decline 
To determine the overall rates of decline in the DCTB populations, an analysis was carried out 
using linear mixed effects models on all patients. DCTB fluctuation curves were fitted using 
LOWESS. The analysis illustrated that CF-dependent DCTB populations declined at a 
marginally faster rate than CF-independent and conventionally culturable organisms (CFUs). 
The slopes obtained were -0,020, -0,010, and -0.007 for CF-dependent, Rpf-independent and 
CF-independent DCTB populations, respectively. A slope of -0.014 was obtained for the 
decline of CFU throughout first-line treatment.   
 
 
Figure 4.7 Rates of decline in differentially culturable and platable tubercle bacteria in 75 patients with 
drug-susceptible tuberculosis. Regression analysis was carried out using locally weighted scatterplot smoothing 
(LOWESS) model to determine the rate of decline for each bacterial population over six months of anti-TB 
treatment. Graphs are fitted with both LOWESS curves (colour lines) and non-linear regression (black lines). 
Culture filtrate (CF)-dependent DCTB are reflected in red (A), resuscitation promoting factor (Rpf) -independent 
DCTB in blue (B), CF-independent DCTB in green and colony forming units (CFU) in purple (D).  
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Overall analysis revealed that there was little material difference between the rates of decline 
in the four populations analysed, with the CF-dependent population declining at a slightly faster 
rate compared to the remaining three populations. The observed trends were in contrast to the 
initial hypothesis and previous reports demonstrating that DCTB are more tolerant to first-line 
anti-TB chemotherapeutics. To further investigate this, decline trends were studied in 
individual patients.  It was clear that DCTB populations declined at different rates in different 
patients and that these trends were lost when the data for all patients were analysed as a 
collective. Hence, an alternate analysis was attempted. Patients were initially grouped into five 
major trends in DCTB behaviour. These included: (1) DCTB resist decline for three days, (2) 
DCTB resist decline for seven days, (3) accumulation DCTB, (4) decline in DCTB and (5) 
atypical DCTB behaviour. Examples of each of these five patterns are shown in Figures 4.8 to 
4.12. Figures are represented up to seven days on anti-TB treatment.  
 
 
Figure 4.8 MPN and CFU analysis of DCTB populations during antimicrobial treatment reveal sub-
populations of bacteria that resist decline during the first three days of treatment. (A) Log bacterial counts 
obtained using MPN and CFU assays are shown during the first week of anti-TB treatment in patient 59006 to 
illustrate pattern 1. Each assay has been fitted with a polynomial trend line to show the pattern of decline. (B) 
Bacterial counts expressed as percent survival compared to baseline were calculated using the following equation: 
[(viable count baseline)/ (viable count time χ)] x 100. In this patient, pattern 1 shows no decrease in CF-dependent (or 
platable bacteria) during the first three days of treatment, but a rapid decline in all bacterial populations at day 7. 
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Figure 4.9 MPN and CFU analysis of DCTB populations during antimicrobial treatment reveal sub-
populations of bacteria that resist decline during the first seven days of treatment. (A) Log bacterial counts 
obtained using MPN and CFU assays are shown during the first week of anti-TB treatment in patient 59002 to 
further illustrate pattern 2. Each assay has been fitted with a polynomial trend line to show the pattern of decline. 
(B) Bacterial counts expressed as percent survival compared to baseline were calculated using the following 
equation: [(viable count baseline)/ (viable count time χ)] x 100. In this patient, pattern 2 shows a decrease in platable 
bacteria during the first seven days of treatment but no decrease in CF-dependent bacteria as detected by the MPN 
assay.  
 
 
Figure 4.10 MPN and CFU analysis of DCTB populations during antimicrobial treatment reveal sub-
populations of bacteria that accumulate during the first three days of treatment. (A) Log bacterial counts 
obtained using MPN and CFU assays are shown during the first week of anti-TB treatment in patient 59030 to 
further illustrate pattern 3. Each assay has been fitted with a polynomial trend line to show illustrate the increase 
in bacterial sub-populations. (B) Bacterial counts expressed as percent survival compared to baseline were 
calculated using the following equation: [(viable count baseline)/ (viable count time χ)] x 100. In this patient, a drastic 
accumulation in Rpf-dependent bacteria, and to a lesser extent CF-dependent and conventionally culturable 
bacteria, is observed.  
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Figure 4.11 MPN and CFU analysis of DCTB populations during antimicrobial treatment reveal bacterial 
sub-populations that decline rapidly during the first week of treatment. (A) Log bacterial counts obtained 
using MPN and CFU assays are shown during the first week of anti-TB treatment in patient 59012 to further 
illustrate pattern 4. Each assay has been fitted with a polynomial trend line to best fit the pattern of decline. (B) 
Bacterial counts expressed as percent survival compared to baseline were calculated using the following equation: 
[(viable count baseline)/ (viable count time χ)] x 100. A drastic decrease in all sub-populations is seen to occur during 
the first few days of treatment.  
 
 
Figure 4.12 MPN and CFU analysis of DCTB populations during antimicrobial treatment reveal sub-
populations of bacteria that exhibit an atypical pattern of decline. (A) Log bacterial counts obtained using 
MPN and CFU assays are shown during the first week of anti-TB treatment in patient 59037 to further illustrate 
pattern 5. Each assay has been fitted with a polynomial trend line to best fit the pattern of decline. (B) Bacterial 
counts expressed as percent survival compared to baseline were calculated using the following equation: [(viable 
count baseline)/ (viable count time χ)] x 100. In general, patients exhibiting an atypical pattern had low starting bacterial 
loads that appear to persist throughout treatment. CFUs were not available for this patient at baseline and days 3 
and 7 due to the CFU plates being contaminated.  
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Figure 4.13 Patients categorized by defined patterns of decline. Seventy five patients that had completed at 
least fourteen days of anti-TB treatment were included for decline analysis. The four sub-categories that patients 
were assigned to included: resist decline (for three and seven days on anti-TB treatment), accumulate DCTB, 
decline in DCTB and atypical DCTB presentation. Patterns were defined according to the patterns observed in the 
CF-dependent population.  
 
4.5.4 Patterns of DCTB decline 
4.5.4.1 The ‘drug tolerant’ or ‘resist decline’ cohort  
Data from 17 of the 75 patients analysed (approximately 23%) exhibited a pattern of decline 
that was characterized by the maintenance of DCTB levels three to seven days following the 
initiation of first-line anti-TB treatment. Nine and eight patients were identified in the three 
and seven day categories respectively. Figure 4.14 and 4.15 illustrates the decline in CFU along 
with DCTB and the decline in tubercle bacilli obtained via routine diagnostic data in 9 patients 
whereby DCTB do not decline within the first three days of treatment. Figure 4.16 and Figure 
4.17 illustrates the same data in patients where DCTB fail to decline during the first week of 
anti-TB treatment. Routine DST to second line agents was not carried out in this study, 
therefore additional drug resistance (although unlikely) cannot exclusively be ruled out as a 
possible contributor to the ‘resist decline’ pattern in some patients.  
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Figure 4.14 Decline in differentially culturable and conventionally culturable tubercle bacilli in nine 
patients exhibiting the drug tolerant/resist decline DCTB pattern during the first three days of standard 
first-line treatment.  (A) The average number of culture filtrate (CF) -dependent bacteria (red), and resuscitation-
promoting factor (Rpf) –independent bacteria (blue) obtained in the CF-supplemented most probable number 
(MPN) assays were plotted for each selected time point during the six months of anti-TB treatment. In addition, 
the CF-independent bacteria (green) obtained in the un-supplemented MPN assay and the average number of 
platable bacteria (purple), obtained by viable colony forming units (CFU) on solid media were plotted for each 
selected time point during the six months of anti-TB treatment. The dotted line (at log 2.0) indicates possible 
background scored as positive growth in the MPN assay. This was determined by assessing residual turbidity 
remaining at later time points during treatment. To more clearly illustrate the drug tolerant/resist decline pattern, 
the box insert illustrates the decline in bacterial load during the first two weeks of treatment. (B) The proportional 
decrease in DCTB during the first two weeks of anti-TB treatment was calculated by setting the average bacterial 
load obtained at enrolment in both the CF-dependent DCTB and platable bacteria to 100%. The average number 
of bacteria cultured at each subsequent time point was calculated as a proportion of the average number of 
organisms obtained at baseline. The shaded grey area illustrates where the proportional decrease in the culturable 
population (as detected by CFU) was far greater than the CF-dependent population. 
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Figure 4.15 Average decline in bacterial load for the three-day drug tolerant/resist decline DCTB pattern 
throughout first-line treatment as determined by routine diagnostic assays. (A) The average time to positivity 
(TTP) (green) for the nine drug tolerant/resist decline patients obtained in the mycobacterial growth indicator tube 
(MGIT) is given for each of the seven time points throughout the six months of anti-TB treatment (left panel). 
The right panel illustrates the average increase in TTP during the first two weeks of anti-TB treatment, shown to 
illustrate the early treatment response.  For comparison, the grey dotted line indicates overall patient average (n = 
75, i.e. the average MGIT TTP for all DCTB decline sub-categories). (B) The average cycle threshold (Ct) value 
(blue) for the nine drug tolerant/resist decline patients obtained from the GeneXpert is given for each of the seven 
time points throughout the six months of TB treatment (left panel). The right panel illustrates the average increase 
in Ct value during the first two weeks of anti-TB treatment, to illustrate early treatment response. For comparison, 
the grey dotted line indicates overall patient average (n = 75 i.e. the average Ct value for all DCTB decline sub-
categories). (C) The average smear positivity was calculated by providing the smear grading at each particular 
time point with a numerical value. P+++, ++, +, scanty and negative smears were scored as 4,3,2,1 and 0, 
respectively. The left panel illustrates the decline in smear grading over six months of TB treatment. The right 
panel illustrates the decrease in smear positivity during the first two weeks of anti-TB treatment, shown to 
illustrate early treatment response. The grey dotted line shows overall patient average (n = 75 i.e. the average 
smear positivity for all DCTB decline sub-categories).  
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Figure 4.16 Decline in differentially culturable and conventionally culturable tubercle bacilli in eight 
patients exhibiting the drug tolerant/resist decline DCTB pattern during the first week of standard first-
line tuberculosis treatment. (A) The average number of culture filtrate (CF) -dependent bacteria (red), and 
resuscitation-promoting factor (Rpf) –independent bacteria (blue) obtained in the CF-supplemented most probable 
number (MPN) assays were plotted for each selected time point during the six months of anti-TB treatment. In 
addition the CF-independent bacteria (green) obtained in the un-supplemented MPN assay and the average number 
of platable bacteria (purple), obtained by viable colony forming units (CFU) on solid media were plotted for each 
selected time point during the six months of anti-TB treatment. The dotted line (at log 2.0) indicates possible 
background scored as positive growth in the MPN assay. This was determined by assessing residual turbidity 
remaining at later time points during treatment.  To more clearly illustrate the resist decline pattern, the box insert 
illustrates the decline in bacterial load during the first two weeks of treatment. (B) The proportional increase in 
DCTB during the first two weeks of anti-TB treatment was calculated by setting the average bacterial load 
obtained at enrolment in both the CF-dependent DCTB (red) and platable bacteria (purple) to 100%. The average 
number of bacteria cultured at each subsequent time point was calculated as a proportion of the average number 
of organisms obtained at baseline. The shaded grey area illustrates where the proportional decrease in the 
culturable population (as detected by CFU) was far greater than the CF-dependent population. 
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Figure 4.17 Average decline in bacterial load for the seven-day drug-tolerant/resist decline DCTB pattern 
throughout first-line treatment as determined by routine diagnostic assays. (A) The average time to positivity 
(TTP) (green) for the eight drug-tolerant/resist decline DCTB patients obtained in the mycobacterial growth 
indicator tube (MGIT) is given for each of the seven time points throughout the six months of anti-TB treatment 
(left panel). The right panel illustrates the average increase in TTP during the first two weeks of anti-TB treatment, 
shown to illustrate the early treatment response.  For comparison, the grey dotted line indicates overall patient 
average (n = 75, i.e. the average MGIT TTP for all DCTB decline sub-categories). (B) The average cycle threshold 
(Ct) value (blue) for the eight drug tolerant/resist decline patients obtained from the GeneXpert is given for each 
of the seven time points throughout the six months of TB treatment (left panel). The right panel illustrates the 
average increase in Ct value during the first two weeks of anti-TB treatment, to illustrate early treatment response. 
For comparison, the grey dotted line indicates overall patient average (n = 75 i.e. the average Ct value for all 
DCTB decline sub-categories). (C) The average smear positivity was calculated by providing the smear grading 
at each particular time point with a numerical value. P+++, ++, +, scanty and negative smears were scored as 
4,3,2,1 and 0, respectively. The left panel illustrates the decline in smear grading over six months of TB treatment. 
The right panel illustrates the decrease in smear positivity during the first two weeks of anti-TB treatment, shown 
to illustrate early treatment response. The grey dotted line shows overall patient average (n = 75 i.e. the average 
smear positivity for all DCTB decline sub-categories).  
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The drug tolerant/resist decline DCTB patient cohort was characterised by high sputum 
bacterial loads at baseline as evident by MPN, CFU and routine diagnostic assays. In the MPN 
assay, CF-dependent bacteria appear to be somewhat drug tolerant and resist decline during the 
first three to seven days of anti-TB treatment. It is important to note that interpreting this pattern 
of decline is limited due to the MPN assay having an upper limit of log 8.7. For instance, in 
patients where bacterial growth was present in all of the MPN wells at baseline (or at early 
treatment time points), the most probable number of bacteria could not accurately be 
established and a value of log 8.7 was used in the analyses; however, a value of >log 8.7 is 
more correct. It is therefore not clear how this particular DCTB population responds to 
treatment.  
Analysis of the routine diagnostic data illustrated a decline in bacterial load at each subsequent 
time point. In the three day resist cohort, the average MGIT TTP increased from 4.4 days at 
baseline to 8 days and 10 days at the 3 and 7 day time points, respectively, illustrating a 
decrease in bacterial burden following treatment initiation. Similarly in the seven day resist 
cohort, the average MGIT TTP increased from 3.1 days at enrolment to 5.5 and 5.8 days at the 
3 and 7 day time points respectively. An increase in Ct values were also observed in these 
patients at each subsequent time point following treatment initiation illustrating a decline in 
bacterial burden. This group of patients also had high smear grades at baseline and during early 
treatment. In all 17 patients (i.e. three and seven day resist decline combined, see Table 4C), 
82.4% had P+++ grading’s at baseline and at the day 3 time point.  
 
4.5.4.2 The ‘accumulate’ cohort 
Seventeen patients out of 75 (approximately 23%) exhibited the accumulate DCTB pattern. 
The proportional decline (or in this case, the accumulation during early treatment) of DCTB 
and conventionally culturable bacteria was calculated for each time point as a percentage of 
the baseline population, which was set to 100%. Patients exhibiting the accumulate DCTB 
profile showed an increase in DCTB during the first week of treatment (Figure 4.18 A and B). 
At day 3, the DCTB population increased to approximately 2800X (ca. 3 log) from that 
observed at baseline. In the proportional analysis, the number of CF-dependent DCTB isolated 
remained above that obtained at baseline until day 35 at which point it dropped to less than 1% 
of the population quantified at baseline.   
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During the first three days of treatment, the CFU increased to approximately 460X that 
observed at baseline but dropped to less than 1% of the initial population at day 7. At day 14 
the CFU increased to 750X that observed at baseline. At day 35 and 56, the percentage of 
culturable bacteria relative to that observed at baseline was 6 and 0.3%. At the end of treatment, 
no culturable bacteria were isolated in this patient cohort.  
 
 
Figure 4.18 Decline in differentially culturable and conventionally culturable tubercle bacilli in seventeen 
patients exhibiting the accumulate DCTB pattern. (A) The average number of culture filtrate (CF) -dependent 
bacteria (red), and resuscitation-promoting factor (Rpf) –independent bacteria (blue) obtained in the CF-
supplemented most probable number (MPN) assays were plotted for each selected time point during the six 
months of anti-TB treatment. In addition the CF-independent bacteria (green) obtained in the un-supplemented 
MPN assay and the average number of platable bacteria (purple), obtained by viable colony forming units (CFU) 
on solid media were plotted for each selected time point during the six months of anti-TB treatment. The dotted 
line (at log 2.0) indicates possible background scored as positive growth in the MPN assay. This was determined 
by assessing residual turbidity remaining at later time-points during treatment. To more clearly illustrate the 
accumulation of DCTB during early treatment, the box insert illustrates the decline in bacterial load during the 
first thirty five days of treatment.  (B) The proportional increase in DCTB during the first two weeks of anti-TB 
treatment was calculated by setting the average bacterial load obtained at enrolment in both the CF-dependent 
DCTB (red) and platable bacteria (purple) to 100%. The average number of bacteria cultured at each subsequent 
time point was calculated as a proportion of the average number of organisms obtained at baseline. The shaded 
grey area illustrates where the proportional decrease in the culturable population (as detected by CFU) was far 
greater than the CF-dependent population. 
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Figure 4.19 Average decline in bacterial load for the accumulate DCTB pattern throughout first-line 
treatment as determined by routine diagnostic assays. (A) The average time to positivity (TTP) (green) for the 
seventeen accumulate DCTB patients obtained in the mycobacterial growth indicator tube (MGIT) is given for 
each time point throughout the six months of anti-TB treatment (left panel). The right panel illustrates the average 
increase in TTP during the first two weeks of anti-TB treatment, shown to illustrate the early treatment response.  
For comparison, the grey dotted line indicates overall patient average (n = 75, i.e. the average MGIT TTP for all 
DCTB decline sub-categories). (B) The average cycle threshold (Ct) value (blue) for the seventeen accumulate 
DCTB patients obtained from the GeneXpert is given for each time point throughout the six months of TB 
treatment (left panel). The right panel illustrates the average increase in Ct value during the first two weeks of 
anti-TB treatment, to illustrate early treatment response. For comparison, the grey dotted line indicates overall 
patient average (n = 75 i.e. the average Ct value for all DCTB decline sub-categories). (C) The average smear 
positivity was calculated by providing the smear grading at each particular time point with a numerical value. 
P+++, ++, +, scanty and negative smears were scored as 4,3,2,1 and 0, respectively. The left panel illustrates the 
decline in smear grading over six months of TB treatment. The right panel illustrates the decrease in smear 
positivity during the first two weeks of anti-TB treatment, shown to illustrate early treatment response. The grey 
dotted line shows overall patient average (n = 75 i.e. the average smear positivity for all DCTB decline sub-
categories). 
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Diagnostic assays conducted for the accumulate DCTB patient cohort were assessed to 
determine if similarities in trends (related to bacterial burden) could be linked to the estimated 
numbers of culturable and DCTB obtained in the CFU and MPN assays [Figure 4.19 and Tables 
4A, 4B and 4C (see Appendices)]. In the MGIT, the TTP decreased during the first three days 
of treatment with average TTPs of 12.7 and 10.4 days reported at baseline and three days 
following treatment initiation, respectively. After seven and fourteen days, the average TTP 
increased to 15.6 and 17.1 days, respectively. The initial decrease in TTP is associated with an 
increase bacterial burden which is mirrored by both the number of bacteria obtained in the CF-
supplemented MPN and CFU assays. The majority of patients (92.3%) from this cohort had 
negative MGIT cultures at the end of treatment, with 35.3% having two consecutive negative 
cultures. The pattern observed in the MGIT was reflected in the GeneXpert, whereby the Ct 
value decreased from 24.0 to 22.6 following three days of anti-TB treatment, indicating an 
increase in bacterial burden. Following seven and 14 days of treatment the average Ct values 
remained relatively stable with average reported Ct values of 24.5 and 24.3, respectively. 
Following 14 days of treatment, the Ct value declined at each consecutive time point. These 
results illustrate that the pattern of Ct values obtained from the GeneXpert assay was similar to 
the accumulate DCTB pattern, with the Ct value being qualitatively ‘high’ during the first two 
weeks of treatment. Auramine smear data also indicated an increase in bacterial burden during 
the first two weeks of anti-TB treatment, with the percentage of patients with a P+++ smear 
grading increasing from 17.6% at baseline to 29.4 and 23.5% at three and seven days post-
treatment initiation, respectively. At fourteen days post treatment initiation, the percentage of 
patients with a P+++ grading decreased to 5.9% of patients.  These results suggest that the CFU 
assay and accumulate DCTB pattern detected by the MPN assays are echoed by TTP obtained 
via the MGIT assay and the GeneXpert along with smear diagnostic assays, respectively. 
 
4.5.4.3 The ‘decline’ cohort 
One group of patients (26.7% of total population) was characterised by a continuous decline in 
both CF-dependent DCTB and conventionally culturable bacteria from baseline to the end of 
first-line treatment. Results showing the bacterial decline in MPN and CFU assays as well as 
routine diagnostic assays for this patient cohort are depicted in Figures 4.20 and Figure 4.21, 
respectively.   
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Figure 4.20 Decline in differentially culturable and conventionally culturable tubercle bacilli in twenty 
patients exhibiting the decline in DCTB pattern. (A) The average number of culture filtrate (CF) -dependent 
bacteria (red), and resuscitation-promoting factor (Rpf) –independent bacteria (blue) obtained in the CF-
supplemented most probable number (MPN) assays were plotted for each selected time point during the six 
months of anti-TB treatment. In addition the CF-independent bacteria (green) obtained in the un-supplemented 
MPN assay and the average number of platable bacteria (purple), obtained by viable colony forming units (CFU) 
on solid media were plotted for each selected time point during the six months of anti-TB treatment. The dotted 
line (at log 2.0) indicates possible background scored as positive growth in the MPN assay. This was determined 
by assessing residual turbidity remaining at later time-points during treatment.  The box insert illustrates the 
decline in bacterial load during the first fifty six days of treatment. (B) The proportional increase in DCTB during 
the first two weeks of anti-TB treatment was calculated by setting the average bacterial load obtained at enrolment 
in both the CF-dependent DCTB (red) and platable bacteria (purple) to 100%. The average number of bacteria 
cultured at each subsequent time point was calculated as a proportion of the average number of organisms obtained 
at baseline. The shaded grey area illustrates where the proportional decrease in the culturable population (as 
detected by CFU) was less than the CF-dependent population. 
 
At baseline, the bacterial load obtained in the CF-supplemented MPN assays yielded 
approximately 3 logs more than that obtained in CFU assays. During treatment, there was 
approximately a 1 log difference (or less) between the MPN and CFU assays, whilst at the end 
of treatment, no viable organisms were present but approximately 2.5 log organisms were still 
obtained in the MPN assay, based on turbidity in the MPN assay. Proportional decline analysis 
conducted during the first two weeks of treatment revealed that DCTB decline rapidly during 
the first three days of treatment, with less than 5% of the initial organism load quantified in the 
CF+ MPN experiments at baseline. The conventionally culturable population, detected by 
viable colonies on solid media, initially declined at a much slower rate with 37% of initial 
organism load observed three days following treatment initiation. In both assays, less than 2% 
of the initial organism load was observed after seven days.   
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Figure 4.21 Average decline in bacterial load for decline in DCTB pattern throughout first-line treatment 
as determined by routine diagnostic assays. (A) The average time to positivity (TTP) (green) for the twenty 
decline in DCTB patients obtained in the mycobacterial growth indicator tube (MGIT) is given for each time point 
throughout the six months of anti-TB treatment (left panel). The right panel illustrates the average increase in TTP 
during the first two weeks of anti-TB treatment, shown to illustrate the early treatment response.  For comparison, 
the grey dotted line indicates overall patient average (n = 75, i.e. the average MGIT TTP for all DCTB decline 
sub-categories). (B) The average cycle threshold (Ct) value (blue) for the twenty decline in DCTB patients 
obtained from the GeneXpert is given for each time point throughout the six months of TB treatment (left panel). 
The right panel illustrates the average increase in Ct value during the first two weeks of anti-TB treatment, to 
illustrate early treatment response. For comparison, the grey dotted line indicates overall patient average (n = 75 
i.e. the average Ct value for all DCTB decline sub-categories). (C) The average smear positivity was calculated 
by providing the smear grading at each particular time point with a numerical value. P+++, ++, +, scanty and 
negative smears were scored as 4,3,2,1 and 0, respectively. The left panel illustrates the decline in smear grading 
over six months of TB treatment. The right panel illustrates the decrease in smear positivity during the first two 
weeks of anti-TB treatment, shown to illustrate early treatment response. The grey dotted line shows overall 
patient average (n = 75 i.e. the average smear positivity for all DCTB decline sub-categories). 
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Analysis of data from routine diagnostic assays carried out on this patient cohort indicated a 
rapid decline in bacterial load after the commencement and throughout TB treatment. Overall, 
these patients had a high starting bacterial burden when compared to the total patient cohort 
with low average TTP and Ct values and high corresponding smear grades. In the MGIT assay, 
the average TTP increased rapidly from 6.1 days to 10.2 days following the commencement of 
treatment. This increase in TTP was sustained throughout treatment (Table 4A). At the end of 
treatment, approximately 92% of these patients were culture negative, with 45% of patients 
having at least two consecutive negative MGIT cultures. As observed in the MGIT, the Ct 
value increased steadily throughout treatment in this patient cohort. At the end of treatment, M. 
tuberculosis was not detected by the GeneXpert assay in 92% of this population. With regards 
to smear microscopy, the observed decline in bacterial load was rapid. At enrolment, all of the 
patients from this cohort had a positive smear grade of P+++, P++ or P+ (60%, 25% and 15%, 
respectively). Three days following the commencement of treatment, 20% of this patient cohort 
had low (scanty) or negative smear grades. The decline and change in smear grade is given in 
Figure 4.21 (C) and Table 4C.  
 
4.5.4.4 ‘Atypical’ presentation 
Lastly, 21 patients (approximately 28% of the analysed population) demonstrated an atypical 
DCTB pattern of decline in both the CF-supplemented MPN and CFU assays. The overall 
pattern of decline observed in these patients was characterised by an initial decline in DCTB, 
and to a lesser extent CFU, during early treatment, followed by an increase in both these 
populations at day seven (Figure 4.22A). The majority of the atypical DCTB patients were 
characterised by low MPNs or CFUs at diagnosis that persisted throughout treatment. Fifteen 
of the sixteen patients had no CFUs at the end of treatment; however, one of these patients still 
had 4 viable colonies emerge on solid media following 180 days of treatment. Furthermore, an 
average of 2.8 log organisms was observed in the CF-supplemented MPN assay at the end of 
treatment.  
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Figure 4.22 Decline in differentially culturable and culturable tubercle bacilli in twenty one patients 
exhibiting the atypical DCTB decline pattern. (A) The average number of culture filtrate (CF) -dependent 
bacteria (red), and resuscitation-promoting factor (Rpf) –independent bacteria (blue) obtained in the CF-
supplemented most probable number (MPN) assays were plotted for each selected time point during the six 
months of anti-TB treatment. In addition the CF-independent bacteria (green) obtained in the un-supplemented 
MPN assay and the average number of platable bacteria (purple), obtained by viable colony forming units (CFU) 
on solid media were plotted for each selected time point during the six months of anti-TB treatment. The dotted 
line (at log 2.0) indicates possible background scored as positive growth in the MPN assay. This was determined 
by assessing residual turbidity remaining at later time-points during treatment. (B) The proportional increase in 
DCTB during the first two weeks of anti-TB treatment was calculated by setting the average bacterial load 
obtained at enrolment in both the CF-dependent DCTB (red) and platable bacteria (purple) to 100%. The average 
number of bacteria cultured at each subsequent time point was calculated as a proportion of the average number 
of organisms obtained at baseline.  
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Figure 4.23 Average decline in bacterial load for atypical DCTB pattern throughout first-line treatment as 
determined by routine diagnostic assays. (A) The average time to positivity (TTP) (green) for the 21 atypical 
DCTB behaviour patients obtained in the mycobacterial growth indicator tube (MGIT) is given for each time point 
throughout the six months of anti-TB treatment (left panel). The right panel illustrates the average increase in TTP 
during the first two weeks of anti-TB treatment, shown to illustrate the early treatment response.  For comparison, 
the grey dotted line indicates overall patient average (n = 75, i.e. the average MGIT TTP for all DCTB decline 
sub-categories). (B) The average cycle threshold (Ct) value (blue) for the 21 atypical DCTB behaviour patients 
obtained from the GeneXpert is given for each time point throughout the six months of TB treatment (left panel). 
The right panel illustrates the average increase in Ct value during the first two weeks of anti-TB treatment, to 
illustrate early treatment response. For comparison, the grey dotted line indicates overall patient average (n = 75 
i.e. the average Ct value for all DCTB decline sub-categories). (C) The average smear positivity was calculated 
by providing the smear grading at each particular time point with a numerical value. P+++, ++, +, scanty and 
negative smears were scored as 4,3,2,1 and 0, respectively. The left panel illustrates the decline in smear grading 
over six months of TB treatment. The right panel illustrates the decrease in smear positivity during the first two 
weeks of anti-TB treatment, shown to illustrate early treatment response. The grey dotted line shows overall 
patient average (n = 75 i.e. the average smear positivity for all DCTB decline sub-categories). 
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Analysis of the routine diagnostic data obtained for the atypical DCTB patient cohort illustrated 
a similar pattern to that observed in the CF-supplemented MPN and CFU assays. In the MGIT 
assay, a decrease in bacterial load is observed during early treatment whereby the average TTP 
increases from 18.9 to 21.9 days. However, following one week of treatment, an increase in 
bacterial load is observed where a TTP of 19.5 days is observed. This increase in bacterial 
burden is short lived and followed by a gradual decline in TB bacilli as indicated by an increase 
in TTP at subsequent time points during the remainder of the treatment period, Table 4A. The 
results reflect the pattern of decline observed in the CF-supplemented MPN assay during early 
treatment. At the end of treatment, all of the atypical DCTB patients were MGIT culture 
negative. This is in contrast to the MPN assay where an average of 2.8 log bacteria were 
cultured. In the GeneXpert assay, the Ct value remained unchanged during the first three days 
of treatment (Ct = 26.3 at enrolment and day 3). In addition, the Ct value remained essentially 
unchanged from day seven to 14 (28.2 and 28.7, respectively). At the end of treatment, M. 
tuberculosis was not detected in 83.3% of this patient population. It is important to note that 
this group of patients are defined by low starting bacillary loads that can be observed in the 
MPN and CFU assays as well as all three diagnostic tests employed. Only one patient in this 
group had a higher starting bacillary load of log 7.2 (CF+ MPN). When removed from analysis, 
the average starting bacillary load for this group of patients decreased from log 5.9 to log 3.2 
in the CF+ MPN assay. Following the removal of this single patient, the Figure depicting the 
decline in DCTB is relatively flat (see Appendix 4D ‘Figure 4A’, page 204).  
 
4.5.5 Baseline factors associated with the various decline trends 
Patient demographic factors associated with the various patterns of decline are shown in Table 
4.3. The ‘no CFU’ column contained eleven patients whereby no CFU’s were cultured at 
baseline or at any time point throughout treatment. The majority of these patients 
(approximately 82%) were HIV-positive. The atypical DCTB category also consisted 
predominantly of HIV-positive individuals (85.7%). Analysis was conducted between all five 
groups (Table 4.3) and between individual patient groups. P-values from statistical tests 
comparing individual groups are given in Appendix 4E (see Tables 4D, 4E, 4H and 4I). In 
terms of HIV-infection status, a significant difference was seen between the resist decline and 
atypical DCTB groups (P = 0.0108, chi-square test, Table 4H), where the atypical DCTB 
patient cohort were more likely to be HIV-positive (86% versus 47%). Age was found to differ 
significantly between most groups, Table 4.3 and Table 4D. Significant differences were also 
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obtained with regards to gender where the resist decline DCTB group differed significantly 
from the no CFU, accumulate and decline groups (Table 4H). Male gender was associated with 
the resist decline DCTB pattern characterised by high baseline bacterial loads. A significant 
difference was observed in BMI between the resist decline and atypical DCTB groups with the 
atypical group having a higher mean BMI (P = 0.0329, unpaired t-test, Table 4D). No 
significant differences were obtained between the individual DCTB decline groups for CD4 T-
cell count, smoking status or the presence/absence of a BCG scar. These findings suggest that 
the patient’s age, HIV-status and gender will most likely be predictive of the pattern of DCTB 
decline. For example, patients that were assigned to the atypical DCTB category were older 
(>39 years of age) and more likely to be HIV-positive (85.7%). Patients assigned to the resist 
decline DCTB sub-category were younger (<31 years of age) and more likely to be male 
(94.1%). 
MPN and CFU assays along with commonly used TB diagnostic tests were analysed at baseline 
to determine whether one or multiple tests could serve as biomarker to predict the pattern of 
DCTB decline, Table 4.4. The resist decline and decline DCTB sub-categories were associated 
with a high bacterial burden in sputum at baseline. Again, it is important to note that the resist 
decline DCTB sub-category may in fact exhibit a decline pattern, but this cannot be assumed 
due to the upper limit of the current MPN assay/format. In the CF+ MPN assay, the median 
bacterial load was log 8.7 for both the resist decline and decline DCTB sub-categories. 
However, in the MPN no CF assay, a higher median bacterial load was present in the resist 
decline patient cohort (log 4.9 versus log 3.0). P-values from statistical tests comparing 
between individual groups are given in the Appendices (see Tables 4E, 4F, 4G and 4J). Overall, 
differences in bacterial burden obtained in all assays could serve as a potential marker for 
DCTB decline. 
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Table 4.3 Demographic factors associated with DCTB patterns of decline 
 
No CFU 
(n = 11) 
Accumulate 
DCTB 
(n = 17) 
Resist 
decline 
(n = 17) 
Decline 
(n = 20) 
Atypical 
(n = 21) 
P-value 
HIV status * 
 Negative, n (%) 
Positive, n (%) 
 
2 (18.2) 
9 (81.8) 
 
7(41.2) 
10(58.8) 
 
9 (52.9) 
8 (47.1) 
 
5 (25.0) 
15 (75.0) 
 
3 (14.3) 
18 (85.7) 
0.0699 
CD4 Count † 
Mean (SD) 
Median  
(IQR) 
 
159.33 
(193.8) 
90.0  
(42.0; 130.0) 
 
297.9 (396.4) 
110.5  
(61.5; 352.0) 
 
208.1 (132.0) 
171.0  
(117.8; 271.0) 
 
191.3 (127.7) 
167.0 
 (102.0; 
292.3) 
 
219.8 (189.5) 
171.0 
 (95.3; 315.0) 
 
 
0.7041 
Gender * 
Male, n (%) 
Female, n (%) 
 
7 (63.6) 
4 (36.3) 
 
9 (52.9) 
8 (47.1) 
 
16 (94.1) 
1 (5.9) 
 
12 (60.0) 
8 (40.0) 
 
15 (71.4)  
6 (28.6) 
 
0.0929 
Age † 
Mean (SD) 
Median 
(IQR) 
 
40.3 (9.7) 
40.0 
(34.0; 46.0) 
 
38.9 (11.5) 
38.0 
(31.0; 47.3) 
 
28.2 (6.0) 
27.0 
(24.0; 31.0) 
 
37.7 (10.6) 
35.5 
(27.8; 48.0) 
 
44.1 (8.4) 
43.0 
(39.0; 50.5) 
 
<0.0001 
BMI † 
Mean (SD) 
Median 
 (IQR) 
 
21.9 (4.1) 
19.8 
 (18.9; 24,6) 
 
20.3 (2.7) 
20.1  
(18.8; 22.3) 
 
19.0 (2.6) 
18.3 
 (17,9; 19,8) 
 
19.6 (3,5) 
18.9  
(17,8; 20,2) 
 
20.8 (3.8) 
19.6  
(17.8; 20.2) 
 
0.2005 
BCG scar * 
Yes, n (%) 
No, n (%) 
Unknown, n (%) 
 
9 (81.8) 
2 (18.2) 
- 
 
 11 (64.7) 
6 (35.3) 
- 
 
14 (82,4) 
 3 (17,6) 
- 
 
14 (70,0) 
5 (25,0) 
1 (5,0) 
 
14 (66,7) 
7 (33,3) 
- 
 
 
0.6956 
Smoking status * 
Yes, n (%) 
No, n (%) 
Unknown, n (%) 
 
6 (54.5) 
4 (36.3) 
1 (9.1) 
 
4 (23.5) 
13 (76.5) 
- 
 
6 (35.3) 
11 (64.7) 
- 
 
7 (35.0) 
11 (55.0) 
2 (10.0) 
 
10 (47.6) 
10 (47.6) 
1(4.8) 
 
 
0.4446 
Abbreviations: n = number of patients; CFU = colony forming units; DCTB = differentially culturable tubercle 
bacilli; SD = standard deviation; IQR = interquartile range; BMI = body mass index and BCG = Bacille Calmette 
Guerin. * Significance was determined between all five groups using the chi-squared test for proportions with a 
95% confidence interval; † P-values were determined between all five groups using analysis of variance 
(ANOVA) with a 95% confidence interval. Significance between groups is depicted in bold.  
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Table 4.4 Baseline TB culture and other diagnostic factors associated with patterns of 
decline 
 
No CFU 
(n = 11) 
Accumulate 
DCTB 
(n = 17) 
Resist 
decline 
(n = 17) 
Decline 
(n = 20) 
Atypical 
(n = 21) 
P-Value 
Log  
CF+ MPN 
Mean (SD) 
Median 
(IQR) 
 
 
3,5 (2,8) 
2,7 
 (1,7; 4,7) 
 
 
4,7 (2,4) 
4,5 
 (2,9; 6,8) 
 
 
8,7 (0,1) 
8,7  
(8,7; 8,7) 
 
 
7,5 (1,5) 
8,7  
(6,1; 8,7) 
 
 
2,5 (1,5) 
2,7  
(1,7; 3,1) 
 
<0.0001 
Log  
MPN no CF 
Mean (SD) 
Median 
(IQR) 
 
 
2,2 (1,9) 
2,0  
(1,0; 2,7) 
 
 
2,5 (2,1) 
2,7  
(0,9; 3,3) 
 
 
5,4 (2,7) 
4,9  
(2,7; 8,7) 
 
 
3,8 (2,4) 
3,0 
 (2,1; 5,3) 
 
 
1,5 (1,2) 
1,7 
 (0,9; 2,7) 
 
<0.0001 
Log CFU 
Mean (SD) 
Median 
(IQR) 
 
- 
- 
 
2,4 (2,0) 
2,3  
(0,0; 4,5) 
 
5,3 (1,4) 
5,6 
 (5,5; 5,9) 
 
4,2 (1,7) 
4,3  
(3,8; 5,2) 
 
1,3 (1,5) 
0,6 
 (0,0; 2,7) 
<0.0001 
GeneXpert 
Ct value 
Mean (SD) 
Median 
(IQR) 
 
 
25,0 (6,1) 
26,1  
(22,4; 27,6) 
 
 
24,4 (6,6) 
23,5  
(18,7; 29,3) 
 
 
15,4 (3,3) 
14,3  
(13,4; 16,2) 
 
 
18,7 (4,2) 
18,4 
 (15,6; 21,5) 
 
 
26,0 (6,8) 
26,1 
 (21,2; 30,4) 
<0.0001 
MGIT TTP 
(days) 
Mean (SD) 
Median 
(IQR) 
 
16,1 (13,5) 
11,0 (6,0; 
19,0) 
 
12,7 (11,7) 
8,0 (6,0; 11,0) 
 
3,7 (1,6) 
4,0 (3,0; 5,0) 
 
6,1 (3,2) 
6,0 (4,0; 7,3) 
 
18,9 (12,5) 
15,0 (11,0; 
19,0) 
 
<0.0001 
Smear * 
% Positive 
% Negative 
 
47,1 
52,9 
 
70,6 
29,4 
 
100 
0 
 
100 
0 
 
42,9 
57,1 
<0.0001 
Abbreviations: CFU = colony forming unit, DCTB = differentially culturable tubercle bacilli, MPN = most 
probable number, CF = culture filtrate, SD = standard deviation, IQR = interquartile range, MGIT = mycobacterial 
growth indicator tube. Ct = cycle threshold. P-values were determined between all five groups using analysis of 
variance (ANOVA) with a 95% confidence interval. * Significance was determined between all five groups using 
the chi-squared test for proportions with a 95% confidence interval Significance between groups is depicted in 
bold.  
 
4.5.6 Hetero-resistance / acquired drug-resistance 
In four of the 80 patients analysed, different DST profiles (as determined by the HAIN 
MTBDRplus assay) were observed at different time points during this study, Table 4.5. These 
differences in drug-susceptibility profiles may either have occurred as a result of hetero-
resistance or acquired/secondary drug-resistance. Hetero-resistance, defined as the presence of 
both drug-susceptible and drug–resistant organisms in the same clinical sample, may arise in a 
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single infection where M. tuberculosis undergo genetic change through a mutation in genes 
associated with drug resistance (Rinder et al., 2001). Acquired drug resistance is defined as the 
development of resistance by spontaneous chromosomal mutations that occur under selective 
pressures of drug treatment (Zhang et al., 2005). From the time points at which susceptible and 
mono-resistant strains were isolated, hetero-resistance is most likely in patients 59045 and 
59050, whereas a previously susceptible M. tuberculosis strains possibly acquired drug-
resistant mutations in patients 59051 and 57172. Further work is required to determine whether 
these observations are accurate and whether these mixed resistance patterns are cause by 
different M. tuberculosis strains (i.e. mixed strain infections). Hetero-resistance has been 
reported in a number of previous studies (Post et al., 2004, Kaplan et al., 2003, Shamputa et 
al., 2004, van Rie et al., 2005) and mixed strain infections have been associated with 
unfavourable treatment outcomes (Theisen et al., 1995, Niemann et al., 2000, Baldeviano-
Vidalon et al., 2005, Kamakoli et al., 2017, van Rie et al., 2005, McIvor et al., 2017). 
 
Table 4.5 Mixed drug-susceptibility patterns identified in four patients during 
treatment 
Patient # Susceptibility pattern 
#1 
Time point and 
sample 
Susceptibility pattern 
#2 
Time point and 
sample 
59045* 
INH resistant  
RIF susceptible  
0 O/N and spot 
3 O/N and spot 
7 O/N 
INH susceptible 
 RIF susceptible  
14 O/N 
59050** 
INH susceptible 
 RIF resistant 
0 O/N INH and RIF susceptible 
0 spot 
3 O/N and spot 
59051† 
INH susceptible 
 RIF susceptible 
0 spot 
3 spot 
7 O/N and spot 
35 spot 
INH resistant  
RIF susceptible 
Unscheduled  
(day 90 O/N) 
57172‡ 
INH susceptible 
 RIF susceptible 
0 O/N and spot 
3 spot 
7 O/N and spot 
14 spot 
180 spot 
INH resistant 
 RIF resistant 
Day 35 spot 
Abbreviations: INH = isoniazid, RIF = rifampicin, O/N = overnight sputum sample, spot = spot sputum sample, 
MGIT = mycobacterial growth indicator tube. Sputum samples were received for all five patients up until the last 
time point (i.e. day 180). * For patient 59045, MGIT cultures (from both O/N and spot samples) were negative at 
days 35, 56 and 180. MGIT cultures were contaminated for the day 7 spot and 14 spot samples. ** MGIT cultures 
for patient 59050 were negative at days 7 (spot sample only), 14, 35, 56 and 180 (O/N and spot samples). The 
MGIT culture for the day 7 O/N sample was contaminated. † For patient 59051, the following MGIT samples 
were culture negative: 0 O/N, 3 O/N, 14 spot, 35 O/N, 56 (O/N and spot) and 180 (O/N and spot). No 
HainMTBDRplus data was available for 14 O/N. ‡ For patient 57172, MGITs were culture negative for the 
following samples: 3 O/N, 14 O/N, 35 O/N and 56 spot. MGITs were contaminated for the day 56 and 180 O/N 
samples. The Hain MTBDRplus was not performed on contaminated or culture negative MGITs.  
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4.5.7 Mixed infection with M. tuberculosis and non-tuberculosis Mycobacteria 
Mixed infection with M. tuberculosis and NTM were identified in four and eight patients from 
the Soweto and Klerksdorp cohorts, respectively. The four NTM identified in the Soweto 
cohort included M. peregrinum, M. gordonae, M. intracellulare and M.scroffulaceum. The 
NTM identified in the Klerksdorp cohort included M. intracellulare (isolated from five 
patients), M. fortuitum (isolated from two patients), M. scrofulaceum and M. avium-
intracellualre. This data along with the time-point at which each NTM was identified is given 
in Table 4.6. The isolation of NTM tended to occur once-off, with the corresponding MGIT 
received for that particular time point (i.e. spot or O/N) being positive for MTBC on the HAIN 
MTBDRplus test. Indeed, the isolation of NTM with pulmonary TB is not uncommon, but 
tends to occur as a result of colonisation, transient infection or contamination of the specimen 
(Jun et al., 2009, Kim et al., 2004, Kobashi et al., 2002).  
 
Table 4.6 Non-tuberculosis mycobacteria isolated in 13 patients during the study 
Patient # Time point and sample NTM identified 
59005 
Unscheduled Month 5 spot and 
Day 180 O/N 
(corresponding MGITs were culture negative) 
M. peregrinum, 
59045 
Day 180 spot 
(Day 180 O/N was MGIT culture negative) 
M. gordonae 
59048 
Day 180 O/N, 
Post day 180 
(Day 180 spot was MGIT culture negative) 
M. scroffulaceum  
M. intracellulare 
59052 
Day 35 spot 
(MTBC in 56 O/N) 
M. intracellulare 
57136 
Day 35 O/N 
(MTBC in spot sample) 
M. intracellulare 
57139 
Day 35 O/N 
(spot culture was negative) 
M. intracellulare 
57146 
Day 14 spot 
(MTBC in O/N sample) 
M. intracellulare 
57152 
Day 56 O/N 
(MTBC in spot sample) 
M. scroffulaceum 
57155 
57155 
Day 3 O/N * 
Day 14 O/N 
(MTBC in spot sample) 
M. intracellulare 
M. fortuitum 
57159 
Day 14 spot 
(MTBC in O/N MGIT) 
M. fortuitum 
57173 
Day 180 O/N 
(spot culture was negative) 
M. avium-intracellualre 
 
57175 
Day 14 spot 
(MTBC in O/N MGIT) 
M. intracellulare 
 
* Day 3 spot sample was not received 
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It is quite possible that the presence of an NTM and mixed M. tuberculosis infection in a sputum 
sample may create a confounding factor in CFU and MPN enumeration. In cases where an 
NTM is identified in the MGIT, additional microbiological tests should be carried out to 
determine if the NTM is a contaminating organism (i.e. isolated only in the MGIT and not in 
the MPN or CFU assay) or whether the NTM was originally present in the sputum sample. In 
the latter case, data from a second sputum sample can be used (i.e. spot sample instead of 
overnight sample), or the data for that particular time point should be omitted. Since NTMs 
were isolated at a single time point in only one sputum sample, suggests that these organisms 
are most likely to be contaminants from the environment. This can be confirmed by performing 
species identification tests, such as the HAIN CM assay, directly on CFU or MPN culture 
positive samples.  
 
4.5.8 End-of-treatment analysis 
4.5.8.1 Positive diagnostic and microbiological assays at the end of treatment 
For end of treatment analysis, 62 patients that had completed 180 days of anti-TB treatment 
and provided study samples were included for analysis. M. tuberculosis was detected in 10 
patients by the GeneXpert assay and three patients were still MGIT culture positive. None of 
the patients had positive smears at the end of treatment. In microbiological assays, one patient 
still had CFUs emerge on solid media. In MPN assays, 41, 39 and 38 patients were positive in 
CF+, Rpf – and CF -unsupplemented assays, respectively (Table 4.7 and Figure 4.24).  
 
Table 4.7 Number of patients positive for M. tuberculosis by diagnostic and 
microbiological assays. 
Diagnostic/ Microbiological assay Number of positive patients, n (%) 
CF+ MPN 41 (66.1) 
Rpf – MPN 39 (62.9) 
MPN no CF 38 (61.3) 
CFU 1 (1.6) 
MGIT culture 3 (4.8) 
GeneXpert 10 (16.1) 
Abbreviations: CF = culture filtrate, MPN = most probable number, Rpf = resuscitation-promoting factor, CFU 
= colony forming unit, MGIT = mycobacterial growth indicator tube.  
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Figure 4.24 Venn diagram illustrating M. tuberculosis positivity at the end of treatment in different 
diagnostic and microbiological assays. The Venn diagram illustrates the number of patients that were positive 
for M. tuberculosis at the end of treatment by a particular assay. The diagnostic assays included were the 
GeneXpert (blue) and MGIT (red). No patients were positive at the end of treatment by smear microscopy. The 
microbiology assays included culture filtrate supplemented MPN assays [CF+ (beige) and Rpf – (green)] as well 
as colony forming unit (CFU) assays. Venn diagram was creating using the following URL: 
http://bioinformatics.psb.ugent.be/webtools/Venn.  
 
Table 4.8 Detection of M. tuberculosis at end-of-treatment in multiple and single assays. 
Diagnostic/microbiological test Total positive 
CF+ MPN and GeneXpert 9 
CF+ MPN and MGIT 1 
CF+ MPN and CFU 1 
GeneXpert 1 
MGIT 2 
CF+  30 
 
The high overlap observed between the CF+ MPN assay and GeneXpert assay in detecting M. 
tuberculosis positive patients at the end of treatment suggests that the GeneXpert may be able 
to detect the presence of DNA from DCTB at the end of treatment (Figure 4.24 and Table 4.8). 
However, the GeneXpert assay is not currently recommended for treatment monitoring and is 
only recommended for initial diagnosis (WHO, 2014).  
 
4.5.9 Reflex assays 
To further assess whether the organisms isolated at the end of treatment were M. tuberculosis 
and not precipitation of drugs, cellular debris or contamination, reflex assays were performed 
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on a subset of samples. The MPN is based on a visual scoring system and the growth of these 
assays varied from minimal to high. Initial reflex assays were performed on samples with 
robust and poor growth ranging from day 14 to day 180. For ‘end-of-treatment’ samples, reflex 
assays were performed on both frozen (-80 °C) stored positive MPN wells and in real-time on 
samples from the last few patients enrolled in the study. In few cases, samples collected at 
unscheduled time points or after treatment completion, i.e., subsequent to the day 180 time 
point, were analysed.  
 
4.5.9.1 Real-time analysis of treatment samples 
A total of 88 samples from 30 patients were reflexed from low positive MPN wells during 
treatment. These samples were collected between 14 to 180 days following treatment initiation. 
In the MGIT only 4 samples were positive (4.5%) compared to the 450 μL culture where 39 
samples were positive (43.3%). In the MGIT, the majority of the samples reflexed were 
negative (53.4%) and many were contaminated (42%). CFUs were cultured from 7 samples 
(8%). In the HAIN MTBDRplus assay, approximately 60% of samples were positive for 
MTBC. These findings are suggestive of possible background in the MPN assay.  
   
Table 4.9 Proportions of positive, negative and contaminated samples obtained in the 
reflex assays. 
 MGIT 450 µL culture CFU 
HAIN 
MTBDRplus® 
Positive 4 (4.5) 39 (43.3) 7 (8.0) 52 (59.1) 
Negative 47 (53.4) 48 (54.5) 73 (83.0) 36 (40.9) 
Contaminated 37 (42) 1 (1.1) 8 (9.0) NA 
 
4.5.9.2 Reflex analysis performed on stored MPN wells 
Following these results, reflex assays were performed on a single frozen sample from 31 
patients at the end of treatment (day 180 samples only). Growth on the reflex MPN assay was 
observed in two patients only (6.5%). No CFUs were obtained from any of these samples. 
Negative and contaminated reflex MPN assays were observed for 23 (74.2%) and 6 (19.4%) 
patients, respectively. MGIT culture and HAIN MTBDRplus reflex assays were not performed 
on frozen end-of-treatment samples. 
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4.5.9.3 Real-time analysis of end-of-treatment and post-treatment samples 
Seventy samples from 19 patients displaying low growth on MPN plates at the end of treatment 
(9 patients at the end of treatment, i.e. 180 days) or following treatment completion (samples 
from 10 patients received after 180 days) were reflexed into a separate 450 µL cultures. Positive 
growth was observed in 67.1% of cases. An example of a positive reflex plate is given in Figure 
4.25. 
 
Figure 4.25 Example of ‘positive’ growth observed in reflex assay in patients 180 days after first-line TB 
treatment. (A) Reflexed MPN plate showing predominantly medium and high turbity growth. (B) Reflexed MPN 
plate showing low growth. Dotted lines divide samples reflexed from individual patients. Circles show wells that 
were labelled with DMN-Tre for microscopy. H = high turbity, M = medium turbity and L = low turbidity.  
 
4.5.10 DMN-Tre staining  
To assess whether the growth seen at the end of treatment (scored as positive on the MPN 
assay) was true M. tuberculosis growth, DMN-Tre staining was performed on end-of-treatment 
samples for a total of six patients. As previously mentioned, the morphology in the MPN wells 
varied greatly between samples during and at the end of treatment with some illustrating thick 
and robust growth adhering to the bottom of the MPN well and others showing poor growth 
that ranged from an opaque suspension in the media to tiny clumps at the bottom of the well. 
Two patients were selected from three growth categories displaying, high, medium and low 
growth. A positive control of H37Rv culture was included in the analysis.  
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Figure 4.26 DMN-Tre labelling of Mycobacterium tuberculosis H37Rv positive control. M. tuberculosis 
H37Rv culture was stained with trehalose conjugated to the solvatochromatic dye 4-N,N-dimethylamino-1,8-
napthalidimide (DMN-Tre). Images from left to right represent DIC, FITC/ GFP and merged images.  White arrow 
illustrates a M. tuberculosis cell that is visible in both the DIC and FITC channel showing successful uptake of 
the DMN-Tre reagent. Red arrow shows a M.tuberculosis cell that is only visible in the DIC where DMN-Tre 
uptake did not occur. Abbreviations: DIC = differential interference contrast, FITC = fluorescein isothiocyanate 
and GFP = green fluorescent protein.  
 
Figure 4.26 illustrates DMN-Tre staining of M. tuberculosis H37Rv culture. Fluorescent bacilli 
visible in both the DIC and FITC channels (shown by white arrows) depict the successful 
uptake of the DMN-Tre reagent, confirming organism viability. Unstained M. tuberculosis that 
are only visible in the DIC channel (red arrow) shows cells that are most likely dead.  
 
 
Figure 4. 27 DMN-Tre labelling of end-of-treatment reflex culture exhibiting high turbidly/growth. A high-
growth reflex culture from patient 57160 growth was stained with trehalose conjugated to the solvatochromatic 
dye 4-N,N-dimethylamino-1,8-napthalidimide (DMN-Tre). Images from left to right represent DIC, FITC/ GFP 
and merged images.  White arrow illustrates M. tuberculosis cell that is visible in both the DIC and FITC channel 
showing successful uptake of the DMN-Tre reagent. Red arrow shows a M.tuberculosis cell that is only visible in 
the DIC channel where DMN-Tre uptake did not occur. Abbreviations: DIC = differential interference contrast, 
FITC = fluorescein isothiocyanate and GFP = green fluorescent protein.  
 
DMN-Tre staining of an end-of-treatment sample (Figure 4.27) confirms the presence of both 
live and dead M. tuberculosis cells isolated from a high turbidity culture. The culture was 
reflexed from a positive MPN well (containing the Rpf – CF) from patient 57160 following 180 
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days of anti-tuberculosis treatment. In terms of the routine diagnostic data, both MGIT cultures 
(from day 180 O/N and spot samples) were culture negative. A low positive GeneXpert (Ct 
value, 29.3) was obtained in day 180 spot sample. The O/N sample was GeneXpert negative.  
 
 
Figure 4. 28 DMN-Tre labelling of end-of-treatment reflex culture exhibiting medium turbidly/growth. A 
medium-growth reflex culture from patient 57139 was stained with trehalose conjugated to the solvatochromatic 
dye 4-N,N-dimethylamino-1,8-napthalidimide (DMN-Tre). Images from left to right represent DIC, FITC/ GFP 
and merged images.  White arrow illustrates M. tuberculosis cell that is visible in both the DIC and FITC channel 
showing successful uptake of the DMN-Tre reagent. Red arrow shows a M.tuberculosis cell that is only visible in 
the DIC where DMN-Tre uptake did not occur. A mixture of cocci and bacilli are present.  Abbreviations: DIC 
= differential interference contrast, FITC = fluorescein isothiocyanate and GFP = green fluorescent protein. 
 
Figure 4.28 illustrates the presence of live M. tuberculosis bacilli isolated from a medium 
turbidity culture. This culture was reflexed from a positive MPN well (un-supplemented, no 
CF) from patient 57139 following 180 days of anti-tuberculosis treatment. When compared to 
the M. tuberculosis H37Rv control and the high turbidity well from patient 57160, the 
fluorescence in these images are less intense. Indeed, it has been demonstrated that stationary 
phase M. smegmatis cultures do take up the dye, but to a lesser extent than actively growing 
cells (Kamariza et al., 2018). The red arrow illustrates the presence of what would appear to be 
a ‘ghost form’ which is visible in the DIC channel but not in the FITC channel.   In addition to 
bacilli, the presence of stained ovoid forms are also visible. The presence of ovoid/coccoid 
cells may indicate the presence of non-replicating organisms (Shleeva et al., 2002). 
Alternatively, these cells could illustrate the presence of a contaminant that is able to 
incorporate DMN-Tre (for example, Corynebacterium). Routine diagnostic data from this 
patient was GeneXpert negative and the end of treatment. Both MGIT cultures were reported 
as contaminated, but it is clear from the microscopy that M. tuberculosis was also present.  
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Figure 4.29 DMN-Tre labelling of end-of-treatment culture exhibiting low turbidly/growth. A medium-
growth reflex culture from patient 57134 was stained with trehalose conjugated to the solvatochromatic dye 4-
N,N-dimethylamino-1,8-napthalidimide (DMN-Tre). Images from left to right represent DIC, FITC/ GFP and 
merged images.  White arrow illustrates M. tuberculosis cell that is visible in both the DIC and FITC channel 
showing successful uptake of the DMN-Tre reagent. Abbreviations: DIC = differential interference contrast, 
FITC = fluorescein isothiocyanate and GFP = green fluorescent protein. 
 
Figure 4.29 shows the presence of one live M. tuberculosis cell isolated from a culture with 
very low turbidity. The culture was reflexed from a positive MPN well from Patient 57134 
(CF+ MPN) following 180 days of anti-tuberculosis treatment. Out of the two end of treatment 
MGIT cultures, one was contaminated and the other was culture negative. Both end-of-
treatment GeneXpert samples were negative for M. tuberculosis. DMN-Tre staining of positive 
MPN wells confirms the presence of viable M. tuberculosis organisms at the end of treatment 
suggesting that complete sterilization of M. tuberculosis is not occurring in all patients.  
Figure 4.30 illustrates the average number of organisms detected in MPN and CFU assays in 
62 patients at the end of treatment. Positive growth was detected in 41 (55%), 39 (52%) and 38 
(51%) patients at the end of treatment in CF+, Rpf – and no CF MPNs, respectively. One patient 
had a positive CFU at the end of treatment. While DMN-Tre microscopy suggests the presence 
of residual organisms at the end of treatment, this analysis was only conducted on six patients 
and further investigation is required to determine whether all positive MPN patients harbour 
organisms at the end of treatment. Given the results from the reflex assays, possible background 
in the form of cellular debris or contaminating oral flora may present in the MPN assay. This 
is evident by the high number of negative and contaminated MGIT cultures from low growth 
MPN wells during and at the end of treatment (see Table 4.9). In the contaminated cultures, it 
is possible that a mixture of M. tuberculosis and other organisms are present. Since the HAIN 
MTBDRplus was positive for MTBC in 60% of reflexed samples, this is likely the case. The 
addition of CF may also stimulate the growth of other organisms whose growth is ordinarily 
suppressed by PANTA in the MGIT (see chapter 6). Furthermore, the limit of detection in the 
MPN assay remains to be established. Nevertheless the presence of positive MPN wells at the 
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end of treatment led to the identification of residual M. tuberculosis bacilli following six 
months of anti-TB treatment. 
 
 
Figure 4.30 Growth detected at the end of treatment in MPN assays. Positive growth was detected in 41, 39 
and 38 patients in CF+ (red), Rpf – (blue) and no CF (green) MPN assays. On average, about 2.5 log growth was 
detected in all three MPN assays. Reflex assays to determine whether this positive growth was due to M. 
tuberculosis and not contaminating organisms was performed.  
 
4.6 DISCUSSION 
Previous work has demonstrated the phenomenon of DCTB in TB patient samples prior to 
treatment (Mukamolova et al., 2010, Chengalroyen et al., 2016).  Furthermore, evidence from 
studies conducted in vitro or on ex vivo M. tuberculosis clinical strains, suggest that these 
organisms are more tolerant to TB drugs (Wayne and Sramek, 1994, Wayne and Hayes, 1996, 
Deb et al., 2009, Mukamolova et al., 2010, Sala et al., 2010, Turapov et al., 2016, Loraine et 
al., 2016). However, how these populations respond to anti-TB chemotherapy has not been 
investigated in vivo.  
In pre-treatment samples it was found that the prevalence of CF-dependent and Rpf-
independent DCTB populations correlated, suggesting that factors, other than Rpfs, present in 
CF are involved in bacterial growth stimulation. Spearman’s rank sum correlation analysis was 
carried out at all time points during treatment and significant correlations were observed, 
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confirming the results obtained in baseline samples. In addition, pre-treatment analysis 
revealed that HIV-negative individuals harbour more DCTB than their HIV-positive 
counterparts. Indeed, analysis of all treatment time points revealed that HIV-negative 
individuals harbour a significantly higher quantum of DCTB and conventionally culturable 
bacteria up to 14 and 35 days following treatment initiation, respectively. These results suggest 
that following one month of anti-TB treatment, HIV-negative individuals may still be more 
infectious than HIV-positive individuals. Indeed at 35 days post-treatment initiation, 56.3% of 
the overall patient cohort was still positive by MGIT culture (mean TTP 28.5 days, Table 4A), 
suggesting that these patients are still capable of transmitting TB. While it was previously 
though that infectiousness rapidly diminishes once treatment is initiated (Rouillon et al., 1976), 
there is evidence to suggest that patients can still transmit TB after two weeks on anti-TB 
chemotherapy (Fitzwater et al., 2010, Schwartzman and Menzies, 2000). 
Regression analysis was conducted on 75 patients using LOWESS models to determine the 
rates of decline for the four populations studied (i.e. CF-dependent, Rpf-independent, CF-
independent and CFU). In contrast to the initial hypothesis, the CF+ population declined at a 
faster rate when compared to the CF-independent and platable bacteria, suggesting that these 
organisms are more susceptible to anti-TB chemotherapy. However, the differences in rates of 
decline were marginal and provided no clarity on the response of DCTB to drug treatment. 
Individual patient analysis illustrated a far greater complexity with respect to the response of 
DCTB to first-line treatment, with a great deal of variation observed between patients. Four 
broad categories of response to treatment were defined, including (i) patients that harbour 
DCTB that are somewhat tolerant to treatment and fail to decline during the first three to seven 
days of treatment, (ii) patients that accumulate DCTB during the onset of early treatment, (iii) 
patients with DCTB that decline rapidly throughout treatment and (iv), patients that exhibit an 
atypical pattern of DCTB decline throughout treatment.  
Approximately 23% of the patients analysed in this study were assigned to the tolerant pattern 
of decline. In these patients, bacterial decline was only seen following one to two weeks of 
treatment. It is important to note that the trend of DCTB response characterised by this group 
of patients is likely to occur due to the MPN assay having an upper limit of log 8.7. Many of 
these patients displayed an MPN of 8.7 log during early treatment because all MPN wells were 
positive in 48-well plates. Hence a more accurate description of the MPN bacterial load in this 
case is >8.7 log. However, as this could not be plotted, a value of 8.7 was used in graphs and 
for statistical analysis.  Therefore, the ‘true’ number of organisms at baseline is not known and 
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this upper limit may have masked the true pattern of DCTB, which could have taken the pattern 
of accumulation or decline. Indeed, this pattern of persistence was not backed up by routine 
diagnostic tests and on average these tests tended to show a decline in bacillary load during 
early treatment, Figure 4.15, 4.17 and Tables 4A, 4B and 4C. However, at 56 and 180 days 
after treatment initiation, this group had the lowest rates of culture negativity at 40.0% and 
86.7%, respectively. These results were reflected in GeneXpert assays and smear microscopy, 
where only 6.3% and 78.6% were M. tuberculosis not detected according to the GeneXpert and 
only 33.3% of this population were smear negative by day 56. These findings suggest that 
patients with DCTB that exhibit some form of antibiotic tolerance during early treatment are 
at higher risk of having a positive TB diagnostic at the end of treatment. Preliminary 
investigations at the CBTBR employing a combined method of flow cytometry and DMN-Tre 
staining on stored decontaminated pellets from four patients indicated that approximately 75% 
of these patients accumulated bacteria during treatment, while in 25% of patients, bacillary 
load declined rapidly following the onset of treatment (unpublished data, Peters et al). Analysis 
of baseline demographics and bacillary load measures showed that young age (less than 31 
years), male gender and high sputum bacillary burden were associated with this pattern of 
decline. The high bacillary load observed in this patient cohort throughout treatment can be 
potentially linked to reduced drug activity in vivo. Indeed, lower concentrations of anti-TB 
drugs in the plasma have been linked to clinical failure and drug resistance (Kimerling et al., 
1998, Sahai et al., 1997). Examples of factors associated with variations in drug absorption 
concentrations include HIV infection status, gender and previous TB disease (McIlleron et al., 
2006). These findings suggest that drug level monitoring should be considered to endure 
optimal absorption of anti-TB agents and so that dosage can be adjusted accordingly if required. 
In the current study, additional sputum and blood plasma samples were collected at each time 
point and are being stored at -80 °C with the intention of conducting future pharmokinetic 
analysis to link the concentration of plasma and sputum drug levels to bacillary load and rate 
of decline. 
Approximately 23% of the patients analysed accumulated DCTB during the first week of anti-
TB treatment. These results are in agreement with previous observations, where treatment of 
axenic M. tuberculosis cultures or clinical strains in patient sputa illustrated tolerance to first-
line antibiotics (Wayne and Hayes, 1996, Chao and Rubin, 2010, Deb et al., 2009, Sala et al., 
2010, Turapov et al., 2016, Mukamolova et al., 2010).  The observations from this patient 
category suggests that stress exerted on these organisms in the form of antibiotic pressure 
198 
 
results in a metabolic shift in these organisms into CF-dependent state. These organisms can 
be recovered following the addition of stimulatory molecules in CF to the culture medium. It 
is interesting to note that on average, this group of patients had a lower starting bacterial load 
as detected by CF-supplemented MPN and CFU assays (approximately log 4.7 and log 2.4, 
respectively), compared to the resist decline and rapid decline patterns. Thirty percent of these 
patients were smear negative at baseline, and these patients had higher MGIT TTPs and 
GeneXpert Ct values than the other groups analysed (with the exception of the atypical group). 
It remains to be investigated as to how transmissible these DCTB populations are and whether 
they are able to cause infection and disease in a new host. There are two possibilities: either 
the deficiency in culturability may imply damage that will render the organism unable to 
establish infection in a new host or ii) the metabolic changes associated with non-culturability 
may provide the organism with a selective advantage allowing it to be protected from the host 
immune system until conditions are favourable (i.e. following host immunological 
impairment). 
The second highest number of patients (roughly 27%) exhibited the same pattern of decline as 
depicted in the LOWESS model for the overall dataset, i.e. a rapid pattern of decline in all 
bacterial populations, particularly the CF-dependent populations, following the onset of 
treatment. This pattern of decline is commonly observed in EBA studies, where bacterial 
decline (measured by CFUs) is rapid following the onset of treatment. Seventy five percent of 
patients in this category were HIV-positive with a median CD4 T-cell count of 171 cells/mm3. 
In terms of TB diagnostics, these patients were all smear positive at baseline and had relatively 
low MGIT TTPs (6.1 ± 3.2 days) and GeneXpert Ct (18.5 ± 4.1) values. These data were 
accompanied by high baseline MPNs and CFUs (mean, log 7.5 and log 4.2, respectively). After 
56 days of treatment, this patient group had the highest percentage MGIT culture negativity 
(66.7%) and M. tuberculosis not detected by GeneXpert (29.4%), suggesting that these patients 
respond well to anti-TB treatment.  An important question to consider is why are DCTB in one 
subset of patients tolerant to first-line treatment, whereas in other patients this population 
declines faster compared to the culturable populations? These DCTB may be more susceptible 
to the bactericidal action of the drugs compared to the culturable population, possibly due to 
damage inflicted by the host immune system. Alternatively, the levels of drug concentrations 
and drug absorption in these patients may be more toxic to these bacilli than that in patients in 
other sub-categories, thus leading to effective killing of these populations. Further work 
looking at the drug concentrations in patient blood and sputum is required to understand this. 
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A substantive number of the patients analysed in this study (28%) were characterized by an 
atypical DCTB response to treatment. In general, these patients had a low starting bacterial 
load, as detected by MPN and CFU assays along with routine diagnostic assays that remained 
low throughout treatment. Most of the patients in this cohort were HIV positive (85.7%). 
Furthermore, this group of patients were significantly older than patients assigned to the other 
three DCTB decline groups [median age 43 years (IQR:  39 to 50.5)]. The low bacterial loads 
obtained in these patients may be due to poor quality sputum samples received as a results of 
EPTB disease (Silva et al., 2014). No data was collected on EPTB and hence, no further 
conclusions can be drawn here. In terms of baseline TB diagnostics, these patients had the 
highest median MGIT TTP [15 days (IQR: 11.0; 19.0)], GeneXpert Ct value [27.0 (IQR: 26.3; 
30.2)] and the highest percentage of smear negative individuals (57.1%). While all these 
patients were culture negative at the end of treatment by MGIT, the majority of these patients 
harboured high proportions of DCTB (approximately 20% relative to their baseline counts, see 
Figure 4A) at the end of treatment.   
Overall, the results from the decline analysis showed that various patterns of M. tuberculosis 
decline are present in different patients. Possible biomarkers to predict how patients may 
respond to treatment were identified using patient demographics (i.e. age) and baseline 
diagnostic tests. However, these deductions are speculative and more detailed analysis in larger 
cohorts is required to investigate this. While reasons for different responses to treatment remain 
to be established, Figure 4.31 proposes why different patterns of decline may be observed 
amongst TB patients.  
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Figure 4.31 Proposed model of varying patterns of DCTB decline. In a normal and hypothetical M. 
tuberculosis population distribution (black line), a mixture of organisms displaying high, medium and low 
susceptibility to anti-TB drugs would exist, possibly due to altered growth states. However, various external 
factors (i.e. host immunity and drug treatment) in combination with inherent bacterial/genetic factors (i.e. bacterial 
strain type etc.), may shift the proportions of these populations to assume altered distributions. For example, 
damage inflicted by host immunity may damage the organisms making them more susceptible to anti-TB 
chemotherapy. These organisms will decline quickly following the administration of TB treatment and a decline 
profile will be apparent (dotted green line). In another scenario, external pressures/factors may drive these 
organisms into a non-culturable state making them phenotypically tolerant to anti-TB medication. In this case, 
DCTB may accumulate during early treatment or a resist profile may be obtained (dotted red line).  
 
For the end of treatment analysis, 13 (21.0%) of patients still had a positive diagnostic test [10 
(16.1%) positive by GeneXpert and 3 (4.8%) positive by MGIT culture]. MPN assays 
supplemented with CF revealed that 41 (66.1%) of patients still has positive cultures at the end 
of treatment. In one patient (1.6%), M. tuberculosis colonies were present at the end of 
treatment on solid media. To confirm whether the high the number of positive cultures obtained 
in the CF+ MPN at the end of treatment were M. tuberculosis, fluorescent microscopy was 
performed on select reflex cultures using DMN-Tre staining of live organisms. Indeed, positive 
bacilli were present at the end of treatment in five out of six patient samples analysed. At the 
end of treatment, M. tuberculosis was not detected in samples from patient 57139 using the 
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GeneXpert assay, but both MGIT cultures were contaminated with no AFB present on ZN 
smears. These findings suggest that DMN-Tre may not be exclusive to M. tuberculosis and 
other bacteria harbouring a mycomembrane, such as members of the Corynebacterium genus, 
may also incorporate DMN-Tre. Alternatively, these organisms may be metabolically 
quiescent. For this, further work is required to determine whether DMN-Tre is capable of 
labelling non-replicating organisms. This can be achieved by labelling of corresponding 
positive and negative CF+ and no CF MPN wells (at the same dilution factor), respectively. 
Furthermore, research is required on a larger number of patients to confirm the presence of 
non-replicating M. tuberculosis at the end of treatment. Currently, this is being carried out at 
the CBTBR using a combination of flow cytometry and DMN-Tre labelling.  
Nevertheless, observations from end of treatment analysis suggests that patients still harbour 
and are able to expectorate live M. tuberculosis at the end of treatment. The majority of these 
organisms can only be detected using specialised culture methods, such as CF+ MPN assays. 
Since these organisms are present in expectorated sputum, it is important for future studies to 
establish whether these organisms are infectious and/or capable of causing relapse disease. As 
these patients were clinically well at the end of treatment, it can be speculated that the majority 
of these patients may now have reverted from active disease to LTBI.  Indeed, these patients 
are currently being followed-up for five years after treatment completion to monitor for 
recurrent TB disease. Molecular-based typing techniques will be employed to differentiate 
between relapse and re-infection. It is generally expected that relapse disease will occur within 
a year following treatment completion, whereas re-infection is more likely to place after one 
year (Marx et al., 2014).  
This study has several limitations. Firstly, as discussed in chapter three, no recombinant Rpf 
work was carried out. Therefore, the observed growth stimulatory effect cannot exclusively be 
attributed to Rpfs and other molecules in CF may stimulate the growth of non-replicating 
organisms. In addition, it is not known whether (or to what extent) growth inhibitory molecules 
are present in CF. Since this work and previously published work has shown that CF can both 
increase as well as decrease the detection of DCTB, the identification of these molecules and 
a mechanistic understanding of the bacterial growth processes is important to confirm that the 
apparent ‘rise and fall’ in DCTB is due to a genuine biological change and not a result of 
varying factors present in CF. However, it must be noted that all efforts were made to 
standardise the preparation of the CF to limit such variability.   A second limitation was that 
the quantification of DCTB was limited by the MPN assay in its current format. Future work 
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to determine the ‘true’ number of DCTB at baseline may involve performing MPN assays over 
two to three 48-well microtitre plates in order to obtain wells with no growth. Alternatively, 
samples received at baseline and during early treatment (i.e. up to day 7) will require dilution 
following decontamination before MPN assays are carried out. The problem with the second 
method is that sputum samples with a low starting bacillary load may be diluted out (for 
example, patients in the atypical cohort), giving a negative baseline (or early treatment) MPN 
assay. Other methods to quantify DCTB, such as flow cytometry may provide a more attractive 
means of detecting DCTB in patient sputum. Lastly, further work is required to determine the 
limit of detection in the MPN assay.  
 
4.7 CHAPTER CONCLUSION AND FUTURE RESEARCH 
Interpreting how mycobacteria respond to treatment in clinical patient samples is difficult since 
two independent biological systems (i.e. bacterium and host) are in a battle for survival. This 
work demonstrates that the DCTB present in treatment naïve sputum responds in complex ways 
upon the initiation of treatment. Four distinct patterns of DCTB behaviour were described, 
namely a drug tolerant DCTB population, DCTB that accumulate, DCTB that decline rapidly 
as well as an atypical DCTB presentation that seems to persist at low levels throughout 
treatment. Various factors such as host immunity, nutrition, drug absorption, pathology, 
bacterial strain type and other genetic predispositions, may influence how these organisms and 
the host will respond to anti-TB treatment. An additional important finding of this work was 
the presence of live M. tuberculosis at the end of treatment. This finding implies that the current 
TB regimen is not sterilizing in all TB patients. The results presented in this chapter define a 
potential and novel role for DCTB in assessing patient response to treatment.  In addition, the 
presence of DCTB following treatment completion may serve as a biomarker for relapse 
disease and allow DCTB positive patients to be targeted for INH-preventative therapy. Further 
work is required in this regard. Additional future work will include the analysis of stored 
sputum and blood samples for drug concentrations by HPLC and/or mass spectrophotometry.
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APPENDICES 
APPENDIX 4A: MGIT TTP FOR LONGITUDINAL ANALYSIS 
TABLE 4A: Average MGIT TTP for all patients and defined patient groups in longitudinal analysis 
 All 3 & 7 Day Resistance Accumulate DCTB Decline Atypical 
 (n = 75) (n = 17) (n = 17) (n = 20) (n=21) 
Baseline n =75 n = 17 n = 17 n = 20 n = 21 
Mean (SD) 10,6 (10,6) 3,7 (1,6) 12,7 (11,7) 6,1 (3,2) 18,9 (12,5) 
Median (IQR) 7,0 (4,0; 12,5) 4,0 (3,0; 5,0) 8,0 (6,0; 11,0) 6,0 (4,0; 7,3) 15,0 (11,0; 19,0) 
Negative (%) 6,7 0 5,9 0 19,0 
Two consecutive negative (%) NA NA NA NA NA 
Day 3 n = 75 n= 17 n = 17 n = 20 n = 21 
Mean (SD) 12,8 (10,4) 6,8 (3,7) 10,4 (6,8) 10,2 (7,4) 21,9 (13,2) 
Median (IQR) 9,0 (6,0; 18,0) 7,0 (5,0; 8,0) 9,0 (7,0; 11,0) 8,0 (6,0; 12,0) 19,0 (11,0; 29,0) 
Negative (%) 6,7 0 0 0 23,8 
Two consecutive negative (%) 0 0 0 0 0 
Day 7 n = 74 n =17 n = 17 n = 20 n = 20 
Mean (SD) 13,6 (10,2) 7,9 (4,4) 15,6 (13,5) 10,7 (4.4) 19,5 (11,5) 
Median (IQR) 11,0 (8,0;16,8) 7,5 (6,0; 10,3) 11,0 (9,0; 17,0) 11,0 (8,8; 13,0) 17,5 (10,8; 23,0) 
Negative (%) 8,1 0 17,6 0 15,0 
Two consecutive negative (%) 0 0 0 0 0 
Day 14 n = 74 n = 17 n = 17 n = 20 n = 20 
Mean (SD) 19,3 (12,5) 12,3 (6,1) 17,1 (11,6) 19,1 (11,2) 27,2 (14,5) 
Median (IQR) 15,0 (11,0; 22,8) 13,0 (9,0; 13,0) 13,0 (11,0; 21,0) 17,0 (12,8; 20,8) 26,5 (12,8; 42,0) 
Negative (%) 17,6 0 11,8 15 40,0 
Two consecutive negative (%) 1,25 0 0 0 4,8 
Day 35 n = 71 n = 17 n = 16 n = 19 n= 19 
Mean (SD) 28,5 (13,9) 22,4 (13,3) 31,6 (14,0) 27,1 (14,3) 32,8 (12,6) 
Median (IQR) 31,0 (16,0;42,0) 17,0 (13,0; 36,0) 42,0 (20,5; 42,0) 22,0 (15,5; 42,0) 42,0 (22,5; 42,0) 
Negative (%) 43,7 23,5 56,3 42,1 52,6 
Two consecutive negative (%) 7,5 0 5,9 5 19,0 
Day 56 n = 68 n = 15 n = 15 n = 18 n = 20 
Mean (SD) 32,1 (13,3) 30,2 (13,3) 31,5 (13,5) 35,0 (12,2) 31,3 (14,5) 
Median (IQR) 42,0 (21,0;42,0) 31,0 (25,5; 42,0) 40,0 (19,0, 42,0) 42,0 (35,5; 42,0) 42,0 (19,3; 42,0) 
Negative (%) 54,4 40,0 46,7 66,7 57,9 
Two consecutive negative (%) 21,25 11,8 23,5 25 28,6 
Day 180 n = 55 n = 14 n = 13 n = 13 n = 15 
Mean (SD) 40,7 (5,7) 39,9 (8,0) 40,1 (6,9) 40,6 (5,0) 42,0 (0,0) 
Median (IQR) 42,0 (42,0;42,0) 42,0 (42,0; 42,0) 42,0 (42,0; 42,0) 42,0 (42,0; 42,0) 42,0 (42,0; 42,0) 
Negative (%) 94,6 86,7 92,3 92,3 100 
Two consecutive negative (%) 37,5 29,4 35,3 45 47,6 
% negative calculated using ‘n’ as denominator for each particular time point. % for two consecutive smear negative samples was calculated using ‘n’ as denominator for total number of patients from group, not time 
point. TTP was excluded from analysis if no acid fast bacilli were present on ZN examination. Abbreviations: n = number of patients analysed; SD = standard deviation; IQR = interquartile range; DCTB = 
differentially culturable tubercle bacilli 
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APPENDIX 4B: GENEXPERT CT VALUES FOR LONGITUDINAL ANALYSIS 
Table 4B. Average XPERT Ct values for all patients and defined patient groups in longitudinal analysis 
 
All 
3 & 7 Day Resist 
decline 
Accumulate DCTB Decline Atypical 
 (n = 75) (n = 17) (n = 17) (n = 20) (n = 21) 
Baseline n = 75 n = 17 n = 17 n = 20 n = 21 
Mean (SD) 21,3 (6,9) 15,4 (3,3) 24,0 (6,5) 18,5 (4,1) 26,3 (6,8) 
Median (IQR) 20,6 (15,5; 26,0) 14,3 (13,4; 16,2) 21,9 (18,7; 29,3) 18,5 (15,3; 21,2) 27,0 (26,3; 30,2) 
MTB Not detected 
(%) 
6,7 0 11,8 0 14,3 
Day 3 n = 74 n = 16 n = 17 n = 20 n = 21 
Mean (SD) 21,5 (6,4) 16,7 (4,1) 22,6 (6,5) 19,1 (3,7) 26,3 (6,4) 
Median (IQR) 20,2 (16,0; 25,7) 16,0 (14,0; 18,8) 23,2 (17,5; 25,9) 19,8 (15,8; 21,2) 28,6 (28,6; 31,0) 
MTB Not detected 
(%) 
5,4 0 5,9 0 14,3 
Day 7 n = 73 n = 16 n = 17 n = 20 n = 20 
Mean (SD) 23,6 (6,5) 19,0 (3,6) 24,5 (7,5) 22,0 (4,2) 28,2 (6,4) 
Median (IQR) 21,1 (18,9; 29,5) 18,8 (16,5; 20,5) 20,5 (19,4; 32,1) 20,8 (19,5; 23,6) 29,8 (29,7; 34,2) 
MTB Not detected 
(%) 
11,1 0 17,6 0 25,0 
Day 14 n = 72 n = 16 n = 16 n = 20 n = 20 
Mean (SD) 24,5 (5,8) 20,6 (3,5) 24,3 (6,0) 23,4 (4,0) 28,7 (6,2) 
Median (IQR) 23,3 (20,4; 28,8) 19,6 (18,3; 22,9) 23,5 (21,0; 25,7) 22,6 (21,5; 26,4) 30,0 (30,0; 34,5) 
MTB Not detected 
(%) 
8,5 0 12,5 0 20,0 
Day 35 n = 70 n = 16 n = 15 n = 19 n = 20 
Mean (SD) 26,8 (5,9) 23,4 (4,7) 26,9 (6,3) 27,2 (5,6) 29,5 (5,5) 
Median (IQR) 27,2 (22,7; 31,2) 24,0 (19,0; 27,2) 25,2 (23,0; 32,7) 27,5 (22,6; 29,2) 30,1 (30,0; 35,0) 
MTB Not detected 
(%) 
14,3 0 13,3 10,5 30,0 
Day 56 n = 68 n = 16 n = 16 n = 17 n = 19 
Mean (SD) 28,2 (5,4) 24,2 (4,3) 28,1 (5,7) 29,6 (4,6) 30,5 (5,2) 
Median (IQR) 26,9 (24,3; 35,0) 24,5 (21,5; 25,7) 26,3 (24,1; 34,9) 28,0 (26,5; 35,0) 33,7 (33,3; 35,0) 
MTB Not detected 
(%) 
26,5 6,3 25,0 29,4 42,1 
Day 180 n = 60 n = 14 n = 15 n = 13 n = 18 
Mean (SD) 33,9 (2,8) 33,2 (4,0) 33,9 (3,0) 34,5 (1,9) 33,9 (2,6) 
Median (IQR) 35,0 (35,0; 35,0) 35,0 (35,0; 35,0) 35,0 (35,0; 35,0) 35,0 (35,0; 35,0) 35,0 (35,0; 35,0) 
MTB Not detected 
(%) 
83,9 78,6 86,7 92,3 83,3 
% MTB not detected calculated using ‘n’ as denominator for each particular time point 
Abbreviations: n = number of patients analysed; SD = standard deviation; IQR = interquartile range; DCTB = differentially culturable 
tubercle bacilli
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APPENDIX 4C: SMEAR DATA FOR LONGITUDINAL ANALYSIS 
Table 4C. Smear data reported as percentage for all patients and stratified by defined sub-categories for 
longitudinal analysis 
 
All 
3 & 7 Day 
Resistance Accumulate DCTB Decline Atypical 
 (n = 75) (n = 17) (n = 17) (n = 20) (n = 21) 
Baseline (%) n = 75 n = 17 n = 17 n = 20 n = 21 
P+++ 37,3 82,4 17,6 55,0 0 
P++ 14,7 11,8 17,6 25,0 4,8 
P+ 14,7 5,9 23,5 20,0 9,5 
Scanty 10,7 0 11,8 0 28,6 
Negative 22,7 0 29,4 0 57,1 
Day 3 (%) n = 75 n = 17 n = 17 n = 20 n = 21 
P+++ 36,0 82,4 29,4 40,0 0 
P++ 12,0 11,8 5,9 25,0 4,8 
P+ 10,7 0 11,8 15,0 14,3 
Scanty 13,3 0 23,5 10 19,0 
Negative 28,0 5,9 29,4 10 61,9 
Day 7 (%) n = 75 n = 17 n = 17 n = 20 n = 21 
P+++ 16,0 41,2 23,5 0 4,8 
P++ 18,7 29,4 11,8 35,0 0 
P+ 16,0 17,6 17,6 30,0 0 
Scanty 14,7 5,9 5,9 25,0 19,0 
Negative 34,7 5,9 41,2 10,0 76,2 
Day 14 (%) n = 74 n = 17 n = 17 n = 20 n = 20 
P+++ 6,8 23,5 5,9 0 0 
P++ 21,6 41,2 11,8 30,0 5,0 
P+ 16,2 17,6 17,6 25,0 5,0 
Scanty 14,9 11,8 11,8 20,0 15,0 
Negative 40,5 5,9 52,9 25,0 75,0 
Day 35 (%) n = 71 n = 17 n = 16 n = 19 n = 19 
P+++ 2,8 5,9 0 5,3 0 
P++ 11,3 35,3 6,3 5,3 0 
P+ 15,5 23,5 18,8 10,5 10,0 
Scanty 12,7 11,8 0 26,3 10,0 
Negative 57,7 23,5 75,0 52,6 8,0 
Day 56 (%) n = 68 n = 15 n = 15 n = 18 n = 20 
P+++ 0 0 0 0 0 
P++ 7,1 13,3 13,3 5,6 0 
P+ 15,7 33,3 13,3 22,2 0 
Scanty 17,1 20,0 13,3 5,6 30,0 
Negative 60,0 33,3 60,0 66,7 70,0 
Day 180 (%) n = 62 n = 16 n = 15 n = 13 n = 18 
P+++ 0 0 0 0 0 
P++ 0 0 0 0 0 
P+ 0 0 0 0 0 
Scanty 0 0 0 0 0 
Negative 100 100,0 100 100 100 
% M. tuberculosis not detected calculated using ‘n’ as denominator for each particular time point 
Abbreviations: n = number of patients analysed; SD = standard deviation; IQR = interquartile range; DCTB = differentially culturable 
tubercle bacilli.
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APPENDIX 4D: DECLINE IN DCTB IN ATYPICAL PATIENT COHORT 
 
Figure 4A. Decline in differentially culturable and culturable tubercle bacilli in twenty patients exhibiting 
the atypical DCTB decline pattern during standard first-line tuberculosis treatment. (A) The average number 
of culture filtrate (CF) -dependent bacteria (red), and resuscitation-promoting factor (Rpf) –independent bacteria 
(blue) obtained in the CF-supplemented most probable number (MPN) assays were plotted for each selected time 
point during the six months of anti-TB treatment. In addition the CF-independent bacteria (green) obtained in the 
un-supplemented MPN assay and the average number of platable bacteria (purple), obtained by viable colony 
forming units (CFU) on solid media were plotted for each selected time point during the six months of anti-TB 
treatment. The dotted line indicates possible background scored as positive growth in the MPN assay. (B) The 
proportional increase in DCTB during the first two weeks of anti-TB treatment was calculated by setting the 
average bacterial load obtained at enrolment in both the CF-dependent DCTB (red) and platable bacteria (purple) 
to 100%. The average number of bacteria cultured at each subsequent time point was calculated as a proportion 
of the average number of organisms obtained at baseline.  
 
APPENDIX 4E: STATISTICAL ANALYSES  
Table 4D. Statistical significance between decline sub-categories for age and BMI.  
 No CFU Accumulate Resist Decline Atypical 
No CFU  0.2238 0.0004 0.5120 0.2550 
Accumulate 0.4662  0.0240 0.4986 0.0073 
Resist 0.0329 0.0902  0.0026 <0.0001 
Decline 0.1265 0.3146 0.5384  0.0385 
Atypical 0.4749 0.9924 0.0978 0.3029  
Statistical comparisons between each category were conducted using unpaired T-tests. The top part of the table 
shows the pairwise comparison between sub-categories according to age (blue) and the bottom part shows the 
pairwise comparison of each category according to patient BMI (orange). According to age, six comparisons 
differed significantly. According to BMI, the resist decline and no CFU group differed significantly.  
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Table 4E. Statistical significance between decline sub-categories for CD4 count and CFU 
 No CFU Accumulate Resist Decline Atypical 
No CFU  0.3556 0.5586 0.6301 0.4453 
Accumulate 0.0014  0.5499 0.3386 0.4841 
Resist <0.0001 <0.0001  0.7686 0.8766 
Decline <0.0001 0.0154 0.0334  0.6236 
Atypical 0.0225 0.0440 <0.0001 <0.0001  
Statistical comparisons between each category were conducted using unpaired T-tests (CD4 T-cell count) and 
Mann-Whitney U tests (CFU). The top part of the table shows the pairwise comparison between sub-categories 
according to CD4 T-cell count (blue) and the bottom part shows the pairwise comparison of each category 
according to CFU (orange). While no groups differed according to CD4 T-cell count, all groups differed 
significantly by CFU.  
 
Table 4F. Statistical significance between decline sub-categories for MGIT and GeneXpert. 
 No CFU Accumulate Resist Decline Atypical 
No CFU  0.3339 0.0010 0.0029 0.8325 
Accumulate 0.5152  0.0036 0.0197 0.1264 
Resist <0.0001 <0.0001  0.0103 <0.0001 
Decline 0.0002 0.0038 0.0152  <0.0001 
Atypical 0.7383 0.2804 <0.0001 <0.0001  
Statistical comparisons between each category were conducted using unpaired T-tests. The top part of the table 
shows the pairwise comparison between sub-categories according to MGIT (blue) and the bottom part shows the 
pairwise comparison of each category according to patient GeneXpert (orange). According to MGIT culture, seven 
out of ten comparisons differed significantly. According to GeneXpert, seven out of ten comparisons differed 
significantly. The significant and non-significant groups were the same amongst the MGIT and GeneXpert.  
 
Table 4G. Statistical significance between decline sub-categories for CF+ MPN and MPN no CF 
 No CFU Accumulate Resist Decline Atypical 
No CFU   0.5084  <0.0001 0.0001 0.1459 
Accumulate 0.9351  <0.0001 <0.0001 0.0068 
Resist 0.0088 0.0031  0.0013 <0.0001 
Decline 0.1714 0.0969 0.0786  <0.0001 
Atypical 0.1275 0.1448 <0.0001 0.0002  
Statistical comparisons between each category were conducted using the Mann-Whitney U test. The top part of 
the table shows the pairwise comparison between sub-categories according to CF+ MPN (blue) and the bottom 
part shows the pairwise comparison of each category according to patient MPN no CF (orange).  Eight and four 
comparisons were statistically different by CF+ MPN and MPN no CF assays, respectively.  
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Table 4H. Statistical significance between decline sub-categories for HIV-1 sero-status and gender 
 No CFU Accumulate Resist Decline Atypical 
No CFU  0.2032 0.0659 0.6640 0.2883 
Accumulate 0.5765  0.6872 0.2949 0.0612 
Resist 0.0397 0.0065  0.0807 0.0108 
Decline 0.8424 0.6658 0.0159  0.3869 
Atypical  0.6515 0.2401 0.0728 0.4405  
Statistical comparisons between each category were conducted using chi-squared test for proportions. The top 
part of the table shows the pairwise comparison between sub-categories according to HIV-1 serostatus (blue) and 
the bottom part shows the pairwise comparison of each category according to gender (orange).  The atypical and 
resist groups differed significantly according to HIV sero-status. According to gender, the resist group was 
significantly different to the no CFU, accumulate and decline groups.  
 
Table 4I. Statistical significance between decline sub-categories for BCG scar and smoking status 
 No CFU Accumulate Resist Decline Atypical 
No CFU  0.9789 0.9712 0.4718 0.3652 
Accumulate 0.0944  0.2435 0.7317 0.8992 
Resist 0.3147 0.4516  0.3828 0.2749 
Decline 0.2913 0.4468 0.9851  0.8187 
Atypical  0.7097 0.1258 0.4442 0.4123  
Statistical comparisons between each category were conducted using chi-squared test for proportions. The top 
part of the table shows the pairwise comparison between sub-categories according to the presence or absence of 
a BCG scar (blue) and the bottom part shows the pairwise comparison of each category according to smoking 
status (orange). No significant differences were found between any groups.   
 
Table 4J. Statistical significance between decline sub-categories for smear status 
 No CFU Accumulate Resist Decline Atypical 
No CFU  0.3869 0.0022 0.0010 0.5291 
Accumulate 0.3869  0.0155 0.0091 0.0874 
Resist 0.0022 0.0155  NA 0.0002 
Decline 0.0010 0.0091 NA  <0.0001 
Atypical  0.5291 0.0874 0.0002 <0.0001  
Statistical comparisons between each category were conducted using chi-squared test for proportions. Significant 
differences were observed comparing six groups. No differences were observed between atypical and no CFU as 
well as accumulate. NA: not applicable – since one row (no patients were smear negative in resist or decline 
categories), chi-square analysis could not be calculated.  
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CHAPTER 5 
HOW DOES THE MPN RELATE TO OTHER TB CULTURE METHODS? 
5.1 INTRODUCTION 
New antibiotics are urgently required to shorten the duration of treatment and to treat the 
increasing number of drug-resistant M. tuberculosis strains (Connolly et al., 2007). Methods to 
monitor response to treatment are important in this regard. The determination of EBA is 
regarded as the first step in the clinical evaluation of a new TB drug (Donald and Diacon, 
2008). Since the introduction of antibiotics, various techniques have been employed to evaluate 
response to chemotherapy (Mitchison, 1950, Crofton et al., 1958, Joiner et al., 1953). One of 
the first studies to formally evaluate this was carried out by the Wissenschaftliche 
Arbeitsgemeinschaft für die Therapie von Lungenkrankheiten by quantifying the decrease of 
AFB in sputum (WATL, 1969). The investigators compared the effectiveness of the anti-TB 
drugs, para-aminosalicylic acid (PAS) and thiocarlide, with each other and also with bed rest 
in 29 patients with pulmonary TB disease. It was found that PAS was the most effective, 
followed by thiocarlide and lastly bed rest (WATL, 1969). In a separate early study, 
monotherapy with RIF, PAS and EMB was studied in 23 TB patients previously treated for 
pulmonary TB disease. In this study, the results indicated that RIF and EMB were equally 
effective and both were more effective than PAS (Schütz, 1968). Since the early 1980s, EBA 
studies have been used to monitor the effectiveness of anti-TB drugs, stemming from the 
ground breaking study conducted by Jindani et al. (1980). In this study, 27 anti-TB drugs and 
regimens were evaluated in 124 African patients with smear-positive, pulmonary TB disease. 
This was achieved by enumeration of CFU before treatment and every two days thereafter for 
two weeks (Jindani et al., 1980). Valuable information was generated from this study as well 
as a greater understanding of the actions of anti-TB drugs during early treatment.  EBA has 
since been defined as “ the fall in counts/mL sputum/day during the first two days of treatment” 
(Mitchison and Strum, 1997). 
 
EBA studies, involving CFU counts on solid media, are currently used for the direct 
quantification of M. tuberculosis to assess treatment response to a particular drug (Johnson et 
al., 2006, Donald et al., 2003, Donald and Diacon, 2008, Jindani et al., 1980, Jindani et al., 
2003, Sirgel et al., 2000, Sirgel et al., 1993, Sirgel et al., 1997). In addition, EBA also allows 
for the assessment of the efficacy of a drug with respect to dosage, pharmokinetics and toxicity 
(Diacon et al., 2012). Solid media, such as  Löwenstein–Jensen, has been traditionally used for 
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the culture of M. tuberculosis; however, this culture method is slow requiring up to four weeks 
for smear-positive samples and up to eight weeks for smear-negative samples (Ryu, 2015). 
Liquid culture, on the other hand, is significantly faster with a reported average TTP of ten 
days in smear-positive TB patients (Pfyffer et al., 1997, Kolibab et al., 2014). Furthermore, 
liquid culture has been shown to be more sensitive and can detect a population of bacteria that 
cannot be cultured on solid media (Bowness et al., 2014, Mitchison and Coates, 2004, 
Mukamolova et al., 2010, Chengalroyen et al., 2016, Dhillon et al., 2013). With the 
development of new anti-TB drugs, methods to replace CFU that offer a faster turnaround and 
can be performed in basic laboratory set-ups are being investigated. Recently, automated liquid 
culture systems (including the BACTEC MGIT 960 and BACTEC 460 TB systems) have been 
suggested as viable alternatives to CFU (Pheiffer et al., 2008, Diacon et al., 2012) . Previous 
experiments investigating the relationship between TTP and CFU/mL have reported strong 
negative correlations (Shin et al., 2007, Bark et al., 2013, Diacon et al., 2010b, Kolibab et al., 
2014, Bowness et al., 2014, Pheiffer et al., 2008) and certain studies have shown a relationship 
between MGIT TTP and treatment outcome (Epstein et al., 1998, Wallis et al., 2000).  
 
Over the past decade, a great deal of interest has been directed towards the study of variable 
populations of M. tuberculosis cells in patients with pulmonary TB disease that may exist in 
altered growth states. As previously discussed, M. tuberculosis cells in artificial culture 
accumulate lipid inclusion bodies as they enter stationary phase (Garton et al., 2002). These 
LBP cells are also present in M. tuberculosis isolated from patient sputum samples (Garton et 
al., 2002, Garton et al., 2008). Previous work has shown that these cells are unable to form 
colonies on solid media (but may grow in liquid media) (Dhillon et al., 2013) and require the 
addition of recombinant Rpf or CF for growth (Mukamolova et al., 2010). Recently, studies 
conducted at the CBTBR in Braamfontein have used the MPN assay to determine the numbers 
of conventionally culturable as well as DCTB in clinical samples (Chengalroyen et al., 2016). 
The relationship between the 48-well MPN assay and currently employed culture methods such 
as traditional CFU on solid media or more recently used automated liquid systems such as the 
BACTEC MGIT 960 system has not been described.  
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5.2 HYPOTHESIS 
The MPN assay, in its currently used 48-well format, correlates with other TB culture methods 
such as CFU assays and the BACTEC MGIT 960, and thus has the potential to be used as an 
EBA tool to assess the response of both conventionally cuturable and DCTB to anti-TB drugs.  
 
5.3 AIM OF STUDY 
To explore the relationship between the MPN assay in the currently described 48-well format 
with MGIT TTP and CFU assays in both axenic cultures and clinical TB samples throughout 
first-line treatment. 
 
5.3.1 Specific objectives of study 
1. Determine the relationship between the MPN assay with currently employed culture  
methods, namely the BACTEC MGIT 960 assay as well as CFU on solid 7H11 media 
in axenic cultures 
2. To describe the relationship between the BACTEC MGIT 960 assay and CFU in serial 
dilutions from M. tuberculosis axenic cultures. Is this finding consistent with that 
obtained in previous studies?  
3. Determine whether MGIT TTP can be predicted based on MPN or CFU counts and vice 
versa? 
4. Determine the relationship between CF-supplemented and un-supplemented MPN 
assays with the TTP obtained in the BACTEC MGIT 960 assay in clinical samples 
collected and analysed in chapter 4. 
5. Determine the relationship between CFU obtained on solid 7H11 agar with the TTP 
obtained in the BACTEC MGIT 960 assay in clinical samples collected and analysed 
in chapter 4. 
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5.4 METHODS 
5.4.1 Preparation of axenic M. tuberculosis cultures 
Duplicate M. tuberculosis H37Rv (Johannesburg strain) cultures were grown to log-phase 
(OD600nm = 0.67) in standard 7H9 broth supplemented with 10% OADC. Ten-fold serial 
dilutions ranging from 103 to 1012 were performed by the addition of 200 µL of undiluted stock 
culture to pre-labelled 2.0 mL Eppendorf tubes containing 180 µL of 7H9 broth.  
 
5.4.2 Colony counts on solid media 
 The number of viable M. tuberculosis cells in each dilution factor was determined using 
standard plate counting. One hundred microliters from each dilution (103 to 1012) was plated 
out onto two 7H11 agar plates supplemented with OADC. Colony counts were determined 
after the incubation of agar plates at 37 ºC after 4 weeks.  
 
5.4.3 MPN assays  
MPN assays were performed for each dilution factor (103 to 1012) as previously described (See 
section 3.4.3.1, page 94). Briefly, 450 µL of 7H9 media was added to 48-well microtiter plates. 
Following MPN plate preparation, 50 µL of each dilution factor was subsequently added in 
triplicate to the first well of the plate after which additional 10-fold dilutions were performed. 
MPN plates were incubated at 37 °C for 42 days after which the assays were scored and data 
analysed. 
 
5.4.4 BACTEC MGIT 960 assay 
 MGIT tubes were inoculated with 800 µL PANTA reconstituted in OADC. The tubes were 
inverted several times after which 800 µL of media was removed from each tube and replaced 
with 800 µL of each serial dilution factor. The tubes were incubated at 37 °C in a MGIT 960 
instrument and removed once the instrument signalled positive. ZN microscopy was performed 
for each positive MGIT to confirm the presence of AFB. Furthermore, 100 µL from each tube 
was plated onto blood agar and incubated for up to 48 hours to confirm the absence of a 
contaminant. The experiment was performed in duplicate. Due to time constraints, a third 
biological replicate was not completed and this remains a limitation. 
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5.4.5 Data analysis 
The relationship between MGIT TTP (obtained using the BACTEC MGIT 960 assay), log CFU 
and log MPN were examined. Previous work has reported both the relationship between log-
transformed as well as untransformed TTP with log CFU (Bowness et al., 2014, Perrin et al., 
2010). Since a better fit was obtained using untransformed MGIT TTP, the relationship 
between this data and log MPN and log CFU are reported. Pearson’s and Spearman’s rank 
correlation analysis and linear regression analysis were employed to describe the relationship 
between these assays in axenic work and clinical work.  
 
5.5 RESULTS 
5.5.1 The relationship between MPN, MGIT TTP and CFU assays in axenic M. 
tuberculosis cultures 
Absolute bacterial counts for MPN and CFU assays were determined using a statistical MPN 
calculation program (obtained from: http://www.wilrich@wiwiss.fu-berlin.de) and manual 
colony counting, respectively. Serial dilutions of an axenic cultures, grown to approximately 
OD600nm = 0.6 to 0.7, were used as starter cultures. TTP was plotted against both log MPN and 
log CFU which yielded a negative relationship. Linear regression analysis (Figures 5.1 and 5.2) 
yielded R2 scores of 0.93 and 0.94 for MPN and CFU assays, respectively. Pearson’s and 
Spearman’s rank correlation analysis showed significant negative correlations between MGIT 
TTP and bacterial burden, Table 5.1 [rp = -0.97 and for both MPN and CFU assays (P < 0.0001 
and P = 0.0003 for MPN and CFU, respectively); rs = -1.00 for both MPN and CFU assays (P 
< 0.0001 and P = 0.0004 for MPN and CFU, respectively)]. These results illustrate that MGIT 
TTP decreases with an increase in bacterial load in either the MPN or CFU assay.  
 
218 
 
 
Figure 5.1 Generation of standard curve for M. tuberculosis using the BACTEC MGIT 960 assay plotted 
against most probable number assay. Ten-fold serial dilutions from log-phase H37Rv Mycobacterium 
tuberculosis cultures were inoculated both into the mycobacterial growth indicator tube (MGIT) to yield a time to 
positivity (TTP) as well as into 48-well micro-titre plates to perform the most probable number (MPN) assay. On 
the x-axis, the MPN is represented as log- transformed data. On the y-axis, the TTP is represented in hours. Data 
are represented as mean ± standard deviation.  
 
 
Figure 5.2 Generation of standard curve for M. tuberculosis using the BACTEC MGIT 960 assay plotted 
against CFU assay. Ten-fold serial dilutions from log-phase H37Rv Mycobacterium tuberculosis cultures were 
inoculated both into the mycobacterial growth indicator tube (MGIT) to yield a time to positivity (TTP) as well 
as into solid 7H11 media to determine the number of colony forming units (CFU). On the x-axis, the CFU is 
represented as log- transformed data. On the y-axis, the TTP is represented in hours. Data are shown as mean ± 
standard deviation 
 
219 
 
Table 5.1 Correlation between MGIT TTP with MPN and CFU assays in axenic cultures 
 MPN CFU 
Pearson’s correlation   
Correlation value (rp) -0.9659 -0.9719 
P-value <0.0001 0.0003 
Spearman’s rank correlation   
Correlation value (rs) -1.0000 -1.0000 
P-value <0.0001 0.0004 
Abbreviations: MPN = most probable number; CFU = colony forming unit; rp = Pearson’s correlation coefficient; 
rs = Spearman’s correlation coefficient. P value significant at 0.05 (95% confidence interval), shown in bold. 
 
Next, the relationship between the MPN assay and CFUs was explored. A positive linear 
relationship was obtained where R2 = 0.94, Figure 5.3. Pearson’s and Spearman’s rank 
correlation analysis revealed a significant positive relationship where rp = 0.97 (P = 0.0004) 
and rs = 1.00 (P = 0.0004). These results indicate that an increase in the number of CFUs 
directly correlated with an increase in the number of bacteria obtained in the MPN assay.  
 
 
 
Figure 5.3 Plot of log CFU per mL against log MPN per mL in axenic M. tuberculosis cultures. Ten-fold 
serial dilutions from log-phase H37Rv Mycobacterium tuberculosis cultures were inoculated both onto the solid 
7H11 media to determine the number of colony forming units (CFU) as well into 48-well micro-titre plates to 
determine the most probable number (MPN). On the x-axis, the MPN is represented as log- transformed data. On 
the y-axis, the CFU is represented as log transformed data. Data are represented as mean ± standard deviation.  
 
220 
 
Table 5.2 shows the average log bacterial counts obtained in the MPN and CFU assays with 
the corresponding MGIT hours to positivity. Furthermore, estimated TTP’s were calculated 
based on bacterial numbers using the MGIT-MPN or MGIT-CFU correlation equations, Table 
5.3.  
 
Table 5.2 Log bacterial counts (MPN and CFU) and MGIT TTP (hours) obtained for 
each M. tuberculosis 10-fold serial dilution factor 
Serial dilution factor 
Mean log MPN  
(SD) 
Mean log CFU  
(SD) 
Mean MGIT TTP, 
hours (SD) 
103 7.61 (1.03) TNTC 117.5 (0.7) 
104 6.82 (0.50) TNTC 135.5 (2.12) 
105 5.30 (0.60) TNTC 145.5 (0.7) 
106 4.20 (0.38) 2.43 (0.20) 176 (7.07) 
107 3.02 (0.49) 1.96 (0.30) 205.5 (7.78) 
108 2.80 (0.65) 1.52 (0.33) 233 (12.73) 
109 2.56 (0.14) 1.36 (0.32) 235.5 (2.12) 
1010 2.3 (0.52) 1.18 (0.05) 254.5 (13.43) 
1011 2.09 (0.23) 0.85 (0.37) 260.5 (14.85) 
1012 1.76 (0.71) 0.59 (0.41) 261 (ND) 
Abbreviations: MPN = most probable number; CFU = colony forming units; MGIT = mycobacterial growth 
indicator tube; TTP = time to positivity; SD = standard deviation; TNTC = too numerous to count; ND =not 
determined.  
 
Table 5.3 Predicted MGIT TTP based on MPN or CFU counts 
Log MPN Log CFU Predicted MGIT TTP (days) 
0.5 0 >12.06 
1 0 11.54 
2 0.79 10.51 
3 1.58 9.47 
4 2.37 8.44 
5 3.16 7.41 
6 3.94 6.37 
7 4.73 5.34 
8 5.52 4.30 
9 6.31 3.27 
Abbreviations: MPN = most probable number; CFU = colony forming units; MGIT = mycobacterial growth 
indicator tube; TTP= time to positivity.  
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Results from serial dilutions performed on axenic M. tuberculosis cultures indicated a strong 
linear relationship between all three culture assays, i.e. MGIT TTP, MPN and CFU assays. 
These results illustrate that the MPN assay performed on NUNC-plates in the 48-well format 
provides a highly sensitive method to determine the number of tubercle bacilli in axenic culture. 
Furthermore, the generation of standard curves from the analysis allowed for the prediction of 
bacterial load in the MGIT culture based on the TTP, or vice versa. In addition, the number of 
CFUs could be determined based on the MPN or vice versa. It is important to note that the 
numbers of bacteria obtained in the MPN assay were higher than those obtained in the CFU 
assay at all dilution factors, providing evidence for a population of bacteria in axenic culture 
that can only be grown in liquid media. Indeed, in the prediction analysis (Table 5.3), no CFUs 
can be cultured when the MPN is log 1 or less (i.e. M. tuberculosis growth is present in 
approximately one or two MPN wells but not on solid media). Furthermore, in samples where 
the MPN is less than log 1 (i.e. 10 organisms or less), the predicted MGIT TTP is greater than 
11 days. Therefore the TTP in low MPN samples can vary anywhere between 11 and 41 days.  
Since it is difficult to accurately count single colonies in samples where bacillary load is high 
(and multiple serial dilutions and plating are required to determine a CFU), the MPN or MGIT 
TTP may be a more attractive method for quantifying bacteria in axenic samples.  
 
5.5.2 The relationship between M. tuberculosis MGIT TTP with CFU and MPN assays 
in sputum samples 
The relationship between MGIT TTP and MPN as well as CFU assays in patient sputum 
samples was investigated. For this, the relationship from the MGIT TTP for sputum samples 
received from each patient sub-category identified in chapter 4 (i.e. resist decline, accumulate, 
decline and atypical presentation of DCTB) was plotted against the equivalent MPN and CFU 
counts for all treatment time points, Table 5.4. The overall relationship between MGIT TTP 
and MPN/CFU for all patient samples (i.e. n = 75) is also reported. Spearman’s rank and 
Pearson’s correlation analysis was performed. Generally, Spearman’s rank correlation analysis 
yielded slightly better r values (with the exception of the atypical group); however, the r values 
were very similar in both tests and the directions were the same, Table 5.4. For this reason, the 
correlation values from the Spearman’s test are reported in the text. In the overall patient 
analysis, 485 matched MGIT-MPN (CF+ and no CF) pairs were available for analysis. In 
addition 484 and 471 MGIT-MPN (Rpf-) and MGIT-CFU matched pairs were available for 
analysis, respectively. A significant negative correlation was obtained between MGIT TTP and 
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MPN assays in all 75 longitudinal patient samples, where rs = -0.61, -0.60 and -0.35 for CF
+, 
Rpf- and MPN no CF assays, respectively. A significant negative relationship was also obtained 
between MGIT TTP and CFU, where rs = -0.55 (P < 0.0001). For linear regression analysis, 
the R2 values were 0.33 (for both CF+ and Rpf- MPN assays), 0.15 for MPN no CF and 0.28 
for CFU, see Figure 5A in the Appendices (page 233). The correlation results from the different 
sub-categories are discussed in separate sections below. 
 
Table 5.4 Correlation between MGIT TTP with MPN and CFU assays in sputum samples 
Category 
Correlation 
value 
 (rp or rs) 
CF+ P-value Rpf - P-value 
No 
CF 
P-value CFU P-value 
Resist 
decline  
rp -0.70 <0.0001 -0.68 <0.0001 -0.44 <0.0001 -0.68 <0.0001 
rs -0.72 <0.0001 -0.69 <0.0001 -0.48 <0.0001 -0.68 <0.0001 
Accumulate  
rp -0.60 <0.0001 -0.57 <0.0001 -0.33 0.0004 -0.45 <0.0001 
rs -0.65 <0.0001 -0.60 <0.0001 -0.35 0.0002 -0.48 <0.0001 
Decline  
rp -0.62 <0.0001 -0.62 <0.0001 -0.38 <0.0001 -0.55 <0.0001 
rs -0.72 <0.0001 -0.70 <0.0001 -0.42 <0.0001 -0.61 <0.0001 
Atypical 
DCTB 
presentation 
rp -0.12 0.1768 -0.14 0.1020 -0.01 0.9079 -0.22 0.0117 
rs -0.08 0.3633 -0.09 0.3148 -0.02 0.8479 -0.17 0.0631 
Overall 
rp -0.58 <0.0001 -0.57 <0.0001 -0.34 <0.0001 -0.53 <0.0001 
rs -0.61 <0.0001 -0.60 <0.0001 -0.35 <0.0001 -0.55 <0.0001 
Abbreviations: CF+ = culture filtrate derived from M. tuberculosis H37Rv; Rpf- = resuscitation-promoting factor 
deficient CF derived from quintuple rpf gene-knockout mutant; CFU = colony forming units; rp = Pearson’s 
correlation coefficient; rs = Spearman’s correlation coefficient. Significant at P less than 0.05 (95% confidant 
interval) shown in bold.  
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5.5.2.1 The relationship between MGIT TTP and MPN/CFU in the resist decline cohort 
Log MPN and log CFU were correlated with MGIT TTP across all time points for patients in 
the resist decline sub-category. One hundred and thirteen matched log CFU and TTP pairs and 
112 matched log MPN (CF+, Rpf - and no CF) and TTP pairs were available for analysis. 
Spearman’s rank sum correlation analysis revealed a significant negative relationship between 
bacterial loads as detected by CF-supplemented and un-supplemented MPN assays as well as 
CFU assays when compared to MGIT TTP. The rs values were -0.72, -0.69 and -0.48 for CF
+, 
Rpf- and MPN no CF MPN assays, respectively (P < 0.0001).  The rs value obtained for the log 
CFU and TTP correlation was -0.68 (P < 0.0001). Linear regression analysis was also 
performed, Figure 5.4. The R2 values were 0.50, 0.46 and 0.20 for the CF+, Rpf- and no CF 
MPN assays, respectively. These results indicate that the MGIT correlates better with MPN 
assays that are supplemented with CF. It was hypothesized that the improved correlation could 
be due to the revival of organisms in the MPN assay that cannot be cultured using standard 
media. The association between DCTB and TTP was investigated in chapter 6 by the addition 
of CF to the MGIT. The results indicated that in the MGIT assay, CF did not stimulate the 
growth DCTB, but rather accelerated the growth of few viable organisms. However, this may 
not be the case in the MPN assay.  The R2 value obtained on solid media was 0.47, similar to 
that obtained in the CF+ and Rpf - MPN assay, suggesting that MGIT TTP can be predicted 
based on the number on CFUs obtained, or vice versa.  
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Figure 5.4 The linear relationship between the number of bacteria obtained in most probable number and 
colony forming unit assays with mycobacterial growth indicator tube time to positivity in patients from the 
resist decline cohort. The number of bacteria obtained by most probable number (MPN) or colony forming unit 
(CFU) assays was correlated with the mycobacterial growth indicator tube (MGIT) time to positivity (TTP) 
obtained for 17 patients in the resist decline DCTB cohort. The data featured contains baseline data as well as data 
from all subsequent time points (i.e. days 3, 7, 14, 35, 56 and 180). On the x-axis, the MPN/CFU is represented 
as log- transformed data. On the y-axis, the MGIT TTP is represented as the number of days to culture TTP. (A) 
CF+ MPN assay (red), (B) Rpf- MPN assay (blue), (C) MPN no CF (green) and (D) CFU assays (purple).  
 
5.5.2.2 The relationship between MGIT TTP and MPN/CFU in the accumulate cohort 
For the accumulate DCTB patient sub-category, one hundred and ten matched log CFU and 
TTP pairs as well as log MPN (CF+, Rpf- and no CF) and TTP pairs were available for analysis. 
Similar to the resist decline DCTB group, Spearman’s rank sum correlation analysis showed a 
significant negative correlation between MGIT TTP and the quantity of bacterial organisms 
detected using MPN and CFU assays. When correlated with MGIT TTP, the rs values were -
0.65, -0.60, -0.35 and -0.48 for the CF+ MPN, Rpf- MPN, MPN no CF and CFU assays, 
respectively (P < 0.0001 for CF+, Rpf- and CFU; P = 0.0002 for MPN no CF). In addition, 
linear regression analysis was carried out. The respective R2 values were 0.37, 0.33, 0.11 and 
0.20, illustrating poor linear relationships, Figure 5B (see page 234 in the Appendices).  
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5.5.2.3 The relationship between MGIT TTP and MPN/CFU in the decline cohort 
Log MPN and log CFU were correlated with MGIT TTP across all time points for patients in 
the decline sub-category. One hundred and twenty nine matched log MPN Rpf- and 128 
matched log MPN (CF+ and no CF) pairs were available for analysis. For log CFU versus 
MGIT TTP, 122 pairs were available for analysis. In this cohort, Spearman’s rank sum 
correlation analysis revealed a significant negative relationship between MGIT TTP and 
bacterial loads obtained by all three MPN (i.e. CF+, Rpf-, no CF) and CFU assays with the 
following scores: rs = -0.72, -0.70, -0.42 and -0.61, respectively (P < 0.0001). Linear regression 
analysis was also performed, Figure 5C (see page 235 in the Appendices). The R2 values 
obtained were 0.39, 0.38, 0.14 and 0.30 for MPN (CF+, Rpf-, no CF) and CFU assays, 
respectively. 
 
5.5.2.4 The relationship between MGIT TTP and MPN/CFU in the atypical DCTB 
presentation cohort 
Log MPN and log CFU were correlated with MGIT TTP across all time points for the 21 
patients in the atypical sub-category. One hundred and thirty five matched log MPN (CF+ and 
no CF) and MGIT TTP pairs were available for analysis. One hundred and thirty three log 
MPN Rpf- and MGIT TTP pairs were available for analysis. For log CFU and MGIT TTP, 126 
pairs were available for analysis. The atypical cohort displayed no correlation between the 
MPN and the MGIT. The Spearman’s rank scores were: rs = -0.07, -0.09 and -0.02 for the CF+, 
Rpf - and no CF MPN assays (P = 0.3633, 0.3148 and 0.8479), Table 5.4. In addition, no 
correlation was observed between the number of CFUs and MGIT TTP (rs = -0.17; P = 0.0631). 
Linear regression analysis was also performed and is shown in Figure 5.5.  
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Figure 5.5. Correlation between the number of bacteria obtained in most probable number and colony 
forming unit assays with mycobacterial growth indicator tube time to positivity in patients from the 
atypical cohort. The number of bacteria obtained by most probable number (MPN) or colony forming unit (CFU) 
assays was correlated with the mycobacterial growth indicator tube (MGIT) time to positivity (TTP) obtained for 
21 patients in atypical DCTB cohort. The data featured contains baseline data as well as data from all subsequent 
time points (i.e. days 3, 7, 14, 35, 56 and 180). On the x-axis, the MPN/CFU is represented as log- transformed 
data. On the y-axis, the MGIT TTP is represented as the number of days to culture TTP. (A) CF+ MPN assay 
(red), (B) Rpf- MPN assay (blue), (C) MPN no CF (green) and (D) CFU assays (purple). 
 
 The poor correlation observed in the atypical cohort can be due to numerous factors. Firstly, 
as the MPN is based on a visual scoring system, the growth recorded in the MPN may have 
been due to a contaminant that may appear similar in morphology to M. tuberculosis. Indeed, 
in chapter 6, a non-specific resuscitative effect was observed following the addition of CF to 
the MGIT (see chapter 6, section 6.5.2.1.1, page 262). As the poorest correlation was observed 
between the MGIT and the CF-supplemented MPN assay in this cohort, the MPN may have 
been contaminated in some patients that would have led to an over estimation of bacterial load 
in the MPN assay at a particular time point. Indeed, in 51 samples a positive MPN was obtained 
when the MGIT sample was culture negative at 42 days. The overall average MPN positivity 
in these samples was low at log 2.36 (IQR: 1.66 – 2.80). It is plausible that some of these wells 
may have been false positives due to drug precipitation, cellular debris or bacterial 
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contamination. The number of positive MPN wells with respective negative MGIT cultures 
was higher at later time points, suggesting that false negative MPN results are more likely to 
occur during late treatment, Table 5.5. In contrast, seven MGITs were positive when the CF+ 
MPN assays were negative (average TTP 17.0 days, IQR: 9.5 – 22.0). The lack of correlation 
is possible also due to the low bacterial load in this patient cohort throughout treatment. The 
axenic work illustrated that a MPN of log 0.5 should yield a MGIT TTP of >12.06 days; 
therefore, in a positive MPN plate with only one of two positive wells, the TTP can vary 
anywhere between 12 and 41 days. Therefore, the range of possible values in MGIT TTP is 
much larger than observed in the MPN assay at low bacterial loads. It is not surprising that the 
atypical category displays no correlation between MPN and CFU as this group of patients was 
characterised by low MPN (and high MGIT TTP) values throughout treatment.  
 
Table 5.5 MPN positive/MGIT negative sample pairs in the atypical patient cohort at 
treatment time-points.  
Time point No. samples MPN positive/ MGIT negative (%) 
0 4 (7.8) 
3 5 (9.8) 
7 1 (2.0) 
14 8 (15.7) 
35 10 (19.6) 
56 11 (21.6) 
180 12 (23.5) 
Abbreviations: MPN = most probable number; MGIT = mycobacterial growth indicator tube 
 
5.5.2.5 The relationship between MGIT TTP and MPN/CFU throughout treatment 
In line with the observations made in section 5.2.2.4 for the ‘atypical’ cohort, previous work 
investigating the relationship between MGIT TTP and CFU showed a decrease in the strength 
of the association throughout therapy (Bark et al., 2011). The decrease in correlation shows 
that CFU is more strongly predictive of MGIT TTP at high bacterial loads. The same appears 
to be true for the MPN assay. In this analysis, Spearman’s rank sum correlation of MGIT TTP 
with MPN and CFU (conducted on 75 patients from all four sub-categories) at selected time 
points also showed a decrease in correlation throughout treatment, Table 5.6 and Table 5.7. A 
significant correlation was observed up to 14 days of anti-TB treatment. At later time points, 
the correlation between MGIT TTP and MPN/CFU was no longer significant. This suggests 
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that current measures of bacterial load are unable to detect some organisms as treatment 
progresses.   
 
Table 5.6 Correlation between MGIT TTP and the CF+ MPN at treatment time-points  
Culture day No of paired samples  Correlation P-value 
0 75 -0.8088 <0.0001 
3 75 -0.5909 <0.0001 
7 72 -0.5603 <0.0001 
14 74 -0.3118 0.0068 
35 69 -0.1307 0.2844 
56 66 -0.03926 0.7543 
180 54 0.2156 0.1174 
 
 
Table 5.7 Correlation between MGIT TTP and CFU at treatment time-points 
Culture day No of paired samples  Correlation P-value 
0 73 -0.6805 <0.0001 
3 71 -0.5061 <0.0001 
7 70 -0.2743 0.0216 
14 72 -0.3471 0.0278 
35 66 -0.1862 0.1344 
56 66 0.1178 0.3463 
180 53 0.03395 0.8093 
 
5.5.3 The relationship between CFU and MPN assays in sputum samples 
Next the relationship between CFU and MPN was investigated. For this, the relationship from 
the MPN for sputum samples received from each patient sub-category identified in chapter 4 
(i.e. resist decline, accumulate, decline and atypical presentation of DCTB) was plotted against 
the equivalent CFU counts for all time points, Table 5.8. The overall relationship between MPN 
and CFU for all patient samples (i.e. n = 75) is also reported. In contrast to the MGIT versus 
MPN/CFU correlation analysis, Pearson’s correlation analysis yielded slightly better r values. 
The r values were very similar in both tests and the directions were the same, Table 5.8. For 
consistency, correlation values from the Spearman’s test are reported in the text. Overall, a 
significant positive correlation was obtained between the MPN and CFU assays, where rs = 
0.64, 0.60 and 0.37 for CF+, Rpf- and MPN no CF assays, respectively (P < 0.0001). For linear 
regression analysis, the R2 values were 0.54, 0.50 and 0.26, Figure 5D (page 235 in the 
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Appendices). The results from the different sub-categories are discussed in separate sections 
below.  
 
Table 5.8 Correlation between MPN and CFU assays in sputum samples 
Category 
Correlation 
coefficient 
CF+ P-value Rpf - P-value No CF P-value 
Resist 
decline 
rp 0.8052 <0.0001 0.7807 <0.0001 0.6158 <0.0001 
rs 0.8028 <0.0001 0.7406 <0.0001 0.5712 <0.0001 
Accumulate 
rp 0.6744 <0.0001 0.6231 <0.0001 0.4423 <0.0001 
rs 0.6027 <0.0001 0.5421 <0.0001 0.3067 0.0010 
Decline 
rp 0.6890 <0.0001 0.6673 <0.0001 0.4119 <0.0001 
rs 0.6527 <0.0001 0.5908 <0.0001 0.2946 0.0009 
Atypical 
rp 0.3439 <0.0001 0.3722 <0.0001 0.2616 0.0030 
rs 0.2312 0.0089 0.2516 0.0047 0.2188 0.0134 
Overall 
(n = 75) 
rp 0.7324 <0.0001 0.7106 <0.0001 0.5098 <0.0001 
rs 0.6372 <0.0001 0.6002 <0.0001 0.3705 <0.0001 
Abbreviations: CF+ = culture filtrate derived from M. tuberculosis H37Rv; Rpf- = resuscitation-promoting factor 
deficient CF derived from quintuple rpf gene-knockout mutant; CFU = colony forming units; rp = Pearson’s 
correlation coefficient; rs = Spearman’s correlation coefficient. Significant at P less than 0.05 (95% confidant 
interval) shown in bold. 
 
5.5.3.1 The relationship between MPN and CFU in the resist decline cohort 
One hundred and fourteen MPN and CFU pairs were available for analysis. Spearman’s rank 
sum correlation revealed a significant positive relationship between bacterial loads detected by 
CFU and MPN assays. The respective rs values were: 0.80, 0.74 and 0.57 for CF
+, Rpf- and 
MPN no CF assays, respectively (P < 0.0001). Linear regression analysis was also preformed, 
Figure 5.6. The R2 values were 0.65, 0.61 and 0.38 for CF+, Rpf- and MPN no CF, respectively.  
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Figure 5.6 Correlation between the number of bacteria obtained in colony forming unit assays with most 
probable number assays in patients from the resist decline cohort. The number of bacteria obtained by colony 
forming unit (CFU) assays was correlated with the number of bacteria obtained from most probable number 
(MPN) assays for 17 patients in the resist decline cohort. The data featured contains baseline data as well as data 
from all subsequent time points (i.e. days 3, 7, 14, 35, 56 and 180). On the x-axis, the CFU is represented as log- 
transformed data. On the y-axis, the MPN is represented as log-transformed data. (A) CF+ MPN assay (red), (B) 
Rpf- MPN assay (blue), (C) MPN no CF (green).  
 
 
5.5.3.2 The relationship between MPN and CFU in the accumulate cohort 
The association between MPN and CFU was investigated for the accumulate cohort. One 
hundred and thirteen CF+/MPN no CF and CFU pairs were available for analysis. For Rpf - and 
CFU, 112 pairs were available. A strong positive correlation was observed between the CFU 
and MPN assays in this patients cohort where rs = 0.60, 0.54 and 0.31 (P < 0.0001 for CF
+ and 
Rpf- and P = 0.0010 for MPN no CF), Table 5.8. Linear regression analysis was also performed 
on all samples throughout treatment, Figure 5E (see page 236 in the Appendices). The R2 values 
were 0.45, 0.39 and 0.20, for CF+, Rpf - and MPN no CF, respectively. 
 
5.5.3.3 The relationship between MPN and CFU in the decline cohort 
One hundred and twenty four MPN and CFU pairs were available for analysis. A positive 
significant relationship was observed between CFU and MPN assays where rs = 0.66, 0.59 and 
0.29 for CF+, Rpf - and MPN no CF assays throughout treatment (P < 0.0001 for CF+ and Rpf- 
and P = 0.0009 for MPN no CF).  Linear regression analysis was carried out where R2 = 0.47, 
0.45 and 0.17 for CF+, Rpf- and no CF MPN assays, Figure 5F (see page 236 in the 
Appendices).   
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5.5.3.4 The relationship between MPN and CFU in the atypical cohort 
Spearman’s rank sum correlation analysis was employed to determine the relationship between 
CFU and MPN in the atypical patient cohort. In contrast to that observed between the MGIT 
and MPN assay (where no association was apparent), a significant positive correlation was still 
observed in this cohort. The scores were rs = 0.23, 0.25 and 0.22 (P = 0.0089, 0.0047 and 
0.0134) for CFU correlated with the CF+, Rpf - and no CF MPNs, respectively. The linear 
relationship between CFU and MPN assays for the atypical cohort is shown in Figure 5.7. 
These results illustrate that the MPN can more accurately predict CFU (and vice versa) at low 
bacterial loads than the MGIT. These results also suggest that the MPN assay (supplemented 
with CF) may be a more favourable assay for future EBA studies than the MGIT for patient 
samples with low bacterial burden. Indeed, correlation analysis performed at each time point 
(for all patients, i.e. sub-categories combined), showed a positive correlation up to 56 days on 
treatment, Table 5.9.  
 
 
Figure 5.7 Correlation between the number of bacteria obtained in colony forming unit assays with most 
probable number assays in patients from the atypical cohort. The number of bacteria obtained by colony 
forming unit (CFU) assays was correlated with the number of bacteria obtained from most probable number 
(MPN) assays for 21 patients in the atypical cohort. The data featured contains baseline data as well as data from 
all subsequent time points (i.e. days 3, 7, 14, 35, 56 and 180). On the x-axis, the CFU is represented as log- 
transformed data. On the y-axis, the MPN is represented as log-transformed data. (A) CF+ MPN assay (red), (B) 
Rpf- MPN assay (blue), (C) MPN no CF (green).  
 
5.5.3.5 Correlation analysis of MPN with CFU throughout treatment 
Previous observations showed that the relationship between MGIT TTP and bacterial load 
(measured by either MPN or CFU assays) was only significant during the first two weeks of 
TB treatment. To determine whether the same trend was true for MPN and CFU, Spearman’s 
correlation analysis was carried out on all 75 patients at individual time points, Table 5.9. The 
analysis showed a significant relationship between the CF+ MPN and CFU up until 56 days of 
treatment.  
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Table 5.9 Correlation between MPN and CFU at treatment time-points  
Culture day No of paired samples  Correlation P-value 
0 73 0.7308 <0.0001 
3 71 0.6303 <0.0001 
7 70 0.5673 <0.0001 
14 73 0.5358 <0.0001 
35 69 0.3315 0.0054 
56 65 0.2502 0.0444 
180 53 0.1417 0.2930 
 
5.6. DISCUSSION 
Since the introduction of anti-TB chemotherapeutics more than 70 years ago, the enumeration 
of M. tuberculosis from patient sputa has been used to evaluate the response to treatment 
against numerous anti-TB agents. Traditionally, this quantification was done by measuring the 
decline in AFB by smear microscopy or by EBA assays measuring the fall in viable CFU in 
patient sputum samples during early treatment (Donald et al., 2003, Jindani et al., 1980, Donald 
and Diacon, 2008, Jindani et al., 2003). While EBA studies are able to show that a potential 
new drug under development has a detectable anti-TB effect, this method is limited in its 
approach as it is unable to detect the response to treatment of DCTB that are unable to grow 
on solid media and require special culture conditions.  The development of an assay to detect 
the killing of these non-replicating tubercle bacilli would allow for the assessment of the 
sterilizing effect of new agents and significantly improve the value of EBA studies. Recently, 
attempts to replace CFUs with liquid-based assays such as the MGIT have been carried out 
with the aim of enhancing sensitivity and obtaining more rapid results (Diacon et al., 2010a, 
Bowness et al., 2014, Bark et al., 2011, Bark et al., 2013). These studies have demonstrated a 
direct correlation between MGIT TTP and CFU; however, the estimation of bacterial quantities 
in MGIT cultures based on the MPN assay is undetermined. Methods of bacterial quantification 
using 48-well micro-titre plates have been described in the literature for the culture and to 
estimate the MPN of tubercle bacilli in sputum. The MPN assay in this 48-well format 
resembles that of the MGIT in that it is liquid based; however, it is miniaturized, carrying less 
than a tenth of the total volume of the MGIT. In this chapter, this unique format of the MPN 
assay was correlated with both CFU and MGIT TTP in axenic M. tuberculosis H37Rv cultures 
as well as in clinical samples taken throughout first-line treatment.  
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In axenic cultures, linear regression analysis revealed that the MPN (no CF) correlated highly 
with both CFU and MGIT (R2 = 0.93 and 0.94, respectively). These results indicate that the 
number of bacteria obtained using the MPN assay can strongly predict MGIT TTP or vice 
versa. The analysis also revealed that the MPN is more sensitive than the CFU as it was possible 
to quantitate less than 1 log of bacterial organisms which the CFU could not quantitate. This is 
in agreement with previous reports that liquid culture is more sensitive than solid culture (Chien 
et al., 2000, Chihota et al., 2010, Srisuwanvilai et al., 2008, Dhillon et al., 2013, Mukamolova 
et al., 2010, Chengalroyen et al., 2016).  
Following the results obtained in axenic M. tuberculosis cultures, retrospective analysis was 
carried out on longitudinal data obtained from 75 patients that were recruited for the study 
described in chapter 4. MPN (with and without CF-supplementation) and CFU data were 
correlated with MGIT TTP throughout first-line treatment. In addition, MPN was correlated 
with CFU. Spearman’s rank sum correlation analysis was performed on the four DCTB decline 
sub-categories described in chapter 4 (i.e. resist, accumulate, decline and atypical). In three of 
these groups, namely the resist, accumulate and decline groups, a significant negative 
correlation was obtained between the CF-supplemented MPN assays and MGIT TTP. These 
correlations were similar, or slightly stronger than that observed between the CFU and MGIT. 
As previously described, the results also revealed a strong negative correlation between CFU 
and MGIT TTP. This negative correlation describes a relationship where an increase in 
bacterial burden (i.e. obtained in either MPN or CFU assays) is associated with a decrease in 
MGIT TTP. It is interesting to note that a stronger correlation was observed between the MGIT 
and the CF-supplemented assays compared to the MPN no CF assays. This is possibly due to 
the resuscitation of non-culturable/damaged organisms present in sputum (Mukamolova et al., 
2010, Chengalroyen et al., 2016).  Alternatively, the addition of CF may be able to rescue the 
growth of bacterial populations that are affected by cell-associated inhibitory activity in 
sputum. Indeed, previous reports have shown that the addition of Rpf-containing supernatant 
was able to overcome the growth inhibition observed in liquid media (i.e. MPN no CF) 
(Mukamolova et al., 2010).  
In the atypical cohort, no correlation was observed MGIT TTP and MPN/CFU when all paired 
samples were analysed. This is most likely due to the low bacillary load observed in these 
patients throughout treatment. To further investigate the relationship between MGIT TTP and 
MPN/CFU with regards to bacillary load, correlation analysis was carried out at specified 
treatment time points for all 75 patients. The results showed that the association was only 
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significant during the first two weeks of anti-TB treatment when sputum bacillary load is at its 
highest. In a previous study, the relationship between MGIT TTP and CFU was assessed in 
107 TB patients at selected time points  during the first two months of anti-TB treatment (i.e. 
days 0, 2, 4, 7, 14, 21, 28 and 60). The investigators reported that the association was strongest 
during early treatment, although the association was still significant at all time points assessed 
(Bark et al., 2011). The patients in this study had baseline sputum smear grades of 3+ and 4+ 
(Strong and Kubica, 1981), the median baseline CFU was log 6.2 and median TTP was 3.0 
days (IQR:2.0 to 4.0) (Bark et al., 2011, Johnson et al., 2003). In contrast, the smear grades in 
the present study varied from smear negative to 4+, the median baseline CFU was log 3.8 
(IQR:1.2 to 5.4) and the median TTP was 6.5 days (IQR: 4.0 to 13.0). The high baseline 
bacterial loads in patients from the Bark et al. (2011) study may explain why correlation was 
significant throughout treatment, whereas in the present study was only significant up to day 
14. Indeed, Bark et al. (2011) reported that MGIT baseline TTP was predictive of sputum 
culture conversion at one to two months and that patients with significantly longer median 
baseline TTP were more likely to have negative cultures after one to two months (Bark et al., 
2011). The results from the present study suggest that the MGIT is least variable during early 
treatment. Furthermore, the MPN cannot accurately predict MGIT TTP (or vice versa) at low 
bacterial loads. 
When CFU (the current gold standard for EBA studies) was correlated with the MPN assay, a 
strong positive correlation was observed in all four patient sub-categories, although the 
association was not as strong in the atypical patient category. Furthermore, the MPN correlated 
with the CFU during the first two months of anti-TB treatment compared to the MGIT that 
only correlated with the CFU during the first two weeks of TB treatment. These results suggest 
that the CF+ MPN assay may be the preferred liquid culture assay (as opposed to MGIT TTP) 
to monitor the efficacy of new TB drugs, particularly with regards to DCTB.   
 
5.7 CHAPTER CONCLUSION AND FUTURE RESEARCH 
In conclusion, these results indicate a strong correlation between the MPN, CFU and MGIT 
assays when bacteria are cultured in the lab. The MPN assay in the 48-well format proves to 
be a highly sensitive method to determine the number of organisms in axenic culture. 
Furthermore, the generation of standard curves from this study has allowed for the prediction 
of bacterial load in MGIT culture based on the TTP or vice versa.  In patient samples, the CF+ 
MPN was comparable to the MGIT TTP during the first two weeks of TB treatment. The same 
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was observed between CFU and MGIT TTP. These results suggest a potential use for the MGIT 
assay in phase 1 EBA studies. The association between CFU and MPN was stronger than that 
observed in the MGIT at later treatment time points and in patients with a lower sputum 
bacillary burden. The ability to measure response of DCTB to anti-TB treatment using the CF+ 
MPN assay will be important in future studies to determine the effect of new TB 
chemotherapeutics on different M. tuberculosis populations.   
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APPENDICES 
APPENDIX 5A: THE RELATIONSHIP BETWEEN MGIT TPP AND BACTERIAL 
LOAD IN ALL PATIENT SAMPLES 
 
Figure 5A. The linear relationship between the number of bacteria obtained in most probable number and 
colony forming unit assays with mycobacterial growth indicator tube time to positivity in all patients. The 
number of bacteria obtained by most probable number (MPN) or colony forming unit (CFU) assays was correlated 
with the mycobacterial growth indicator tube (MGIT) time to positivity (TTP) obtained for all 75 patients (i.e. all 
DCTB categories comined). The data featured contains baseline data as well as data from all subsequent time 
points (i.e. days 3, 7, 14, 35, 56 and 180). On the x-axis, the MPN/CFU is represented as log- transformed data. 
On the y-axis, the MGIT TTP is represented as the number of days to culture TTP. (A) CF+ MPN assay (red), (B) 
Rpf- MPN assay (blue), (C) MPN no CF (green) and (D) CFU assays (purple).  
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APPENDIX 5B: THE RELATIONSHIP BETWEEN MGIT TPP AND BACTERIAL 
LOAD IN THE ACCUMULATE DCTB COHORT 
 
 
Figure 5B. Correlation between the number of bacteria obtained in most probable number and colony 
forming unit assays with mycobacterial growth indicator tube time to positivity in patients from the 
accumulate DCTB cohort. The number of bacteria obtained by most probable number (MPN) or colony forming 
unit (CFU) assays was correlated with the mycobacterial growth indicator tube (MGIT) time to positivity (TTP) 
obtained for 17 patients in accumulate DCTB cohort. The data featured contains baseline data as well as data from 
all subsequent time points (i.e. days 3, 7, 14, 35, 56 and 180). On the x-axis, the MPN/CFU is represented as log- 
transformed data. On the y-axis, the MGIT TTP is represented as the number of days to culture TTP. (A) CF+ 
MPN assay (red), (B) Rpf- MPN assay (blue), (C) MPN no CF (green) and (D) CFU assays (purple).  
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APPENDIX 5C: THE RELATIONSHIP BETWEEN MGIT TPP AND BACTERIAL 
LOAD IN THE DECLINE DCTB COHORT 
 
Figure 5C. Correlation between the number of bacteria obtained in most probable number and colony 
forming unit assays with mycobacterial growth indicator tube time to positivity in patients assigned to the 
decline DCTB cohort. The number of bacteria obtained by most probable number (MPN) or colony forming unit 
(CFU) assays was correlated with the mycobacterial growth indicator tube (MGIT) time to positivity (TTP) 
obtained for 20 patients in decline DCTB cohort. The data featured contains baseline data as well as data from all 
subsequent time points (i.e. days 3, 7, 14, 35, 56 and 180). On the x-axis, the MPN/CFU is represented as log- 
transformed data. On the y-axis, the MGIT TTP is represented as the number of days to culture TTP. (A) CF+ 
MPN assay (red), (B) Rpf- MPN assay (blue), (C) MPN no CF (green) and (D) CFU assays (purple).  
 
APPENDIX 5D: THE RELATIONSHIP BETWEEN MPN AND CFU IN ALL 
PATIENT SAMPLES 
 
 
Figure 5D. Correlation between the number of bacteria obtained in colony forming unit assays with most 
probable number assays in all patients. The number of bacteria obtained by colony forming unit (CFU) assays 
was correlated with the number of bacteria obtained from most probable number (MPN) assays for 75 patients 
analysed in the longitudinal cohort from Chapter 4 (i.e. n = 75). The data featured contains baseline data as well 
as data from all subsequent time points (i.e. days 3, 7, 14, 35, 56 and 180). On the x-axis, the CFU is represented 
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as log- transformed data. On the y-axis, the MPN is represented as log-transformed data. (A) CF+ MPN assay 
(red), (B) Rpf- MPN assay (blue), (C) MPN no CF (green).  
 
APPENDIX 5E: THE RELATIONSHIP BETWEEN MPN AND CFU IN THE 
ACCUMULATE DCTB COHORT 
 
 
Figure 5E. Correlation between the number of bacteria obtained in colony forming unit assays with most 
probable number assays in patients from the accumulate cohort. The number of bacteria obtained by colony 
forming unit (CFU) assays was correlated with the number of bacteria obtained from most probable number 
(MPN) assays for 17 patients in the accumulate cohort. The data featured contains baseline data as well as data 
from all subsequent time points (i.e. days 3, 7, 14, 35, 56 and 180). On the x-axis, the CFU is represented as log- 
transformed data. On the y-axis, the MPN is represented as log-transformed data. (A) CF+ MPN assay (red), (B) 
Rpf- MPN assay (blue), (C) MPN no CF (green).  
 
APPENDIX 5F: THE RELATIONSHIP BETWEEN MPN AND CFU IN THE 
DECLINE DCTB COHORT 
 
 
 
Figure 5F. Correlation between the number of bacteria obtained in colony forming unit assays with most 
probable number assays in patients from the decline cohort. The number of bacteria obtained by colony 
forming unit (CFU) assays was correlated with the number of bacteria obtained from most probable number 
(MPN) assays for 20 patients in the decline cohort. The data featured contains baseline data as well as data from 
all subsequent time points (i.e. days 3, 7, 14, 35, 56 and 180). On the x-axis, the CFU is represented as log- 
transformed data. On the y-axis, the MPN is represented as log-transformed data. (A) CF+ MPN assay (red), (B) 
Rpf- MPN assay (blue), (C) MPN no CF (green).  
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CHAPTER 6 
ENHANCED DETECTION OF M. TUBERCULOSIS IN SMEAR-NEGATIVE/HIV 
POSITIVE TB PATIENTS WITH REDUCED BACTERIAL LOAD BY 
SUPPLEMENTATION OF THE BACTEC MGIT 960 CULTURE SYSTEM WITH 
CULTURE FILTRATE 
 
6.1 INTRODUCTION 
Although the introduction of anti-retroviral therapy (ART) programs has saved the lives of 
millions of HIV-positive individuals in resource-limited settings (UNAIDS, 2003, Haberer et 
al., 2017, Volberding and Deeks, 2010), mortality amongst patients with advanced disease 
during the first year of ART initiation is common (Gupta et al., 2011, Lawn et al., 2008). South 
Africa remains the epicentre for HIV/TB co-infection, with TB being the leading cause of death 
in patients co-infected with HIV (WHO report 2016). This has been verified in autopsy cases 
where a systematic review and meta-analysis of 36 eligible studies reported a pooled TB 
prevalence of 39.7% [95% confidence interval (CI) 32.4 – 47%] in HIV-infected adults (Gupta 
et al., 2015).  The post-mortem TB prevalence varied by region with pooled estimates in adults 
of 43.2% in sub-Saharan Africa (20 studies), 27.1% in the Americas (eight studies) and 63.2% 
in South Asia (eight studies) which correlated with the estimates of the National TB prevalence. 
Furthermore, approximately 50% of these cases remained undiagnosed at death, highlighting 
current limitations in the approach to TB prevention, diagnosis and treatment in HIV-infected 
individuals (Gupta et al., 2015).  
 
6.1.1 How does HIV- infection affect TB diagnosis? 
TB patients co-infected with HIV have an altered, atypical clinical presentation of disease with 
reduced prevalence of cavities due to impaired granuloma formation and higher rates of EPTB 
disease (Palmieri et al., 2002). As a result, these patients have reduced numbers of organisms 
in their sputum samples when compared to their HIV-uninfected counterparts (Hargreaves et 
al., 2001, Getahun et al., 2007). In resource-limited settings, screening for TB is predominantly 
done by sputum staining for AFB which has a low sensitivity that is further reduced with 
declining CD4 T-cell counts (Singhal et al., 2011). As TB diagnosis and management is 
predominantly based on sputum, there is a reduced sensitivity in TB tests amongst HIV/TB co-
infected patients who are often smear negative (Getahun et al., 2007).  
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High rates of smear negative TB disease and attempts to reduce the number of TB-related 
deaths in HIV-infected individuals has led to the expanded use of empiric treatment (defined 
as treatment in the absence of microbiological confirmation of TB disease) (Scott et al., 2017). 
The WHO recommends that HIV-positive patients who screen negative for TB are placed on 
INH preventative therapy (IPT) and empiric treatment is only used in seriously ill patients in 
peripheral settings (WHO, 2013). However, whilst IPT has proved to be a successful 
intervention (Group, 2015, Comstock et al., 1979, Comstock et al., 1967), concerns regarding 
the tolerability of INH and the treatment of sub-clinical TB with a single antibiotic, has resulted 
in more clinicians rejecting this method of treatment (Balcells et al., 2006). The Thibela TB 
study was carried out to investigate the direct protective effect of IPT on gold miners with 
LTBI in South Africa (Churchyard et al., 2014, Fielding et al., 2011). A high prevalence of 
HIV-infection along with exposure to silica dust and crowded working and living condition put 
miners at high risk for TB disease (Corbett et al., 2000). Analysis of the direct effect of INH in 
10,909 miners illustrated a reduction in TB incidence during treatment (adjusted rate ratio, 
0.42; 95% CI); however, this protection was short-lived. It was recommended that continuous 
IPT is considered for individuals at highest risk for TB (i.e. HIV-positive or with silicosis). 
Overall, the investigators concluded that a 9-month course of community-wide IPT did not 
improve TB control in South Africa (Churchyard et al., 2014). Another large scale trial, named 
‘REMEMBER’ (Reducing Early Mortality and Early Morbidity By Empirical TB treatment 
Regimens) sought to investigate whether empiric treatment would reduce ART early mortality 
compared to IPT in high burden settings (Hosseinipour et al., 2016).  Results from this multi-
centre clinical trial showed that empiric treatment did not reduce mortality in adult outpatients 
at 24 weeks post-ART initiation compared to IPT.  
 
6.1.2 Current TB diagnostics and the gold standard 
Culture remains the gold standard tool for the diagnosis of TB, but is limited in its application 
in that it can take up to six weeks to yield a positive result, a process that is further protracted 
in HIV-infected patients (Johnson et al., 1998, Brindle et al., 1993). In recent years, there has 
been substantive advances in molecular diagnostics with several NAATs to rapidly detect M. 
tuberculosis in patient samples. Among these tests is the recently endorsed Xpert MTB/RIF 
assay (Cepheid) that detects M. tuberculosis and resistance to RIF (which serves as a marker 
for multi-drug resistant TB) within two hours. In a prospective clinical study conducted in 
South Africa, this assay was demonstrated to have superior sensitivity when compared to other 
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NAATs, including the Hain MTBDRplus (Hain Lifescience, Nehren, Germany) and 
LightCycler Mycobacterium Detection (LCTB) (Roche), as well as sputum smear microscopy 
in an HIV and TB endemic region (Scott et al., 2011). Whilst suggestions to replace smear 
microscopy with the GeneXpert MTB/RIF assay for the initial diagnosis of TB have been put 
forward, the availability of this test remains scarce and is most likely hampered due to cost 
(Fenner et al., 2013). While the GeneXpert has excellent sensitivity in smear-positive sputum 
samples, sensitivity is decreased in smear-negative samples, usually associated with HIV-
infection (Steingart et al., 2013, Lawn et al., 2011, Sohn et al., 2014, Zeka et al., 2011). The 
new Ultra assay, which is currently being rolled-out in various provinces across South Africa, 
was shown to have enhanced sensitivity compared to the GeneXpert and was able to detect 
more cases of smear-negative, culture positive TB (Chakravorty et al., 2017). The overall 
sensitivity in 277 clinical sputum samples (Ultra versus Xpert) increased from 81% (95% CI, 
74.9, 86.2) to 87.5% (95% CI, 82.1, 91,7); in sputum smear-negative samples the sensitivity 
improved from 66.1%  (95% CI, 56.4, 74.9) to 78.9% (95% CI, 70.0, 86.1) (Chakravorty et al., 
2017). These results suggest that the GeneXpert Ultra is expected to perform better in HIV-
infected individuals.  
 
Smear microscopy and NAATs yield rapid results; however, a limitation of these assays is that 
they do not give any indication as to whether the organisms are alive or dead. Furthermore, the 
sensitivity of these assays is reduced compared to culture (Bicmen et al., 2011). Whist these 
assays may serve a purpose in the initial diagnosis of TB, they cannot be used to monitor 
response to treatment (WHO, 2014). In addition, MGIT culture is used for down the line DST 
for many first and second-line anti-TB drugs for detection of drug-resistance. This allows for 
the prescription of appropriate treatment and limits the emergence of further resistance that 
may stem from inappropriate treatment. The above highlights the urgent need to develop 
methods to decrease the rates of culture TTP for TB diagnosis and treatment management in 
HIV-positive individuals, who often present with low numbers of bacteria in the sputum and 
are difficult to diagnose. The emergence of drug-resistant M. tuberculosis strains has further 
exacerbated the need for rapid and sensitive TB tests that can provide a diagnosis and guide 
treatment in this group of individuals. Indeed a systematic review of the published literature 
reported that HIV/AIDS was significantly associated with an increase in MDR-TB [estimated 
pooled odds ratio (OR) 1.24; 95%] (Mesfin et al., 2014). Further analysis revealed that these 
estimates were higher for primary MDR-TB (pooled OR 2.28; 95%), a finding consistent with 
previous work (Suchindran et al., 2009). Possible explanations for this association may include 
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the rapid disease progression in immune-compromised individuals in areas where MDR-TB is 
prevalent. HIV-positive individuals may also have increased contact with MDR-TB infected 
patients due to increased hospitalization or in social settings with poor infection control (Mesfin 
et al., 2014). While a common concept with respect to drug resistance suggests that the 
acquisition of resistance mutations is associated with a fitness cost, more recent evidence 
suggests that these strains are equally as transmissible as their drug-susceptible counterparts 
(Gagneux et al., 2006, Dheda et al., 2017, Van Rie and Warren, 2015). This is evident in a 
number of studies that have linked MDR- and XDR-TB with primary transmission (Ghandi et 
al., 2006, Klopper et al., 2013, Gilpin et al., 2008, Cox et al., 2010, Andrews et al., 2008).  In 
settings where the transmission of drug-resistant TB occurs due to primary transmission (i.e. 
infection with a drug-resistant strain as opposed to drug-susceptible strain that acquires 
resistance through the course of treatment), the rapid diagnosis and treatment of individuals 
harbouring these strains should be a high priority.  
 
6.1.3 Efforts to enhance culture performance 
In light of the above, new methods to improve culture performance are urgently required and 
enhanced recovery of DCTB may prove beneficial in this regard. In previous work, the addition 
of Rpf (as recombinant proteins or presumed to be the growth stimulatory molecules in CF) to 
standard culture medium increased the yield of sputum culture (Mukamolova et al., 2010) and 
allowed for the culture of M. tuberculosis that would ordinarily be negative by conventional 
methods (O'Connor et al., 2015, Chengalroyen et al., 2016). A few studies have embarked on 
investigating the effect of recombinant Rpf or CF on reducing culture TTP in conventional and 
routine diagnostic assays. The results and findings of these studies are summarized in Table 
6.1 and are subsequently discussed.  
 
6.1.3.1 The effect of recombinant RpfB on the growth of axenic M. tuberculosis cultures 
Wu et al. (2008) performed various experiments investigating the relationship between 
recombinant RpfB supplementation and mycobacterial growth using Middlebrook 7H9, 
BACTEC 960 and Lowenstein Jensen medium (Wu et al., 2008). In the Middebrook 7H9, M. 
bovis BCG strains were inoculated into media at high (6 X 104 CFU per mL) and low (2 X 104 
per mL) inoculum levels. Growth curves were conducted by measuring the OD600nm at specified 
time intervals. 
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Table 6.1 Summary of studies using recombinant Rpf or CF to enhance culture performance 
Year 1999 2008 2014 2014 2015 
Author Sun and Zhang Wu Huang Kolwijck O’Connor 
Methods      
Culture system 
Liquid 
incubation 
followed by 
plating on solid 
media 
Middlebrook 
7H9, 
BACTEC 960, 
Lowenstein-
Jensen 
BacT/Alert MP BACTEC 960 MPN assay 
Recombinant (r) 
Rpf or CF? 
CF rRpfB 
rRpfB and 
rRpfE 
CF 
CF 
 (prepared 
from: H37Rv 
and 
ΔABCDE)  
Samples      
Axenic cultures 
or patient 
samples (n)  
Axenic: M. 
tuberculosis 
H37Rv 
(8 month aged 
cultures)  
Axenic: 
M. bovis BCG 
and M. 
tuberculosis 
H37Rv 
Patients 
(12) 
Patients 
(15) 
Patient 
(1) 
If patient 
samples: 
     
# of sputum 
samples collected 
NA NA 23 79 1 
lymph node 
aspirate 
# Pre-treatment 
samples 
 
NA NA NS 19 0 
# Treatment 
samples 
NA NA NS 60 1 
Key study 
conclusion/s: 
CF ↑ viability 
of aged 
cultures and 
↑ growth of 
small inocula 
in liquid media 
rRPF 
promoted 
proliferation of 
M. 
tuberculosis in 
7H9 media, 
BACTEC 960 
and LJ 
↑ sensitivity in 
samples that 
require longer 
culture times 
by standard 
procedures and 
↓ TTP in heat 
treated samples 
TTP reduced in 
sputum samples 
collected during 
the first eight 
weeks of TB 
treatment.  
M. 
tuberculosis 
cultured 
from 
otherwise 
undetectable 
extra-
pulmonary 
TB 
Abbreviations: rRpf = recombinant resuscitation-promoting factor, CF = culture filtrate, n = number, NA = not 
applicable, NS = not specified, LJ = Lowenstein-Jensen, TTP = time to positivity, ↑ = increase, ↓ = decrease.  
 
Results from the high inoculum experiments showed that supplementation with RpfB had no 
effect on mycobacterial growth compared to the control. In contrast, supplementation with 
RpfB was shown to have a marked effect on bacterial growth at low starting inoculum levels 
where the final cell density was three to five times greater than the un-supplemented 7H9 
media. These results were in agreement with a previous study where the addition of M. 
tuberculosis H37Rv derived CF increased the viability of aged cultures and promoted the 
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growth of low-level inocula (Sun and Zhang, 1999). In the BACTEC MGIT 960 experiments, 
four MGITs were included in the experiments: i) BACTEC 960 (control), ii) BACTEC 960 + 
OADC, iii) BACTEC 960 + RpfB and iv) BACTEC 960 + OADC + RpfB. Supplementation 
of BACTEC MGIT 960 culture media with RpfB reduced the TTP of higher-level inoculum 
densities (103 to 105; starting bacterial solution contained 106 CFU) similar to that achieved by 
supplementation with OADC (Wu et al., 2008). The biological activity was most prominent at 
the 106 inoculum density where the addition of RpfB in combination with OADC yielded 
positive growth at 17 days post-inoculum, compared to the control tube, which flagged positive 
after 37 days (TTP was 33 and 37 days post-inoculation following supplementation with either 
OADC or RpfB, respectively). These results suggest that stimulation of non-replicating 
bacteria could shorten the duration of culture period required for TB diagnosis. In the final set 
of experiments, the addition of RpfB to solid Löwenstein–Jensen media resulted in large, high-
density M. bovis BCG colonies compared to un-supplemented plates that contained smaller and 
fewer colonies (Wu et al., 2008). These experiments highlighted a potential use for Rpf in 
detection of TB infection in clinical samples where the bacterial load is low. However, this 
study had several limitations: firstly, the authors reported that the recombinant RpfB protein 
was insoluble, but the solubilisation of this protein, and whether function was restored, was not 
reported. Similarly, it was reported that this protein was purified under denaturing conditions, 
but details regarding its renaturation were not given. Therefore, the observations observed may 
have been due to a non-physiologic action of a denatured protein and not a direct result of 
recombinant RpfB. Lastly, no quantitative results of CFUs were given. This is problematic as 
there is no additional confirmation of bacterial load in the experiments. 
 
6.1.3.2 The effect of recombinant Rpf on reducing time to positivity in patient samples 
The addition of recombinant RpfB and RpfE to the BacT/Alert MP culture system was 
investigated (with respect to shortening time to culture positivity) in twelve smear positive 
patients from Hefei infectious Disease Hospital (Huang et al., 2014). The addition of 20 nm 
RpfB or RpfE reduced the TTP in samples where the control TTP, performed under standard 
laboratory procedures, was greater than 20 days. As the ZN staining score did not correlate 
with liquid culture TTP (R2 = 0.36), the investigators speculated that sputum samples may 
harbour varying proportions of lipid body positive (LBP) M. tuberculosis, and a high 
proportion of these non-replicating organisms may account for the reduction in TTP. To 
investigate this, an additional eleven sputum samples (designated A to K) were collected to 
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determine the effect of LBP-bacilli on TTP. Auramine-Nile Red staining illustrated the 
presence of LBP-positive M. tuberculosis in all sputum samples; however, the proportions 
varied from 20 to 70%. In agreement with their first conclusion, the TTP was shortened in 
samples where the control TTP was greater than 20 days (the TTP was reduced in 3 out of 11 
samples). Collective data from the two sample groups (first 12 sputum samples, 1-12, and 
additional 11 samples, A-K) illustrated that the addition of recombinant Rpf non-significantly 
shortened the TTP (28.8, 21.6 and 22.2 days for the control, the RpfB and RpfE supplemented 
cultures, respectively; P < 0.05). It is unclear whether the reported reduction in TTP was 
calculated from all 23 samples or only in the samples were TTP was reduced in the two sample 
groups. The investigators did however report that the effect (i.e. a reduction in TTP compared 
to the control) was not observed in samples with a shorter culture TTP using standard 
procedures. To further investigate whether non-replicating M. tuberculosis were responsible 
for the observed decrease in TTP, sputum samples were heat treated for 60 ºC for ten minutes 
to kill the replicating bacteria. It was assumed in this case that non-replicating bacteria were 
heat tolerant. Indeed, previous work on in vitro cultures illustrated that non-replicating M. 
tuberculosis induced in an anaerobic environment can tolerate heat treatment of 70 ºC for ten 
minutes (Shleeva et al., 2011). Following heat treatment, the proportion of lipid body-negative 
samples was reduced compared to untreated sputum samples (55% versus 5%; P < 0.001). 
Furthermore, heat treated samples were undetected by standard culture methods, but could be 
detected following RpfB supplementation, and in some cases, RpfE supplementation (Huang 
et al., 2014).  
 
6.1.3.3 The effect of early stationary phase culture supernatant on the growth of M. 
tuberculosis from patients on treatment 
Kolwijck et al. (2014) investigated whether supplementation of MGIT tubes with early 
stationary phase culture supernatant (ESPSN) derived from M. tuberculosis H37Rv could aid 
in the detection of a population of non-culturable M. tuberculosis cells during TB 
chemotherapy (Kolwijck et al., 2014). For this, 500 μL of sputum (n = 79) from 15 patients 
were inoculated into a total of four MGIT tubes: two with ESPSN (containing 4 mL original 
medium and 4 mL ESPN) and two with 8 mL of original medium (control). Both pre-treatment 
(n = 19) and treatment samples from the first two months of treatment were analysed [day 1 to 
7 (n=27), day 14 (n = 13), day 21 (n = 2), day 28 (n = 6), day 35 (n = 2), day 42 (n = 4), day 
49 (n = 3) and day 56 (n = 3)]. One control MGIT and one ESPN-supplemented MGIT was 
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harvested following 7 days incubation for CFU analysis and the remaining two tubes were 
incubated in the BACTEC MGIT 960 to obtain a TTP. Overall, ESPN was shown to non-
significantly accelerate the TTP (18.2 ± 128 hours, mean ± SD, P = 0.572, Mann-Whitney U-
test) and in contrast, decrease the number of platable bacteria obtained by CFU analysis (0.54 
± 0.35 log CFU, mean ± SD, P = 0.572, Mann-Whitney U-test). The authors note that when 
categorized by length of treatment (i.e. less than 7 days versus greater than 14 days), there was 
a significant trend towards increased ΔTTP with length of treatment duration (7.2 ± 32 hours 
versus 37.8 ± 212 hours, P = 0.01, Kruskal-Wallis test).  
 
6.1.3.4. The effect of Rpfs in diagnosing extra-pulmonary TB disease 
The effect of Rpfs on improving diagnosis in EPTB was first reported in a case study involving 
a 32 year old Asian male (O'Connor et al., 2015). Prior to referral, three sputum samples from 
this patient were smear- and culture-negative for M. tuberculosis; however, pathological 
intrathoracic lymphadenopathy was seen using computerised tomography. Various clinical 
samples (including an endobronchial ultra-sound-guided transbronchial needle aspiration of 
the enlarged paratracheal node) were collected for histopathological analysis and 
mycobacterial culture, with an additional lymph node aspirate collected to research the effect 
of Rpfs on culture yield. For this MPN assays were carried out with and without Rpf-containing 
culture supernatant as previously described (Turapov et al., 2014). After 50 days incubation, 
no growth was detected in standard liquid culture medium (i.e. MPN no CF) or on agar plates; 
however, a positive culture was obtained following 25 days incubation in the MPN assay Rpf-
containing culture supernatant (i.e. CF+ MPN), where the estimated bacterial count was 4.5 
cells per/mL. M. tuberculosis was confirmed by AFB smear microscopy and PCR using M. 
tuberculosis specific primers. Furthermore, mycobacterial interspersed repetitive-unit-
variable-number of tandem repeats strain typing identified the isolate as Dehli/Central Asian 
(O'Connor et al., 2015). This study illustrates that in some instances CF may be required to 
stimulate the growth of M. tuberculosis from EP sites that would otherwise remain undetected 
using standard culture methods. Indeed, in a recent study, CF-dependent DCTB [termed culture 
supernatant (CS) -dependent DCTB) were identified in 10/19 (52.6%) EPTB samples from 18 
culture positive M. tuberculosis patients, demonstrating that CS-dependent DCTB are not 
exclusive to sputum and pulmonary TB disease (Rosser et al., 2017a).   
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Considering the preliminary findings of the aforementioned studies, the addition of Rpf/CF to 
standard culture media appears to be an attractive avenue to improve TTP and the sensitivity 
of currently employed TB diagnostics. However; the use of recombinant Rpfs in resuscitating 
non-culturable organisms is limited and requires further investigation due to the unstable nature 
of these proteins. In addition to improving culture methods to detect M. tuberculosis, the use 
of CF (or recombinant Rpf) could be further explored for DST, thereby shortening the time to 
start appropriate treatment for patients with drug resistant TB. Improving culture TTP and yield 
will also be beneficial for molecular epidemiological studies (i.e. IS6110 restriction fragment 
length polymorphism genotyping requires culture material) and advanced ‘omic’ studies, since 
the methodology employed for these studies still require positive culture material (Asmar and 
Drancourt, 2015, Hayer et al., 2013, Ryu, 2015, Rosser et al., 2017b).  
 
6.2 HYPOTHESIS 
1. Modification of the BACTEC MGIT 960 culture assay through supplementation of the 
media with CF derived from M. tuberculosis H37Rv (containing Rpfs) will decrease 
the time to detection of M. tuberculosis in sputum samples collected from HIV- positive 
individuals, with smear negative/paucibacillary disease.  
2. Modification of the BACTEC MGIT 960 culture assay by reduction of total volume of 
culture will decrease the TTP of M. tuberculosis in sputum samples collected form 
HIV-positive individuals, with smear negative/paucibacillary disease.  
 
6.3 AIM OF THE STUDY 
The aim of this study was to determine whether modification of the BACTEC 960 MGIT 
culture assay through supplementation of the media with CF would improve detection in 
sputum samples collected from HIV-1 positive patients infected with active, drug-susceptible 
TB disease. This will enhance early diagnosis of TB and timely initiation of drug treatment 
thereby reducing further transmission within the community.  
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6.3.1 Specific Objectives 
1. To determine whether modification of the MGIT by the addition of CF will reduce 
the TTP in axenic M. tuberculosis cultures 
2. To determine whether a reduction in MGIT volume will reduce the TTP in axenic 
cultures 
3. To determine whether the modification of the MGIT by the addition of CF will 
increase the sensitivity of the assay by decreasing the number of false negative 
cultures associated with HIV/TB co-infection in patient sputum samples. 
4. To determine the proportional decrease in TTP in the MGIT supplemented with CF 
from M. tuberculosis H37Rv in comparison to the original format. 
5. To assess whether a reduction in the volume of MGIT media (with or without CF-
supplementation) results in a change in TTP. 
6. To quantitate the number of DCTB and by performing MPN assays containing CF 
and standard media, respectively. 
7. To determine the number of platable (culturable) bacteria by performing CFU 
assays.  
 
6.4 METHODS  
6.4.1. Preparation of culture filtrate 
CF was prepared from M. tuberculosis H37Rv cultures as previously described (see section 
3.4.3.1.1, page 94) with and without the addition of Tween 80 (polysorbate 80, 
polyoxyethylene sorbitan monooleate). Briefly, Freezer stocks containing 1 mL aliquots of 
cells were grown in standard media, sub-cultured and grown to an OD600nm of 0.6 – 0.9 after 
which the cells were harvested by centrifugation. The supernatant was filtered through a sterile 
0.22 µm syringe filter to obtain the CF.  
 
6.4.2 Quality controls 
Quality controls were performed to ensure the sterility of the CF as previously described (see 
section 3.4.3.1.2, page 98). In addition, a MGIT control was included to ensure that no bacterial 
contamination was present following preparation of the CF. For this, 3.5 mL of MGIT media 
was removed from a MGIT and replaced with 3.5 mL CF. The control was also inoculated with 
800 mL PANTA reconstituted in OADC. The MGIT was labelled ‘CF control’ with the 
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appropriate date and scanned into the BACTEC MGIT 960 instrument and incubated for 42 
days to ensure the absence of M. tuberculosis as well as other contaminants. For an example 
of the quality controls, see Appendix 5A.  
 
6.4.3 Detection of differentially culturable and conventionally culturable tubercle bacilli 
MPN assays were performed as previously described in section 3.4.3.1 (page 94). CF-
supplemented (CF+ only) and –un-supplemented 7H9 media was used for MPN assays. For 
axenic experiments, CFU assays were performed on all serial dilutions as described in section 
3.4.3.2 (page 104). For patient samples, approximately 500 µL of decontaminated sputum 
sediment was used to perform MPN and CFU assays. CFU assays were performed from the 
decontaminated sputum to determine the number of platable bacteria as described in section 
3.4.3.2. Neat to 103 serial dilutions were performed. GeneXpert and smear microscopy was 
done at CLS. 
 
6.4.4 Methods specific to axenic experiments 
6.4.4.1 Preparation of bacterial strains 
Three H37Rv cultures were grown to OD600nm = 0.6. These cultures were subsequently diluted 
to an OD600nm = 0.05 in standard 7H9 media. Serial dilutions were subsequently performed 
from the diluted cultures (103 to 106). Five hundred μL of each serial dilution was inoculated 
into five different MGIT tubes (see section 6.4.4.2). The experiment was repeated in triplicate 
from three separate cultures. A total of 62 MGIT tubes (including two control tubes) were 
required for this experiment. The experiment was repeated as above, where 100 μL (as opposed 
to 500 μL) of each serial dilution was inoculated into each of the five MGIT tubes. This was 
done to assess how reductions in the numbers of bacteria inoculated affected any possible TTP 
enhancement. 
 
6.4.4.2 Preparation of modified MGITs 
Five MGIT tubes were required for each experiment. The preparation of each tube is described 
below: 
 
 
254 
 
The first MGIT tube (A) served as the control and was not modified (7 mL of original MGIT 
media). For the second MGIT tube (B), 3.5 mL of MGIT medium was removed and replaced 
with 3.5 mL of freshly prepared CF (7 mL volume with 1:1 ratio of media and CF). MGIT tube 
C was prepared in the same manner as MGIT tube B, however, the CF added was prepared 
from bacterial cultures grown in media containing Tween 80. To investigate whether a reduced 
MGIT volume would result in a faster TTP, an additional two MGITs were prepared. For the 
reduced volume control, five mL of media was removed from MGIT tube D (2 mL of original 
MGIT media). Six mL of MGIT medium was removed from the last MGIT tube (E) and 
replaced with 1 mL of freshly prepared CF (2 mL volume with 1:1 ratio of media and CF). 
Following preparation of the five MGIT tubes, 800 μL and 230 μL of PANTA reconstituted in 
OADC was added to MGIT tubes containing 7 mL and 2 mL volumes of media, respectively.  
 
Table 6.2 MGITs prepared for axenic culture experiments 
Experimental conditions MGIT A MGIT B MGIT C MGIT D MGIT E 
Modified?      
CF-supplemented?      
Reduced volume?      
CF prepared from cultures 
grown in Tween 80? 
     
Designated name and 
colour 
Control 
green 
CF+ 
red 
CF+  
(Tween 80) 
blue 
2 mL  
(no CF) 
teal 
2 mL CF+ 
orange 
Abbreviations: MGIT = mycobacterial growth indicator tube, CF = culture filtrate, Tween 80 = polysorbate 80, 
polyoxyethylene sorbitan monooleate.  
 
6.4.4.3 Processing and inoculation of MGITs 
Following preparation of the MGIT tubes, 500 μL of each serial dilution factor from cultures 
one, two and three were inoculated into MGIT tubes A, B, C, D and E. Each tube was labelled 
with the appropriate culture number (i.e. 1, 2 or 3) and dilution factor (i.e. 103, 104, 105 or 106). 
A control MGIT containing a 1:1 ratio of CF and original media was prepared.  
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6.4.5 Methods specific to clinical samples 
This component of the study was conducted to determine whether the addition of CF to the 
MGIT in a ratio of 1:1 with the original MGIT media (consisting of 110 µL fluorescent 
indicator and 7 mL of modified 7H9 broth base) would both, increase the sensitivity of the 
assay by allowing for the further identification of M. tuberculosis in isolates that are negative 
after 42 days incubation in the control MGIT or decrease the time to positivity when compared 
to control samples containing no CF. A ratio of 1:1 CF to 7H9 broth in the MGIT (as opposed 
to broth only) allowed for the replenishment of nutrients utilized by the bacteria during culture. 
This approach has been used successfully in other published work (Mukamolova et al. 2008).  
 
6.4.5.1 Patients/Sources of sputum 
One hundred and twenty newly diagnosed HIV-positive patients were recruited for the study 
at a rate of one to three patients per week through the clinical platforms of the PHRU on the 
basis of a positive GeneXpert result (Ethics clearance certificate number: M161058, see 
Appendix 3A, page 133). HIV-positive patients were selected based on previous observations 
that these individuals present with low numbers of bacteria in the sputum and are difficult to 
diagnose with culture. Hence, the greatest benefit in CF-supplementation of MGIT culture is 
expected in this group. Once informed consent was obtained, a spot sample was collected at 
baseline after which the patient was placed onto a standard first-line TB regimen. The 
enrolment and exclusion criteria are given below: 
 
Enrolment criteria: 18 years and older, able to produce a sputum sample > 3 ml, HIV sero-
positive, no previous history of TB/TB treatment. 
Exclusion criteria: Unable to produce a sputum sample > 3ml, HIV sero-negative, drug resistant 
TB. 
 
Sputum collection was performed in a designated area away from staff and other patients. In 
order to minimize contamination, the patients were asked to rinse their mouths with water and 
take several deep breaths before coughing into a pre-labelled sputum jar. A blood sample was 
also taken from patients who did not have a recent CD4 count (more than 3 months) report. 
After collection, sputum samples were placed in a plastic bag and immediately transported to 
CLS where decontamination and diagnostic tests were performed. Samples were kept at 4 ºC 
(preferably in the dark) during transportation and whilst awaiting decontamination. Samples 
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were batched and processed once a week for decontamination and MGIT assays. The 
diagnostic tests performed included auramine smear microscopy (to differentiate patients into 
smear-negative and smear-positive groups), GeneXpert and conventional MGIT culture 
(designated MGIT ‘A’). A smear grading was performed on all smear-positive samples.  
 
6.4.5.2 Processing at of routine diagnostic data at Clinical Laboratory Services 
Sputum decontamination, smear microscopy, GeneXpert, CD4 counts and MGIT culture (for 
35 patients only) were performed at CLS as described in Appendix 3B, chapter 3.  
 
6.4.5.3 Experimental design and set-up of protocols one, two and three  
The 120 patients recruited for this study were divided and processed according to three 
different protocols which are detailed out below. Results from the first two protocols yielded 
unexpected results, leading to subsequent modification of the protocols. A methods overview 
is given in Figure 6.1.  
 
 
Figure 6.1 Methods map for patient samples. Patient samples were processed by protocols one, two and three 
as the study progressed. These protocols represent variations that were introduced as results were obtained and 
the hypothesis modified. In protocol one, the addition of culture filtrate [CF+ (Tween 80)] prepared from M. 
tuberculosis H37Rv cultures to the MGIT did not decrease time to positivity (TTP). Since most probable number 
(MPN) assays revealed the presence of differentially culturable tubercle bacilli (DCTB), the effect of culture 
volume on MGIT TTP was investigated. In protocol two, four MGITs were included. Two had a reduced overall 
total volume of 2 mL of which one was supplemented with a 1:1 ratio of MGIT media to CF. Results showed that 
a reduction in overall culture volume (with or without CF) did not decrease TTP. In protocol three, Tween 80 was 
removed from the M. tuberculosis cultures from which the CF was derived. The MGIT tubes for protocol three 
were prepared in the same manner as protocol two but Tween 80 deficient CF was used. This method resulted in 
a reduction in overall TTP in CF-supplemented MGITs.  
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6.4.5.3.1 Protocol one – does the addition of CF enhance TTP? 
The BACTEC MGIT 960 mycobacterial detection system was used to ascertain whether the 
addition of CF to the MGIT could enhance the sensitivity of this assay. For the first 35 patients, 
two MGIT tubes were prepared for each patient. The first MGIT tube served as the control, 
was not modified and was labelled ‘A’. The second MGIT tube, contained 50% of H37Rv CF 
and was labelled ‘B’. For the preparation of tube B, 3.5 mL of MGIT media was removed with 
a sterile pipette and substituted with 3.5 mL of freshly prepared CF. This was followed by the 
addition of 800 µL of PANTA reconstituted in OADC supplement.  Once prepared, each MGIT 
tube was inoculated with 500 µL of decontaminated sputum sample after which they were 
scanned into the BD BACTEC MGIT 960 instrument for incubation and monitoring of growth. 
The preparation and inoculation of MGIT tubes A and B are shown in Figure 6.2. Positive 
cultures were confirmed as MTBC by ZN staining and the MGIT TBc identification test (TBc 
ID) (BD diagnostics, Sparks, MD). The TBc ID test is a highly sensitive and specific lateral-
flow immune-chromatographic assay that is able to detect the MPB64 antigen for the 
confirmation of MTBC strains (Yu et al., 2011, Martin et al., 2011).  Positive MGITs were also 
streaked out onto blood agar to rule out the presence of a contaminant. In the indication of any 
contaminant, the pair of MGITs were excluded from analysis, even if smear microscopy 
detected the presence of M. tuberculosis. 
  
 
Figure 6.2 Set-up of mycobacterial growth indicator tubes A and B for protocol one. Two mycobacterial 
growth indicator tubes (MGITs) were prepared for the first 35 patients recruited into the study. Three and a half 
mL of MGIT media was removed from MGIT tube B, and replaced with 3.5 mL of freshly prepared culture filtrate 
(CF) derived from M. tuberculosis H37Rv. Both MGIT tubes A and B were subsequently inoculated with 800 μL 
of Polymyxin B, Amphotericin B, Nalidixic acid, Trimethoprim and Azlocillin (PANTA) reconstituted in Oleic 
acid, Albumin, Dextrose, Catalase (OADC). Following preparation of MGIT tubes A and B, both were inoculated 
with 500 μL of decontaminated patient sputum. Each tube was incubated in the BACTEC MGIT 960 instrument 
until flagging positive or negative after which time to positivity was recorded.  
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6.4.5.3.2 Protocol two – does reduction in total MGIT volume reduce TTP? 
Preliminary analysis of the initial 35 patients recruited indicated a slight increase in TTP 
following the addition of CF. The MPN assays on the other hand, showed the presence of a 
population of bacteria that could only be cultured in the presence of CF. As the MPN assay is 
performed in a smaller culture volume (total volume 500 μL) compared to the MGIT (total 
volume approximately 8.3 mL), the effect of culture volume on TTP was investigated in the 
MGIT in the second protocol. Here it was hypothesized that a smaller culture volume would 
enhance any growth stimulatory effects by molecular crowding. For this an additional two 
MGITs with a reduced volume of original medium (C) and original medium supplemented with 
CF (D) were prepared, Figure 6.3. MGIT tubes A and B were prepared as described in section 
6.4.5.3.1. Sputum samples from 15 patients were processed according to protocol two. 
 
 
Figure 6.3 Set-up of mycobacterial growth indicator tubes A, B, C and D for protocol two. Four 
mycobacterial growth indicator tubes (MGITs) were prepared for fifteen patients. The control MGIT, A, was not 
modified and processed using standard procedures. MGIT tube B was prepared by removing 3.5 mL of MGIT 
media and replacing it with 3.5 mL of freshly prepared culture filtrate (CF) derived from M. tuberculosis H37Rv. 
MGIT tube C was prepared by removing 5 mL of MGIT media. MGIT D was prepared by substituting 6 mL of 
MGIT media with 1 mL of CF. Following MGIT preparation, 800 μL and 230 μL of Polymyxin B, Amphotericin 
B, Nalidixic acid, Trimethoprim and Azlocillin (PANTA) reconstituted in Oleic acid, Albumin, Dextrose, Catalase 
(OADC) was added to MGITs A/B and C/D, respectively. All four MGITs were inoculated with 500 μL of 
decontaminated patient sputum. Each tube was incubated in the BACTEC MGIT 960 instrument until flagging 
positive or negative after which time to positivity was recorded. 
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6.4.5.3.3 Protocol three – does removal of Tween 80 from CF enhance MGIT TTP? 
The third protocol was used for the remaining 69 patients recruited into the study. To assess 
possible reasons for the observed increase in MGIT TTP following CF supplementation, (see 
Results, section 6.5.2.1 and 6.5.2.2 for protocols one and two, respectively) Tween 80 was 
removed from the 7H9 media for the growth of M. tuberculosis H37Rv strains used in the 
preparation of CF.  
 
6.4.6 Data analysis 
Axenic cultures: To determine statistical significance between groups, the students paired t-
test was used. Analysis was two-sided and a 95% level of statistical significance was employed. 
Patient samples: For patient demographics, differences between patients processed by 
protocols one, two and three were determined using the chi-squared test for proportions and 
analysis of variance (ANOVA). To determine statistical significance between MGIT TTP (in 
hours) in modified and control MGITs, the Wilcoxon signed-ranks tests was used. Correlations 
between MGIT time to positivity and smear status was assessed by the Pearson’s and 
Spearman’s correlation coefficients and linear regression analysis. Patients were further 
stratified according to smear status (positive versus negative). All statistical analyses were two-
sided and performed at a 95% level of significant using GraphPad Prism, version 6.01 for 
Windows (GraphPad Software, San Diego, California, USA).  
6.5 RESULTS  
6.5.1 Modification of the MGIT by CF-supplementation and reduction of the total 
volume, decreases time to positivity in axenic culture 
The association between culture volume and CF-supplementation on culture TTP in the MGIT 
system was investigated in axenic cultures with the hypothesis that a reduction in culture 
volume will reduce TTP due to molecular crowding of bacteria and growth stimulatory factors. 
Figure 6.4 and Table 6.3 illustrates the decrease in culture TTP in modified MGIT formats.  
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Figure 6.4 Modification of the BACTEC mycobacterial growth indicator tube (MGIT) enhances time to 
detection in Mycobacterium tuberculosis H37Rv, Experiment 1. The culture time to positivity (TTP) in the 
control MGIT (green) was compared to four experimental MGITs using axenic M. tuberculosis H37Rv cultures 
prepared at different inocula. The control MGIT was unmodified. Modified MGITs consisted of a culture filtrate 
(CF)+ MGIT (containing 3.5 mL standard media and 3.5 mL CF) (red), CF+ MGIT containing CF derived from 
M. tuberculosis H37Rv grown in standard 7H9 media supplemented with the detergent Tween 80 (blue), 2 mL 
(no CF) MGIT (teal) and 2 mL (CF+) MGIT (containing 1mL standard media and 1 mL CF) (orange). All MGITs 
were inoculated with 500 μL of prepared bacterial inoculums. The experiment was repeated in triplicate. Error 
bars represent the standard deviation. Statistical significance was determined using the students paired t-test with 
a 95% confidence interval (CI). * /** Significant with a 95% and 99% CI, respectively (i.e. P<0.05 and P<0.01). 
 
 
Table 6.3 MGIT modification by culture filtrate supplementation and volume reduction reduces 
time to detection in axenic M. tuberculosis cultures, Experiment 1.  
 Days of culture (Mean ± SD)  
M. 
tuberculosis 
dilution 
factor 
Control 
CF+ 
(-Tween 80) 
CF+ 
(+Tween 80) 
2 mL 
 (no CF) 
2 ml CF+ 
(- Tween 80) 
CFU 
(mean ± SD) 
103 6.94 ± 0.12 6.56 ± 0.24 6.46 ± 0.11 6.46 ± 0.19 6.29 ± 0.13 TNTC 
104 8.26 ± 0.28 7.83 ± 0.29 7.83 ± 0.18 7.82 ±  1,24 7.71 ± 0.29 83.50 ± 6.36 
105 9.40 ± 0.34 8.94 ± 0.10 8.88 ± 0.22 8.99 ± 0,16 8.86 ± 0.21 35.67 ± 9.79 
106 10.15 ± 0.12 9.71 ± 0.13 9.35 ± 0.34 9.71 ± 0,29 9.68 ± 0.34 11.0 ± 2.94 
Abbreviations: CF+ = culture filtrate derived from M. tuberculosis H37Rv; + Tween 80 = CF was prepared in 
7H9 media supplemented with Tween 80; – Tween 80 = CF was prepared from media deficient in Tween 80; 
CFU = colony forming units; TNTC = too numerous to count. Data represent the average of three independent 
experiments.  
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Preliminary analysis in axenic cultures illustrated that the greatest improvement in MGIT TTP 
was obtained following supplementation of the MGIT with CF prepared from bacterial strains 
grown in the presence of Tween 80. Figure 6.4 and Table 6.3 indicate that at a 103 inoculum 
density a significant decrease in time to positivity (TTP) was observed in all four modified 
MGITs when compared to the control (P < 0.05 and 0.01, students paired t-test). A non-
significant decrease was observed it 104 and 105 inoculum densities. A significant decrease in 
TTP was observed in the two 7 mL CF-supplemented MGITs at the 106 inoculum density [P = 
0.0472 and 0.0260 for CF+ and CF+ (Tween 80), respectively]. Two negative control MGITs 
(with and without CF-supplementation) were included in each experiment to rule out 
contamination and CF+ sterility. Plating of positive MGIT on blood agar incubated for 48 hours 
confirmed that positive cultures were not contaminated.  
 
Since previous studies found that the greatest change in culture TTP occurred in samples with 
very low bacterial loads, the experiment was repeated and only 100 μL (as opposed to 500 μL) 
of axenic culture from each respective serial dilution was inoculated into each MGIT, Figure 
6.5 and Table 6.4. Again, the greatest improvement in MGIT TTP (when compared to the 
control) was observed in the CF+ (Tween 80) MGIT. Significant differences were observed in 
the 103, 104 and 105 dilution factors (P = 0.0091, 0.0029 and 0.0019, respectively). A significant 
decrease in MGIT TTP was also observed between the control and CF+ MGIT at 104 and 105 
inoculum densities (P = 0.0017 and 0.0064, respectively). In contrast to experiment 1, reduction 
in total culture volume (2 mL no CF) did not result in a decrease in MGIT TTP.  
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Figure 6.5 Modification of the BACTEC mycobacterial growth indicator tube (MGIT) enhances time to 
detection in Mycobacterium tuberculosis H37Rv, Experiment 2. The culture time to positivity (TTP) in the 
control MGIT (green) was compared to four experimental MGITs using axenic M. tuberculosis H37Rv cultures 
prepared at different inocula. The control MGIT was unmodified. Modified MGITs consisted of a culture filtrate 
(CF)+ MGIT (containing 3.5 mL standard media and 3.5 mL CF) (red), CF+ MGIT containing CF derived from 
M. tuberculosis H37Rv grown in standard 7H9 media supplemented with the detergent Tween 80 (blue), 2 mL 
(no CF) MGIT (teal) and 2 mL (CF+) MGIT (containing 1mL standard media and 1 mL CF) (orange). All MGITs 
were inoculated with 100 μL of prepared bacterial inoculums. The experiment was repeated in triplicate. Error 
bars represent standard deviations. Statistical significance was determined using the students paired t-test with a 
95% confidence interval (CI). * /** Significant with a 95% and 99% CI, respectively (i.e. P<0.05 and P<0.01). 
 
Table 6.4 MGIT modification by culture filtrate supplementation and volume reduction reduces 
time to detection in axenic Mycobacterium tuberculosis cultures, Experiment 2.  
 Days of culture (mean ± SD)  
M. 
tuberculosis 
dilution factor 
Control 
CF+ 
(-Tween 80) 
CF+ 
(+Tween 80) 
2 mL 
 (no CF) 
2 ml CF+ 
(- Tween 
80) 
CFU 
(mean ± 
SD) 
103 8,60 ± 0,13 8,17 ± 0,18 7,07 ± 0,20 8,67 ± 0,07 8,35± 0,17 TNTC 
104 10,51 ± 0,31 9,83 ± 0,26 8,50 ± 0,38 10,60 ± 0,31 10,17 ± 0,36 253 ± ND 
105 12,54 ± 0,65 11,75 ± 0,70 9,68 ± 0,46 12,64 ± 0,64 12,13 ± 0,54  84 ± 50.3 
106 14,83 ± 2,15 13,42 ± 0,94 11,44 ± 1,13 15,10 ± 1,56 14,42 ± 1,62  18.7 ± 13.0 
Abbreviations: CF+ = culture filtrate derived from M. tuberculosis H37Rv; + Tween 80 = CF was prepared in 
7H9 media supplemented with Tween 80; – Tween 80 = CF was prepared from media deficient in Tween 80; 
CFU = colony forming units; TNTC = too numerous to count. Data represent the average of three independent 
experiments. 
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6.5.2 Patient samples 
The participant disposition flow chart is given in Figure 6.6. One hundred and twenty patients 
were recruited into the study from which, 119 samples were processed. One patient was a 
screen failure. Thirty five, 15 and 69 sputum samples from these patients were processed 
according to protocols one, two and three respectively. As mentioned previously, these 
protocols were iterative attempts to improve the study outcome by modification of the methods. 
The patient demographics are shown in Table 6.5.  
 
 
Figure 6.6 Patient disposition flow chart. A total of 120 patients were recruited into the study, of which one 
was classified as a screen failure. These patients were treatment naïve, HIV-positive individuals with a strong 
indication of TB disease through a positive GeneXpert result. Sputum samples from 35, 15 and 69 patients were 
processed according to protocols one, two and three, respectively. In the first protocol, culture was performed in 
two mycobacterial growth indicator tubes (MGIT) [one control and one supplemented with culture filtrate (CF)] 
for each patient. Arrows indicate MGIT pairs that were excluded due to CF or MGIT contamination. A total of 
19 pairs were available for analysis. In protocol two, culture was performed in one control MGIT and three 
modified MGITs, designated B, C and D.  MGITs C and D had a reduced total volume of 2 mL, with MGIT tube 
D containing a 1:1 ratio of MGIT media to CF. CF prepared for protocols one and two was derived from M. 
tuberculosis H37Rv grown in 7H9 media supplemented with 0.05% Tween 80. Protocol 3 was performed in the 
same manner as protocol two with the exception that CF was derived from M. tuberculosis H37Rv grown in 7H9 
media that was not supplemented with 0.05% Tween 80. 
 
 
The majority of the patients recruited were male (63.4%) and the median age of study 
participants was 38 years (IQR: 32 – 44 years old). Most patients (67.7%) had a normal BMI 
and the median CD4 T-cell count was 130.5 cells/mm3. Predominately, spot sputum samples 
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were collected from patients (83.9%). In some cases, overnight sputum samples were collected 
(16.1%). In terms of pathology, the majority of patients did not present with lymphadenopathy 
(92.5%). Furthermore, in the majority of patients (approximately 40%), no cavities were seen 
on the chest X-ray. No significant differences in clinical characteristics were observed between 
patients processed according to protocols one, two and three (Table 6.5).  
 
Table 6.5 Patient demographics 
Variable Overall 
(n = 93) 
Protocol 1 
(n = 19) 
Protocol  2 
(n = 14) 
Protocol 3 
(n = 60) 
P-value 
Demographics      
Male, n (%) 59 (63.4) 13 (68.4) 10 (71.4) 36 (60.0) 0.6394 * 
Female, n (%) 34 (36.6) 6 (31.6) 4 (28.6) 24 (40.0)  
Age, yr, median 
(IQR) 
38.0 (32.0 – 
44.0) 
36.0 (33.5 – 43.5) 41.5 (31.0 – 46.8) 38.0 (31.8 – 44.0) 0.4395 † 
BMI      
Underweight, n (%) 21 (22.6) 2 (10.5) 3 (21.4) 16 (26.7) 0.1766 * 
Normal, n (%) 63 (67.7) 17 (89.5) 10 (71.4) 36 (60.0)  
Overweight, n (%) 9 (9.7) 0 (0.0) 1 (7.1) 8 (13.3)  
Median (IQR), kg/m2 
20.4 
(18.5 – 22.7) 
19.8 
(18.5 – 21.1) 
19.5 
(18.7-20.8) 
21.0 
(18.4 – 23.3) 
0.1894 † 
Immunology 
cells/mm3, median 
(IQR) 
130.5 
(61.5 – 274.3) 
104.0 
(51.5 – 181.0) 
271.0 
 (158.0 – 281.0) 
131.0 
(61.5 – 310.5) 
0.2320 † 
Sample      
Spot 78 (83.9) 16 (84.2) 12 (85.7) 50 (83.3) 0.9755 * 
Overnight 15 (16.1) 3 (15.8) 2 (14.3) 10 (16.7)  
Lung Pathology      
Lymphadenopathy 
Yes 
7 (7.5) 1 (5.3) 1 (7.1) 5 (8.3) 0.8989 * 
No 86 (92.5) 18 (94.7) 13 (92.9) 55 (91.7)  
Cavitation 
1 
37 (39.8) 8 (42.1) 7 (50.0) 22 (36.7) 0.1574 * 
2 24 (25.8) 8 (42.1) 4 (28.6) 12 (20.0)  
3 17 (18.3) 3 (15.8) 2 (14.3) 12 (20.0)  
ND 15 (16.1) 0 (0.0) 1 (7.1) 14 (23.3)  
Definition of abbreviations: n = number; yr = year; BMI = body mass index; IQR = interquartile range; ND = 
note done. For cavitation, 1: absent, 2: single or multiple cavities with diameter of <4cm in aggregate and 3: single 
or multiple cavities with diameter ≥4cm in aggregate. * P-values were determined using the chi-squared test for 
proportions with a 95% confidence interval; † P-values were determined using analysis of variance (ANOVA) 
with a 95% confidence interval.  
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6.5.2.1 Change in MGIT TTP in patient samples processed by protocol one 
6.5.2.1.1 Contamination 
Out of the initial 35 samples processed, data from 19 MGIT pairs were available for analysis. 
Reasons for the exclusion of 16 samples included a high contamination rate that was observed 
in the initial 22 samples processed, which suggests a possible non-specific resuscitative effect 
of the CF that may have stimulated the growth of other organisms present in the sputum. These 
organisms would ordinarily be suppressed by the addition of the antibiotic mixture, PANTA. 
Whilst AFB were observed in the ZN stain, the presence of a contaminant as detected by blood 
agar and the ZN stain made it impossible to include the MGIT TTP in the analysis as these 
tubes most likely flagged positive due to the presence of a contaminant as opposed to the M. 
tuberculosis. A contamination rate of 27.3% was observed in CF-supplemented MGIT tubes 
versus 9.1% in un-supplemented MGIT tubes. During each batch of processing, a PANTA 
control and CF control tube were included to ensure the sterility of the media (see section 6.4.2. 
and Appendix 5A). These quality controls were negative, suggesting that the contamination 
was most likely due to other micro-organisms in the sputum samples (ordinarily suppressed by 
PANTA) and not introduced during the preparation of the MGIT test and control tubes.  
 
To address the high rates of contamination, the concentration of PANTA added to both the test 
and the control MGIT tube was increased. The contamination rates decreased from 27.3% to 
11.6% in the CF- supplemented MGIT tube and from 9.1% to 3.8% in the un-supplemented 
MGIT tube. The improved contamination rates were just above and within the acceptable range 
that is given at up to 8% for liquid media, respectively (Siddiqi and Rüsch-Gerdes, 2006).  
 
6.5.2.1.2 Changes in MGIT time to positivity following CF supplementation 
To investigate the changes in TTP between the control and the CF- supplemented MGIT, the  
number of days and hours to positivity was converted to the total number of hours taken to flag 
positive for each tube (Total hours = χ number of days x 24 + χ number of hours).  These results 
are given in Figure 6.7 for each individual patient and overall data is summarized in Table 6.6. 
Next, the change in TTP was calculated using the following equation: ΔTTP = TTP control – 
TTP CF+. 
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Figure 6.7 The effect of culture filtrate on the time to positivity in clinical samples analysed in protocol 1. 
In the experimental group (red bars), mycobacterial growth indicator tubes (MGIT) were prepared to yield a 1:1 
ratio of culture filtrate (CF) to standard MGIT media (total volume 7 ml before the addition of PANTA 
reconstituted in OADC). The control MGIT (green bars) was cultured using standard laboratory procedures. The 
time to positivity (TTP) of the cultures are depicted in days. The dashed line indicates 20 days. 
  
Figure 6.7 illustrates the hours to positivity in control and CF+ supplemented MGIT tubes. For 
the most part, a marginal increase in TTP was observed following the addition of CF+ to the 
MGIT (observed in 13 out of 19 patients). The median increase in TTP in these 13 patients was 
40.0 hours (IQR: 20.0; 70.0). The remaining six patients showed a median decrease of 8.5 
(IQR: 5.8; 32.3) hours in TTP following supplementation with CF+. Interestingly, the patient 
who showed the most dramatic decrease in TTP (Patient 21) had a TTP of greater than 20 days 
in the control MGIT. The dotted horizontal line in Figure 6.7, denotes a TTP of greater than 20 
days. These results are in agreement with that reported in previous studies where a significant 
decrease in TTP can only be seen in a low starting inoculum load (Huang et al., 2014, Wu et 
al., 2008, Sun and Zhang, 1999) 
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Table 6.6 Culture growth in conventional and CF-supplemented MGITs 
Variable Control MGIT CF+ MGIT P- value 
Mean (SD), hours 246.6 (132.9) 254.1 (94.6) 0.0457 
Median (IQR), hours 238.0 (149.0 – 278.0) 244.0 (189.0 – 322.0)  
Minimum, hours 86.0 78.0  
Maximum, hours 703.0 474.0  
Definition of abbreviations: CF = culture filtrate; MGIT = mycobacterial growth indicator tube; TTP = time to 
positivity; SD = standard deviation and IQR = interquartile range. To determine statistical significance between 
the two groups, the Wilcoxon signed-ranks test was used with a 95% confidence interval. 
 
The overall TTP in the control versus CF+ supplemented MGIT tubes is given in Table 6.6. In 
the control MGIT, a median TTP of 238.0 hours (IQR: 149.0 – 278.0), equivalent to 9.9 days 
was obtained versus 244.0 hours (IQR: 189.0 – 322.0) in the CF+ MGIT, equivalent to 10.2 
days. This result was found to be significant (P = 0.0457; Wilcoxon signed-ranks test). The 
maximum number of hours was reduced in the CF- supplemented test, due to a decrease in TTP 
in MGIT cultures with low starting bacterial load. The result was in contrast to the predicted 
hypothesis and to further investigate it, DCTB were assessed in the corresponding samples. 
 
6.5.2.1.3 Are the changes in TTP associated with the presence of CF-dependent bacteria? 
To assess whether the increase/decrease in TTP following CF-supplementation was associated 
with CF-dependency, the resuscitation index (RI – MPN/CFU) for each patient was calculated 
using the following equation: log (CF+ MPN/CFU). Figure 6.8 indicates that the majority of 
patients analysed (17/19) harboured CF-dependent DCTB. Only two patients had no DCTB, 
where the CFU obtained was greater than the MPN. These results suggest that the observed 
changes in TTP are not associated with the stimulation of non-culturable organisms, but rather 
accelerate the growth where few M. tuberculosis bacilli are present. It is however noteworthy, 
that the sputum sample that benefitted the most from CF-supplementation in reducing TTP in 
MGIT, from patient 21, displayed the highest quantum of DCTB.  
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Figure 6.8 Distribution of CF-dependent bacteria in a cross sectional group of patients with tuberculosis. 
Individual patients with their relative proportions of CF-dependent bacteria are represented on the y-axis. CF-
dependency is reported using the resuscitation index (RI) using the following equation: RI = Log (CF+ 
MPN/CFU), reflected in red. In instances where no colony forming units (CFU) were obtained, a value of 1 was 
used as the denominator. In two patients (25 and 20), no CF-dependent bacteria were cultured in the most probable 
number assay (MPN), but CFUs were isolated on solid media.  
 
6.5.2.2. Change in MGIT TTP in patient samples processed by protocol two 
In contrast to the hypothesis, the addition of CF+ to the MGIT using the first protocol resulted 
in an overall increase in culture TTP. Conversely, bacterial load measured by the MPN and 
CFU assays illustrated that the majority of clinical samples tested contained a population of 
CF-dependent DCTB. To investigate these discrepancies two additional MGITs with a lower 
culture volume were included in the second protocol. In this case, the hypothesis was that a 
reduction in culture volume will enhance growth stimulatory effects of CF.  
Overall, the analysis of results from protocol two indicated an increase in TTP in all three of 
the modified MGITs when compared to the control which was unexpected, Figure 6.9 and 
Table 6.7. These changes in TTP were significant between the control and the CF+ and 2 mL 
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(CF+) MGITs, where the P-values obtained were 0.0125 and 0.0059, respectively. Hence, a 
reduction in total MGIT volume also resulted in an increase in TTP and a P-value of 0.0604 
was obtained.  
 
 
Figure 6.9 Overall culture time to positivity in control and modified mycobacterial growth indicator tubes. 
The time to positivity (TTP) obtained in the control mycobacterial growth indicator tube (MGIT), performed 
under standard laboratory conditions was compared to three modified MGITs in 14 patients. One MGIT TTP in 
the 2 ml (CF+) experiment was removed as this culture was contaminated (n = 13). Error bars represent medians 
and interquartile ranges. To determine statistical significance, the Wilcoxon signed-ranks test was used with a 
95% confidence interval. The control MGIT (green) was conducted using standard laboratory procedures. 
Modified MGITs consisted of the 2 ml [no culture filtrate (CF)] MGIT (teal), CF+ MGIT (containing 3.5 mL 
standard media and 3.5 mL CF) (red) and 2 mL (CF+) MGIT (containing 1mL standard media and 1 mL CF). An 
overall increase in MGIT TTP was obtained in all three experimental conditions, but the increases observed where 
not significant (P>0.5).  
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Table 6.7 Culture growth in control, CF-supplemented and reduced volume MGITs (protocol 2) 
Variable 
Control  
n = 14 
CF+ 
n = 14 
2 ml (no CF) 
n = 14 
2 ml (CF+) 
n = 13 
Mean TTP (SD), hours 347.4 (233.0) 387.0 (198.9) 467.1 (319.7) 425.2 (187.4) 
Median TTP (IQR), hours 
272.0  
(187.0 – 461.3) 
353.5 
 (248.3 – 484.5) 
320.0  
(253.3 – 808.3) 
467.0  
(261.0 – 553.5) 
Minimum TTP, hours 108.0 150.0 120.0 146.0 
Maximum TTP, hours 923.0 935.0 1008.0 766.0 
Definition of abbreviations: CF = culture filtrate; MGIT = mycobacterial growth indicator tube; TTP = time to 
positivity; SD = standard deviation and IQR = interquartile range 
 
In the case of protocol two, two patients had a control MGIT with recorded TTPs that were 
greater than 20 days. M. tuberculosis was not detected in either of these patients by the 
GeneXpert assay, both were smear negative and no bacteria were seen in the MPN or CFU 
assays.  The TTPs were 38 days and 30 days for patient 38 and 47, respectively. In patient 38, 
the TTP was reduced to 11 days in the 2 mL (CF+) tube; however, no AFB was observed on 
the ZN slide, TBc Id test was negative and growth was present on the blood agar, showing that 
the reduction in TTP was likely due to a contaminating organism. The TTP obtained from this 
MGIT was removed from analysis and only 13 samples were analysed in the 2 mL (CF+) 
experiment. Results from patient 47 showed that the TTP was reduced in both CF-
supplemented MGITs. A reduced TTP of 18 and 28 days was obtained in the 7 mL and 2 mL 
MGITs, respectively. The TBc ID test was positive, blood agar was negative and AFB was 
observed on the ZN slide. These data suggested again that the largest benefit in CF-
supplementation of MGIT culture should occur in samples with low bacterial loads. 
 
6.5.2.3 Change in MGIT TTP in patient samples processed by protocol three 
The results obtained from protocols one and two were unexpected, as the CF+ appeared to have 
an inhibitory effect on the growth of M. tuberculosis in the MGIT format. This was in contrast 
to observation in the MPN assay, where growth was stimulated. It was hypothesized that the 
addition of Tween 80 to the 7H9 media from which the CF+ was derived may have contributed 
to the increase in MGIT TTP (although this was not the case in axenic samples). To assess the 
overall changes in TTP between the control and three modified MGIT tubes in protocols one 
271 
 
and two, Tween 80 was removed from the 7H9 media that the M. tuberculosis H37Rv bacterial 
strains were grown in. The remaining 69 patients recruited were processed following protocol 
three. Here, the hypothesis was that removal of Tween 80 will result in clumping of bacteria, 
which would then settle to the bottom of the MGIT tube. The fluorescent dye in MGIT tubes 
is retained at the bottom of the tube in a silica matrix. If bacteria settle to the bottom quickly, 
this may enhance TTP in CF-supplemented tubes. Figure 6.10 and Table 6.8 illustrate that the 
addition of CF+ to the MGIT, in this format, decreases the overall TTP. In the control MGIT, a 
median TTP of 274.5 hours (IQR: 163.3 – 392.3), equivalent to 11.4 days was obtained versus 
250.0 hours (IQR: 177.0 – 370.0), equivalent to 10.4 days in the CF+ MGIT. This result was 
found to not be significant (P = 0.1558, Wilcoxon signed-ranks test). The result obtained using 
protocol three were in contrast to that obtained using protocols one and two, where the addition 
of CF+ to the MGIT resulted in an overall increase in TTP. It is speculated that while Tween 
80 may have had a beneficial effect in reducing the overall TTP in experiments conducted in 
axenic cultures, it a chaotropic agent and may have an inhibitory effect in M. tuberculosis 
populations derived from sputum samples. Indeed, studies have shown Tween 80 to be toxic 
to mycobacterial growth in the absence of bovine serum albumin (Meyers et al., 1998, Wayne, 
1994, Lyon et al., 1963, Masaki et al., 1990). Alternatively, since Tween 80 is a detergent, this 
may have prevented bacterial clumping leading to a distribution of bacterial organisms 
throughout the MGIT tube. This dispersal of organisms may have affected the gradient of 
oxygen depletion, causing reduced fluorescence and thus an increase in TTP. Further work is 
required to prove this hypothesis. A significant decrease in TTP was also obtained between the 
2 mL (no CF) and 2 mL (CF+) MGITs where the median TTP decreased from 273.3 hours (11.4 
days) to 263.0 hours (11.0 days) (P = 0.0105, Wilcoxon signed-ranks test). While the reduced 
volumes resulted in an overall increase in TTPs compared to the control, the benefit of CF+ in 
reducing TTP is observed between these two MGITs.  
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Figure 6.10 Overall time to positivity (hours) in the mycobacterial growth indicator tube (MGIT) with 
reduced volume and with and without culture filtrate supplementation. Scatterplots depicting mycobacterial 
growth indicator tube (MGIT) time to positivity (TTP) in the overall patient cohort was determined using three 
different experimental conditions in the MGIT. The control MGIT (green) was conducted using standard 
laboratory procedures. Modified MGITs consisted of the CF+ MGIT (red: containing 3.5 mL standard media and 
3.5 mL CF), 2 mL [no culture filtrate (CF)] MGIT (teal), and 2 mL (CF+) MGIT (orange: containing 1mL standard 
media and 1 mL CF). Error bars represent medians and interquartile ranges. To determine statistical significance, 
the Wilcoxon signed-ranks was used with a 95% confidence interval. Overall, a significant increase in mean TTP 
was observed between the control and 2 mL (CF+). A non-significant decrease in mean TTP was observed between 
the control and CF+ MGIT.  
 
Table 6.8 Culture growth in control, CF-supplemented and reduced volume MGIT tubes for all 
patients (protocol 3) 
Variable Control  CF
+ 2 mL (no CF) 2 ml (CF+) 
 n = 60 n = 59 n = 57 n = 57 
Mean (SD), hours 305.9 (178.9) 291.0 (174.7) 364.8 (266.9) 340.0 (243.2) 
Median (IQR), hours 
274.5 
(163.3 – 392.3) 
250.0 
(177.0 – 370.0) 
273.3 
 (170.5 – 467.0) 
263.0 
(175.5– 400.5) 
Minimum, hours 78.0 71.0 80.0 78.0 
Maximum, hours 1008.0 1008.0 1008.0 1008.0 
Definition of abbreviations: CF = culture filtrate; MGIT = mycobacterial growth indicator tube; TTP = time to 
positivity; SD = standard deviation and IQR = interquartile range 
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The association between culture volume and TTP was also investigated. In contrast to what 
was observed in axenic cultures (experiment 1), a reduction in the total MGIT volume (7 mL 
to 2 mL prior to the addition of PANTA/OADC) resulted in an overall increase in TTP, i.e. 
average 364.8 hours versus 305.9 hours. It was initially hypothesized that a reduction in MGIT 
volume may have resulted in a reduction in TTP due to increased quorum sensing. Indeed, this 
reduction in TTP was observed in axenic cultures, albeit marginal. It is suspected that this 
increase in TTP may be due to a reduction in the amount of nutrients available in reduced 
volume MGITs, particularly the 2mL (CF+) MGIT. Alternatively the increase in TTP may 
result from the increase in concentration of inhibitory factors present in sputum. The inhibitory 
activity of sputum against M. tuberculosis growth in liquid media has been previously 
described (Mukamolova et al., 2010). The observation that un-supplemented MPN counts (i.e. 
MPN no CF) were lower than CFUs led to hypothesis that cell-associated inhibitory activity is 
present in sputum. When M. tuberculosis H37Rv cultures were inoculated into low-positive 
patient sputum samples (rendered negative by freezing) and incubated at 4ºC for 24 hours, 
substantial growth inhibition was observed in the un-supplemented MPN assay (Mukamolova 
et al., 2010). Currently it is not known what factors are responsible for the observed growth 
inhibition; however, secreted leukocyte protease inhibitors on the surface of sputum derived 
M. tuberculosis cells have been suggested as a possible explanation (Gomez et al., 2009, 
Mukamolova et al., 2010).  
 
As the preliminary findings indicated that the greatest change in TTP was observed in patients 
with a low bacterial load, auramine smear grade was correlated with MGIT TTP obtained in 
both the control MGIT and the CF+ MGIT, Figure 6.11. Pearson’s and Spearman’s correlation 
analysis revealed a significant negative correlation between auramine staining score and 
control and CF+ MGIT TTP (rp = -0.6968 and -0.5342, P>0.0001; rs = -0.7926 and -0.6363, 
P>0.0001). Linear regression analysis revealed a poorer linear relationship between auramine 
staining score and CF+ MGIT TTP compared to the control MGIT TTP (R2 = 0.28 versus 0.48). 
Following CF-supplementation, regression analysis revealed a decreased in both the slope and 
the y-axis intercept.  The average TTP across staining scores was reduced in smear negative 
patients only (19.38 days versus 16.59 days). Following this observation, patients were 
stratified into auramine smear-positive and smear–negative. A total of 22/69 patients processed 
by protocol three were smear negative. Four of these patients had negative cultures in all four 
MGITs and were removed from analysis. In addition, contaminated cultures were removed 
from analysis.   
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Figure 6.11 Increase in culture positivity is correlated with decreasing smear grade. Culture positivity 
obtained using the Mycobacterial growth indicator tube (MGIT) was correlated with auramine smear grade. Time 
to positivity was plotted for both the control (green) and culture filtrate (CF) supplemented (red) MGIT. P+++, 
P++, P+, scanty and negative smear grades were quantified as 4,3,2,1 and 0 respectively. The average TTP of 
P+++, P++, P+, scanty and negative auramine staining scores was 6.48, 8.96, 14.66, 14.45 and 19.38 days in the 
control MGITs, respectively. The average TTP of P+++, P++, P+, scanty and negative auramine staining scores 
was 7.00, 9,47, 16.49, 14.56 and 16.59 days in the CF+ MGITs, respectively A significant negative linear 
relationship was obtained between auramine smear grade and time to positivity in the control and CF+ MGIT 
systems (R2 = 0.48 and 0.28, respectively. Pearson’s and Spearman’s correlation, P<0.0001, 95% confidence 
interval).  
 
In smear negative patients, the TTP was reduced in the CF+ MGIT when compared to the 
control with median TTPs of 364.0 and 406.0 hours, respectively (P = 0.2788, Wilcoxon 
signed-ranks test). In terms of the reduced volume MGIT culture, TTP was non-significantly 
reduced in the 2 mL (CF+) MGIT when compared to the 2 mL (no CF) MGIT, with median 
TTPs of 396 versus 529 hours, respectively (P = 0.7869, Wilcoxon signed-ranks test).  
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Table 6.9 Culture growth in control, culture filtrate-supplemented and reduced volume 
MGITs in smear negative patients 
Variable Control  CF+ MGIT 2 mL (no CF) 2 mL (CF+) 
 n = 18 n = 17 n = 16 n = 15 
Mean (SD), hours 465.0 (211.2) 398.2 (224.7) 581.7 (294.2) 491.6 (276.7) 
Median  
(IQR), hours 
406.0 
(346.3 – 542.5) 
364.0  
(233.0 – 542.5) 
529.0 
(325.0 – 949.0) 
396.0  
(263.0 – 617.0) 
Minimum, hours 214.0 177.0 226.0 154.0 
Maximum, hours 1008.0 1008.0 1008.0 1008.0 
Definition of abbreviations: CF = culture filtrate; MGIT = mycobacterial growth indicator tube; TTP = time to 
positivity; SD = standard deviation and IQR = interquartile range 
 
To further investigate the effect CF+ in reducing MGIT TTP in samples with a low bacterial 
load,  five patients that qualitatively had a ‘low’ Gene Xpert report (Ct value range: 22 to 28) 
were subsequently removed from analysis. Therefore, additional analysis was conducted on 
smear negative individuals who had ‘very low’ GeneXpert CT (i.e. cycle threshold >28) values 
and on samples where M. tuberculosis was not detected using the GeneXert. A non-significant 
decrease in TTP was observed in the 7 mL and 2 mL supplemented MGITs (median TTP: 407.5 
and 468.0 hours) when compared to the control and 2 mL (no CF) MGITs (median TTP: 480.0 
and 613.0 hours) (P = 0.1968 and 0.1309, Wilcoxon signed-ranks test), Table 6.10 and Figure 
6.12A. In one patient, the addition of CF+ to both the 7 mL and 2 ml MGITs showed an increase 
in TTP compared to the respective controls (Figure 6.13 and Table 6.11). As this effect was in 
contrast to what was observed in the other samples, it was suspected that a laboratory error may 
have occurred and these tubes may have been mislabelled. When this patient was removed 
from analysis, the decrease in TTP between the control and CF+ MGIT in both 7 mL and 2 mL 
MGITs approached significance (Figure 6.12 B; P = 0.0635 and 0.0742, Wilcoxon signed-
ranks test).  
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Figure 6.12 Time to positivity in control and modified mycobacterial growth indicator tubes in smear 
negative and GeneXpert very low/negative patients. Scatterplots depicting MGIT time to positivity (TTP) in 
patients that were both smear negative and had a very low or negative Gene Xpert test was determined using four 
different experimental conditions in the Mycobacterial growth indicator tube (MGIT). (A) Data includes patient 
83. (B) Patient 83 was removed from analysis. Error bars represent medians and interquartile ranges. To determine 
statistical significance, the Wilcoxon signed-ranks test was used with a 95% confidence interval. The control 
MGIT (green) was conducted using standard laboratory procedures. For the modified MGITs, one standard 
volume MGIT (7 mL) containing a 1:1 ratio of MGIT media and culture filtrate (CF) was prepared (red). The 
volumes of two MGITs were reduced to 2 mL, one with no CF (teal) and the other containing a 1:1 ratio of MGIT 
media and CF (orange). The dotted line separates MGITs with and without CF-supplementation. Significance 
with a 95% confidence interval is depicted in bold (P<0.05).  
 
Table 6.10 Culture growth in control, culture filtrate-supplemented and reduced volume MGIT 
in smear negative patients with GeneXpert very low/M. tuberculosis not detected.  
Variable Control CF+ MGIT 2 mL (no CF) 2 ml (CF+) 
 n = 13 n = 12 n = 13 n = 11 
Mean (SD), hours 
536.8 (203.7) 445.8 (250.9) 673.3 (274.7) 523.3 (305.8) 
Median (IQR), 
hours 
480.0 
(386.5– 680.0) 
407.5 
(266.8 – 469.5) 
613.0 
(417.0 – 1008.0) 
468.0 
(275.8 – 810.5) 
Minimum, hours 
329.0 177.0 319.0 145.0 
Maximum, hours 
1008.0 1008.0 1008.0 1008.0 
Definition of abbreviations: CF = culture filtrate; MGIT = mycobacterial growth indicator tube; TTP = time to 
positivity; SD = standard deviation and IQR = interquartile range. Data includes patient MP83.  
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Figure 6.13 The effect of the addition of culture filtrate on the time to positivity in smear negative and Gene 
Xpert very low/negative clinical samples.  In the experimental group, MGIT tubes were prepared to yield a 1:1 
ratio of culture filtrate (CF) to standard MGIT media (total volume 7 mL before the addition of PANTA 
reconstituted in OADC). The control MGIT (green bars) was cultured using standard laboratory procedures. The 
time to positivity (TTP) of the cultures are depicted in days. The dashed line indicates 20 days. * Patient 105: the 
TTP from the 2 mL CF+ MGIT (red) is represented relative to the control. All other samples show the control and 
CF+ MGIT pairs.  
 
Figure 6.13 illustrate the TTP obtained in the BACTEC 960 culture system in control and CF+ 
MGITs (both 7 mL MGITs, with the exception of 105 where the result from the 2 mL CF+ 
MGIT is used) in 12 smear negative patients with GeneXpert results that were qualitatively 
very low or M. tuberculosis negative. For patient 105, the 2 mL CF+ TTP was used as the CF+ 
MGIT was negative after 42 days incubation. This MGIT was positive for MTBC using the 
TBc ID test and no contamination was present on the blood agar plate. Patients showing the 
greatest decrease in TTP following CF-supplementation included patients 74, 75, 82, 104, 105 
and 106. As previously discussed, the addition of CF+ increased the TTP in patient 83 which 
may have possibly occurred due to a laboratory error.  
Next the association between change in TTP and the presence of DCTB was investigated 
(Table 6.11, page 276). Patients showing the greatest change in TTP (i.e. 74, 75, 82, 83, 104, 
105 and 106) all had very low Gene Xpert results (i.e. CT value >28) or M. tuberculosis was 
not detected using this assay. In addition, the majority of these patients had no CFUs, and the 
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three that did had less than 10 platable bacilli per mL. Furthermore, the RI was calculated to 
determine the quantum of resuscitatable bacteria in the sputum sample, calculated as log (CF+ 
MPN/CFU). In most cases, the patients showing the greatest culture acceleration following 
supplementation of the MGIT with CF+ were negative for both the MPN and CFU assay. In 
three patients, however, the calculated RI was below 1, indicating the presence of very few CF+ 
dependent bacilli. In one patient (106) the addition of CF to the MGIT was able to stimulate 
the growth of M. tuberculosis and yield a positive MGIT culture where the control sample was 
negative. The GeneXpert and MPN for this patient was negative, but 1 single M. tuberculosis 
colony emerged on one of the two neat solid media plates, predicting approximately 5 bacilli 
per mL of sputum.  
In contrast, smear negative patients that did not show a drastic change in TTP (i.e. 55, 56, 72, 
88, 107, 110, 113, 115 and 118) generally harboured more than 35 bacteria per mL as 
determined by CFU (with the exception of patient 113). DCTB were also present in patients 
where an increase in TTP was obtained following CF-supplementation (110, 115 and 118). 
These findings suggest that growth factors present in CF+ are more likely to have an effect in 
the BACTEC MGIT 960 system by accelerating the growth of few viable organisms present in 
sputum as opposed to resuscitating non-culturable organisms.  
To further assess whether the reduced TTP observed in the CF+ MGIT was due to accelerating 
the growth of few viable organisms and not from resuscitation of non-culturable bacilli, weekly 
growth in CF-supplemented and un-supplemented MPN assays from 31 patients was assessed 
over six weeks. After one week’s incubation at 37 °C, the average log bacterial growth in the 
CF+ assay was 3.2 versus log 1.3 in the un-supplemented MPN assay. After two weeks, the 
quantum of organisms in the CF+ and un-supplemented MPN assays was log 7.7 and log 3.5, 
respectively. By the third week, on average growth in the CF+ MPN had reached log 8.2 versus 
log 7.7 in the un-supplemented assays. At the end of the six week incubation period, the growth 
in the un-supplemented MPN assay was similar to that obtained in the CF+ MPN assay (log 8.2 
versus log 8.1). It is however important to acknowledge that interpretation of these results are 
limited due to the upper limit of log 8.7 in the MPN assay; Nevertheless, these results show an 
accelerated growth in the CF-supplemented MPN compared to the un-supplement MPN assay 
during the first few weeks of growth.  
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Table 6.11 Change in MGIT TTP is associated with low sputum bacterial load rather 
than the presence of differentially culturable tubercle bacteria in smear negative patients 
Patient 
No. 
ΔTTP 
(hours) 
GeneXpert Log MPN 
Log 
CFU 
Log RI 
  Qualitative 
Ct value 
(Average) 
CF+ 
Media 
(No CF) 
  
106 595 MTB ND NA 0 0 0.70 No DCTB 
75 529 Very low 31.5 0 0 0 0 
105* 391 MTB ND NA 0.85 0.85 0 0.85 
82 221 Very low 30.98 0 0 0 0 
74 196 MTB ND NA 0 0 0 0 
104 170 MTB ND NA 1.25 0 1.00 0.25 
72 21 MTB ND NA 0 0 1.54 No DCTB 
88 21 low 23.58 3.26 0 3.02 0.23 
57 12 Very low 29.98 0 0 C NA 
113 12 Very low 31.46 0 0 1.00 No DCTB 
56 11 low 27.20 0 0 4.06 No DCTB 
107 1 MTB ND NA 1.93 1.46 1.78 0.15 
55 -6 low 25.58 0 0 3.78 No DCTB 
110 -8 low 24.24 5.49 4.34 4.29 1.20 
115 -27 low 23.86 2.66 0 2.06 0.60 
118 -62 Very low 29.78 2,26 0 2,06 0.30  
83 -386 MTB ND NA 0.85 0 0.70 0.15 
Definition of abbreviations: MPN = most probable number; CFU = colony forming units; CT = cycle threshold; 
CF = culture filtrate; MTB ND = M. tuberculosis not detected; NA = not applicable; DCTB = differentially 
culturable tubercle bacilli. Negative values indicate an increase in MGIT TTP following CF-supplementation of 
the MGIT. Data are arranged according to ΔTTP. * The change in TTP for patient 105 was calculated using the 2 
mL CF+ result.  
 
 
Figure 6.14 Average weekly bacterial growth in culture filtrate-supplemented and un-supplemented most 
probable number assays in patient samples. The average weekly growth in culture filtrate (CF)-supplemented 
(red) and un-supplemented MPN assays (green) from 31 patients was recorded. MPN plates were incubated at 37 
ºC and scored every seven days for up to six weeks. More bacteria were isolated in the CF-supplemented MPN 
assays during the first three weeks of incubation.  
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6.6 DISCUSSION 
In resource poor countries where TB is endemic, AFB smear microscopy is widely utilised 
because it is affordable, easy to perform and has a fast turnaround. While AFB smear-
microscopy can be specific, its sensitivity is variable (Ryu, 2015). Furthermore, the high burden 
of HIV/AIDS has led to an increase in the number of smear-negative pulmonary TB cases, with 
frequencies of 24 to 61% reported (Getahun et al., 2007). These figures illustrate that smear-
negative patients represent a significant caseload of the overall global TB burden (Siddiqi et 
al., 2003). It is generally accepted that individuals who are smear-positive are more infectious 
than those that are smear-negative (Hernandez-Garduno et al., 2004). For this reason, the 
diagnosis and treatment of smear-positive individuals is commonly seen as priority. However 
patients who are smear-negative are also capable of transmitting TB disease and are associated 
with at least one-sixth of culture-positive TB episodes (Bicmen et al., 2011, Behr et al., 1999, 
Hernandez-Garduno et al., 2004, Tostmann et al., 2008, Campos et al., 2016). When compared 
to smear-positive individuals, patients who are smear-negative or have extra-pulmonary TB 
disease are more likely to experience treatment delays, hospitalisation and poorer treatment 
outcomes (Whitehorn et al., 2010, Hargreaves et al., 2001).  
Sputum culture remains the gold standard for the diagnosis of TB disease and is 100-fold more 
sensitive than smear-microscopy (Caulfield and Wengenack, 2016). In addition, the material 
obtained from positive culture can be used for downstream DST. As liquid culture is faster than 
culture on solid media, it is generally preferred as it improves patient management and clinical 
outcomes (Moreira et al., 2015). With regards to growth of clinical M. tuberculosis strains, on 
average 10 days are required for culture positivity in liquid culture compared to 20 to 25 days 
on solid media (Caulfield and Wengenack, 2016, Pfyffer et al., 1997, Cruciani et al., 2004, 
Tortoli et al., 1999, Hanna et al., 1999). For these reasons, automated liquid culture systems 
such as the BACTEC MGIT 960 are widely employed for TB culture and DST (Cruciani et al., 
2004, Dheda et al., 2016). MGIT TTP has been shown to correlate directly with bacterial load 
(as determined by CFUs on solid media) (Bark et al., 2011) as well as smear grade (Olaru et 
al., 2014). Whilst the BACTEC MGIT 960 instrument has a high sensitivity for the recovery 
of mycobacteria (Hanna et al., 1999), recent reports have shown that in few cases this system 
fails to detect mycobacteria at the end of the 42 day incubation protocol (Mahomed et al., 2017, 
Pang et al., 2016). These false negatives have been attributed to the granular growth pattern of 
the organism which may result in oxygen consumption remaining below the detection threshold 
(Mahomed et al., 2017). The sputum decontamination procedure has also been proposed as a 
281 
 
stress that may damage certain organisms resulting in a false negative result in the MGIT (Pang 
et al., 2016). The above factors highlight the urgent need to develop more timeous and sensitive 
culture methods to diagnose M. tuberculosis. In this study, the addition of CF+ to the BACTEC 
MGIT 960 on accelerating the TTP and increasing the sensitivity in HIV-positive individuals 
was investigated.   
The most noteworthy finding of this study was that the addition of CF+ (derived from M. 
tuberculosis cultures grown in the absence of the detergent, Tween 80), to the MGIT BACTEC 
960 system decreased the TTP in smear-negative patients with pulmonary TB. The effect was 
most prominent in patients that had very low bacterial loads as detected by GeneXpert, or where 
M. tuberculosis was below the limit of detection. Indeed, the majority of patients that benefited 
from the addition of CF+, had less than 10 bacteria per mL sputum (as determined by CFU 
assays) and were negative in CF-supplemented and un-supplemented MPN assays. As, the limit 
of detection of widely used nucleic acid amplification tests, such as the Gene Xpert is 131 
bacteria per mL (Helb et al., 2010), our findings suggest that this method of culture may be 
particularly useful in identifying patients with disseminated TB disease where bacterial loads 
in sputum are extremely low and cannot be detected using current molecular methods. As the 
decrease in TTP did not correlate with the presence of DCTB (as detected by the MPN assay), 
our data further suggest that we have created an acceleration growth model as opposed to a 
resuscitative model, or perhaps a combination of both.  
 
In one patient, the sputum was negative for all routine diagnostic tests performed (i.e. smear 
negative, culture negative and GeneXpert negative); however, M. tuberculosis was cultured in 
the CF+ MGIT after 17 days incubation. In addition, 1 colony emerged on solid 7H11 media. 
In terms of quality control, the blood agar was negative showing an absence of bacterial 
contamination and the MGIT TBc ID test was positive. This phenomenon has been previously 
described in a case study where an EP specimen was negative by standard laboratory methods, 
but positive following supplementation of the MPN assay with CF+ (O'Connor et al., 2015).  
 
Another noteworthy finding of this study was that a reduction in culture volume resulted in a 
significant decrease in bacterial growth as evident by an increase in MGIT TTP.  It was 
hypothesized that the decrease in culture volume would result in an increase in the 
concentration of growth inhibitory factors present in sputum, possibly explaining this. 
Alternatively, the concentration of residual sodium hydroxide from the decontamination 
282 
 
procedure may have affected bacterial growth. A decrease in TTP between the 2 mL no CF and 
2 mL (CF+) tube illustrates that factors present in CF+ may be able to promote the growth of 
bacterial organisms in the presence of these inhibitory substances or rescue damaged 
organisms. These findings are in agreement with previous work (Mukamolova et al., 2010). It 
was also found that the addition of Tween 80 had a detrimental effect on TTP and removal of 
this detergent from bacterial cultures from which CF+ was derived improved bacterial growth. 
This is an important methodological finding for future work investigating the effect of CF+ on 
TTP.  
 
Our study had several limitations. The first was that CF+ is likely to contain other molecules 
(other than Rpfs) that may stimulate or inhibit the growth of M. tuberculosis. Further work 
investigating the effect of recombinant Rpf on reducing TTP in a HIV-positive, smear-negative 
population may prove to have an added benefit in stimulating the growth of M. tuberculosis. 
However, the literature investigating the effect of recombinant Rpf on M. tuberculosis growth 
is limited.  The work carried out by Mukamolova et al. (2010) probably provided the strongest 
evidence, where RpfE was effective at stimulating growth in five out of 25 patients studied. 
While RpfB was reported to be effective, the data was not provided. Furthermore, the effect of 
recombinant RpfB and RpfE was not reported in the other 20 patients. The authors also reported 
that since CF was the most potent, it was used more extensively. Huang et al (2014) added 20 
nM recombinant RpfB and RpfE to the BACTEC MGIT 960 to investigate the effect on TTP 
in 15 patients. Overall, the addition of these proteins was found to improve TTP in only five/12 
patient samples. These samples required long culture times to flag positive using standard 
procedures.  For these reasons, the decrease in TTP cannot solely be attributed to Rpfs and 
further work investigating the responsible growth stimulatory compounds in CF+ is required 
 
 Furthermore, our preliminary analysis indicated an increase in bacterial contamination in the 
CF-supplemented MGITs most likely due to a non-specific resuscitative effect of Rpfs or other 
molecules present in CF+. To address this, we increased the PANTA concentration to twice the 
original concentration used in standard laboratory practice in both the control (2 mL and 7mL) 
and CF-supplemented MGITs. A main concern was that an increase in the antibiotic 
concentration would decrease the recovery and impact the growth of M. tuberculosis, although 
previous reports have shown that the use of MGIT with 2X PANTA reduced overall 
contamination rates without affecting the culture yield (Peres et al., 2011). In addition, the 
baseline oxygen concentration may have varied between the control and modified MGITs. As 
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the BACTEC MGIT 960 measures growth via oxygen fluorescence-quenching technology, 
these changes may have accounted for the decrease in TTP. For example, a lower baseline 
oxygen concentration may have been present in the CF-supplemented media due to the growth 
of the laboratory strain H37Rv in the preparation of CF+. However, the drastic decrease in TTP 
in patient samples with low bacterial load in the CF+ MGIT does not support this hypothesis. 
The use of recombinant Rpf (or other recombinant identified growth factors) is important in 
this regard as it would also result in minimal modification of the MGIT and not affect the 
baseline oxygen concentration.  
 
CONCLUSION/ FUTURE RESEARCH 
The results indicate a promising and potential use for CF-supplementation in enhancing the 
culture detection rate and sensitivity of the currently used culture diagnostic methods such as 
the BACTEC MGIT 960 assay. Furthermore, the culture-based detection can be enhanced in 
one of the most vulnerable patient populations (i.e. HIV-positive patients with paucibacillary 
disease) where TB is difficult to diagnose and subsequently treat. Current TB diagnostic 
algorithms may therefore benefit by the addition of specialized culture whereby a MGIT 
containing CF+ is included for patients that are auramine smear-negative. Research exploring 
the potential use of CF+ and recombinant Rpfs is required for a greater cohort of patients with 
smear negative TB disease where molecular diagnostic tests may not be adequately sensitive 
to diagnose TB in these patients. Also, the possible application of specialist culture to the 
timeous diagnosis of TB in patients with sub-clinical disease will have positive outcomes for 
both the individual patient and reducing the transmission of disease within the community. In 
terms of feasibility, methods to simplify the addition of CF+ or recombinant Rpfs to the MGIT 
is required so that it can be performed routinely in most laboratories. This may include working 
with biomedical/pharmaceutical companies to commercialise the product, i.e. lyophilized CF 
that can be added to the MGIT during set-up or producing MGITs that already contain growth 
stimulatory molecules.  
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APPENDIX 6A: CULTURE FILTRATE AND MEDIA QUALITY CONTROL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date Processed PCR
RV Media H37Rv (CF) Media H37Rv (strain) Control CF+ H37Rv
17.06.2016 Contam Contam Contam Contam H37Rv ND ND yes
23.06.2016 NG NG NG NG H37Rv ND ND yes
30.06.2016 NG NG NG NG H37Rv ND ND yes
07.07.2016 Contam Contam Pink Cols Pink Cols H37Rv Negative (CLS) Negative (CLS) yes
14.07.2016 NG NG NG NG H37Rv Negative (CLS) Negative (CLS) yes
28.07.2016 NG NG NG NG H37Rv Negative (CLS) Negative (CLS) yes
06.08.2016 NG NG NG NG H37Rv Negative (CLS) Negative (CLS) yes
11.08.2016 NG NG NG NG H37Rv Negative (CLS) Negative (CLS) yes
18.08.2016 NG NG NG NG H37Rv Negative (CLS) Negative (CLS) yes
25.08.2016 NG NG NG NG H37Rv Negative (CLS) Negative (CLS) yes
31.08.2016 NG NG NG NG H37Rv Negative (CLS) Negative (CLS) yes 
08.09.2016 NG NG NG NG H37Rv Negative (CLS) Negative (CLS) yes
15.09.2016 NG NG NG NG H37Rv Negative (CLS) Negative (CLS) ND
22.09.2016 NG NG NG NG H37Rv Negative (CLS) Negative (CLS) ND
06.10.2016 NG NG NG NG H37Rv Negative Negative ND
13.10.2016 NG NG NG NG H37Rv Negative Negative ND
21.10.2016 NG NG NG NG Bacterial Contam Negative Negative ND
27.10.2016 NG NG NG NG H37Rv ND † ND † ND
10.11.2016 NG NG NG NG H37Rv Negative Negative ND
17.11.2016 NG NG NG NG H37Rv Negative Positive * ND
24.11.2016 NG NG NG NG H37Rv Negative Negative ND
01.12.2016 NG NG NG NG H37Rv Negative Negative ND
09.12.2016 NG NG NG NG H37Rv Negative Negative ND
19.01.2017 NG NG NG NG H37Rv Negative Negative ND
26.01.2017 NG NG NG NG H37Rv Negative Negative ND
03.02.2017 NG NG NG NG H37Rv Negative Negative ND
18.02.2017 NG NG NG NG H37Rv Negative Negative ND
23.02.2017 NG NG NG NG H37Rv Negative Negative ND
ND: not done. H37Rv strain was confirmed by PCR analysis from 07/06/2016 to 08/09/2016.
† Not enough culture filtrate (CF) to set up controls; Aliquots of RV CF and media incubated to ensure sterility
* Results included as RV  CF aliquotes were clean. In addition MGIT TTP did not vary between control MGITs and CF+ supplemented MGITs
Liquid 7H11 MGIT
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FINAL SUMMARY 
Key findings:  
In this thesis, DCTB were characterized in sputum samples from patients with active, drug-
susceptible TB disease. In line with previous observations, four distinct populations of DCTB 
were observed in treatment naïve patients (chapter 3). In most patients, mixed populations of 
both CF-dependent and Rpf-independent bacteria emerged suggesting that stimulatory 
molecules, other than Rpfs, are involved in the resuscitative or growth stimulatory process. 
Furthermore, sputum samples obtained from HIV-negative individuals had a higher quantum 
of DCTB than HIV-positive patients, suggesting a possible role for host immunity in generating 
DCTB. In contrast to previous reports, CD4 T-cell count was not correlated with DCTB.  To 
assess how DCTB respond to chemotherapy, patients were followed-up throughout their 
treatment. Four patterns of DCTB decline were described, namely (i) drug-tolerant populations 
that resists decline during early treatment, (ii) populations that accumulate during early 
treatment, (iii) populations that decline rapidly following the onset of treatment and (iv) 
populations exhibiting an atypical DCTB presentation. Following treatment completion, 
DCTB were cultured in two thirds of the patient population, suggesting that complete 
bacteriological sterilization of the lung was not achieved. Whether or not these residual 
organisms can emerge later to cause relapse disease requires further investigation.  
The presence of DCTB (cultured in the MPN assay) was correlated with existing TB culture 
diagnostic tests, including CFU and MGIT. The MPN was found to directly correlate with both 
these assays in axenic cultures and in patient samples (when supplemented with CF). 
Furthermore, in patient samples the MPN assay correlated better with CFU when compared to 
the MGIT in samples with a low bacterial burden and at later treatment time-points. These 
observations suggest that the MPN assay may be a useful tool to monitor the sterilizing effect 
of potential new drugs on DCTB populations. In a separate patient cohort, the addition of CF 
to the MGIT was found to have a beneficial effect on reducing the turn-around-time in HIV-
positive, smear-negative patient samples. In contrast to the hypothesis, a reduction in MGIT 
TTP was not associated with the presence of DCTB. As dramatic changes in TTP were 
observed in patients with a low bacillary burden, it is postulated that the addition of CF to the 
MGIT may accelerate the growth of few viable organisms rather than resuscitate non-culturable 
organisms.  
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Implications: 
The quantification and monitoring of how DCTB respond to treatment has numerous clinical 
implications. For instance, DCTB may serve as a novel biomarker for treatment response and 
possible relapse disease. In addition, patients that are ‘DCTB positive’ at the end of treatment 
could possibly be candidates for isoniazid preventative therapy to prevent subsequent relapse.  
The use of CF to unmask DCTB populations in the MPN assay has potential implications in 
EBA studies to monitor the sterilising effect of new anti-TB compounds on DCTB populations. 
The addition of CF to routinely used diagnostic culture assays, such as the BACTEC MGIT 
960, has implications in TB diagnosis, treatment monitoring and DST. The results indicated 
that the addition of CF was particularly effective in patient sputum samples with a low bacillary 
load. Studies to optimise the use of CF, or recombinant stimulatory molecules, in routine 
culture assays would be an important technical advancement in reducing the time required to 
yield a positive culture. The addition of CF to the MGIT would also be beneficial in terms of 
shortening the time required for DST. This would result in patients receiving prompt and 
appropriate TB treatment, thus reducing transmission within the community.  
 
Quo Vadis: 
Mechanistic studies are required to identify the relevant stimulatory molecules in CF as well 
as to provide a more in-depth understanding of bacterial culturability. In terms of clinical work 
the following questions still need to be answered: 
1. What is the link between residual DCTB at the end of treatment and relapse disease?  
2. Are DCTB more likely to present in patients with a long history of disease (long 
standing latent infection) compared to patients who rapidly progress to active TB 
disease? 
3. Are DCTB associated with certain M. tuberculosis strain types? 
4. Which host factors are responsible for the formation of DCTB? 
5. Are DCTB influenced by blood and sputum drug concentration levels? To investigate 
this pharmokinetic studies using HPLC or mass spectrophotometry are required to 
analyse drug concentration levels.  
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One sentence summary: This review provides a synthesis on the prevalence of mixed tuberculosis infection, which can provide insight on transmission
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ABSTRACT
Tuberculosis (TB) disease can be characterized by genotypic and phenotypic complexity in Mycobacterium tuberculosis bacilli
within a single patient. This microbiological heterogeneity has become an area of intense study due its perceived
importance in drug tolerance, drug resistance and as a surrogate measure of transmission rates. This review presents a
descriptive analysis of research describing the prevalence of mixed-strain TB infections in geographically distinct locations.
Despite significant variation in disease burden and a rampant human immunodeficiency virus (HIV)-TB co-epidemic, there
was no difference in the prevalence range of mixed infections reported in African countries when compared to the rest of
the world. The occurrence of recurrent TB was associated with a higher prevalence of mixed-strain infections, but this
difference was not reported as statistically significant. These interpretations were limited by differences in the design and
overall size of the studies assessed. Factors such as sputum quality, culture media, number of repeated culture steps,
molecular typing methods and HIV-infection status can affect the detection of mixed-strain infection. It is recommended
that future clinical studies should focus on settings with varying TB burdens, with a common sample processing protocol to
gain further insight into these phenomena and develop novel transmission blocking strategies.
Keywords: tuberculosis; recurrent disease; relapse; re-infection; mixed infections; heteroresistance
INTRODUCTION
Efforts to contain tuberculosis (TB) with combination
chemotherapy for the past 50 years have met with mixed
success as this disease remains a global public health concern
and is now the leading cause of death due to an infectious
bacterial agent (WHO 2016a). Current TB treatment is char-
acterized by a variety of disease outcomes including clinical
cure, treatment failure and the development of latent infection,
with the latter two carrying the risk of subsequent relapse
disease. Chemotherapy of TB is complex and while ultimately
aimed at eliminating tubercle bacilli, treatment can also result
in the selection of various forms of antimicrobial resistance.
This can lead to emergence of one dominant resistant bacterial
genotype or the appearance of heteroresistance, comprising
mixtures of drug-susceptible and drug-resistant organisms.
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This complexity in bacterial populations, which can occur in
a single patient, presents unique challenges and hampers the
rapid clearance of organisms during chemotherapy. In addition,
differences in bacterial growth states can further contribute to
the establishment of drug-tolerant populations as chemothera-
peutic agents are generally targeted at metabolic pathways that
are a hallmark of active bacterial replication (Zumla, Nahid and
Cole 2013; Kana et al. 2014). This is evidenced by the demon-
stration that sputum from TB patients contains a mixture
of actively replicating and differentially culturable tubercle
bacteria (DCTB), the latter displaying tolerance to first-line TB
chemotherapeutics (Mukamolova et al. 2010; Chengalroyen et al.
2016; Loraine et al. 2016). It is proposed that these drug-tolerant
populations provide the framework for the selection and emer-
gence of genetically stable drug-resistant strains (Loraine et al.
2016). In view of this, the genomic plasticity and resulting strain
complexity of Mycobacterium tuberculosis populations during
infection is a key feature of the success of this deadly pathogen
and merits further consideration. As a result, the complexity
in M. tuberculosis population dynamics in human populations
has become the focus of intense study. The advent of molecular
typing methods and next-generation sequencing technologies
has allowed for the genetic characterization of M. tuberculosis
strains at a resolution that was previously not possible (Gan
et al. 2016; Dheda et al. 2017).
DNA fingerprinting technologies, developed over the past
two decades, have been widely used to study the diversity of
M. tuberculosis strains and to investigate episodes of exogenous
re-infection and relapse (van Rie et al. 1999; Bandera et al. 2001;
Caminero et al. 2001), as well as the presence of heteroresis-
tance in sputum isolates (Kaplan et al. 2003; Post et al. 2004;
Shamputa et al. 2004), and the occurrence of mixed M. tuber-
culosis strain infections (Warren et al. 2004; van Rie et al. 2005;
Shamputa et al. 2006; Cohen et al. 2011). Prior to these advances,
TB disease was assumed to occur as a consequence of infec-
tion with a single M. tuberculosis strain, this event was thought
to confer a measure of protection against infection with a sec-
ondary strain (Stead 1967). Recurrence of the disease was un-
derstood to be the result of endogenous re-activation of a non-
replicating, immune-subversive variant of the strain that was
responsible for the original disease episode (Stead 1967). In
this context, the importance of re-infection remained relatively
unexplored. However, molecular-based genotyping has subse-
quently demonstrated that exogenous re-infection with differ-
ent M. tuberculosis strains does indeed occur in both high- and
low-incidence settings, thus confirming that previous infection
does not provide protection against subsequent infection (Small
et al. 1993; van Rie et al. 1999; Sonnenberg et al. 2001; Kruuner
et al. 2002; Andrews et al. 2008; Charalambous et al. 2008). Fur-
thermore, studies have shown that many TB cases occur as a
result of recent transmission and depending on setting; these
transmission events are likely to take place outside of the house-
hold within the community (Verver et al. 2004; Dheda et al. 2017).
High rates of re-infection have important implications for TB
control strategies and highlight the need to reduce TB transmis-
sion in the community, together with the importance of early di-
agnosis, coupled with treatment initiation. TB disease due to re-
cent transmission and re-infection has become an increasingly
relevant topic of study in the era of human immunodeficiency
virus (HIV) infection, as the resulting reduced immunity may
result in vulnerable populations becoming increasingly suscep-
tible to infection or re-infection with M. tuberculosis. Moreover,
increased transmission in communitieswith a diversity of circu-
latingM. tuberculosis strains can lead to mixed-strain infections,
which have been documented in many distinct geographical lo-
cations, emphasizing the importance of interventions that limit
or interrupt transmission. The complex environment of the lung
as a site for TB disease, combined with sustained exposure to
tubercle bacilli in high-TB-endemic settings, enhances the oc-
currence ofmixed-strain infections, which have been associated
with unfavorable treatment outcomes (Theisen et al. 1995; Nie-
mann et al. 2000; Baldeviano-Vidalon et al. 2005; van Rie et al.
2005; Kamakoli et al. 2017). Given the emerging importance of
phenotypic diversity in bacterial populations during TB patho-
genesis, this review takes a retrospective view of published stud-
ies that report the prevalence of mixed-strain infections within
select populations. The prevalence of these phenomena was in-
terrogated amongst studies conducted within and outside the
African continent to identify patient and population-level risk
factors associated with mixed-strain TB infections, as well as
possible avenues for future research. Recurrent TB and factors
associated with relapse versus re-infection are discussed, to-
gether with any association with mixed-strain infections. For
clarity, the terminology and methods used to describe and
study these clinically complex presentations of TB disease are
detailed below.
DEFINITIONS AND TERMINOLOGY
Definitions of terms and descriptions of features relating to TB
disease, pathogenesis and epidemiology that are commonly en-
countered in the literature and feature in this review are given
below. These are further clarified in Fig. 1.
Primary TB disease
Primary TB, Fig. 1, is defined as disease in a patient who has
never been treated for TB or has taken anti-TB medication for
less than a month (WHO 2014).
Endogenous re-activation
Endogenous reactivation refers to incident cases of TB (both
new and recurrent) that occur as a result of re-activation/re-
emergence of a previous infection that was contained by the
host immune response, in the case of individuals with latent
TB infection, and/or the application of chemotherapy in patients
with active TB disease, Fig. 1. This is in contrast to TB disease
(both new and recurrent) that is a result of a recent transmis-
sion event (Mathema et al. 2006).
Recurrent TB disease
Recurrent TB refers to a repeat occurrence (second, third or sub-
sequent episode) of TB disease in a patient that occurs as a result
of either relapse or re-infection. Recurrent TB occurs after the
previous/initial episode has been classified as clinically cured
according toWHO guidelines [smear or culture-negative sputum
specimens in the last month of treatment and on at least one
previous occasion, (WHO 2016a)].
Re-infection
Recurrent TB disease also occurs as a result of re-infection,
whereby a patient is exogenously infected with a Mycobacterium
tuberculosis strain that is distinct from the organism that caused
the original infection, Fig. 1B (Mathema et al. 2006). A caveat here
is that in high-incidence settings, patients, on rare occasions,
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Figure 1. Recurrent disease andmixed-strainM. tuberculosis infections. Shown are the various scenarios that give rise to recurrent TB disease andmixed infections. (A)
Relapse disease occurs due to the re-emergence of anM. tuberculosis strain that caused the original infection, suggesting that complete eradication of tubercle bacteria
was not achieved during the primary disease episode. In this case, the second disease episode results from the presence of persisting organisms that emerge when
treatment is stopped and environmental factors are favorable for bacillary survival. (B) Re-infection occurs when a patient is infected with an M. tuberculosis strain
that is distinct from the strain that caused the original infection. High rates of re-infection can be attributed to both environmental and host factors. Alternatively,
an individual can be functionally cured, with no surviving bacteria but can then be re-infected with the same strain that caused the primary disease episode. In the
absence of molecular tools to distinguish these events, this would result in the incorrect classification of re-activation, see (A). (C) Mixed infections can occur in both
primary TB disease and recurrent TB disease. During primary disease, mixed infections can occur during a single infectious episode, whereby two genetically distinct
strains are present at the same time during the initial infectious episode. Alternatively, infection with a second distinct strain (super infection) can occur during latent
infection or active disease. Re-infection with a second strain may also result in re-activation of an underlying strain.
may be exposed to or be infected by a very similar or the same
strain as in the primary infection, which makes differentiation
between relapse and re-infection in these particular cases diffi-
cult.
Relapse
Relapse disease is defined as a second (or third) episode of
active TB disease due to re-emergence of the original infec-
tion, as determined by genotypic analysis of the prevailing
tubercle bacilli (Mathema et al. 2006). As indicated for re-
infection, substantive homogeneity in M. tuberculosis strains
in any given setting, combined with high transmission rates,
will make the classification relapse versus re-infection dif-
ficult. In these cases, whole-genome sequencing (WGS) to
identify minor differences will provide the greatest insight
(Gan et al. 2016).
Mixed-strain TB infection
This refers to TB disease caused by more than one clonally dis-
tinct M. tuberculosis strain, either through a single transmis-
sion event involving more than one distinct strain or through
multiple transmission events (super-infection) during a single-
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disease episode, Fig. 1C. The simultaneous transmission of mul-
tiple strains resulting in mixed infection may occur in popula-
tions of vulnerable individuals, whereby both strains are able
to bypass the host’s defense system and resist killing (Warren
et al. 2004). Super-infection can also occur when the severity
of a current disease episode is such that it compromises the
host innate immune response to a point that leads to increased
susceptibility to infection with a secondary strain (Warren et al.
2004). Alternatively, mixed-strain infections can arise if a subse-
quent infectious episode, which was caused by a distinct strain,
results in relapse of the original infection, yielding disease with
two uniqueM. tuberculosis strains that may have the same or dif-
ferent drug susceptibility profiles.
Heteroresistance
The term heteroresistance refers to the occurrence of popula-
tions of both drug-susceptible and drug-resistant isolates within
the same clinical sample (Rinder 2001). This phenomenon may
arise in a single infection as tubercle bacilli undergo genetic
change through mutation of genes associated with drug resis-
tance. It may also arise in mixed-strain infections, whereby one
strain is resistant to a particular TB drug, while the other strain
is susceptible. When heteroresistance occurs within the same
strain type, it involves sub-populations ofM. tuberculosis, for ex-
ample resistant mutants co-existing with susceptible wild-type
genotypes of specific resistance-related genes such as katG or
rpoB in the same sputum specimen. This phenomenon is known
as clonal heteroresistance, which is dependent solely on within-
host processes affecting a single causative strain, in comparison
to a mixed infection that is reliant on the presence of more than
one strain.
METHODOLOGY USED TO STUDY RECURRENT
TB AND STRAIN HETEROGENEITY
Numerous approaches have been employed to describe the
microbiological complexity associated with TB disease, fur-
ther detailed below. While some methods rely on variations in
the biochemical properties of tubercle bacilli, the most popu-
lar methods used for the identification of mixed-strain infec-
tions include IS6110-based restriction fragment length polymor-
phism (IS6110 RFLP) analysis, spacer oligonucleotide genotyping
(spoligotyping) and the mycobacterial interspersed repetitive-
unit-variable-number of tandem repeats (MIRU-VNTR) typing.
In more recent work, metagenomics (Kay et al. 2015) and WGS
approaches have been used (Ford et al. 2012; Gan et al. 2016).
Phage typing of Mycobacterium tuberculosis strains
Mixed-strain infections were first described in the 1970s using
phage typing of M. tuberculosis cultures (Mankiewicz and Liivak
1975; Bates, Stead and Rado 1976). This method demonstrated
that distinct strains of M. tuberculosis could be isolated from a
single sputum sample by the typing ofmultiple colonies on solid
culture media (Mankiewicz and Liivak 1975).
IS6110 RFLP typing
IS6110 RFLP typing is an attractive tool to study transmission
dynamics and relatedness of M. tuberculosis isolates (Cave et al.
1994; Warren et al. 2004). Strain identification using this method
relies on the number and position of the transposable inser-
tion sequence element, IS6110, in M. tuberculosis strains after
restriction digestion, yielding a unique fingerprint pattern (van
Embden et al. 1993). In studies investigating recurrent TB dis-
ease, strains exhibiting an identical banding pattern to the pri-
mary infectious episode point to relapse of TB disease, whereas
re-infection and recent transmission is implied when distinct
banding patterns are obtained. IS6110 RFLP technology has also
been utilized to identify mixed infections either by the identi-
fication of low-intensity banding patterns (LIBs) present in the
same sputum sample (de Boer et al. 2000) or by the identifica-
tion of unique fingerprints from the selection of multiple single
colonies from the original sample (de Viedma et al. 2003; Das
et al. 2004; Shamputa et al. 2004). One limitation of this method
is that the identification of LIBs requires that at least 10% of the
extracted DNA originates from the minority strain in order to
be detected (Cohen et al. 2012). An additional limitation is that
it fails to reliably discriminate between strains with less than
six IS6110 copies i.e. low-copy-number isolates (Gutacker et al.
2006). Some of these strains, displaying identical banding pat-
terns on IS6110 typing, have been shown to have unique genetic
identities when using a secondary genotyping method (Bauer
et al. 1999; Rhee et al. 2000).
Spoligotyping
Spoligotyping is the most commonly used PCR-based method
for genotyping and differentiating between M. tuberculosis com-
plex (MTBC) strains and is based on the visualization of 43 in-
terspersed spacer sequences in a genomic direct repeat locus of
MTBC strains (Kamerbeek et al. 1997). Although spoligotyping is
a popular and simple molecular tool used in the study of molec-
ular epidemiology, it has lower discriminatory powerwhen com-
pared to IS6110 RFLP typing and is generally not recommended
for use on its own in the study of mixed infections or transmis-
sion patterns (Kremer et al. 1999).
MIRU-VNTR typing
This method uses PCR to categorize the number and sizes of re-
peats in aminimumof 12 independent loci, each ofwhich have a
unique repeat sequence (Barnes and Cave 2003). As this method
examines heterogeneity within a limited set of loci, its discrim-
inatory power is linked to the number of loci that are evaluated.
An advantage of MIRU-VNTR typing is that it can identify strains
that are under-represented in a mixed-strain infection. Thus, a
minority strain representing as little as 1% of the entire bacte-
rial population can be identified using this technique (de Viedma
et al. 2005). One limitation of this method is that it may present
difficultly in differentiating between mixed infection and mi-
croevolution of strains (Cohen et al. 2012).
Whole-genome sequencing
WGS has become an established method in the field of molecu-
lar epidemiology. The application of this technology provides the
capability of in-depth analysis into the diversity ofM. tuberculosis
strains that cannot be achieved by other currently used molec-
ular methods. However, its use has been hampered by high cost
and the complexity of data analysis but it is likely that the appli-
cation of WGS will increase as new-generation sequencing be-
comes more affordable and simpler data analysis tools become
available.
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APPROACH FOR RETROSPECTIVE ANALYSIS
To retrospectively assess the prevalence of mixed-strain in-
fections, the published literature was interrogated for reports
that described these and related occurrences. Publications se-
lected for analysis were obtained through the Pubmed database
(www.ncbi.nlm.gov/pubmed) using the following keywords and
Boolean operators: (mixed OR multiple) AND tuberculosis AND
(strain OR strains), which yielded 1749 hits. Relevant English
articles published from the beginning of records till December
2016 that reported the occurrence of mixed-strain infections us-
ing molecular genotyping techniques in adult TB patients were
chosen. These articles were selected using several criteria which
included, geographic location, patient population, recurrent TB
andwhere possible, congruent processing protocols.We also en-
deavored to differentiate our analysis to a previous review pub-
lished 4 years ago (Cohen et al. 2012), which affected our inclu-
sion/exclusion of studies. Studies with a starting sample size
of less than 10 patients were excluded from analysis. In addi-
tion, relevant articles that were referenced by papers obtained
through the original search were also included for analysis. The
analysis of mixed infections was further stratified by primary
and recurrent disease. In some instances, where not reported,
the proportion of mixed infections was calculated in each co-
hort based on the information available. The resulting synthe-
sis of research on mixed Mycobacterium tuberculosis infections
worldwide, spanning over the last 15–17 years is provided in this
review.
MIXED MYCOBACTERIUM TUBERCULOSIS
INFECTIONS
Studies of TB cases in deceased patients from the 18th century,
while limited, revealed that in five out of eight bodies investi-
gated using metagenomics, more than one Mycobacterium tuber-
culosis genotype was identified, suggesting that mixed-strain in-
fection may have been a common occurrence during a time of
rampant TB in Europe (Kay et al. 2015). Current studies investi-
gating the frequency of present day mixed M. tuberculosis infec-
tions confirm that they can occur regularly but the frequency of
detection varies according to the design of the studies, the sam-
ple size and methodology used.
African versus non-African studies
For the greatest coverage possible, geographically distinct re-
gions covering Africa and countries outside Africa, respectively,
were included in this review and the findings summarized in Ta-
bles 1 and 2. The rationale for this stratificationwas based on the
observation that countries in Africa (especially southern Africa)
carry a high burden of HIV-associated TB (WHO 2016a,b). We hy-
pothesized that the compromised immune response in individ-
uals associated with these dual epidemics, together with a high
incidence of TB and elevated transmission rates, would give rise
to a greater prevalence of mixed infections on the African conti-
nent. The reported TB incidence figures per 100 000 population
in the select countries used for this analysis were South Africa,
834; Rwanda, 63; Zambia, 406; Malawi, 164; Uganda, 161. In sim-
ilar studies from outside of Africa, the TB incidence figures per
100 000 population were Spain, 12; India, 167; Bangladesh, 227;
Georgia, 106; China, 68; Kyrgyzstan, 142; Vietnam, 140; Guyana,
93; Surinam, 33 and Pakistan, 270 (WHO 2016b). Amongst stud-
ies fromAfrican countries, 15 that investigated the occurrence of
mixed infections in patients with pulmonary TB were included
for analysis. These studies were selected on the basis of the
methodology employed as well as the number of patient sam-
ples analyzed. Of the selected African studies, nine were con-
ducted in South Africa, and the remaining six were carried out
in Rwanda, Zambia, Malawi (one study from each country) and
Uganda (three studies). The frequency of mixed infections ob-
served in sputum samples from African studies varied between
2.3% and 19% (Table 1). Frequencies of mixed infections reported
in 19 studies performed in countries outside of Africa were sim-
ilar to those in Africa and varied from <0.4% to 15.7% (Table 2).
Given the substantive variation in overall study design, it is un-
clear whether the difference in the upper limit of mixed infec-
tion prevalence, 14%–19%, can be considered as significant. Pos-
sible reasons for the large variation in the occurrence of mixed
infection in any particular setting or between the select studies
are outlined below.
Effect of quality, volume and processing of specimens
A major contribution to variations between studies in similar
settings is likely to be sputum collection and processing. The
collection of a single, low-volume sputum sample may greatly
decrease the odds of finding mixed infection episodes. For ex-
ample, a poor-quality sputum sample containing a significant
amount of upper airway secretions is unlikely to be represen-
tative of the entire M. tuberculosis population in the bronchial
tree, while the collection of multiple sputum samples may in-
crease the odds of sampling from different cavities within the
lung. Several studies reviewed here, relied on the collection of
sputum cultures from multiple pre-treatment specimens to in-
crease the sensitivity of their assay (Richardson et al. 2002a;
Shamputa et al. 2006; Peng et al. 2013). Similarly, for the demon-
stration of mixed infections, typing of cultures from multiple
sputum samples from smear-positive individuals, collected se-
rially over time, was used (Braden et al. 2001; Baldeviano-Vidalon
et al. 2005; van Rie et al. 2005; Dickman et al. 2010; Mallard et al.
2010; Mulenga et al. 2010; Cohen et al. 2011). Considering this, an
in-depth comparison of findings between these studies was not
possible due to differences in methodology and study design.
However, intra-study comparisons of the frequency of mixed in-
fections have concluded that the analysis of a single sputum
sample, as opposed to multiple samples, decreases the likeli-
hood of detecting mixed infections (Shamputa et al. 2006; Peng
et al. 2013).
Effect of specimen processing
We hypothesize that additional factors that could affect the
detection of mixed-strain infections include delays in trans-
portation, breaks in cold-chain transport and delays in sputum
processing. Furthermore, it is not known whether the decon-
tamination procedure may result in a loss of bacterial popula-
tions. To our knowledge, no research has focused on the impact
of these procedures on detecting mixed strains, and further re-
search is required to corroborate these hypotheses. Findings of
studies on mixed infections are also not directly comparable as
the population structure of mixed infection is strain genotype
and culture medium dependent (Hanekom et al. 2013). More-
over, the clonal composition of cultures from clinical specimens
could be modified by the culture techniques used (Martı´n et al.
2010). Hanekom et al. (2013) used a PCR-based molecular typ-
ing approach to identify strain genotypes in both Lo¨wenstein-
Jensen (LJ) and mycobacterial growth indicator tube (MGIT) cul-
tures. The investigators noted that Beijing and Haarlem strain
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families weremore likely to be associated withmixed infections
and showed a predilection for some culturemedia (BeijingMGIT,
P = 0.02, LJ P <0.01; Haarlem MGIT P < 0.01, LJ P = 0.01). Other
strains investigated included the Latin AmericanMediterranean
(LAM) and S-family genotypes (Hanekom et al. 2013). In addi-
tion, mixed infections were identified in 23 of 206 MGIT cul-
tures and 28 of 206 LJ cultures, indicating that LJ media may be
marginally preferable to liquidmedia in identifyingmixed infec-
tions (Hanekom et al. 2013). In a separate study, the clonal com-
plexity of M. tuberculosis populations from clinical specimens
was investigated by mixing strains in different volumetric pro-
portions before culturingwas performed. UsingMIRU-VNTR typ-
ing, marked changes in the clonal composition were observed,
including strains with different resistance profiles. The authors
concluded that clonal complexity can be lost after culture, there-
fore genotyping techniques should be optimized in such a way
that they can be performed directly on clinical samples (Martı´n
et al. 2010). Four studies included herein were performed di-
rectly on sputum samples of which three used a PCR ampli-
fication method to detect different lineages (Mokrousov et al.
2009; Huang et al. 2010; Mallard et al. 2010; Wang et al. 2011).
PCR methods to detect Beijing and non-Beijing lineages identi-
fied mixed infection frequencies to occur at 3% and 11% (Huang
et al. 2010; Wang et al. 2011) while PCR to detect LAM and Beijing
lineages reported mixed infection frequencies of 2.8% (Mallard
et al. 2010). In the remaining study, 13.7% was identified by 12
locus MIRU-VNTR typing (Mokrousov et al. 2009). Another study
investigated the proportion of mixed infections in both sputum
and liquid culture-positive medium and reported a frequency of
2.1% and 4.6%, respectively (Wang et al. 2011). In a subsequent
study, Wang et al. (2015) further sub-cultured the mixed strains
initially observed and selected 30 clones from the sub-culture for
each mixed infection. The authors reported that after the addi-
tion of a culture step, 8 of 12 (66.7%) strains with mixed infec-
tions had converted into a single genotype (Wang et al. 2015).
Mixed-strain infections involving heteroresistance may also be
missed if sputum samples are collected from a patient who has
started treatment at a time when resistance is being amplified
by first-line therapy (Hingley-Wilson et al. 2013). Pre-treatment
samples may therefore be preferable for studies trying to iden-
tifymixed infections/clonal heteroresistancewithin an infecting
bacterial population.
Techniques used for demonstrating mixed infections
The prevalence ofmixed-strain infections varied between<0.4%
using IS6110 genotyping on colonies from 543 patients in In-
dia (Das et al. 2004), to 15.4% using the same technique on 12
HIV-negative autopsy cases in theWestern Cape (du Plessis et al.
2001). In studies employing MIRU-VNTR typing, mixed infec-
tionswere detected at an average frequency of 5.6% in Shanghai,
China, with re-treatment cases having a higher rate of mixed in-
fections than new TB cases (15.6% versus 4.1%) (Fang et al. 2008).
Compared to these figures, mixed infections were encountered
in 10% of all TB cases in Botswana (Shin et al. 2014). Only one
study used spoligotyping as its primary method of genotyping
and reported mixed infections to occur in 18% of samples an-
alyzed, which is high in comparison to rates reported in other
studies using other molecular methods (Andrews et al. 2008).
Frequencies of certain Mycobacterium tuberculosis
genotypes involved in mixed infections
In the African studies, the incidence of mixed infections var-
ied from 2.3% in diagnostic sputum cultures in patients from
Cape Town, South Africa (Richardson et al. 2002a) to 19% in spu-
tum cultures obtained from other patients suspected of suf-
fering from TB from the same region (Warren et al. 2004). The
highest frequency of mixed infections in sputum samples was
obtained using a novel PCR technique demonstrating that pa-
tients analyzed in the study were simultaneously infected with
a Beijing and non-Beijing M. tuberculosis strains (Warren et al.
2004). These results probably underestimate the frequency of
mixed infections in this population as the PCR was conducted
with primers specific to the Beijing lineage, andmixed infections
may have also been present within the non-Beijing lineages.
However, this method was still superior to spoligotyping, which
identified only 4.5% ofmixed cases in the same population (War-
ren et al. 2004). In another study, a PCR-based approachwas used
to determine the occurrence ofmixed infections in sputum sam-
ples taken from patients in Malawi (Mallard et al. 2010). The in-
vestigators applied two lineage-specific PCR assays to sputum
samples, targeting the LAM and non-LAM genotypes, as LAM
strains are the most common genotypes present in northern
Malawi. This yielded mixed infections in 2.8% of sputum sam-
ples, significantly lower than the 19% mixed infection rates ob-
served in the Cape Town study that investigated the occurrence
of Beijing and non-Beijing strains (Warren et al. 2004; Mallard
et al. 2010). It was proposed that the differences found between
the two studies could be explained by differences in the annual
risk of infection [3% in Cape Town (Kritzinger et al. 2009) versus
1% in the rural Karongo district in Malawi (Crampin, Glynn and
Fine 2009)]. Alternatively, inherent properties such as transmis-
sibility of the Beijing versus LAM genotypes could explain the
discrepancy. In addition, there were differences in the methods
employed in the two studies.
Middelkoop et al. (2014) investigated factors associated with
M. tuberculosis strain success in a high-TB-burdened commu-
nity, with high strain diversity. Using IS6110 RFLP, the au-
thors noted that only 4% of strain types were persistently
successful over a 10-year study period. These were strains
from the W-Beijing family (W451 W724, W181, W330) and
four from the CC-related lineage (CC27, CC61, CC73, CC77),
as well as NG24 and AI265 strains. As host factors exam-
ined, such as age and gender, were not associated with strain
success, it was concluded that pathogen rather than host
characteristics appear to play a greater role in strain success
(Middelkoop et al. 2014).
Effect of disease burden on prevalence of mixed
infections
A high number of incident cases should logically influence the
frequency of mixed infections, as was the case with the in-
creased prevalence of 19% of mixed infections identified in the
Cape Town study by Warren et al. (2004). However, Richardson
et al. (2002a) who conducted their study in the same setting but
found the frequency of mixed infections to be markedly lower,
at 2.3%. This result was similar to the mixed infection rate seen
in Bangladesh (2.1%) and Spain (2.6%). As mentioned previously,
detailed comparisons between these studies are not scientifi-
cally valid due to differences in study design and methodology;
however, the findings do suggest that overall disease burden is
not the only arbiter of strain diversity or mixed infections. Alter-
natively, the differences in methods used in these studies may
have resulted in an underestimate of mixed infections, as stud-
ies that used IS6110-based RFLP as their primary typing tech-
nique tended to report a low incidence of mixed infections, Ta-
bles 1 and 2. In contrast, when used in a congregate setting,
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IS6110-based RFLP on multiple pre-treatment sputum samples
identifiedmixed infections at a frequency of 9% in adult inmates
in a prison TB hospital in Georgia (Shamputa et al. 2006). When
MIRU-VNTR was used as a secondary typing tool, mixed infec-
tions were observed in 13.1% of the patients. The high mixed
infection rates seen in this study occurred in settings of over-
crowding coupled with a high incidence of TB.
Mixed infections in extra-pulmonary sites
While the majority of analyses reported herein was focused
on sputum, the occurrence of mixed infections has also been
demonstrated in extra-pulmonary samples taken from culture-
positive biopsy specimens in two studies, both reporting a fre-
quency of 9% (Cohen et al. 2011; Lieberman et al. 2016). Sam-
pling of different anatomical sites in another study yielded a
frequency of 3.6% (Chaves et al. 1999) while a frequency of 6%
was recorded in another study where both extra-pulmonary
and pulmonary specimens were collected (de Viedma et al.
2003). In an autopsy study, using lung and extra-pulmonary
samples, a mixed infection frequency of 15.4% was reported
(du Plessis et al. 2001). The highest frequency of mixed infec-
tions involving extra-pulmonary samples was reported by Ssen-
gooba et al. (2015) who found that 51% of HIV-infected indi-
viduals with CD4 counts > 200 cells/mm3 displayed discordant
M. tuberculosis genotypes between isolates from blood and spu-
tum samples, respectively, providing evidence of substantive
mixed infection frequencies in different body compartments
(Ssengooba et al. 2015). In agreement with this, genomic anal-
ysis of postmortem lung and extra-pulmonary biopsies from
44 HIV-positive patients in KwaZulu-Natal reported that M. tu-
berculosis sub-lineages, including mixed infections, were dis-
tributed differentially throughout the lung, pointing towards
temporary barriers to pathogen migration in the lung (Lieber-
man et al. 2016). In addition, multiple genotypes were identi-
fied between M. tuberculosis organisms in the lungs and extra-
pulmonary sites, which may have occurred through a single
transmission event involving multiple genotypes or by means
of super-infection episodes (Lieberman et al. 2016). The genomic
diversity identified by the occurrence of mixed-strain infections
as well diversified sub-lineages provide an interesting record
of evolution and dissemination across the body in HIV-infected
individuals.
RECURRENT TB DISEASE
A select few studies analyzed here investigated whether mixed
infections were more likely to occur during a primary versus a
recurrent disease episode. From these, the frequency of mixed
infectionswere reported as being higher in the recurrent disease
episode in seven out of 13 studies, although most of these stud-
ies found this difference not to be significant (Warren et al. 2004;
Fang et al. 2008; Huang et al. 2010; Wang et al. 2011, 2015; Shin
et al. 2014; Pang et al. 2015). The six remaining studies reported
lower frequencies of mixed infections in the recurrent episode,
Tables 1 and 2. However, in three of these studies, less than 20%
of the patients analyzed were recurrent cases, making it difficult
to draw any definitive conclusions on the likelihood of previous
TB exposure being a risk factor for mixed-strain infections.
A review of earlier studies yielded little consensus regard-
ing the proportions of recurrent disease due to relapse and re-
infection (Lambert et al. 2003). Although re-infection is most
likely to occur in geographical locations where the incidence
of TB disease is high (Romeyn 1970; Vynnycky and Fine 1997;
Godfrey-Faussett et al. 2000; Richardson et al. 2002b; Middelkoop
et al. 2015), studies performed in low- tomoderate-incidence set-
tings have also reported high rates of re-infection (Caminero
et al. 2001). A poor association between re-infection and re-
current TB disease in high-burden settings has also been re-
ported, suggesting that a consistent trend in this regard is lack-
ing (Shamputa et al. 2007; Luzze et al. 2013). Annual rates of
relapse versus re-infection in patients with recurrent disease
in Cape Town, South Africa, indicate that relapse generally oc-
curred within a year following treatment, while re-infection, re-
sponsible for at least half of all cases of recurrent disease in
this study, predominated after the first year following treatment
(Marx et al. 2014; Guerra-Assunc¸a˜o et al. 2015). Hence, it is dif-
ficult to make direct comparisons between studies where the
length of follow-up after treatment differs. Co-infection with
HIV and antiretroviral treatment has been shown to be associ-
ated with increased risk for recurrent disease due to re-infection
as opposed to relapse (Godfrey-Faussett et al. 1994; Sonnenberg
et al. 2001; Middelkoop et al. 2012, 2015; Guerra-Assunc¸a˜o et al.
2015). It was also demonstrated that there is a 2.4 times higher
hazard ratio for recurrent disease in HIV-1-positive individu-
als, compared to HIV-1-negative counterparts (Sonnenberg et al.
2001). The risk of re-infection has also been linked to previ-
ous TB infection, where disease attributable to re-infection af-
ter successful treatment completion was four times higher than
that attributable to new TB disease (Verver et al. 2005). A ma-
jor limitation of this study is that the HIV status of most pa-
tients was unknown; however, the authors concluded that re-
infections observed could not be explained by HIV status alone,
as theHIV prevalence in this study groupwas relatively low (1.2%
to 5.2% in antenatal clinics and 11% amongst newly diagnosed
TB patients). These findings suggest that a subset of individuals
within a populationmay be predisposed to TB disease, with pre-
vious TB exposure itself being a risk factor for recurrent disease.
We hypothesize that mixed infection prevalence will be higher
in these individuals.
INTERPRETATION AND RECOMMENDATIONS
Interruption of TB transmission is pivotal to eliminating this
disease from human society (Pai et al. 2016). The science sur-
rounding transmission of the tubercle bacillus is an evolving dis-
cipline and much work is still needed to elucidate the biophys-
ical, environmental, genetic and immunologic determinants in
those individuals that transmit disease and those that get in-
fected. We propose that the analysis of mixed infection rates
provides an interesting and useful proxy for the level of trans-
mission in communities within TB-endemic regions. However,
retrospective analyses of studies conducted in various settings
to assess this are difficult due to numerous factors which in-
clude differences in study design, sample processing, bacterial
culture and molecular typing tool employed. Although molec-
ular approaches for identifying mixed-strain TB infections are
limited in their sensitivity, studies relying on sputum samples
alone have reported that up to 19% of individuals are infected
with more than one Mycobacterium tuberculosis strain. Further-
more, studies utilizing a combination of both pulmonary and
extra-pulmonary samples have reported mixed infections to oc-
cur at a frequency of up to 51%. As these results are likely to
be a conservative estimate, this suggests that mixed-strain in-
fections occur at reasonably high frequencies. Whether this is
a result of high transmission rates in endemic settings remains
unclear asmixed infection rates seems similar in high- and low-
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burden settings, based on the studies analyzed herein. Various
factors need to be considered when assessing the prevalence or
risk of mixed infections. These are detailed below.
What is the role of HIV?
From our collective analysis, factors associated with mixed-
strain infection among HIV-infected patients include prior TB
treatment [adjusted prevalence ratio, 2.11] and CD4+ T-cell
count < 100 cells/μl (adjusted prevalence ratio, 10.18), sug-
gesting that patients with advanced immune suppression are
at increased risk of contracting a mixed-strain infection (Shin
et al. 2014). Consistent with this, a study in Uganda on 113
smear and culture-positive patients established that mixed in-
fections are more likely to occur in HIV-seropositive individ-
uals, 37.5% versus 12.6% in HIV-positive versus HIV-negative
patients with TB, respectively (Dickman et al. 2010). These re-
sults may still underestimate the proportion of mixed infec-
tions as TB/HIV co-infection often results in disseminated/extra-
pulmonary disease, therefore reducing the chances of detect-
ing mixed infections from pulmonary specimens alone, which
may be paucibacillary in nature (de Viedma et al. 2003; Dick-
man et al. 2010). Various studies have now shown that multi-
ple genotypes can be detected by sampling from both respira-
tory and extra-pulmonary sites in HIV-positive individuals, illus-
trating the presence of migration routes within and between or-
gans. To our knowledge, no studies have investigated this sam-
pling strategy in HIV-negative individuals. Despite the demon-
strated increased risk of mixed infections in HIV-infected indi-
viduals, we found no substantive differences in mixed infection
incidence when collectively comparing studies within Africa, an
HIV-endemic region, and the rest of the world. This could re-
flect the lack of studies in the correct populations or the above-
mentioned limitations in our comparative analysis.
How do mixed infections affect disease/treatment
outcome?
The presence of mixed-strain infections involving heteroresis-
tance results in poor treatment outcome (Theisen et al. 1995;
Niemann et al. 2000; Baldeviano-Vidalon et al. 2005; van Rie et al.
2005; Kamakoli et al. 2017). For this reason, patients with various
forms of drug-resistant TB may require a combination of first-
and second-line antibiotics to target both drug-sensitive and -
resistant organisms, respectively (Post et al. 2004; van Rie et al.
2005). Diagnostically, if only the sensitive strain is cultured from
a mixed-strain infection, the administration of a drug-sensitive
regimen will result in the selection of the resistant strain. This
highlights the importance of early detection of mixed-strain in-
fections with different resistance profiles to tailor the treatment
regimen accordingly.
Mixed infections and the immune response
It has been demonstrated that different M. tuberculosis strains
elicit distinct immune responses in the lung, ultimately lead-
ing to differences in disease pathology and mortality (Post et al.
2004). Consistent with this, immune protection conferred by
one M. tuberculosis strain may differ when compared to dis-
tantly related strains due to differences in antigenic prop-
erties. Indeed, studies assessing the effectiveness of Bacille
Calmette-Guerin (BCG) have varied worldwide and are possi-
bly complicated by the heterogeneity in M. tuberculosis strains
circulating within vaccinated communities (Fine 1995). Direct
intra-tracheal injection of BALB/c mice indicated that BCG
vaccination was less effective against infection with Beijing
strains when compared to H37Rv (Lopez et al. 2003). Further-
more, infection with Beijing strains was characterized by ex-
cessive pneumonia, early but short-lived tumor necrosis factor-
α (TNF-α) and nitric oxide synthetase (INOS) expression and
an increase in mortality, while infection with M. canetti re-
sulted in limited pneumonia, sustained TNF-α and INOS ex-
pression in the lung, with 100% survival (Lopez et al. 2003).
This indicates that different M. tuberculosis strains elicit varying
immune-pathological events. In this regard, the simultaneous
interaction between multiple strains and the host immune sys-
tem in a mixed infection scenario remains to be explored. In ad-
dition, it is not knownwhether all resident strains in an infected
individual are transmitted simultaneously orwhether one strain
is more transmissible than the other. These remain as critical
knowledge gaps that limit the development of novel interven-
tions to reduce transmission.
Phenotypic heterogeneity
An important aspect of sputum microbiology, for which there
has been growing appreciation, is the failure to detect non-
replicating organisms that could influence the probability of di-
agnosing mixed-strain infections (Dartois et al. 2016). It is pre-
dicted that a sub-population of organismswithstands treatment
and can enter into a drug-tolerant, quiescent state (Kell and
Young 2000). Consistent with this, M. tuberculosis grown under
hypoxic conditions is able to enter into a drug-tolerant, non-
replicating state and accumulate lipid inclusion bodies (Garton
et al. 2008). Bacteria with a similar physiology have been iso-
lated directly from patient sputum, suggesting that these cells
reflect those studied in vitro (Garton et al. 2008). Subsequentwork
has also demonstrated that pre-treatment sputum samples are
dominated by a DCTB population that can only be grown in liq-
uid media (Mukamolova et al. 2010; Chengalroyen et al. 2016; Lo-
raine et al. 2016). Considering this, we hypothesize that it is pos-
sible that specific strains of M. tuberculosis adopt this differen-
tially culturable state, and thus are not identifiable by routine
culture. Currently, there is no data to corroborate this, but the
upregulation of the DosR regulon in W-Beijing strains, and con-
comitant accumulation of triacylglycerides, suggests that this
family of strains may have a greater propensity to adopt these
differential growth states (Reed et al. 2007). Hence, the associ-
ation of Beijing lineage 2 strains with relapse (Lan et al. 2003;
Bryant et al. 2013) may be linked to a proportion of this strain
assuming a differentially culturable state, thereby providing the
organism with an adaptive advantage against immune assault
and drug treatment. Furthermore, the occurrence of DCTB could
result in an underestimation ofmixed infections as some strains
may not emerge on solid media.
Limitations in molecular typing tools
Current molecular methods do not provide adequate informa-
tion on themechanism of transmission and order in which each
individual infection was acquired, for the latter continuous and
very expensive molecular surveillance would be required. This
information would be invaluable in the interpretation of epi-
demiological data. For example, in a scenario where re-infection
resulted in the re-activation of an underlying strain, IS6110may
only identify the secondary strain which could be interpreted as
the strain causing the original infection and result in inaccurate
identification of the source of infection in contact tracing. High
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rates ofmixed infections in a recurrent disease episode highlight
the importance of re-infection in disease transmission, which
has previously been questioned (Stead 1967). These limitations
call for wider use of high-resolution techniques such as WGS.
Diagnosing mixed infections
In high-burden settings, where the majority of TB disease is
likely (but not necessarily) due to re-infection /recent infec-
tion, TB control strategies will be highly reliant on the early
identification and early treatment of infectious individuals to
prevent transmission of both drug-susceptible and -resistant
strains within the community. High rates of disease recurrences
due to re-infection pose a serious problem to vulnerable popu-
lations, such as HIV-infected mining communities where post-
treatment prophylaxis was proposed as an important public
health strategy (Sonnenberg et al. 2001). Exogenous re-infection
has also been implicated in the acquisition of drug resistance in
patients (Andrews et al. 2008). Several studies in South Africa in-
vestigating extremely drug-resistant (XDR)-TB have been associ-
ated with primary transmission (Ghandi et al. 2006; Klopper et al.
2013). These cases have been attributed to ‘super spreaders’—a
small percentage of infected individuals who have the propen-
sity to transmit TB disease as identified by a cough aerosol sam-
pling system (Jones-Lo´pez et al. 2013). The long-term treatment
outcome in patients with XDR-TB is very poor, and the growing
infectious pool of drug-resistant TB disease is of major concern
as it threatens global TB control efforts (Dheda et al. 2010).Where
drug resistance is often the result of primary transmission of re-
sistant strains, the rapid identification and treatment of patients
harboring these strains should be a high priority. Furthermore, if
mutations are more likely to emerge from certain strains associ-
ated with re-infection, strain differentiation may need to be in-
cluded in the diagnostic process for early identification and the
development of tailored treatment regimens. With regard to im-
plementation, while the addition of strain typing to current di-
agnostic algorithms in high-income, low-burden nations would
seem plausible, the introduction of this technology in develop-
ing nations with a high disease burden would be unrealistic due
to the high costs and the laboratory expertise required. These
challenges highlight the need for the development of simpler
and more affordable technologies for the characterization of TB
strains (e.g. point-of-care multiplex tool to differentiate strain
type). Successful interventions to decrease transmission will re-
duce the levels of recurrent TB disease (due to re-infection) as
well as reduce the opportunities for mixed-strain TB infection.
CONCLUDING REMARKS
Molecular fingerprinting techniques have allowed for the dif-
ferentiation of recurrent TB disease into relapse versus re-
infection, as well as the identification of TB infection with mul-
tiple strains. The development of improved techniques for the
identification of relapse, re-infection and mixed infections has
important implications for the understanding of TB epidemi-
ology and the implementation of related technologies in TB-
control programs, patientmanagement and outcome analysis of
clinical trials. Ongoing research using WGS to provide more de-
tailed insight into these phenomena is imperative to design ef-
fective transmission intervention strategies. However, a limita-
tion with the substantive research effort in these areas over the
last two decades is the lack of a common sample collection and
processing protocol for specimens to allow for a direct compari-
son of mixed infections and recurrent disease in geographically
distinct settings with varying burdens of disease. Such studies
should take high priority on the global TB research agenda.
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